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  Dendritic	  Cell	  PLC-­‐γ	   	   	   Phospholipase	  C	  –γ	  Poly	  (I:	  C)	   	   Polyinosine-­‐Polycytidylic	  Acid	  	  
	  	  
XIX	  
PRR	   	   	   Pattern	  Recognition	  Receptor	  	  PdBu/PMA	   	   Phorbol	  12,13	  Myristate	  Acetate	  	  qPCR	   	   	   Quantitative	  PCR	  RNA	   	   	   Ribonucleic	  Acid	  	  Rpm	   	   	   Revolutions	  per	  Minute	  	  RORγT	   	   Retinoic	  acid	  receptor-­‐related	  orphan	  receptor	  gamma	  T	  ROS	   	   	   Reactive	  oxygen	  species	  	  RMPI	  	   	   	   Roswell	  Park	  Memorial	  Institute	  media	  RT	   	   	   Reverse	  Transcription	  SD	   	   	   Standard	  Deviation	  	  SDS	   	   	   Sodium	  Dodecyl	  Sulphate	  	  S/Ser	   	   	   Serine	  SEM	   	   	   Standard	  Error	  of	  the	  Mean	  SOCS	   	   	   Suppressor	  of	  Cytokine	  Signalling	  STAT	  	   	   	   Signal	  Transducer	  and	  Activator	  of	  Transcription	  T/Thr	   	   	   Threonine	  	  TAK	   	   	   Transforming	  Growth	  Factor-­‐Beta-­‐Activated	  	  	  Kinase	  T-­‐bet	   	   	   T-­‐box	  expressed	  in	  T	  cells	  	  TCR	   	   	   T	  Cell	  Receptor	  	  TGF-­‐β	   	   	   Transforming	  Growth	  Factor	  Beta	  	  	  TLR	   	   	   Toll-­‐Like	  Receptor	  TNF	   	   	   Tumour	  Necrosis	  Factor	  TRAF	   	   	   TNF-­‐Receptor-­‐Associated	  Factor	  TRAM	   	   	   TRIF-­‐Related	  Adaptor	  Molecule	  	  Treg	   	   	   Regulatory	  T	  cell	  	  TRIF	   	   	   TIR-­‐Related	  Adaptor	  Protein	  Inducing	  Interferon	  Tris	   	   	   Tris	  (hydroxymethyl)	  aminoethane	  V	   	   	   volts	  v/v	   	   	   Volume/Volume	  WT	   	   	   Wild	  Type	  w/v	   	   	   Weight/Volume	  Z	   	   	   Zymosan	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1.2 	  Innate	  immune	  system	  	  	   The	  front	  line	  of	  the	  innate	  immune	  system	  is	  barrier	  protection	  whereby	  anatomical	   and	  physiological	   barriers	   effectively	   prevent	   infection,	   such	   as	   the	  epithelial	   barrier	   provided	   by	   intact	   skin	   or	   the	   low	  pH	   of	   the	   stomach.	  When	  pathogens	   successfully	   breach	   these	   barriers	   the	   innate	   immune	   cells	   must	  rapidly	   respond	   to	   provide	   initial	   defense	   by	   engulfing	   pathogens	   as	   well	   as	  infected	   or	   dying	   cells,	   in	   a	   process	   known	   as	   phagocytosis.	   In	   addition	   to	  providing	   the	   early	   immune	   response	   the	   innate	   immune	   system	   also	   has	   the	  ability	  to	  communicate	  with	  and	  drive	  the	  adaptive	  immune	  response	  towards	  a	  pathogen,	   thereby	   linking	   the	   two	   branches	   of	   the	   immune	   system	   together	  (extensively	  reviewed	  (Basset	  et	  al.	  2003)	  (Janeway	  &	  Medzhitov	  2002)).	  	  	  
1.2.1 Innate	  immune	  cell	  subsets:	  cells	  of	  the	  myeloid	  lineage	  	  






















	  Figure	  1.1	  Development	  of	  innate	  and	  adaptive	  immune	  cells	  from	  hematopoietic	  stem	  cells	  	  Hematopoietic	   stem	   cells	   (HSCs)	   give	   rise	   to	   common	   progenitors	   including	  common	   myeloid	   progenitor	   cells	   (CMPs)	   and	   common	   lymphoid	   progenitor	  cells	   (CLPs)	   which	   make	   up	   the	   innate	   and	   adaptive	   immune	   systems	  respectively.	   CMPs	   give	   rise	   to	   erythrocytes,	   megakaryocytes,	   mast	   cells,	  granulocyte	  precursors	  and	  monocytes.	  	  Granulocyte	  precursors	  go	  onto	  to	  give	  rise	   to	   neutrophils,	   eosinophils	   and	   basophils.	   Monocytes	   further	   differentiate	  into	  dendritic	  cells	  and	  macrophages.	  CLPs	  give	  rise	  to	  B	  	  and	  T	  lymphocytes	  as	  well	  as	  natural	  killer	  (NK)	  cells.	  B	  lymphocytes	  upon	  activation	  differentiate	  into	  plasma	   cells	   that	   secrete	   antibodies.	   T	   lymphocytes	   under	   go	   further	  development	  within	  the	  thymus	  to	  generate	  multiple	  subsets	  including	  TCRαβ+	  and	   TCRγδ+	   cells	   as	   well	   as	   CD4+	   and	   CD8+	   positive	   subsets.	   Adapted	   from	  
(Imhof	  &	  Aurrand-­‐Lions	  2004)	  and	  (Geissmann	  et	  al.	  2010).	  	  
1.2.1.2 	  Neutrophils	  	  	   Neutrophils	  are	   the	  most	  common	  white	  blood	  cell	  within	   the	  body	  and	  are	   one	   of	   the	   first	   cells	   to	   sense	   and	   respond	   to	   an	   infection.	  Neutrophils	   are	  present	   in	   the	   blood,	   but	   are	   also	   attracted	   to	   sites	   of	   inflammation	   upon	  infection	   by	   local	   soluble	   mediators,	   such	   as	   cytokines	   and	   chemokines,	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produced	   by	   epithelial	   cells	   upon	   damage,	   stress	   or	   infection.	   The	   role	   of	  neutrophils	   is	   two-­‐fold,	   they	  are	  able	   to	  phagocytose	  pathogens	  and	  undergo	  a	  process	  called	  degranulation	  whereby	  anti-­‐microbial	  granules	  are	  released,	  both	  of	   which	   strongly	   promote	   pathogen	   clearance	   (reviewed	   (Kolaczkowska	   &	  Kubes	  2013)).	  	  
1.2.1.3 Monocytes	  and	  dendritic	  cells	  	  	   Monocytes	  primarily	  reside	  within	  the	  bone	  marrow	  and	  can	  give	  rise	  to	  a	  variety	  of	  innate	  immune	  cell	  subsets	  within	  peripheral	  tissues	  via	  migration	  in	  the	   blood.	   Monocytes	   routinely	   differentiate	   into	   macrophages	   under	   normal	  circumstances	   to	   promote	   immune	  homeostasis,	   this	   is	   known	   to	   occur	  within	  the	   steady	   state	   (Auffray	   et	   al.	   2009;	   Swirski	   et	   al.	   2009).	   Upon	   inflammation,	  circulating	  monocytes	   can	   proliferate	   and	   give	   rise	   to	   specialised	  macrophage	  populations	   upon	   extravasation	   from	   the	   blood	   via	   the	   epithelium	   into	  peripheral	  tissues	  (Serbina	  et	  al.	  2008).	  Dendritic	  cells	  within	  the	  innate	  immune	  system	   are	   derived	   from	   the	   common	   myeloid	   progenitor	   within	   the	   bone	  marrow	   and	   migrate	   into	   peripheral	   tissues	   to	   carry	   out	   distinct	   functions	  (Ginhoux	  &	  S.	  Jung	  2014).	  	  	  Importantly,	  neutrophils,	  macrophages	  and	  DCs	  are	  characterised	  by	  the	  ability	   sense,	   respond	   and	   phagocytose	   pathogens	   and	   dying	   or	   infected	   cells	  (Savina	  &	  Amigorena	  2007).	  DCs	  are	  highly	  efficient	  at	  this	  and	  process	  acquired	  antigen	   for	   presentation	   upon	   the	   cell	   surface	   via	   major	   histocompatibility	  complex	   (MHC)	   class	   II	   along	  with	   soluble	  mediators,	   including	   cytokines	   and	  chemokines,	   to	   the	   instruct	   adaptive	   immune	   system	   and	   generate	  immunological	  memory	  (Hespel	  &	  Moser	  2012).	  	  
1.2.1.4 Basophils	  and	  mast	  cells	  	  	   Other	   innate	   cells	   such	   as	   basophils	   and	   eosinophils	   primarily	   function	  through	   their	   ability	   to	   perform	   degranulation,	   which	   is	   the	   release	   of	  cytoplasmic	  granules	  that	  contain	  proteins	  and	  enzymes	  that	  are	  highly	  effective	  in	  clearing	  parasites	  from	  the	  body.	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Finally,	   mast	   cells	   are	   are	   characterised	   by	   immunity	   against	   parasitic	  infections	   but	   have	   a	   well	   documented	   role	   within	   allergic	   responses	  predominantly	   through	   the	   release	   of	   large	   amounts	   of	   histamine	   upon	  activation	  (Wernersson	  &	  Pejler	  2014).	  	  
1.2.1.5 Macrophages	  
	  	  Macrophages	   are	   highly	   heterogeneous	   cells	   that	   are	   able	   to	   perform	  different	  functions	  depending	  on	  the	  subset	  and	  anatomical	  location	  (Wynn	  et	  al.	  2013).	   The	   main	   function	   performed	   by	   macrophages	   is	   phagocytosis	   of	  pathogens	   such	   as	   bacteria	   after	   activation	   of	   PPRs,	   which	   also	   induces	   the	  production	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  IFNγ	  and	  TNFα,	  both	  of	  which	  alert	  and	  recruit	  other	   immune	  cells	  of	  an	  existing	   infection.	  Macrophages	  also	  play	   an	   important	   role	   in	   phagocytosing	   apoptotic	   cells	   promoting	   tissue	  homeostasis	   (Henson	   &	   Hume	   2006)	   (Muñoz	   et	   al.	   2010).	   This	   is	   largely	  achieved	   by	   scavenger	   receptors	   expressed	   on	   macrophages	   which	   are	   now	  recognised	  as	  a	  subclass	  of	  PPR	  (Canton	  et	  al.	  2013).	  Macrophages	  differentiate	  from	   circulating	  monocytes	  within	   the	   blood.	   In	   contrast	   to	  DCs,	  macrophages	  are	  not	  migratory	  cells	  and	   instead	   reside	   in	  peripheral	   tissues.	  Tissue	   specific	  subsets	   of	   macrophages	   include;	   kupffer	   cells	   (liver),	   Langerhans	   cells	   (skin),	  microglia	  (central	  nervous	  system)	  and	  osteoclasts	  (bone)	  (Davies	  et	  al.	  2013).	  	  Recent	  studies	  have	  developed	   the	   idea	  of	  macrophage	  polarisation	   into	  two	  distinct	  subsets,	  to	  mimic	  the	  nomenclature	  used	  for	  Th	  subsets	  (Martinez	  &	  Gordon	  2014).	  	  	  Classically	   activated	   macrophages	   are	   described	   as	   pro-­‐inflammatory	  ‘M1’	  macrophage	  that	  are	  characterised	  by	  the	  induction	  by	  IFNγ	  and	  TNFα	  (Dale	  et	  al.	  2008)	  and	  known	  to	  play	  a	  major	  role	  in	  the	  immune	  response	  to	  invading	  pathogens	  including	  bacteria	  and	  viruses.	  Due	  to	  the	  pro-­‐inflammatory	  nature	  of	  classically	   activated	   macrophages	   they	   have	   also	   been	   implicated	   in	   multiple	  chronic	   inflammatory	   diseases	   such	   as	   rheumatoid	   arthritis,	   systemic	   lupus	  erythematous	   (SLE)	   and	   irritable	   bowel	   diseases	   (Mosser	   &	   Edwards	   2008)	  (Hamilton	  &	  Tak	  2009).	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Alternatively	   activated	   macrophages,	   also	   know	   as	   ‘M2’,	   which	   are	  characterised	   as	   anti-­‐inflammatory	   phenotype	   with	   high	   production	   of	   IL-­‐10.	  More	  recently,	  alternatively	  activated	  macrophages	  have	  been	  renamed	  wound	  healing	  or	   regulatory	  macrophages	   (Gordon	  &	  Martinez	  2010).	  Wound	  healing	  macrophages	  are	  activated	  in	  response	  to	  IL-­‐4	  and	  although	  the	  exact	  source	  of	  IL-­‐4	  remains	  to	  be	  elucidated	  it	  is	  thought	  to	  be	  highly	  likely	  that	  it	  is	  produced	  by	  basophils	  or	  eosinophils	   in	   response	   to	   tissue	  damage	  or	   stress	   (Loke	  et	   al.	  2007).	  It	  should	  be	  highlighted	  however	  that	   in	  regard	  to	  both	  of	   these	  distinct	  macrophages	  subsets	  it	  still	  remains	  to	  be	  elucidated	  if	  these	  subsets	  are	  stable	  and	  do	  not	  simply	  convert	  depending	  on	  context.	  
1.2.1.6 Dendritic	  cells	  	  	   Ralph	   Steinman	   and	   Zanvil	   Cohn	   discovered	   the	   existence	   of	   dendritic	  cells	  in	  the	  1970's	  and	  their	  importance	  within	  the	  immune	  system	  was	  met	  with	  skepticism	   (Steinman	   &	   Cohn	   1973).	   DCs	   are	   classed	   as	   professional	   antigen	  processing	   and	   presenting	   cells	   within	   the	   innate	   immune	   system	   with	   the	  unique	   ability	   to	  not	   only	   induce	  T	   cell	   activation	  but	   also	   subsequently	   shape	  the	   differentiation	   of	   specific	   T	   cell	   subsets	   (Steinman	   &	   Witmer	   1978)	  (Steinman	  2012).	  DCs	  can	  also	  be	   further	  categorised	  depending	  on	  expression	  of	  distinct	  cell	  surface	  markers,	  anatomical	  location	  and	  more	  appropriately	  the	  function	   they	   perform	   within	   the	   immune	   system	   and	   immune	   response	  (reviewed(Mildner	   &	   S.	   Jung	   2014)).	   Research	   into	   therapeutically	   harnessing	  DCs	  ranges	  from	  studies	  into	  wealth	  of	  diseases	  including	  improving	  vaccination	  to	   infectious	   disease,	   cancer	   prevention	   and	   within	   autoimmune	   disease	  (Palucka	  &	  Banchereau	  2012)	  (Ganguly	  et	  al.	  2013).	  	  Following	   activation	   by	   infection	   of	   inflammatory	   stimuli,	   DCs	   undergo	  maturation,	   which	   results	   in	   dramatic	   changes	   in	   their	   antigen	   uptake,	  processing	  and	  presentation	  capabilities.	  This	  maturation	  process	  involves	  three	  consecutive	   processes;	   upregulation	   of	   MHC	   class	   II	   for	   presentation	   of	  processed	   antigen,	   costimulatory	   molecules	   (including	   CD40,	   CD80,	   CD86,	  ICOSL)	  which	  act	   as	   a	   secondary	   confirmation	  promoting	  T	   cell	   activation,	   and	  CCR7	   upregulation	   which	   promotes	   migration	   to	   T	   cell	   rich	   zones	   within	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lymphoid	  tissue	  that	  express	  high	  levels	  of	  CCL19/21,	  the	  ligand	  for	  CCR7	  (Dieu	  et	   al.	   1998;	   Yanagihara	   et	   al.	   1998)	   (Sozzani	   et	   al.	   1998).	   Mature	   DCs	   also	  upregulate	   the	   production	   of	   context	   dependent	   cytokines,	   which	   in	   turn	  instructs	  T	  cell	  differentiation	  into	  specific	  cell	  subsets	  (Sallusto	  et	  al.	  1999;	  Tan	  &	  H.	  C.	  O'Neill	  2005).	  	  	  	  As	  well	  as	  from	  detecting	  infection,	  DC	  subsets	  also	  have	  an	  essential	  role	  in	  establishing	  tolerance	  whereby	  multiple	  studies	  have	  shown	  depletion	  of	  key	  regulators	  within	  DC	  subsets	  or	   indeed	  constitutive	  deletion	  of	  DCs	  themselves	  can	  lead	  to	  autoimmunity	  (Travis	  et	  al.	  2007)	  (Melillo	  et	  al.	  2010)	  (S.	  J.	  Kim	  et	  al.	  2011)	  (Ohnmacht	  et	  al.	  2009).	  	  However,	   the	   involvement	   of	   DCs	   in	   the	   generation	   of	   tolerance	   is	   also	  complex	  and	  bidirectional	  whereby	  DCs	  can	  also	  participate	  in	  the	  development	  of	   autoimmunity	   towards	   self	   by	   promoting	   the	   differentiation	   of	   Th17	   cells,	  which	  are	  frequently	  the	  basis	  of	  autoimmune	  inflammation	  (Bettelli	  et	  al.	  2007).	  Contrasting	   roles	   of	   the	   promotion	   or	   inhibition	   of	   the	   immune	   response	   is	  shown	  in	  Figure	  1.2.	  	  	  
	  Figure	  1.2	  Activation	  and	  maturation	  of	  dendritic	  cells	  within	  the	  innate	  immune	  system	  orchestrates	  the	  adaptive	  immune	  response	  Depending	   on	   the	   inflammatory	   context,	   DCs	   can	   undergo	   activation	   and	  maturation	   and	   subsequently	   drive	   the	   activation,	   proliferation	   and	  differentiation	   into	   various	   subsets	   of	   CD4+	   T	   helper	   cells.	   Adapted	   from	  (Ganguly	  et	  al.	  2013).	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As	  mentioned,	  DCs	  are	  a	  heterogeneous	  population	  and	  exist	  in	  two	  major	  populations	   including	   conventional	   DCs	   (cDCs)	   and	   plasmacytoid	   DCs	   (pDCs).	  Both	  of	  these	  subsets	  are	  phenotypically	  and	  functionally	  distinct	  in	  the	  role	  they	  perform	   within	   the	   immune	   system	   and	   in	   a	   resulting	   immune	   response	  (Satpathy	  et	  al.	  2012).	  	  
1.2.1.6.1 	  Conventional	  DCs	  	   cDCs	   are	   characterised	   by	   multiple	   key	   attributes.	   cDCs	   are	   highly	  migratory	  cells	   that	  are	  also	  present	   in	  non-­‐lymphoid	  tissues	  within	  the	  steady	  state,	  constantly	  surveying	  the	  body	  for	  antigen	  whether	  pathogen	  or	  self	  (Merad	  et	  al.	  2013).	  cDCs	  also	  have	  superior	  antigen	  processing	  and	  presenting	  abilities	  (Segura	  &	  Villadangos	   2009)	   (Joffre	   et	   al.	   2012).	   Finally,	   cDCs	   have	   a	   superior	  ability	  to	  prime	  naïve	  T	  cells	  responses	  (Banchereau	  &	  Steinman	  1998).	  	  cDCs	   can	   be	   divided	   in	   two	   major	   subgroups	   based	   upon	   localisation	  within	  tissues	  or	  their	  migratory	  pathways	  through	  the	  body	  (Figure	  1.3).	  	  Migratory	  cDC	  subset	   is	  most	   frequently	   identified	  by	  CD11b+	  cDCs	  and	  CD11b-­‐	  CD103+	  cDCs	  subsets.	  CD11b+	  cDCs	  are	  found	  in	  the	  lymph	  node	  that	  act	  as	   sentinels	   to	   sense	   antigen	   throughout	   the	   body.	   This	   subset	   is	   frequently	  attributed	   to	  being	   in	   the	   steady	  state	  and	   for	   their	   role	   in	   the	  maintenance	  of	  peripheral	   tolerance	   (Jakubzick	   et	   al.	   2008).	   However	   upon	   inflammation	   and	  infection	  CD11b+	  cDCs	  are	  key	  in	  the	  initiation	  of	  the	  adaptive	  immune	  response.	  The	   migratory	   CD11b-­‐	   CD103+	   cDC	   subsets	   are	   more	   commonly	   found	   in	  mucosal	  linings	  such	  as	  the	  small	  intestine	  where	  they	  perform	  distinct	  functions	  and	  are	  discussed	  later	  in	  this	  chapter	  (Helft	  et	  al.	  2010)	  (del	  Rio	  et	  al.	  2010).	  	  The	  second	  major	  group	  of	   cDCs	   is	   the	   lymphoid	   resident	  DCs,	   found	   in	  major	   lymphoid	   tissues	   including	   the	   spleen,	   lymph	   nodes	   and	   the	   thymus.	  Lymphoid	   resident	   cDCs	   are	   divided	   into	   3	   distinct	   groups	   by	   expression	   of	  distinct	  surface	  markers	  including	  CD4+	  cDCs,	  CD8α+	  cDCs	  and	  double	  negative	  CD4-­‐CD8α-­‐	  cDCs	  (Vremec	  et	  al.	  1992)	  (Vremec	  et	  al.	  2000).	  	  CD8α+	   cDCs	   are	   specialised	   DCs	   with	   the	   ability	   to	   perform	   cross	  presentation,	   a	   process	   in	   which	   exogenous	   antigen	   is	   phagocytosed	   and	  displayed	  on	  MHC	  class	  I	  to	  CD8+	  CTLs	  (Haan	  et	  al.	  2000)	  (Schliehe	  et	  al.	  2011).	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cells( 	  Figure	  1.3	  DC	  subsets:	  differentiation	  and	  trafficking	  Monocyte	  derived	  DCs	  and	  pDCs	  circulate	  within	  the	  blood	  populating	  the	  lymph	  nodes	  and	  the	  spleen	  during	  the	  inflammatory	  response.	  cDC	  subsets	  are	  broadly	  divided	   into	   two	   subsets	   including	   lymphoid	   resident	   and	   migratory	   and	  maintain	  homeostasis	  within	  the	  steady	  state.	  CD4-­‐	  CD8α-­‐	  DN	  cDCs,	  CD4+	  cDCs	  and	  CD8α+cDCs	  are	  lymphoid	  resident	  whereas	  CD103+	  cDCs,	  CD11b+	  cDCs	  and	  Langerhans	  cells	  migrate	  throughout	  the	  body	  and	  travel	  to	  secondary	  lymphoid	  organs.	  Adapted	  from	  (Belz	  &	  Nutt	  2012).	  	  
1.2.1.6.2 	  Plasmacytoid	  DCs	  	   pDCs	   are	  morphologically,	   phenotypically	   and	   functionally	   distinct	   from	  cDCs	   and	   exist	   as	   a	   small	   population	   that	   primarily	   reside	   in	   the	   blood	   and	  circulate	   to	   lymphoid	   tissues	   throughout	   the	   body	   (Sozzani	   et	   al.	   2010)	  (Randolph	  et	  al.	  2008).	  The	  key	  differences	  between	  cDCs	  and	  pDC	  subsets	  are	  depicted	   in	  Figure	  1.4.	  Although	   the	  exact	   identity	  of	   a	  distinct	   and	   committed	  pre-­‐	  pDC	  precursor	  has	  not	  yet	  been	  elucidated	  it	  is	  known	  that	  the	  upregulation	  of	  the	  basic	  helix-­‐loop-­‐helix	  transcription	  factor	  (E	  protein)	  E2-­‐2	  is	  to	  be	  crucial	  for	   pDC	   development	   (Cisse	   et	   al.	   2008)	   (Reizis	   2010).	   Functionally,	   pDCs	   are	  specifically	  important	  against	  viral	  infection	  as	  they	  specialise	  in	  the	  production	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  Figure	  1.4	  Key	  differences	  between	  cDCs	  and	  pDC	  subsets	  cDCs	  are	  highly	  migratory	  cells	  with	  superior	  antigen	  presentation	  skills	  yet	  are	  involved	   in	  both	   tolerance	   towards	  self	  during	   the	  steady	  state	  but	  also	  during	  the	   immune	   response	   and	   therefore	   naïve	   T	   cell	   activation.	   pDCs	   in	   contrast	  circulate	  within	   the	   blood	   and	   are	   key	  mediators	   during	   an	   anti-­‐viral	   immune	  response	  due	  to	  their	  superior	  type	  I	  IFN	  production.	  Adapted	  from	  (Takeuchi	  &	  
Akira	  2009).	  	  
1.2.2 Pathogen	  recognition	  receptors	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The	  first	  step	  towards	  an	  immune	  response	  is	  the	  sensing	  of	  an	  invading	  pathogen.	   This	   is	   achieved	   by	   the	   use	   of	   germline	   encoded	   multiple	   pattern	  recognition	   receptors	   (PRRs)	  by	   innate	   immune	  cells.	  The	   four	  main	   classes	  of	  PPRs	   used	   by	   the	   innate	   immune	   system	   include:	   Toll-­‐like	   receptors	   (TLRs),	  NOD-­‐like	  receptors	  (NLRs),	  Retinoic	  acid-­‐	  inducible	  gene	  (RIG)-­‐I	  -­‐like	  receptors	  (RLRs)	  and	  C-­‐type	  lectin	  receptors	  (CLRs)	  and	  more	  recently	  identified	  cytosolic	  DNA	  sensors	  (CDSs)	  	  (extensively	  reviewed	  (Akira	  et	  al.	  2006)).	  	  	  PRRs	   are	   germline-­‐encoded	   receptors	   that	   recognise	   highly	   conserved	  pathogen	  associated	  molecular	  patterns	  (PAMPs).	   	  PRRs	  also	  have	  the	  ability	  to	  recognise	  markers	   of	   cellular	   stress	   that	   are	   released	   by	   damaged	   or	   infected	  cells,	  these	  signals	  are	  collectively	  termed	  danger	  associated	  molecular	  patterns	  (DAMPs).	   Activation	   of	   these	   receptors	   promotes	   the	   transcription	   of	  multiple	  genes	  involved	  in	  the	  inflammatory	  response;	  this	  response	  is	  specific	  depending	  on	  the	  activated	  PRRs.	  	  
1.2.2.1 Toll	  like	  receptors	  	  	   Toll-­‐like	   receptors	   (TLRs)	   are	   a	   family	   of	   PRRs	   expressed	   on	   the	   cell	  surface	   and	  within	   the	   cell	   found	   in	   endosomal	   and	   lysomal	   compartments	   of	  multiple	   cells,	   including	  macrophages	   and	  DCs	   (reviewed	   (L.	   A.	   J.	   O'Neill	   et	   al.	  2013)).	  	  TLRs	   are	   a	   type	   I	   transmembrane	   proteins	   that	   are	   conserved	   between	  humans	   and	   insects.	   TLRs	   comprise	   of	   an	   ectodomain,	  which	   contains	   leucine-­‐rich	  repeats	  allowing	  the	  recognition	  of	  PAMPs,	  a	   transmembrane	  region	  and	  a	  cytosolic	  toll-­‐1R-­‐receptor	  (TIR)	  (that	  resembles	  the	  IL-­‐1R)	  domain	  that	  facilitate	  downstream	  signalling	  cascades	  after	  TLR	  ligation.	  To	  date,	  13	  TLR	  receptors	  have	  been	  discovered	  including	  10	  (TLR1-­‐10),	  which	   are	   expressed	   in	   humans,	   and	   12	   TLRs	   in	   (TLR1-­‐9	   and	   TLR11-­‐13)	   are	  expressed	  in	  mice	  (Akira	  &	  Takeda	  2004).	  Importantly,	  TLR	  family	  members	  are	  expressed	  differently	  among	  subsets	  of	  immune	  cells.	  TLRs	  are	  also	  expressed	  on	  non-­‐immune	  cells	  including	  epithelial	  cells	  in	  the	  intestine	  and	  within	  the	  skin	  to	  maximise	   environmental	   sensing	   at	   vulnerable	   areas	  of	   the	  body.	   	   The	  various	  receptors,	  their	  specific	  ligands	  and	  their	  location	  are	  described	  in	  Table	  1.1.	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TLR2	   resides	   on	   the	   plasma	  membrane	   and	   recognises	   lipid-­‐containing	  PAMPS	   including	   lipoteichoic	   acid	   and	   di	   and	   tri-­‐acylated	   lipopeptides.	   TLR2	  achieves	  this	  by	  forming	  a	  dimeric	  complexes	  with	  another	  chain	  of	  TLR2	  former	  a	  homodimer	  or	  by	  dimerising	  with	  	  TLR1	  or	  TLR6	  to	  form	  heterodimers	  (M.	  S.	  Jin	  et	  al.	  2007)	  (J.	  Y.	  Kang	  et	  al.	  2009).	  TLR4	  does	  this	  in	  combination	  with	  MD2	  and	  CD14	  (H.	  M.	  Kim	  et	  al.	  2007)	  (B.	  S.	  Park	  et	  al.	  2009a).	  TLR4	  was	  the	  first	  TLR	  to	   be	   discovered	   binds	   lipopolysaccharide	   (LPS),	   a	  major	   component	   of	   Gram-­‐negative	  bacteria	  cell	  wall	   that	  causes	  endotoxin	  shock	   largely	  mediated	  by	  the	  release	   of	   TNFα	   and	   IFNγ	   by	   activated	  macrophages	   (Sparwasser	   et	   al.	   1997).	  Mice	   deficient	   in	   TLR4	   are	   hyposensitive	   to	   LPS	   (Hoshino	   et	   al.	   1999).	   TLR5	  recognises	   flagellin	   found	  on	  flagellated	  bacteria	  (F.	  Hayashi	  et	  al.	  2001)	  and	   is	  highly	  expressed	  within	   the	  gut	   including	  DCs	  within	   the	   lamina	  propria	  of	   the	  small	  intestine	  (Uematsu	  &	  Akira	  2009).	  	  TLR3,	   7,8	   and	   9	   recognise	   viral	   nucleic	   acids	   and	   are	   expressed	  within	  endosomal	   membrane.	   The	   intracellular	   localisation	   of	   these	   TLRs	   allows	   the	  immune	   system	   to	   sense	   non-­‐self	   nucleic	   acids	   that	   are	   produced	   during	   viral	  replication	  after	  a	  virus	  infects	  a	  cell.	  The	  activation	  of	  TLR3,	  7,8	  and	  9	  leads	  to	  the	   induction	   of	   signalling	   	   pathways	   to	   produce	   type	   I	   IFN,	   that	   mediates	  antiviral	   responses	   (Uematsu	   &	   Akira	   2007)	   (González-­‐Navajas	   et	   al.	   2012).	  TLR3	   is	   located	   within	   cell	   endosomes	   and	   recognises	   double	   stranded	   RNA	  (dsRNA)	   produced	   by	   viruses	   during	   replication	   (Alexopoulou	   et	   al.	   2001)	  (Weber	  et	  al.	  2006)	  (Leonard	  et	  al.	  2008).	  TLR7	  and	  TLR8	  recognise	  ssRNA	  and	  have	  been	  shown	  to	  recognise	  multiple	  viruses	   including	   Influenza,	  Sendai	  and	  Coxsackie	  B	  viruses	  (Lund	  et	  al.	  2004)	  (Heil	  et	  al.	  2004)	  (Diebold	  et	  al.	  2004)	  but	  also	  recognise	  bacteria	   including	  Group	  B	  Streptococcus	  (Mancuso	  et	  al.	  2009).	  TLR9	  recognises	  unmethylated	  CpG	  DNA	  motifs	   found	   in	  bacterial	   and	  viruses,	  and	  induces	  pleiotropic	  immune	  responses	  that	  are	  cell	  type	  specific	  (Hemmi	  et	  al.	  2000)	  (Kumagai	  et	  al.	  2008).	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TLR	   Specific	  ligands	   Location	  TLR1:2	  heterodimer	   Multiple	  triacylated	  lipoproteins	  (Gram-­‐	  bacteria)	  
Plasma	  membrane	  
TLR2	   Lipopeptides	  Lipoproteins	  Gram+	  bacteria	  Lipomannans	  (Fungi	  and	  mycobacteria)	  	  
Plasma	  membrane	  
TLR2:	  TLR6	  heterodimer	   Bacterial	  diacylated	  lipoproteins	  (Gram+	  bacteria)	  
Plasma	  membrane	  
TLR3	   Double	  stranded	  RNA	  (Viruses)	   Endosome	  TLR4	   LPS,	  heat	  shock	  proteins	  fibrinogen	  	  
Plasma	  membrane	  
TLR5	   Flagellin	   Plasma	  membrane	  
TLR6	   Multiple	  diacylated	  lipopeptides	   Plasma	  membrane	  TLR7	   Single	  stranded	  RNA	  (Viruses)	   Endosome	  TLR8	   Single	  stranded	  RNA	  Poly	  T	  oligonucleotides	  (Viruses)	  
Endosome	  
TLR9	  	   Unmethylated	  CPG	  DNA	  (Bacteria	  and	  herpes	  viruses)	   Endosome	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TLR10	  (Human	  only)	   Unknown	   Plasma	  membrane	  TLR11	  (Mouse	  only)	   Profilin	  (Uropathogenic	  bacteria)	   Plasma	  membrane	  TLR12	  (Mouse	  only)	   Profilin	  (Uropathogenic	  bacteria)	   Plasma	  membrane	  TLR13	  (Mouse	  only)	   23S	  ribosomal	  RNA	  sequence	   Endosome	  Table	  1.1	  Toll	  like	  receptor	  family,	  their	  ligands	  and	  expression	  location	  
Adapted	  from	  (Takeda	  et	  al.	  2003)	  (Botos	  et	  al.	  2011)	  (Akira	  &	  Takeda	  2004)	  	  	  	  	  	  	  
1.3 	  Adaptive	  immune	  system:	  cells	  of	  the	  lymphoid	  lineage	  	   The	   adaptive	   immune	   system	   includes	  B	   cells,	   T	   cells	   and	   natural	   killer	  (NK)	   cells.	   The	   adaptive	   immune	   system	   arises	   from	   the	   lymphoid	   committed	  lineage	   within	   the	   bone	  marrow.	   B	   lymphocytes	   develop	   in	   the	   bone	  marrow	  from	   common	   lymphoid	   progenitor	   cells	   (CLPs)	   that	   are	   derived	   from	   HSCs	  (Kondo	   et	   al.	   1997)	   (Figure	   1.1).	   In	   contrast	   to	   cells	   of	   the	  myeloid	   lineage,	   T	  lymphocytes	   undergo	   development	   in	   the	   thymus	   after	   CLPs	   that	   have	  differentiated	  from	  HSCs	  have	  populated	  the	  thymus.	  During	  the	  development	  of	  B	   and	   T	   lymphocytes	   within	   the	   bone	   marrow	   and	   thymus	   respectively,	   both	  subsets	   undergo	   gene	   rearrangement	   to	   successfully	   generate	   a	   unique	   B	   cell	  receptor	  (BCR)	  and	  T	  cell	  receptor	  (TCR)	  respectively.	  After	  development,	  B	  and	  T	   lymphocytes	   migrate	   into	   the	   periphery,	   circulate	   the	   blood	   and	   enter	  peripheral	   lymphoid	   tissues	   including	   the	   lymph	   nodes,	   spleen	   and	   mucosal	  lymphoid	  tissues	  of	  the	  respiratory	  tract	  and	  the	  gastrointestinal	  tract..	  It	  should	  also	   be	   noted	   that	   natural	   killer	   cells	   (NK	   cells)	   also	   arise	   from	   the	   lymphoid	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lineage,	  another	  type	  of	  cytotoxic	  lymphocyte	  that	  are	  required	  during	  microbial	  infection	  and	  the	  control	  of	  several	  types	  of	  tumors	  (Vivier	  et	  al.	  2008).	  	  Importantly,	   the	   adaptive	   immune	   system	   is	   heavily	   dependent	   upon	  innate	   immune	   cell	   instruction	   to	   orchestrate	   and	   regulate	   responses.	   Upon	  successful	   activation	   of	   the	   adaptive	   immune	   system,	   activated	   adaptive	  lymphocytes	   will	   feedback	   to	   amplify	   and	   regulate	   innate	   immune	   responses	  creating	  a	  very	  effective	  and	  elegant	  system.	  	  
1.3.1 B	  lymphocytes	  	   B	   lymphocytes	   have	   three	   principle	   functions	   which	   are:	   to	   produce	  specific	  antibodies	  to	  antigens	  that	  are	  present	  on	  pathogens,	  to	  perform	  the	  role	  of	  antigen	  presentation	  and	  to	  form	  immunological	  memory	  in	  the	  form	  of	  long	  lived	  memory	  B	  lymphocytes.	  	  Within	  development	  within	   the	  bone	  marrow,	  B	   lymphocytes	  undergo	  a	  complex	  progression	  of	  differentiation	  and	  maturation	   to	  generate	  a	   functional	  and	  specific	  BCR	  that	  is	  specific	  to	  one	  antigen.	  This	  process	  is	  tightly	  regulated	  and	  failure	  to	  produce	  a	  functional	  BCR	  will	  result	  in	  a	  form	  of	  programmed	  cell	  death	  known	  as	  apoptosis	  (reviewed	  (Cooper	  2015)).	  	  It	  is	  also	  essential	  that	  the	  BCR	  does	  not	  recognise	  self-­‐antigens	  or	  is	  auto-­‐reactive.	  	  After	  successful	  maturation	  B	  cells	   leave	  the	  bone	  marrow	  and	  populate	  various	   lymphoid	   tissues	   throughout	   the	   body.	   Upon	   recognition	   of	   a	   B	   cells	  cognate	  antigen	  they	  become	  activated	  and	  undergo	  proliferation.	  The	  activation	  of	   B	   cell	   results	   in	   processes	   such	   as	   somatic	   hyper-­‐mutation	   (SHM)	   and	  antibody	  class	  switching	  whereby	  B	  cells	  can	  heighten	  their	  specificity	  or	  avidity	  for	  their	  specific	  antigen.	  Activated	  B	  cells	  can	  also	  become	  plasma	  cells,	  which	  are	  able	  to	  release	  large	  amounts	  of	  antibodies	  during	  an	  immune	  response;	  this	  typically	   takes	   place	   in	   germinal	   centers	   within	   lymphoid	   tissues	   (De	   Silva	   &	  Klein	   2015).	   Follicular	   helper	   T	   cells	   assist	   this	   process	   by	   providing	   specific	  cytokines	  that	  can	  also	  shape	  the	   immune	  response	  depending	  on	  the	   invading	  pathogen	   (Breitfeld	   et	   al.	   2000)	   (reviewed(Crotty	   2011)).	   Within	   germinal	  centers,	  B	   cells	   typically	  undergo	  multiple	   rounds	  of	  proliferation	  and	  antigen-­‐affinity	   driven	   selection	   (Shlomchik	   &	  Weisel	   2012).	   Activated	   B	   cells	   release	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antibodies,	  which	  are	  secretory	  form	  of	  the	  BCR.	  These	  antibodies	  are	  therefore	  antigen-­‐specific,	  although	   isotypes	  may	  be	  different	   if	   the	  B	  cell	  has	  undergone	  class	  switching.	  A	  mature	  naïve	  B	  cell	  expresses	  immunoglobulin	  M	  (IgM)	  as	  the	  BCR,	  but	   four	  additional	   isotypes	  of	  antibody	  exist	  which	   include:	   IgG,	   IgA,	   IgD,	  and	  IgE,	  all	  of	  which	  have	  distinct	  functions.	  After	  an	  infection	  is	  eliminated	  a	  subset	  of	  B	  cells	  can	  become	  long-­‐lived	  memory	   B	   cells	   that	   provide	   humoural	   immunity	   to	   pathogens	   in	   the	   future.	  These	   memory	   B	   cells	   require	   less	   help	   to	   instigate	   the	   initial	   response	   to	   a	  known	   infection,	   and	   for	   this	   reason	   are	   extremely	   efficient	   at	   clearing	   a	  pathogen	  before	  it	  can	  establish	  an	  active	  infection	  (reviewed	  (Tarlinton	  &	  Good-­‐Jacobson	  2013)).	  	  	  
1.3.2 T	  lymphocyte	  subsets	  and	  differentiation	  	   T	   lymphocytes	   undergo	   development	   within	   the	   thymus	   where	   T	   cells	  will	  generate	  a	  functional	  TCR	  ((Koch	  &	  Radtke	  2011)).	  The	  TCR	  is	  composed	  of	  a	   heterodimers,	   approximately	   95%	   of	   T	   cells	   express	   the	   αβ	   chains	   and	   5%	  express	   a	   γδ	   chain,	   however	   this	   percentage	   is	   highly	   disposed	   to	   change	  depending	   on	   anatomical	   location,	   infection	   and	   indeed	   during	   disease.	  	  Expression	  of	  these	  two	  distinct	  TCR	  defines	  the	  two	  divergent	  lineages	  of	  T	  cells	  that	  perform	  distinct	   roles	  within	   the	   immune	  system	  and	  within	  homeostasis.	  	  The	  TCRαβ+	  subsets	  primarily	  reside	  in	  peripheral	  lymphoid	  organs	  such	  as	  the	  spleen	   and	   lymph	   nodes.	   In	   contrast,	   the	   TCRγδ+	   T	   cells	   are	   most	   prominent	  within	   the	   epithelial	   layers	   such	   as	   the	   skin,	   lung	   and	   intestinal	   epithelium	  (Girardi	   2006).	   	   TCRγδ	   T	   cells	   display	   a	   much	   more	   limited	   diversity	   of	   TCR	  when	   compared	   to	  TCRαβ+	  T	   cells,	   this	   is	   thought	   to	   account	   for	   the	   ability	  of	  TCRγδ+	   T	   cells	   to	   respond	   to	   conserved	   ligands	   expressed	   by	   pathogens	   and	  stressed	   cells	   in	   sites	  within	   the	   body	   that	   are	   highly	   susceptible	   to	   infection,	  such	  as	  mucosal	  linings	  (Xiong	  &	  Raulet	  2007).	  	  Additionally,	  T	  lymphocytes	  will	  also	  express	  one	  of	  the	  MHC	  co-­‐receptors	  CD4	   or	   CD8	   thereby	   creating	   two	   functionally	   distinct	   groups	   termed	   CD4+	   T	  
	  	  
17	  
cells	  and	  CD8+	  T	  cells	  (Koch	  &	  Radtke	  2011).	  CD4+	  T	  cells	  and	  CD8+	  T	  cells	  are	  restricted	  to	  antigen	  recognition	  via	  MHC	  class	  II	  and	  MHC	  class	  I	  respectively.	  	  	  T	   cells	   that	   develop	   successfully	   migrate	   from	   the	   thymus	   to	   populate	  secondary	   lymphoid	   tissues	   and	   perform	   distinct	   roles	   within	   the	   immune	  system.	  	  	  Resting	  naïve	  CD8+	  T	  cells,	  also	  known	  as	  cytotoxic	  T	  lymphocytes	  (CTLs)	  are	  characterised	  by	  their	  ability	  to	  sense	  and	  react	  to	  pathogens	  by	  substantial	  expansion	   and	   differentiation	   into	   cytotoxic	   effector	   cells	   ((N.	   Zhang	   &	   Bevan	  2011)).	  CTLs	   recognise	  antigen	  displayed	  on	  MHC	  class	   I	  molecules,	  most	   cells	  within	  the	  body	  express	  MHC	  class	  I	  to	  display	  intracellular	  contents.	  This	  allows	  CTLs	   to	   scan	   cells	   for	   the	   presence	   of	   foreign	   peptides	   on	   the	   cell	   surface	  indicating	   that	   a	   cell	   is	   infected,	   particularly	   in	   the	   case	   of	   viral	   infection.	  	  Activated	  CTLs	   can	  kill	   target	   cells	   through	  enzymatic	  means	  by	   the	   release	  of	  perforin,	   a	   cytolytic	   protein	   that	   forms	   pores	   in	   the	   target	   cell	   membrane	  (Russell	  &	  T.	  J.	  Ley	  2002)	  (Catalfamo	  &	  Henkart	  2003).	  	  Naïve	   CD4+	   T	   cells	   that	   experience	   their	   cognate	   antigen	   and	   become	  activated	  and	  instructed	  by	  cytokines	  from	  APCs	  include	  subsets	  called	  T	  helper	  cells	   (Th)	  which	   includes	  multiple	   subgroups	   including;	  Th1,	  Th2,	  Th17,	   and	  T	  regulatory	  T	   cells	   (Treg)	   (Zhu	   et	   al.	   2010).	   The	   specific	   cytokines	   that	   instruct	  the	   differentiation	   of	   each	   subset	   and	   the	   identification	   of	   distinct	   CD4+	   Th	  subsets	  by	  transcription	  factors	  are	  detailed	  in	  Figure	  1.5.	  	  Th1	   cells	   are	   particular	   effective	   in	   cell-­‐mediated	   immune	   response	  against	   intracellular	   pathogens,	   the	   most	   characterised	   of	   which	   is	   the	  requirement	   for	   Th1	   cells	   for	   protection	   against	   Mycobacterium	   tuberculosis	  (Flynn	   et	   al.	   1993).	  Naïve	   CD4+	  T	   cells	   are	   promoted	   to	   differentiate	   into	   Th1	  cells	  by	  the	  production	  of	  interleukin	  (IL)-­‐12	  (Hsieh	  et	  al.	  1997)	  and	  express	  the	  transcription	   factor	   T-­‐bet	   (Szabo	   et	   al.	   2000).	   Characteristically,	   Th1	   cells	  produce	  high	   levels	  of	   interferon-­‐gamma	  (IFNγ)	   (Wenner	  et	   al.	   1996)	  which	   is	  known	  to	  activate	  macrophages	  during	  an	  immune	  response	  (Mosser	  2003).	  	  	  IL-­‐4	   promotes	   the	   differentiation	   of	   Th2	   cells	   from	   naïve	   CD4+	   T	   cells	  (Swain	   et	   al.	   1990).	   The	   Th2	   subset	   is	   defined	   by	   the	   presence	   of	   the	   GATA3	  transcription	  factor	  (W.	  Zheng	  &	  Flavell	  1997)	  and	  characteristically	  produce	  IL-­‐4,	  IL-­‐3	  and	  IL-­‐15	  Th2	  cells	  have	  been	  well	  documented	  to	  be	  extremely	  effective	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at	   clearing	   parasitic	   pathogens,	   mainly	   through	   the	   ability	   of	   IL-­‐3	   and	   IL-­‐15	  cytokines	   to	  activate	  mast	   cells	  and	  promote	  degranulation	   (Shelburne	  &	  Ryan	  2001).	  	  Th17	   cells	   are	   defined	   by	   the	   production	   of	   IL-­‐17	   and	   presence	   of	   the	  retinoic-­‐acid	  receptor-­‐related	  orphan	  receptor	  gamma	  T	  (RORγT)	  transcription	  factor	   (Korn	   et	   al.	   2009).	   Th17	   cells	   have	   been	   implicated	   in	   a	   variety	   of	  inflammatory	   diseases	   due	   to	   their	   ability	   to	   cause	   tissue	   damage	   by	   pro-­‐inflammatory	  nature	  of	  IL-­‐17	  	  (Langrish	  et	  al.	  2005).	  	  Naïve	  CD4+	  T	  cells	  under	  instruction	  of	  anti-­‐inflammatory	  cytokines	  such	  as	  TGF-­‐β	   can	  differentiate	   into	   a	   regulatory	  T	   cell	   (Treg)	   subset;	   this	   subset	   is	  discussed	  in	  depth	  in	  the	  following	  section.	  	  Finally,	   naïve	   CD4+	   T	   cells	   under	   the	   instruction	   of	   IL-­‐21	   and	   IL-­‐6	   can	  differentiate	   into	  a	   follicular	  helper	  T	   cell	   subset	   (Tfh)	   (Vogelzang	  et	   al.	  2008),	  which	   as	   mentioned	   function	   to	   provide	   B	   cell	   help	   within	   germinal	   centers	  during	   an	   immune	   response	   and	   facilitate	   the	   development	   of	   memory	   B	   cell	  populations.	  	  	  	  
	  Figure	  1.5	  CD4	  T	  cell	  differentiation	  into	  distinct	  T	  helper	  subsets	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Naïve	   CD4+	   T	   cells	   undergo	   proliferation	   and	   differentiation	   following	   a	  resulting	   immune	   response	   to	   pathogens	   or	   during	   normal	   immune	   cell	  homeostasis	   in	   the	  case	  of	  Treg	  subsets.	  Subset	  differentiation	   is	  dependent	  on	  specific	   cytokines	   received	   during	   T	   cell	   activation	   by	   APCs.	   Th	   subsets	   are	  defined	   by	   present	   of	   specific	   transcription	   factors	   and	   production	   of	  characteristic	  cytokines	  and	  ultimately	  their	  specific	  function	  within	  the	  immune	  system	  and	  within	  an	  immune	  response.	  Adapted	  from	  (Wan	  2010)	  	   The	  existence	  of	  multiple	  helper	  T	  cell	  subsets	  allows	  the	  immune	  system	  the	   flexibility	   to	   tailor	   an	   immune	   response	   according	   to	   the	   type	   of	   pathogen	  that	  encountered	  or	  indeed	  during	  normal	  immune	  homeostasis.	  	  	  
1.3.2.1 Regulatory	  T	  cells	  (Tregs)	  	  	   This	   thesis	   has	   a	   particular	   focus	   on	   Treg	   cells	   and	   therefore	   a	   more	  detailed	  description	  of	  this	  CD4+	  regulatory	  T	  cell	  subset	  is	  required.	  An	   immune	   response	   involving	   the	   adaptive	   immune	   system	   is	   very	  potent	  and	  within	  a	  healthy	  individual	  these	  responses	  must	  be	  tightly	  regulated.	  In	   order	   to	   provide	   balance	   suppressive	   regulatory	   CD4+CD25+	   Tregs	   exist	  	  (reviewed	  extensively	  (Rudensky	  2011)	  (Josefowicz	  et	  al.	  2012)).	  	  The	  presence	  of	   a	   regulatory	   T	   cell	   subset	   capable	   of	   suppression	  was	   first	   noted	   in	   studies	  observing	   protection	   from	   inflammatory	   lesions	   in	   mice	   receiving	   CD4+CD25	  (IL-­‐2Rα)	   +	   T	   cells	   after	   thymectomy	   (Asano	   et	   al.	   1996).	   	   These	   findings	  promoted	  further	  exploration	  to	  define	  the	  development	  and	  function	  of	  Tregs,	  leading	  to	  the	  discovery	  of	  the	  transcription	  factor	  forkhead	  box	  P3	  (FoxP3),	  as	  a	  master	  regulator	  of	  both	  the	  development	  and	  function	  of	  Tregs	  (Fontenot	  et	  al.	  2003).	   	   The	   significance	   of	   the	   Foxp3	   transcription	   factor	   is	   highlighted	   in	  studies	  whereby	  loss	  of	  function	  mutations	  within	  FoxP3	  result	  in	  severe	  multi-­‐organ	   autoimmune	   and	   inflammatory	   disorder	   (IPEX)	   and	   a	   similar	   disease	   in	  the	   transgenic	  mouse	   strain	  scurfy	  (Brunkow	  et	  al.	  2001)	   (Bennett	  et	   al.	  2001)	  (Wildin	  et	  al.	  2001).	  Additional	  studies	  have	  also	  shown	  that	   loss	  of	  FoxP3	  and	  resulting	  pathologies	  are	  caused	  by	  the	  lack	  of	  regulation	  of	  CD4+	  T	  cells	  within	  
scurfy	   mice	   (Blair	   et	   al.	   1994),	   further	   emphasising	   the	   indispensible	  requirement	  for	  Tregs	  in	  the	  normal	  regulation	  and	  homeostasis	  of	  the	  immune	  system.	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  Figure	  1.6	  Generation	  of	  natural	  and	  inducible	  Tregs	  Tregs	   can	   be	   divided	   into	   two	   distinct	   subsets	   characterised	   by	   their	   site	   of	  development	  however	  both	  subsets	  arise	  from	  CD4+	  T	  cells.	  nTreg	  arise	  within	  the	   thymus	   upon	   generation	   of	   a	   self-­‐reactive	   TCR	   and	   response	   towards	   self	  antigen	   whereas	   iTreg	   are	   converted	   within	   the	   periphery	   in	   response	   to	  environmental	  cues	  such	  as	  TGF-­‐β,	   IL-­‐10	  and	  retinoic	  acid,	   commonly	   found	   in	  GALTs.	  Adapted	  from	  (Josefowicz	  et	  al.	  2012).	  	  	  	  	  	   Despite	   the	   accumulating	   knowledge	   defining	  molecular	  mechanisms	   of	  Tregs	   development	   and	   their	   obvious	   role	   within	   immune	   regulation,	   the	  understanding	  of	  molecular	  mechanism	  of	  suppression	  by	  Tregs	   is	  still	   limited.	  Evidence	   largely	   from	   in	   vitro	   studies	   have	   indicated	   multiple	   mechanism	   of	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  Figure	  1.7	  Mechanisms	  of	  suppressive	  functions	  by	  Tregs	  CD4+	  FoxP3+	  Tregs	  regulate	  the	  immune	  response	  and	  maintain	  homeostasis	  via	  multiple	  mechanisms.	   Including;	   cell	   contact	  mediated	  cell	  death	  performed	  by	  the	  release	  of	  granzyme	  B,	  out	  competing	  other	  T	  lymphocytes	  via	  sequestering	  available	  IL-­‐2,	  CTLA-­‐4	  mediated	  down-­‐regulation	  of	  co-­‐stimulatory	  molecules	  on	  APCs	  but	  also	  by	  delivering	  an	  inhibitory	  signal	  via	  CD28	  expressed	  on	  CD4+	  T	  lymphocytes	   and	   finally	   the	   production	   of	   potent	   anti-­‐inflammatory	  mediators	  such	  as	  IL-­‐10	  and	  TGF-­‐β.	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   Memory	  Treg	  subsets	  have	  also	  been	  shown	  to	  exists	   in	  mice	  with	   their	  identification	   largely	   based	   on	   the	   expression	   of	   the	   αEβ7	  integrin	   (CD103)	   on	  CD4+	  FoxP3+	  populations	  (Huehn	  et	  al.	  2004).	  CD103	  is	  most	  commonly	  found	  on	  intraepithelial	  lymphocytes	  within	  mucosal	  linings	  such	  as	  the	  intestinal	  tract	  and	   the	   lung,	   in	   this	   context	   TGF-­‐β	   has	   been	   shown	   to	   be	   essential	   for	   the	  upregulation	   of	   CD103	   in	   this	   population	   (R.	   Suzuki	   et	   al.	   2002).	   	   In	   non	  lymphocyte	  cells,	  CD103	  as	  also	  been	  shown	  to	   identify	  an	   important	  subset	  of	  tolergenic	  DCs	  within	  the	  gastrointestinal	   lymphoid	  associated	  tissues	  (GALTs),	  most	  known	  for	  their	  ability	  to	  promote	  the	  development	  of	  Tregs	  within	  these	  tissues	   discussed	   in	   detail	   later	   in	   this	   chapter.	   Growing	   evidence	   support	   the	  use	  of	  CD103+	  as	  a	  excellent	  marker	  for	  activated	  memory	  like	  Tregs	  that	  have	  undergone	   rounds	   of	   proliferation	   after	   activation	   by	   antigen	   in	   a	   specific	  context	   and	   have	   heightened	   suppressive	   function	   when	   compared	   to	   CD103-­‐	  Tregs	  (Lehmann	  et	  al.	  2002)	  (Huehn	  et	  al.	  2004)	  (Suffia	  et	  al.	  2005)	  (Banz	  et	  al.	  2003)	  (McHugh	  et	  al.	  2002)	  {Siewert:2007hz}.	  	  Furthermore,	  these	  studies	  have	  lead	  to	  CD103+	  Tregs	  being	  proposed	  as	  inflammation	  seeking	  Tregs	  due	  to	  the	  high	   surface	   expression	   of	   inflammatory	   chemokine	   receptors	   including	   CCR5	  (D.	   Zhao	   et	   al.	   2008),	   which	   is	   known	   to	   be	   required	   for	   the	   migration	   of	   T	  lymphocytes	  into	  inflamed	  tissues	  	  (Huffnagle	  et	  al.	  1999)	  (Murai	  et	  al.	  1999).	  	  	  
1.4 	  Intestinal	  immune	  system	  	  	   This	  thesis	  has	  a	  particular	  focus	  on	  immune	  cells	  residing	  in	  the	  gut	  and	  intestinal	   inflammation	   therefore	   an	   introduction	   on	   the	   specific	   details	   of	   the	  intestinal	  (also	  known	  as	  mucosal)	  immune	  system	  is	  required.	  The	   immune	  system	  can	  be	  generally	  divided	   into	  two	  separate	  entities:	  the	   central	   immune	   system,	   which	   includes	   primary	   and	   secondary	   lymphoid	  sites	   such	   as	   the	   thymus	   and	   spleen	   respectively,	   and	   the	   mucosal	   immune	  system,	  which	  includes	  the	  airways,	  the	  intestines	  and	  urogenital	  tract	  which	  are	  vulnerable	   sites	   for	   entry	   of	   pathogens	   due	   to	   their	   proximity	   to	   the	   external	  environment.	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The	  intestine	  represents	  the	  largest	  compartment	  of	  the	  immune	  system	  containing	  the	   largest	  number	  of	   immune	  cells	   found	  in	  any	  tissue	  of	   the	  body.	  The	  intestine	  plays	  the	  essential	  role	  in	  the	  uptake	  of	  nutrient	  and	  fluid	  yet	  at	  the	  same	   time	   must	   maintain	   the	   protective	   barrier	   to	   avoid	   infection.	   For	   this	  reason	   the	   intestinal	   immune	   system	   has	   evolved	   intricate	   mechanisms	   to	  distinguish	   between	   harmful	   pathogens,	   food	   antigens	   and	   natural	   commensal	  bacteria	  (also	  known	  as	  gut	  microbiota).	  As	  the	  centralised	  and	  mucosal	  immune	  systems	  are	  therefore	  faced	  with	  different	  challenges	  they	  as	  a	  result	  have	  very	  distinct	   characteristics.	   For	   example,	   in	   contrast	   to	   the	   centralised	   immune	  system,	   the	   intestinal	   immune	   system	   is	   a	   highly	   tolergenic	   environment	  with	  vast	  amounts	  of	  anti-­‐inflammatory	  cytokines	  present	  including	  IL-­‐10	  and	  TGF-­‐β.	  	  	  The	   mucosal	   immune	   system	   within	   the	   intestine	   consists	   of	   two	  anatomically	  distinct	  sites	   including:	  organised	  structures	  of	   the	  gut-­‐associated	  lymphoid	  structures	  (GALT)	  including	  the	  Peyers	  patches	  found	  in	  the	  wall	  of	  the	  small	  intestine,	  and	  conversely	  effector	  sites	  directly	  within	  the	  epithelial	  layers	  of	   the	   intestine	   including	   the	   intraepithelial	   layer	   (IEL)	   and	   lamina	   propria,	  which	   contain	   distinct	   subsets	   of	   immune	   cells	   (reviewed	   (Mowat	   &	   Agace	  2014)).	  	  	  	  
1.4.1 Gut	  associated	  lymphoid	  tissue	  (GALT)	  	   As	   mentioned,	   the	   GALTs	   are	   localised	   lymphoid	   structures	   within	   the	  small	   intestine	   the	   most	   studied	   of	   which	   includes	   the	   Peyers	   patches	   (PPs)	  found	  within	  but	  also	  the	  draining	  lymph	  nodes	  of	  the	  intestinal	  tract	  including	  the	   mesenteric	   lymph	   node	   (mLN).	   These	   locations	   are	   principle	   sites	   for	  priming	  adaptive	  immune	  responses	  within	  the	  intestine.	  	  The	  main	  draining	  lymph	  node	  for	  the	  GALT	  is	  the	  mLN,	  which	  is	  located	  alongside	  the	  anterior	  mesenteric	  artery	  within	  the	  mesentery.	  In	  mice,	  the	  mLN	  is	   usually	   made	   up	   of	   4-­‐5	   connecting	   lymph	   nodes	   with	   organized	   lymphoid	  structure	   including	  T	  cell	  and	  B	  cell	  zones.	  Lymph	  fluid	  drained	   from	  the	  small	  intestine	   and	   upper	   colon	   are	   brought	   to	   the	   mLN	   via	   the	   lymphatics.	   The	  importance	   of	   the	  mLN	   in	   governing	   oral	   tolerance	   to	   both	   food	   antigens	   and	  commensal	   bacteria	   has	   been	   demonstrated	   by	   in	   vivo	   studies	   in	   which	   mice	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  Figure	   1.8	   Antigen	   recognition	   in	   gut	   associated	   lymphoid	   tissues	   within	   the	  small	  intestine	  	  
Three	   major	   routes	   of	   antigen	   acquisition	   and	   recognition	   occur	   within	   the	   small	  
intestine.	  (A)	  Enteric	  antigen	  is	  brought	  into	  the	  intestine	  after	  digestion	  of	  food	  and	  
fluid	  by	  the	  stomach.	  M	  cells	  that	  are	  specialized	  for	  the	  uptake	  of	  antigen	  from	  the	  
lumen	   of	   the	   intestine	   and	   are	   found	   strategically	   placed	   in	   the	   follicle-­‐associated	  
epithelium	  (FAE)	  of	  the	  PPs.	  Acquired	  antigen	  is	  transported	  via	  M	  cells	  to	  a	  DC	  rich	  
sub	   epithelial	   dome	   (SED)	   where	   DCs	   can	   promote	   tolerance	   or	   activate	   T	   cells.	  
Activated	  T	  cells	  can	  then	  provide	  B	  cell	  help	  to	  promote	  the	  production	  of	  IgA	  from	  
plasma	   cells.	   	   Activated	   T	   cells	   may	   also	   travel	   from	   the	   PP	   to	   the	   mLN	   via	   the	  
afferent	  lymphatics	  to	  further	  promote	  immune	  responses.	  (B)	  Specialized	  intestinal	  
DCs	   populating	   the	   lamina	   propria	   extend	   dendrites	   through	   spaces	   between	   the	  
epithelial	  layer	  to	  constantly	  sample	  antigen.	  After	  phagocytosis	  antigen-­‐loaded	  DCs	  
travel	   via	   the	   afferent	   lymphatics	   to	   the	   mesenteric	   lymph	   node	   to	   stimulate	   an	  
adaptive	  immune	  response	  or	  to	  promote	  tolerance.	  (C)	  luminal	  enteric	  antigen	  from	  
the	  gut	  can	  also	  enter	  the	  intestinal	  blood	  supply	  and	  travel	  via	  the	  blood	  into	  other	  
secondary	  lymphoid	  organs	  such	  as	  the	  spleen.	  Phagocytosis	  of	  antigen	  delivered	  to	  
the	   spleen	   by	   splenic	   DCs	   may	   also	   initiate	   the	   immune	   response.	   Adapted	   from	  
(Mowat	  2003;	  Koboziev	  et	  al.	  2010)	  
1.4.2 Specialised	  cell	  subsets	  of	  the	  intestinal	  immune	  system	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The	   intestinal	   immune	   system	   within	   the	   gut	   wall	   itself	   is	   further	  compartmentalised	   into	   two	   distinct	   layers	   including	   the	   intraepithelial	   layer	  and	   the	   lamina	   propria,	   both	   of	   which	   are	   home	   to	   unique	   immune	   cell	  populations.	  	  The	   lamina	   propria,	   which	   consists	   of	   loose	   connective	   tissue,	   exists	  beneath	   the	   basolateral	   (tissue-­‐facing)	   surface	   of	   the	   gut	   epithelium.	   	  Multiple	  cells	  from	  both	  the	  innate	  and	  adaptive	  immune	  system	  are	  found	  here	  including	  specialised	  DCs,	  macrophages,	   neutrophils,	   NKT	   cells,	  mast	   cells,	   CD4+	   T	   cells,	  CD8+	  T	   cells	   and	  B	   cells.	   In	   contrast,	   the	   intraepithelial	   layer	   contains	   a	  much	  more	   homogenous	   cell	   subset	   in	   which	   the	   most	   abundant	   cell	   types	   are	  intraepithelial	  lymphocytes	  (IELs),	  of	  which	  are	  mainly	  TCRγδ+	  T	  cells.	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  Figure	  1.10	  Development	  of	  natural	  and	  induced	  IEL	  subsets	  located	  within	  the	  intraepithelial	  layer	  of	  the	  small	  intestine.	  	  	  Conventional	   selection	   within	   the	   thymus	   gives	   rise	   to	   CD4+	   TCRαβ+	   and	  CD8αβ+	   TCRαβ+	   T	   cells	   that	   are	   activated	   after	   antigen	   recognition	   by	   DCs	  within	  the	  mLNs	  and	  PPs	  and	  subsequently	  populate	  the	  intraepithelial	  layer	  as	  “induced	  IELs”.	  In	  contrast,	  alternative	  selection	  within	  the	  thymus	  of	  CD4-­‐CDαβ-­‐	  TCRαβ+	  and	  CD4-­‐	  CD8αβ-­‐	  TCRγδ+	  populate	  the	  intraepithelial	  as	  “natural	  IELs”.	  














	  TCRαβ+	  CD8αα-­‐	  TCRαβ+	  CD8αα+	  	  TCRγδ+	  CD8αα-­‐	  TCRγδ+	  CD8αα+	  	  	  
	  During	  development	  in	  thymus	  by	  self	  antigen	  
	  
Induced	  IEL	  	  
(Type	  A)	  
	  TCRαβ+	  CD4+	  CD8αα-­‐	  TCRαβ+	  CD4+	  CD8αα+	  	  TCRαβ+	  CD8αβ+	  CD8αα-­‐	  TCRαβ+	  CD8αβ+	  CD8αα+	  	  	  
	  Arise	   from	   TCRαβ+	   CD4+	   T	  naïve	   T	   cells	   or	   TCRαβ+	  CD8αβ+	  by	  antigen	  recognition	  within	  the	  periphery	  
Table	  1.2	  Characteristics	  of	  IEL	  subsets	  in	  mice	  
	   IELs	  perform	  multiple	  immunological	  functions;	  as	  they	  are	  located	  with	  the	   epithelium	   of	   the	   gut	   they	   are	   one	   of	   the	   first	   lines	   of	   defense	   against	  pathogens	   to	   provide	   immediate	   responses.	   IEL	   also	   have	   strong	   cytotoxic	  abilities	   demonstrated	   by	   the	   abundance	   of	   cytotoxic	   granules	   they	   contain	   as	  well	  as	  being	  key	  early	  produces	  of	  effector	  cytokines	  including	  IFN-­‐γ,	  IL-­‐2,	  IL-­‐17	  and	   IL-­‐4	   during	   a	   variety	   of	   viral	   and	   bacterial	   infections	   (Shires	   et	   al.	   2001;	  Chardès	   et	   al.	   1994;	   Müller	   et	   al.	   2000)	   .	   As	   IELs	   are	   antigen	   experienced	   (in	  contrast	   to	   naïve	   T	   cells)	   they	   are	   able	   to	   immediately	   perform	   these	  immunological	  functions	  thereby	  providing	  rapid	  responses.	  In	  addition	  to	  clear	  roles	   in	   the	   initiation	   of	   an	   immune	   response,	   IELs	   also	   perform	   important	  regulatory	   functions	   to	   maintain	   gut	   homeostasis	   and	   healthy	   gut	   epithelium.	  
	  	  
31	  
The	  role	  for	  γδ+	  T	  cells	  in	  promotion	  of	  gut	  homeostasis	  has	  been	  demonstrated	  whereby	   depletion	   of	   γδ+	   T	   cells	   resulting	   in	   abnormal	   gut	   morphology	   and	  reduced	  IgA	  production	  (Fujihashi	  et	  al.	  1999;	  Roberts	  et	  al.	  1996).	  	  
1.4.2.2 Immune	  cells	  within	  the	  lamina	  propria	  	  	   As	  discussed,	   in	  contrast	   to	   the	   intraepithelial	   layer	   that	   largely	  consists	  of	  T	  lymphocyte	  subsets,	  the	  lamina	  propria	  is	  populated	  by	  a	  variety	  of	  immune	  cells	   including	   specialised	   gut	   DC	   subsets,	   B	   cells,	   IgA	   producing	   plasma	   cells	  macrophages,	  as	  well	  as	  containing	  T	  lymphocyte	  subsets	  including	  TCRαβ+	  and	  TCRγδ+	   subsets	   (Figure	   1.9).	   	   	   Of	   the	   TCRαβ+	   subsets	   both	   CD4+	   and	   CD8+	  subsets	   also	   exist	  within	   the	   lamina	   propria.	   The	   CD4+	   compartment	   is	   highly	  diverse	   and	   subsets	   are	   frequently	   identified	   on	   the	   effector	   cytokines	   they	  produce	  including	  IFNγ	  producing	  Th1	  cells,	  IL-­‐17	  producing	  Th17	  cells	  and	  IL-­‐10	  producing	  FoxP3+	  Tregs	  which	  perform	  distinct	  roles	  within	  the	  intestine.	  	  	   Plasma	   cells	   within	   the	   lamina	   propria	   are	   also	   distinct,	   whilst	   most	  plasma	   cells	  within	   the	  periphery	  produce	   IgM,	  plasma	   cells	  within	   the	   lamina	  propria	  produce	  IgA	  (Brandtzaeg	  &	  Johansen	  2005).	   	  Secreted	  IgA	   is	   important	  for	   limiting	   bacterial	   association	   upon	   the	   epithelial	   cell	   surface	   thereby	  restricting	  the	  penetration	  of	  microbiota	  across	  the	  gut	  epithelium	  (K.	  Suzuki	  et	  al.	  2004).	  	  	  
1.4.3 Specialised	  DC	  subsets	  within	  the	  intestinal	  immune	  system	  	   As	   well	   as	   the	   abundance	   of	   specialised	   gut	   lymphocytes	   within	   the	  intestinal	   immune	  system,	  specialised	  DC	  subsets	  play	  an	   important	  role	   in	   the	  maintenance	   of	   tolerance	   and	   gut	   homeostasis,	   which	   have	   been	   extensively	  studied	  in	  mice	  (reviewed	  (A.	  Iwasaki	  2007).	  	  DCs	   can	   be	   found	   in	   all	   lymphoid	   tissue	   associated	   with	   the	   intestine	  including	   the	   PPs	   and	   mLN	   as	   well	   as	   being	   scattered	   throughout	   the	  subepithelial	   	   layer	   including	  the	   	   lamina	  propria	  of	   the	  small	   intestine	  and	  the	  colon	  (Mowat	  2003)	  (Chirdo	  et	  al.	  2005)	  (Wilson	  2003).	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The	   most	   frequent	   DC	   found	   within	   this	   context	   are	   CD103+	   DCs	  (reviewed	  (Scott	  et	  al.	  2011)).	  The	  CD103+	  DC	  subset	  have	  a	  multitude	  of	  unique	  characteristics,	  one	  of	  which	  is	  the	  ability	  imprint	  T	  and	  B	  cells	  to	  return	  to	  the	  lamina	   propria	   of	   the	   small	   intestine	   after	   becoming	   activated	   and	   circulating	  through	   the	   periphery.	   This	   is	   achieved	   by	   the	   expression	   of	   retinal	  dehydrogenase	   enzymes	   	   by	   CD103+	   DCs	   which	   catalyses	   retinoic	   acid	   from	  retinol	   (Vitamin	   A)	   which	   stimulates	   the	   upregulation	   of	   gut	   specific	   homing	  molecules	   including	   CCR9	   and	   α4β7	   on	   CD8+	   T	   cells	   and	   B	   cells(Johansson-­‐Lindbom	  et	  al.	  2005)	  (Johansson-­‐Lindbom	  &	  Agace	  2007).	  Additionally,	  CD103+	  DCs	  are	  most	  notorious	  for	  their	  ability	  to	  promote	  the	  differentiation	  of	  naïve	  CD4+	  T	  cells	  into	  FoxP3+	  Tregs	  via	  the	  production	  of	  multiple	   regulatory	   factors	   including	   IL-­‐10,	   TGF-­‐β	   and	   indoleamine-­‐2,	   3-­‐dioxygenase	  (IDO)	  (S.	  G.	  Kang	  et	  al.	  2007)	  (Benson	  et	  al.	  2007).	  	  	  
1.5 	  Cell	  signalling	  	  downstream	  of	  immune	  receptors	  	  	  
1.5.1 General	  principles	  of	  signalling	  	  	   Activation	   of	   receptors	   on	   the	   cell	   surface	   results	   in	   cell	   signalling	  cascades,	  this	  allows	  external	  signals	  or	  cues	  to	  be	  transmitted	  into	  the	  cell.	  One	  of	   the	  most	   common	   enzymes	   that	   potentiate	   cell-­‐signalling	   cascades	   includes	  protein	  kinases.	  	  Protein	  kinases	  are	  defined	  as	  a	  group	  of	  enzymes	  that	  have	  the	  ability	  to	  catalyse	   the	   covalent	   attachment	   of	   a	   phosphate	   group	   to	   a	   protein.	   This	  reversible	   process	   is	   termed	   phosphorylation.	   Phosphorylation	   works	   in	  multiple	  ways	  such	  as	  the	  activation,	  translocation,	  inhibition	  or	  altered	  binding	  properties,	  or	   the	  degradation	  of	   the	  altered	  protein	   (Ubersax	  &	  Ferrell	  2007).	  Protein	  kinases	  are	  categorised	   into	   two	  main	  groups	  based	  on	   the	  amino	  acid	  residues	  within	  proteins	  that	   they	  are	  able	   to	  phosphorylate	   including	  tyrosine	  kinases	  and	  serine/threonine	  kinases.	  	  To	   regulate	   or	   reverse	   phosphorylation,	   protein	   phosphatases	   exist.	   The	  process	  of	  de-­‐phosphorylation	  is	  crucial	  for	  the	  regulation	  and	  the	  attenuation	  of	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signalling	  cascades.	  The	  process	  of	  signalling	  cascades,	  phosphorylation	  and	   its	  regulation	   is	   used	   by	   many	   cellular	   systems	   to	   control	   specific	   cell	   changes	  including	  the	  activation	  of	  transcription	  factors	  and	  ultimately	  gene	  regulation	  to	  shape	  how	  a	  cell	  responds	  to	  environmental	  or	  intracellular	  cues.	  	  Human	  mutations	   and	   polymorphisms	   within	   protein	   kinases	   have	   been	  linked	  to	  multiple	  human	  diseases,	  including	  multiple	  components	  that	  belong	  to	  immune	  signalling	  networks	  	  (reviewed	  (Cohen	  2014)).	  	  
1.5.2 T	  cell	  receptor	  (TCR)	  signalling	  	  	  	   The	   structure	   of	   the	   TCR	   and	   downstream	   signalling	   events	   after	   TCR	  activation	  are	  illustrated	  in	  Figure	  1.11.	  The	  TCR	  is	  composed	  of	  the	  αβ	  heterodimer,	  which	  is	  a	  homodimer	  of	  two	  ζ	  chains	  that	  are	  linked	  by	  a	  disulphide	  bond	  and	  four	  CD3	  chains	  (CD3δ,	  CD3γ,	  and	   two	   CD3ε),	   which	   together	   forms	   the	   CD3	   complex.	   Both	   the	   CD3	   and	   ζ	  chains	   contain	   a	   signalling	   motif	   -­‐	   immunoreceptor	   tyrosine-­‐based	   activation	  motif	  (ITAM)	  within	  the	  cytoplasmic	  domain	  (Weiss	  &	  Littman	  1994).	  The	  TCR	  itself	   has	   no	   intrinsic	   enzymatic	   activity	   and	   therefore	   relies	   on	   the	   kinase	  activity	   of	   the	   SRC	   kinase	   family	   (SFKs)	   including	   lymphocyte	   specific	   protein	  tyrosine	   kinase	   (Lck)	   and	   Fyn	  which	   are	   the	   first	   kinases	   to	   be	   activated	   after	  TCR	   activation	   (Palacios	  &	  Weiss	   2004)	   (Salmond	   et	   al.	   2009).	   	   TCR	   signalling	  cascades	   are	   extensively	   reviewed	   in	   the	   following	   references	   ((Acuto	   et	   al.	  2008;	  Smith-­‐Garvin	  et	  al.	  2009)).	  	  	   The	   two	   most	   popular	   models	   of	   TCR	   triggering	   have	   been	   discussed	  recently	   (Brownlie	   &	   Zamoyska	   2013).	   Following	   TCR	   ligation	   and	   the	  interaction	  of	   CD4	  or	  CD8	  molecules	  with	  peptide-­‐MHC	   class	   II	   or	  MHC	   class	   I	  respectively,	  Lck	   is	  promptly	   recruited	   to	   the	  vicinity	  of	   the	  TCR/CD3	  complex	  and	  phosphorylates	   the	   ITAM	  motifs	   (Veillette	   et	   al.	   1988)	   (Shaw	  et	   al.	   1989).	  Activation	  of	  SFKs	  is	  performed	  by	  CD45,	  a	  tyrosine	  phosphatase.	  The	  activation	  of	   SFKs	   and	   the	   phosphorylation	   of	   ITAM	  motifs	   leads	   to	   the	   recruitment	   and	  activation	   of	   zeta	   chain	   associated	   protein	   kinase	   (ZAP70)	   (reviewed	   (Weiss	  2010)).	  After	  activation	  and	  subsequent	  conformational	  change	  ZAP70	  is	  able	  to	  phosphorylate	  multiple	  targets	  including	  the	  linker	  for	  activation	  of	  T	  cells	  (LAT)	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T"cell"regulaYon" 	  Figure	  1.11	  TCR	  signalling	  	  The	  TCRαβ	  receptor	  is	  made	  up	  of	  the	  heterodimer	  of	  TCRα	  and	  TCRβ	  subunits.	  Three	  CD3	  units	  also	  make	  up	  the	  complex	  on	  the	  cell	  surface	  to	  transmit	  signals	  into	  the	  cell	  interior.	  The	  γ,	  δ	  and	  ε	  CD3	  contain	  one	  single	  ITAM	  motif	  whereas	  the	  CD3ζ	  chains	  contain	  3	  tandem	  ITAM	  motifs.	  TCR	  activation	  via	  peptide-­‐	  MHC	  complex	   leads	   to	   the	  activation	  of	  Lck	  and	  Fyn,	  which	  associate	  with	   the	   ITAM	  motifs	  of	  the	  CD3	  complex	  and	  subsequently	  activates	  PLCγ	  and	  Ras-­‐dependent	  pathways.	  Activation	  of	  these	  downstream	  signalling	  cascades	  ultimately	  results	  in	   the	   activation	   of	   specific	   gene	   expression,	   which	   go	   on	   to	   regulate	   T	   cell	  activation	   responses.	   Adapted	   from	   (Smith-­‐Garvin	   et	   al.	   2009)	   (Brownlie	   &	  Zamoyska	  2013).	  	  	  
1.5.3 TLR	  signalling	  	  	  	   In	  contrast	  to	  B	  and	  T	  lymphocytes	  that	  express	  antigen	  specific	  receptors	  including	  the	  BCR	  and	  TCR,	  innate	  immune	  cells	  instead	  use	  conserved	  pathogen	  recognition	  receptors,	  the	  most	  characterised	  of	  which	  are	  the	  TLRs.	  	  	  The	   large	   diversity	   of	   responses	   implemented	   after	   activation	   of	   a	   set	  group	   of	   TLRs	   can	   be	   explained	   by	   the	   existence	   of	  multiple	   adaptor	   proteins	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containing	   TIR	   domains	   that	   are	   recruited	   after	   TLR	   activation	   to	   direct	   and	  propagate	   distinct	   responses.	   The	   mammalian	   TLR	   family	   contains	   5	   known	  adaptor	  proteins	  including;	  myeloid	  differentiation	  primary	  response	  protein	  88	  (MyD88),	   TIR	   domain	   containing	   adaptor-­‐inducing	   interferon-­‐β	   (TRIF),	  TIRAP/Mal	   and	   TRAM	   (extensively	   reviewed	   (L.	   A.	   J.	   O'Neill	   &	   Bowie	   2007;	  Kawai	  &	  Akira	  2010)).	  Based	  on	  this,	  TLR	  signalling	  can	  be	  broadly	  split	  into	  two	  major	  groups,	  MyD88	  dependent	  or	  TRIF	  dependent.	  All	  TLRs	  except	  TLR3	  are	  known	  to	  signal	  through	  MyD88.	  	  Additionally,	  TLR4	  is	  the	  only	  TLR	  to	  recruit	  4	  adaptor	  proteins	  and	  activate	  both	  MyD88	  and	  TRIF	  signalling	  pathways.	  	  TLRs,	  their	  adaptor	  proteins	  and	  signalling	  cascades	  are	  illustrated	  in	  Figure	  1.12.	  	  	  
1.5.4 MyD88	  dependent	  pathway	  	   MyD88	  is	  composed	  of	  a	  death	  domain	  (DD)	  in	  addition	  to	  a	  TIR	  domain	  and	  is	  essential	  for	  the	  recruitment	  to	  the	  TIR	  domain	  of	  the	  receptor.	  	  Upon	   activation	   MyD88	   recruits	   and	   interacts	   with	   IL-­‐1	   receptor	  associated	  kinase	  4	  (IRAK4),	  which	  becomes	  activated	  by	  phosphorylation	  (Lin	  et	  al.	  2011)	  (Warner	  &	  Nuñez	  2013).	  	  IRAK4	  goes	  on	  to	  recruit	  and	  activate	  other	  IRAK	  family	  members	  including	  IRAK1	  and	  IRAK2	  (Kawagoe	  et	  al.	  2008).	  	  After	   activation	   the	   IRAKs	   dissociate	   from	   MyD88	   and	   interact	   with	  TNFR-­‐associated	   factor	   6	   (TRAF6).	   TRAF6	   acts	   as	   an	   E3	   ubiquitin	   ligase	   to	  promote	  the	  formation	  of	  a	  K63-­‐linked	  polyubiquitin	  chain	  on	  TRAF6	  itself.	  This	  ubiquitination	  activates	  a	  scaffolding	  complex	  allowing	  TGF-­‐β	  activated	  kinase	  -­‐1	  (TAK1),	  TAB2	  and	  TAB2/3	  to	  come	  into	  close	  proximity	  to	  the	  IKK	  complex	  (Sato	  et	   al.	   2005)	   (Mendoza	   et	   al.	   2008).	   This	   results	   in	   the	   activation	   of	   the	   Iκκ	  complex	   which	   contains	   IKK-­‐α,	   IKK-­‐β	   and	   NF-­‐κB	   essential	   modulator	   (NEMO)	  also	  known	  as	  IKKγ	  (Kanayama	  et	  al.	  2004).	  Subsequently,	  the	  phosphorylation	  of	  IκBα	  (an	  inhibitory	  protein	  of	  NF-­‐κB)	  allows	  it	  to	  undergo	  degradation	  leading	  to	  the	  freeing	  of	  NF-­‐κB	  (Z.	  J.	  Chen	  et	  al.	  1996)	  (Vallabhapurapu	  et	  al.	  2008).	  	  NF-­‐κB	  can	  then	  translocate	  to	  the	  nucleus	  to	  promote	  gene	  transcription	   including	  induction	  of	  several	  pro-­‐inflammatory	  genes.	  	  Simultaneously,	  active	  TAK1	  can	  activate	  the	  MAPK	  pathway	  that	  results	  in	   the	  activation	  of	  AP-­‐1,	  which	   is	   crucial	   for	   the	   induction	  of	  various	   cytokine	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genes.	  TAK-­‐1	  achieves	   this	  by	  phosphorylating	  multiple	  MAP	  kinases	  which	  go	  onto	   phosphorylate	   proteins	   including	   ERK1,	   ERK2,	   p.38	   and	   c-­‐Jun	  N-­‐terminal	  kinases	  (Jnk)	  which	  is	  discussed	  later	  in	  this	  chapter.	  	  	  Distinctively,	   the	   activation	   of	   TLR7	   and	   TLR9	   led	   to	   an	   additional	  response	   in	   addition	   to	   classical	   NF-­‐κB	   induced	   cytokines	   involving	   the	  production	  of	  type	  I	  IFNs.	  This	  is	  achieved	  in	  pDCs	  by	  MyD88	  forming	  a	  complex	  with	   IRAK-­‐1,	   TRAF6,	   TRAF3,	   IKK-­‐α	   and	   interferon	   regulatory	   family	   7	   (IRF7)	  (Honda	  et	  al.	  2005).	  Phosphorylated	  IRF7	  functions	  to	  translocate	  to	  the	  nucleus	  and	  drive	  genes	  that	  control	  type	  I	  IFN	  production	  (Honda	  et	  al.	  2006).	  	  	  	  	  








	   	  Figure	  1.12	  TLRs,	  adaptor	  proteins	  and	  signalling	  cascades	  	  
TLR5.	  TLR11,	  TLR4	  and	  heterodimers	  of	  TLR2-­‐TLR1	  or	  TLR2-­‐TLR6	  bind	  their	  ligands	  on	  
the	   cell	   surface	   whereas	   TLR3,	   TLR7-­‐8	   and	   TLR9	   are	   localised	   to	   the	   endosomes	  
within	  the	  cell.	  TLR4	  localises	  at	  both	  the	  plasma	  membrane	  and	  within	  endosomes.	  
Following	  TLR	   ligation	   the	  TIR	  domains	  of	  TLRs	  engage	  with	  TIR	  domain	  containing	  
adaptor	  molecules	  MyD88,	  TIRAP/Mal,	  TRIF	  or	  TRAM.	  This	  engagement	  propagates	  
downstream	   signalling	   cascades	   that	   include	   interaction	   between	   IRAK	   family	  
members	  and	  TRAF	  leading	  to	  the	  activation	  of	  MAPKs	  p.38	  and	  Jnk	  which	  mediate	  the	  activation	   of	   specific	   transcription	   factors	   to	   drive	   gene	   transcription.	   Additionally,	  TAK1	  indirectly	  mediates	  the	  activation	  of	  Tpl2	  which	  is	  required	  for	  ERK1/2	  activation	  downstream	   of	   TLR	   ligation.	   The	   two	  main	   families	   of	   transcription	   factors	   activated	  include	   the	   NFκB	   family	   and	   IRF	   including	   IRF3	   and	   IRF7.	   But	   other	   transcription	  factors	  CREB	  and	  AP1.	  Adapted	  from	  (Liew	  et	  al.	  2005)	  














































































1.5.6 MAPK	  signalling	  	  	  	   Mitogen	  activated	  protein	  kinases	  (MAPKs)	  are	  serine/threonine	  kinases	  with	   14	   in	   total	   which	   are	   divided	   into	   7	   groups	   have	   been	   identified	   in	  mammalian	   cells	   (reviewed	   (Cargnello	   &	   Roux	   2011)).	   Conventional	   MAPKs	  include	   extracellular-­‐regulated	   kinases	   1	   and	   2	   (ERK1/2),	   c-­‐Jun	   amino	   (N)-­‐terminal	   kinases	   1/2/3	   (JNK1/2/3),	   p.38	   isoforms	   (α,	   β,	   γ	   and	   δ),	   and	   ERK5.	  Atypical	  MAPKs	  include	  ERK3/4,	  ERK7	  and	  Nemo-­‐like	  kinase	  (NLK).	  	  
1.5.6.1 PRR	  activation	  of	  MAPKs	  	  All	   PPRs	   including	   TLRs,	   CLRs,	   NLRs	   and	  RLRs	   upon	   ligation	   activate	  multiple	  downstream	  signalling	  cascades	  including	  the	  NF-­‐κB	  and	  MAPKs	  pathways,	  both	  of	  which	  are	  essential	  in	  generating	  an	  immune	  response	  (reviewed	  (Arthur	  &	  S.	  C.	  Ley	  2013)).	  	  MAPK	  signalling	  cascades	  are	  illustrated	  in	  	  Figure	  1.13.	  	  The	   activation	   of	   MAP3Ks	   by	   multiple	   stimuli,	   including	   PPR	   ligation,	  results	   in	   the	   activation	   of	   downstream	  MAP2Ks	   and	   subsequent	   activation	   of	  MAPKs.	   Activated	   MAPKs	   go	   to	   phosphorylate	   numerous	   substrates,	   which	  broadly	  include	  other	  protein	  kinases	  and	  transcription	  factors.	  ERK1,	  ERK2	  and	  p.38	  MAPKs	  activate	  activated	  protein	  kinase	  2	  (MK2),	  MK3	  and	  MK5,	  ribosomal	  S6	   kinases	   1	   (RSKs)	   including	  RSK1,	   RSK2	   and	  RSK3,	  mitogen	   stress	   activated	  kinases	   (MSKs)	   and	  MAPK	   signal	   integrating	   kinase	   (MNK)	  MNK1	   and	  MNK2.	  Jnk1,	   Jnk2	   and	   Jnk3	   activate	   c-­‐Jun	   and	   ATF1	   (Raman	   et	   al.	   2007)	   (Weston	   &	  Davis	   2007),	   finally	   ERK3	   and	   ER4	   activate	   MK5	   (Seternes	   et	   al.	   2004).	   In	  addition,	   p.38	   isoforms	   and	  ERK5	   can	   also	   activate	  myocyte	   enhancer	   factor	   2	  (MEF2)	  family	  of	  transcription	  factors	  (M.	  Zhao	  et	  al.	  1999).	  	  The	  activation	  of	  MAPK	  signalling	  cascades	  and	  their	  exact	  role	  within	  the	  immune	   system	   are	   beginning	   to	   become	   elucidate	   accumulating	   evidence	   has	  highlighted	  their	  global	  requirement	  for	  normal	  cytokine	  production	  in	  myeloid	  cells.	  Specifically,	   recent	  studies	  have	  highlighted	   the	  role	  of	  MSK1	  and	  MSK	  as	  negative	   regulators	   of	   TLR	   mediated	   proinflammatory	   cytokine	   production	  (Ananieva	   et	   al.	   2008),	   including	   the	   inhibition	   of	   prostaglandin	   production	  within	   a	   IL-­‐10	   mediated	   feedback	   loop	   after	   LPS	   stimulation	   in	   macrophages	  (MacKenzie	   et	   al.	   2013).	   RSKs	   have	   also	   been	   implicated	   in	   the	   endocytosis	   of	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TLR	  after	   receptor	   ligation	  within	  DCs	   (Zaru	  et	  al.	  2007).	  Furthermore,	  MK1/2	  are	  known	  to	  be	  required	  for	  TNFα	  production	  in	  macrophages	  (Kotlyarov	  et	  al.	  1999).	   Jnk	   isoforms	   have	   recently	   been	   implicated	   in	   the	   mediation	   of	  macrophage	  polarisation	  (Rincón	  &	  Davis	  2009).	  	  The	  MEF2	  transcription	  factor	  family	   has	   been	   implicated	   in	   multiple	   immunological	   processes	   including	  myeloid/lymphoid	   lineage	  commitment	   (Gerstein	  2009)but	  are	  also	   implicated	  in	  IL-­‐10	  cytokine	  transcription	  within	  T	  lymphocytes	  (Liopeta	  et	  al.	  2009).	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  Figure	  1.13	  Mitogen	  activated	  protein	  kinase	  signalling	  pathways	  The	  mitogen	  activated	  kinase	  (MAPK)	  pathways	  consist	  of	  a	  cascade	  comprising	  of	   3	   kinases:	   MAP3Ks	   that	   are	   activated	   by	   multiple	   stimuli,	   which	   go	   on	   to	  activate	  downstream	  MAP2Ks,	  which	  subsequently	  activate	  MAPKs.	  MAPKs	  have	  diverse	   substrates	   including	   transcription	   factors	   and	   a	   family	   of	   kinases:	  MAPKAPKs.	   Non-­‐MAPK	   targets	   such	   as	   MNK1/2	   and	   MEF2	   are	   also	   activated	  downstream	  of	  MAPK	  cascades.	  Adapted	  from	  (Arthur	  &	  S.	  C.	  Ley	  2013).	  
	  





































































dimers	  translocate	  to	  the	  nucleus	  to	  bind	  a	  variety	  of	  DNA	  sequences	  called	  κB	  sites	  to	  modulate	  gene	  expression.	  	  In	  most	  cells,	  NFκB	  complexes	  are	  in	  complex	  with	  inhibitory	  IκB	  proteins	  including	   IκBα,	   IκBβ,	   IκBε,	   IκBζ.	   When	   signalling	   pathways	   are	   activated,	  including	   downstream	   of	   TLR	   activation,	   the	   IκB	   is	   phosphorylated	   by	   IKK	  complex	   (IKKα,	   IKKβ	   and	   NEMO)	   resulting	   in	   its	   tagging	   for	   proteasomal	  degradation	   (Liu	   &	   Z.	   J.	   Chen	   2010).	   This	   releases	   NFκB	   from	   the	   inhibitory	  complex,	  allowing	  it	  to	  translocate	  to	  the	  nucleus	  where	  it	  will	  subsequently	  bind	  to	   NFκB	   target	   sequences	   within	   the	   promoter	   of	   NFκB	   genes	   (Huang	   &	  Miyamoto	  2001).	  	  NFκB	   is	   known	   to	   be	   critical	   in	  multiple	   aspects	   of	   the	   immune	   system	  including	   lymphoid	   organogenesis	   and	   lymphoid	   architecture	   for	   primary	   and	  secondary	   lymphoid	   follicle	   formation,	   lymphocyte	   development	   and	   indeed	  down	  stream	  of	  innate	  immune	  receptors	  including	  TLRs	  to	  drive	  the	  production	  of	   pro	   and	   anti-­‐inflammatory	   cytokines	   that	   go	   to	   the	   mediate	   the	   immune	  response	   (Bonizzi	   &	   Karin	   2004)	   (Hayden	   &	   Ghosh	   2011)	   (Gerondakis	   &	  Siebenlist	  2010)	  	  
1.5.6.3 Negative	  regulation	  of	  innate	  immune	  cell	  signalling	  	  	  	   During	   an	   immune	   response	   the	   immune	   system	  must	   also	   maintain	   a	  constant	   balance	   between	   activation	   and	   inhibition	   to	   prevent	   the	   over-­‐activation	  of	  an	  inflammatory	  response.	  Due	  to	  this,	  TLR	  activation	  and	  signalling	  	  cascades	  must	  be	  tightly	  regulated.	  	  	  There	  are	  multiple	  such	  negative	  regulators	  within	  the	  TLR	  and	  other	  PRR	  signalling	  	  cascades	  that	  are	  broadly	  split	  into	  two	  major	   groups;	   suppressor	   of	   cytokine	   signalling	   	   proteins	   (SOCs)	   (Yoshimura	  2012)	  and	  protein	  inhibitor	  of	  activated	  STAT	  (PIAS)	  proteins	  (Shuai	  2006).	  	  
	  
1.6 	  Protein	  kinase	  D	  (PKD)	  kinases	  	  	   Protein	   kinase	   D	   (PKD)	   enzymes	   are	   a	   family	   of	   closely	   related	  serine/threonine	  kinases,	  which	   in	  mammals	   consists	  of	   three	   isoforms:	  PKD1,	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PKD2	  and	  PKD3.	  PKD	  was	  originally	  described	  as	  a	  member	  of	   the	  PKC	   family,	  named	   PKCμ	   however	   was	   later	   discovered	   to	   have	   structural,	   enzymological	  and	   regulatory	   distinct	   processes	   from	   PKC	   family	  members	   (Johannes et al. 
1994; A. Hayashi et al. 1999).	  As	  such,	  PKD	  family	  members	  are	  classed	  within	  the	   CaMK	   protein	   kinase	   superfamily	   whereas	   PKC	   family	   members	   exist	   in	  protein	  kinase	  A,	  G	  and	  C	  (AGC	  family)	  Figure 1.14.	   Importantly,	  PKD	  does	  not	  phosphorylate	  a	  multitude	  of	  known	  PKC	  substrates	  implying	  that	  PKD	  isoforms	  have	   distinct	   substrate	   specificity	   and	   therefore	   a	   unique	   role	   from	   PKC	  isoforms.	  PKD	   is	   a	   key-­‐signalling	   component	   of	   the	   DAG	   signalling	   	   network	   in	  which	  PKD	  mediates	  signal	  transduction	  by	  DAG	  and	  PLC	  after	  activation	  by	  PKC	  mediated	  or	   atypical	  pathways	  of	  PKD	  activation	   that	   includes	  oxidative	   stress	  and	   Src	   kinases	   mediated	   activation.	   As	   such,	   PKD	   enzymes	   act	   as	   a	   point	   of	  convergence	  and	  for	  integration	  for	  multiple	  signalling	  cascades.	  	  Signalling	  via	  PKD	  is	  induced	  by	  a	  remarkable	  number	  of	  stimuli	  including	  DAG,	  phorbol	  esters,	   growth	   factors,	  GPCR	  agonists	  and	  hormones	  and	  antigen	  receptor	  stimulation	  via	  either	  the	  BCR	  and	  TCR	  within	  lymphocytes	  (Guha	  et	  al.	  2002;	  Matthews	  et	  al.	  1997;	  Rozengurt	  et	  al.	  1997;	  Zugaza	  et	  al.	  1996;	  Zugaza	  et	  al.	   1997)	   (Wong	   &	   Z.-­‐G.	   Jin	   2005).	   As	   a	   result	   of	   this,	   PKD	   enzymes	   have	  therefore	   been	   implicated	   in	   a	   vast	   array	   of	   biological	   processes	   including;	  apoptosis,	   cell	   survival,	   Golgi	   organization	   and	   plasma	   membrane	   directed	  transport,	   angiogenesis,	   cancer	   and	   immune	   cell	   responses	   (extensively	  reviewed	  (Rozengurt	  2011)	  ).	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  Figure	  1.14	  Annotation	  of	  human	  kinome	  of	  PKD	   isoforms	  within	  CAMK	  family	  and	  PKC	  isoforms	  within	  the	  AGC	  family	  of	  kinases.	  	  
Illustration	  reproduced	  courtesy	  of	  Cell	  Signalling	  Technology,	  Inc.	  	  
(www.cellsignal.com)	  	  
1.6.1 Isoforms	  and	  conservation	  of	  PKD	  family	  	   In	   mammals	   3	   PKD	   isoforms	   exist,	   of	   which,	   the	   first	   member,	   PKD1	  discovered	   in	   human	   and	   mouse	   in	   1994	   (Johannes	   et	   al.	   1994),	   followed	   by	  PKD3	  in	  1994	  (Valverde,	  Sinnett-­‐Smith,	  et	  al.	  1994a)	   	  and	  finally	  PKD2	  in	  2001	  (A.	  Hayashi	  et	  al.	  1999).	  In	  contrast	  to	  mammals,	  in	  the	  nematode	  Caenorhabditis	  
elegans	  (C.	  elegans)	  there	  are	  two	  PKD	  homologues	  including	  DKF-­‐1	  and	  DKF-­‐2	  (Feng	   et	   al.	   2007;	   Feng,	   Ren	   &	   Rubin	   2006a;	   Feng,	   Ren,	  Wu,	   et	   al.	   2006b).	   In	  
Drosophila	  melanogaster	   (D.	  Melanogaster)	  only	  one	  PKD	  homologue	  is	  present	  (Maier	  et	  al.	  2006).	  Sequence	  conservation	  from	  insect	   to	  mammal	   is	  strikingly	  similar.	  The	  conserved	  nature	  of	  the	  family	  of	  kinases	  indicates	  an	  important	  role	  for	   PKD	   isoforms	   from	   basic	   to	   complex	   cellular	   processes.	   	   The	   evolutionary	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development	  of	  human	  PKD	  isoforms	  in	  multiple	  species	  can	  be	  seen	  in	  the	  PKD	  family	  tree	  (Figure	  1.15)	  	  	   	  	  
W09C5.5 (C. elegans) 
DKF-2 (C. elegans) 
ZGC:175248 (Zebrafish) 
PKD1 (Chicken) 
PKD1 (House mouse) 
PKD1 (Norway rat) 
PKD1 (Human) 
PKD1 (Zebrafish) 
PKD2 (House mouse) 
PKD2 (Norway rat) 
PKD2 (Human) 
PKD3 (Norway rat) 




PKD (Fruit fly) 	  	  Figure	   1.15	   Family	   tree	   of	   PKD	   isoforms	   and	   their	   evolutionary	   history	   in	  multiple	  species	  Illustration	  reproduced	  courtesy	  of	  www.treefam.com.	  	  	  
1.6.2 Structure	  and	  phosphorylation	  sites	  of	  PKD	  kinases	  	   Although	   the	   three-­‐dimensional	   structure	   of	   PKD	   has	   not	   yet	   been	  resolved	  multiple	  studies	  have	  provided	  insight	  into	  defining	  structural	  features	  of	  PKD	  isoforms.	  The	  three	  mammalian	  isoforms	  of	  PKD	  share	  a	  similar	  modular	  structure	  consisting	  of	  a	  conserved	  C-­‐terminal	  kinase	  domain,	  C1a	  and	  C1b	  CRD	  domains,	  which	  are	  the	  DAG	  binding	  regions	  of	  PKD,	  and	  a	  N-­‐terminal	  regulatory	  domain	  containing	  a	  pleckstrin	  homology	  (PH)	  domain	  (Figure	  1.16).	  (A.	  Hayashi	  et	   al.	   1999)	   (Johannes	   et	   al.	   1994)	   (Valverde,	   Sinnette-­‐Smith,	   et	   al.	   1994b)	  (Sturany	  et	  al.	  2001)	  (Iglesias	  et	  al.	  1998).	  Non-­‐phosphorylated	  PKDs	  have	  little	  catalytic	  activity	  and	  must	  first	  of	  all	  become	  activated	  to	  go	  on	  to	  activate	  down-­‐stream	  substrates	  to	  perform	  its	  biological	  functions.	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  Figure	  1.16	  Structure	  of	  murine	  PKD	   isoforms,	  phosphorylation	  and	  regulatory	  sites	  and	  implicated	  functions	  Schematic	  representation	  of	  PKD	  isoforms.	  The	  catalytic	  domain	  containing	  the	  kinase	   activation	   loop	   is	   shown	   in	   green,	   PH	   domain	   is	   shown	   in	   purple,	   the	  regulatory	   PH	   domain	   is	   shown	   in	   purple	   and	   cysteine	   rich	   domains	   (CRD),	  involved	   in	   DAG	   binding,	   are	   shown	   in	   blue.	   Phosphorylation	   sites	   and	   their	  implicated	   functions	   are	   shown.	   	   Numbers	   correspond	   to	   the	   percentage	  sequence	   similarity	   to	   PKD1	   is	   depicted	   in	   each	   region	   of	   PKD2	   and	   PKD3.	  
Adapted	  from	  (Fu	  &	  Rubin	  2011)	  and	  (Rozengurt	  et	  al.	  2005).	  	  	  PKD	  kinases	  have	  three	  major	  phosphorylation	  sites	  including;	  two	  serine	  residues	  within	  the	  activation	  loop,	  a	  tyrosine	  site	  within	  the	  PH	  domain	  and	  one	  autophosphorylation	   loop	   (except	   on	   PKD3).	   The	   serine	   sites	   within	   the	  activation	  loop	  include	  Ser744	  and	  Ser748	  of	  PKD1,	  Ser706	  and	  Ser710	  in	  PKD2,	  and	  Ser730	  and	  Ser734	  on	  PKD3	  respectively.	  	  These	  serine	  residues	  are	  directly	  phosphorylated	  by	  up-­‐steam	  PKC	  isoforms.	  Within	  the	  PKD1	  and	  PKD2	  isoform	  autophosphorylation	  sites	  include	  a	  Ser916	  site	  within	  PKD1,	  which	  corresponds	  to	   Ser876	   on	   PKD2.	   Tyrosine	   residues	   within	   the	   PH	   domain	   include	   Tyr464,	  Tyr439,	  and	  Tyr457	  for	  PKD1,	  PKD2	  and	  PKD3	  respectively.	  The	  mechanisms	  of	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PKD	   activation	   have	   been	   extensively	   studied	   and	   characterised	   (reviewed	  (Rozengurt	   et	   al.	   2005)	   (Fu	  &	  Rubin	  2011)).	   	  Multiple	   studies	   established	   that	  PKD	   becomes	   activated	   through	   the	   direct	   phosphorylation	   of	   two	   conserved	  serine	   residues	  within	   the	  activation	   loop	  by	  upstream	  activated	  PKC	   isoforms	  {Waldron:2002ko}	   (Waldron	   et	   al.	   1999)	   (Zugaza	   et	   al.	   1996).	   Subsequent	  autophosphorylation	  within	  PKD1	  and	  PKD2	   isoforms	  serves	   to	  confer	   full	  and	  sustained	  activation	  (Matthews	  et	  al.	  1999)	  (Jacamo	  et	  al.	  2008)	  	  (Sinnett-­‐Smith	  et	   al.	   2009).	   Key	   autophosphorylation	   sites	  within	   PKD1/2	   isoforms	   have	   also	  been	   shown	   to	   play	   a	   role	   the	   tertiary	   structure	   of	   the	   kinase	   and	  may	   play	   a	  potential	  regulatory	  role	  for	  the	  duration	  of	  signaling	  by	  PKD	  (Rybin	  et	  al.	  2009).	  	  	  The	   PH	   domains	   are	   known	   to	   serve	   as	   an	   essential	   regulatory	   function	   as	  deletion	   results	   in	   constitutive	   activity	   (Iglesias	   &	   Rozengurt	   1998;	   Iglesias	   &	  Rozengurt	   1999).	   These	  distinct	   regions	   of	   PKD	  have	  high	   sequence	  homology	  between	  the	  3	  mammalian	  isoforms	  but	  also	  in	  other	  species.	   	  For	  example,	  the	  amino	  acid	  sequence	  homology	  of	  the	  CRD	  domains	  and	  kinase	  domains	  between	  mammalian	   and	   C.elegans	   is	   over	   70%	   identical.	   Furthermore,	   the	   key	   PKC	  phosphorylation	  sites	   located	  within	  the	  catalytic	  domain	  are	  highly	  conserved,	  as	  they	  are	  identical	  in	  C.elegans	  and	  human.	  
1.6.3 Expression	  and	  localisation	  of	  PKD	  kinases	  	  	   Expression	  studies	  assessing	  PKD	   isoform	  mRNA	  transcription	  has	  been	  performed	   using	   in-­‐situ	   hybridization	   to	   accurately	   assess	  which	   isoforms	   are	  expressed	  in	  specific	  tissues	  during	  mouse	  embryonic	  development	  (Oster	  et	  al.	  2006).	   All	   three	   PKD	   family	   members	   were	   shown	   to	   be	   expressed	   early	   in	  development	   however	   later	   embryonic	   development	   PKD	   isoform	   expression	  became	   more	   differentiated	   with	   tissue	   specific	   preferential	   expression	   of	  different	  isoforms.	  Interestingly,	  later	  in	  embryonic	  development	  (E.18.5)	  PKD2	  was	  shown	   to	  become	  preferentially	  expressed	   in	   the	   intestinal	  villi	  within	   the	  lumen	   of	   the	   intestine.	   This	   study	   demonstrates	   the	   strikingly	   different	   and	  unique	  expression	  patterns	  of	  PKD	  isoforms	  in	  certain	  tissues	  during	  embryonic	  development,	  further	  highlighting	  that	  PKD	  cellular	  and	  tissue	  localisation	  must	  play	  a	  fundamental	  part	  in	  PKD	  functional	  properties.	  In	  regard	  to	  specific	  PKD	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isoform	  expression	  within	  cells	  has	  been	  difficult	  due	  to	  lack	  of	  isoform	  specific	  antibodies,	  largely	  due	  to	  the	  high	  sequence	  similarity	  between	  the	  isoforms.	  	  In	  regard	  to	  localisation,	  PKD	  isoforms	  have	  been	  shown	  to	  undergo	  rapid	  redistribution	  upon	  stimulation.	  PKD1	  and	  PKD2	  undergo	  translocation	  from	  the	  cytosol	  to	  the	  DAG	  rich	  regions	  within	  the	  plasma	  membrane	  (Rey,	  Young,	  et	  al.	  2001b).	  Subsequently,	  PKD1/2	  isoforms	  relocate	  from	  the	  plasma	  membrane	  to	  the	  nucleus	  after	  PKC	  mediated	  activation	  (Rey,	  Sinnett-­‐Smith,	  et	  al.	  2001a).	   In	  contrast,	   PKD3	   is	   constantly	   shutting	   between	   the	   cytoplasm	   and	   the	   nucleus	  (Rey	  et	  al.	  2006).	  Additionally,	  pools	  of	  PKD	  isoforms	  have	  been	  reported	  within	  the	   Golgi	   complex	   (Yeaman	   et	   al.	   2004)	   	   (Liljedahl	   et	   al.	   2001)	   (Malhotra	   &	  Campelo	   2011)	   and	   the	   	   mitochondria	   (Cowell,	   Döppler,	   et	   al.	   2009a).	   	   The	  importance	   of	   PKD	   localisation	   has	   been	   demonstrated	   by	   studies	   that	   have	  harnessed	   alternatively	   targets	   PKD	   indicate	   that	   the	   cellular	   location	   of	   PKD	  kinases	   elicits	   different	   cellular	   responses	   in	   T	   cells	   (Spitaler,	   Emslie,	  Wood	  &	  Cantrell	  2006a).	  As	   such,	   PKD	   isoforms	   can	   regulate	   downstream	   targets	   in	   multiple	  locations	  within	  the	  cell	  and	  subsequently	  control	  a	  range	  of	  cellular	  activities.	  	  	  
1.6.4 Cell	  signal	  transduction	  pathways	  of	  PKD	  	   A	  plethora	  of	  studies	  have	  attempted	  to	  unravel	  the	  exact	  mechanism	  by	  which	  PKD	  kinases	  become	  activated,	  often	  this	  is	  dependent	  on	  specific	  cell	  type,	  isoform	  expression	  and	  abundance,	  cellular	  localisation,	  and	  the	  type	  of	  stimulus	  used.	   To	   date,	   two	   main	   mechanisms	   of	   PKD	   activation	   have	   been	   elucidated	  within	   the	   literature,	   including	   typical	   PKD	   activation	   by	   PKC	   and	   atypical	  activation	  of	  PKD	  by	  oxidative	  stress	  and	  Src	  mediated	  pathways.	  	  	  
1.6.4.1 Conventional	  PKC	  mediated	  activation	  of	  PKD	  	   Second	   messengers	   play	   a	   key	   role	   during	   the	   beginning	   of	   multiple	  signalling	  pathways	   including	  DAG,	  which	  acts	  as	   lipid	  secondary	  messenger	   in	  multiple	   cells	   (reviewed	   (Carrasco	   &	   Mérida	   2007)).	   Within	   the	   adaptive	  immune	  system	  DAG	  signalling	  has	  been	  shown	  to	  be	  an	  essential	  component	  in	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T	  cell	  development	  whereby	  mice	  lacking	  certain	  diacylglycerol	  kinases	  (DGKs)	  display	   T	   cell	   development	   defects	   (reviewed	   (Zhong	   et	   al.	   2008)).	   Several	  studies	   have	   also	   confirmed	   the	   role	   of	   DAG	   signalling	   in	   acting	   as	   a	   braking	  mechanism	  during	  immune	  cell	  responses	  where	  by	  loss	  of	  DAG	  signalling	  leads	  to	  hyper	  activation	  in	  these	  cells.	  (Zhong	  et	  al.	  2003)	  	  DAG	  regulates	  the	  activation	  of	   two	  major	  signalling	  pathways	   involving	  PKC	   family	   members	   and	   PKD.	   There	   are	   10	   PKC	   family	   members	   that	   are	  categorised	  into	  3	  groups	  based	  on	  their	  activation	  requirements;	  classical	  PKCs	  (cPKCs:	   PKCα,	   PKCβI,	   PKCβII	   and	   PKCγ),	   require	   calcium,	   diacylglycerol	   and	  phosphatidylserine,	   novel	   PKCs	   (nPKC:	   PKCδ,	   PKCε,	   PKCη	   and	   PKCθ),	   require	  diacylglycerol,	   phosphatidylserine	   but	   are	   calcium	   independent,	   and	   atypical	  PKCs	   (aPKC:	   PKCζ	   and	   PKCι),	   that	   only	   require	   phosphatidylserine	   (reviewed	  (Griner	  &	  Kazanietz	  2007)).	  DAG	  stimulated	  nPKCs	  including	  PKCδ,	  PKCε,	  PKCη	  and	  PKCθ	  are	  potent	  activators	  of	  PKD	  however	  Ca2+	  and	  DAG	  activated	  cPKCs	  have	  also	  been	  shown	  to	  activate	  PKD	  (J.	  Li	  et	  al.	  2004).	  cPKC	  isoforms	  undergo	  activation	   in	   response	   to	  Ca2+,	  DAG	  and	  phorbol	   ester,	   in	   contrast	  nPKC	  do	  not	  undergo	   activation	   in	   response	   to	   increased	   Ca2+	   	   and	   are	   only	   recruited	   and	  activated	   in	   response	   to	   DAG	   and	   phorbol	   ester	   mimics.	   Importantly,	   PKC	  isoforms	  similarly	  to	  PKD	  bind	  DAG	  via	  the	  CRD	  domains	   located	  within	  the	  N-­‐terminus	  (Steinberg	  2008)	  	  (Rozengurt	  et	  al.	  2005).	  DAG	  therefore	  also	  promotes	  the	   localisation	   and	   redistribution	   of	   PKC	   and	   PKD	   kinases	   during	   proximal	  signaling	   events.	   	   	   Phorbol	   esters	   such	   as	   phorbol	   12,13,-­‐bibutyrate	   (PDBu),	  which	  act	  as	  pharmacological	  mimetic	  of	  DAG	  are	  commonly	  used	  to	  activate	  the	  entire	  pool	  of	  available	  PKD	  within	  experimental	  studies.	  The	  activation	  of	  PKD	  by	  phorbol	  ester	  and	  DAG	  was	  first	  demonstrated	  in	  cell	  free	  stimulation	  studies	  (Van	  Lint	  et	  al.	  1995).	  Studies	  by	  Rozengurt	  and	  colleagues	   showed	   that	  PKC	  directly	   interacts	  with	   PKD	   via	   its	   PH	   domain	   and	   directly	   phosphorylates	   two	   serine	   residues	  within	  the	  activation	  loop	  of	  PKD	  (Zugaza	  et	  al.	  1996).	  	  Within	  the	  same	  studies,	  it	   was	   confirmed	   that	   PKD	   is	   activated	   downstream	   of	   PKC	   signalling	   cascade	  using	   specific	   PKC	   inhibitor	   studies	   that	   also	   potently	   blocked	   PKD	   activation	  despite	  PKC	  inhibitors	  not	  directly	  blocking	  PKD	  activity	  itself.	  	  Confirmation	  of	  a	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PKC	  mediated	   PKD	   activation	   pathway	  was	   demonstrated	   upon	   cotransfection	  studies	  utilising	  mutant	  active	  forms	  of	  novel	  PKCs.	  	  Multiple	   studies	   have	   now	   extensively	   characterised	   the	   PKC	   mediated	  activation	   of	   PKD	   signal	   transduction	   pathway.	   Ligand	   binding	   to	   several	  reported	   receptors	   including	   seven-­‐transmembrane,	   tyrosine	   kinase	   and	   G	  protein	  coupled	  receptors,	  have	  been	  shown	  to	  result	  in	  PKD	  activation.	  Ligation	  of	  these	  receptors	  results	   in	  the	  production	  of	  DAG	  after	  the	  hydrolysis	  of	  PIP2	  by	   PLC	   that	   is	   membrane	   bound.	   Due	   to	   its	   hydrophobic	   properties	   direct	  binding	   of	   PKC	   to	   DAG	   retains	   DAG	   at	   the	   cell	   membrane	   facilitating	   the	  activation	   of	   PKC,	  which	   during	   the	   accumulation	   of	  DAG	   translocate	   from	   the	  cytosol	   to	   the	   plasma	   membrane.	   This	   binding	   also	   allows	   PKC	   to	   undergo	  dramatic	  conformational	  change	  that	  releases	  the	  pseudosubstrate	  domain	  from	  the	   substrate-­‐binding	   site,	   facilitating	   substrate	   binding,	   phosphorylation	   and	  ultimately	  the	  activation	  of	  downstream	  signalling	  molecules	  (Colón-­‐González	  &	  Kazanietz	  2006).	  The	  accumulation	  of	  DAG	  at	  the	  plasma	  membrane	  also	  recruits	  PKD,	  which	  is	  then	  activated	  by	  PKC.	  	  Further	   studies	   have	   shown	   that	   prolonged	   receptor	   stimulation,	  particularly	   through	   Gq-­‐couple	   protein	   receptor	   stimulation	   by	   bombesin	   and	  vasopressin,	   results	   in	   PKD	   phosphorylation	   within	   the	   activation	   loop	   which	  becomes	  PKC	   independent	  and	   is	   then	  sustained	  by	  auto-­‐phosphorylation	   loop	  activation	  (Jacamo	  et	  al.	  2008;	  Sinnett-­‐Smith	  et	  al.	  2009).	  	  	  
1.6.4.2 Atypical	  PKD	  activation	  	  	   PKD	   has	   been	   shown	   to	   be	   a	   key	   sensor	   of	   oxidative	   stress	   by	   several	  studies.	  PKD1	  becomes	  activated	  after	  stimulation	  of	  cells	  with	  multiple	  induces	  of	   oxidative	   stress	   including	  Rotenone,	  pervanadate,	   hydrogen	  peroxide	   (H202)	  and	  diphenyleneiodonium	  (Storz	  &	  Toker	  2003)	  (Storz	  et	  al.	  2005);	  (J.	  Song	  et	  al.	  2006a)	  (Waldron	  et	  al.	  2004);	  (Cowell,	  Yan,	  et	  al.	  2009b);	  (J.	  Song	  et	  al.	  2009).	  In	  contrast	   to	   DAG	   accumulation	   and	   PKC	   mediated	   activation	   of	   PKD,	   oxidative	  stress	   within	   cells	   has	   been	   shown	   to	   result	   in	   tyrosine	   phosphorylation	   at	  tyrosine	   sites	  463	   (PKD1)	  and	   tyrosine	  694	  on	  PKD2	  within	   the	  PH	  domain	  of	  PKD.	  	  Using	  RNA	  interference	  techniques	  (RNAi)	  Storz	  and	  colleagues	  were	  first	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to	   demonstrate	   that	   knock	   down	   of	   endogenous	   PKD	   present	   in	   HeLa	   cells	  rendered	   them	   more	   sensitive	   to	   cell	   death	   after	   oxidative	   stress	   stimulating	  treatments	   (Storz	   &	   Toker	   2003).	   The	   mechanism	   by	   which	   PKD	   is	   activated	  following	  oxidative	  stress	  involves	  tyrosine	  kinases	  including	  Src	  activation	  and	  subsequent	  downstream	  Abl	  activation,	  which	  then	  directly	  phosphorylate	  PKD	  on	   tyrosine	   residues	   within	   the	   PH	   domain.	   It	   has	   been	   proposed	   that	   this	  promotes	   a	   conformation	   change	  whereby	   the	   PH	   domain	   then	   uncovers	   PKD	  activation	   loop	   facilitating	  phosphorylation	  of	   these	   sites	   to	   achieve	   full	   kinase	  activity.	  Oxidative	  stress	  however	  also	   leads	  to	   the	  activation	  of	  PKC	  mediating	  the	   phosphorylation	   of	   PKD	   on	   activation	   loop	   (Ser744/Ser748)	   and	   it	   was	  subsequently	  shown	  that	  the	  nPKC	  PKCδ	  isoform	  mediates	  this	  phosphorylation	  and	  activation	  of	  PKD	  (Storz	  et	  al.	  2004).	  	  	  In	  regard	  to	  the	  biological	  function	  of	  oxidative	  stress	  mediated	  activation	  of	  PKD	  it	  has	  also	  been	  shown	  that	  activation	  of	  PKD	  in	  this	  manner	  is	  required	  for	   subsequent	   downstream	   NFκB	   activation,	   this	   is	   specific	   to	   the	   oxidative	  stress	   pathway	   as	   it	   does	   not	   occur	   via	   bradykinin	   or	   platelet	   derived	   growth	  factor	  (PGDF)	  stimulation.	  Additionally,	  PKD	  has	  been	  shown	  to	  be	  required	  for	  the	  induction	  of	  manganese-­‐dependent	  superoxide	  dismutase	  (mSOD)	  via	  NFκB,	  elucidating	  a	  potential	  mechanism	  for	  why	  knock-­‐down	  of	  PKD	  leads	  to	  more	  cell	  death	   in	   response	   to	  oxidative	   stress	   (Storz	   et	   al.	   2005).	  Collectively,	   oxidative	  stress	  and	  Src	  mediated	  pathway	  of	  PKD	  activation	  appear	  to	  play	  an	  important	  role	   in	   the	   elicitation	   of	   signaling	   pathways	   that	   led	   to	   the	   activation	   NFκB	  mediated	  transcription	  of	  pro-­‐survival	  genes.	  However,	  the	  direct	  targets	  of	  PKD	  that	  mediates	  this	  NFκB	  response	  remain	  to	  be	  elucidated.	  	  The	   two	   major	   pathways	   of	   PKD	   activation	   are	   summarised	   in	   Figure	  1.17.	   	  	  
	  	  
53	  
	  Figure	  1.17	  Schematic	  detailing	  activation	  of	  PKD	  via	  two	  main	  pathways	  Multiple	  receptor	  ligation	  have	  been	  shown	  to	  activate	  PKD	  via	  a	  PKC	  dependent	  pathway	   including	   TCR	   and	   BCR	   after	   antigen	   recognition	   and	   GPCR	   agonists	  such	   as	   bombesin	   and	   angiotensin.	   Accumulation	   of	   DAG	   activates	   PKC,	  which	  goes	  on	  to	  phosphorylate	  and	  activate	  PKD	  isoforms	  within	  activation	  loop	  sites.	  PKC	   independent	   pathways	   include	   activation	   of	   PKD	   by	   oxidative	   stress	  pathway	  via	  Src-­‐Abl	  cascade,	  however	  phosphorylation	  of	  PKD	  in	  this	  pathway	  is	  in	  the	  form	  of	  tyrosine	  phosphorylation	  within	  the	  PH	  domain	  of	  PKD	  isoforms.	  In	  both	  instances	  this	  leads	  to	  auto-­‐phosphorylation	  in	  PKD1	  and	  PKD2	  isoforms	  and	  downstream	  substrate	  phosphorylation.	  	  	  
1.6.5 Downstream	  targets	  and	  biological	  functions	  of	  PKD	  isoforms	  	  	   Early	  studies	  investigating	  the	  role	  of	  PKD	  isoforms	  in	  cellular	  processes	  involved	   over-­‐expression	   studies,	   the	   use	   of	   dual	   PKC-­‐PKD	   pharmacological	  inhibitors	   and	   RNAi	   techniques,	   which	   were	   mainly	   performed	   in	   cell	   lines.	  Although	  these	  studies	  were	  required	  to	  ascertain	  the	  structure	  and	  mechanism	  of	  activation	  of	  PKD,	  many	  of	  the	  original	  papers	  do	  not	  clarify	  which	  isoform	  is	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being	   studied,	  making	   the	   definition	   of	   biological	   roles	   for	   specific	   isoforms	   of	  PKD	  from	  the	  early	  literature	  difficult.	  	  To	   date,	   only	   a	   number	   of	   direct	   substrates	   of	   PKD	   have	   been	  demonstrated	   (reviewed	   (Fu	   &	   Rubin	   2011)).	   These	   include	   a	   range	   of	  substrates	  that	  are	  known	  to	  play	  diverse	  biological	  functions	  from	  cell	  survival	  and	  motility	  to	  gene	  transcription	  and	  are	  summarised	  below	  in	  Table	  1.3.	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  Protein	   Function	   Reference	  Class	  IIa	  HDACs	  (4-­‐5-­‐7-­‐9)	   Transcriptional	  de-­‐repression	  14-­‐3-­‐3	  binding	   (Dequiedt	  et	  al.	  2005)	  (Vega	  et	  al.	  2004)	  (Parra	  et	  al.	  2005)	  PI4KIIIβ	   Activation	  and	  stabilisation	  via	  14-­‐3-­‐3	  binding	   {Hausser:2005bx}	  {Hausser:2006ho}	  KI220	   Undetermined	   {Iglesias:2000ke}	  HSP27	   Pro	  survival	  chaperone	  activity	   (Hutti	  et	  al.	  2004;	  Döppler	  et	  al.	  2005)	  CREB	   Transcriptional	  activation	   (Yeaman	  et	  al.	  2004)	  	  	  CERT	   Inhibition	  of	  docking	  with	  PI4P	   {Fugmann:2007et}	  SSH1L	   Disrupts	  association	  with	  F-­‐actin	  via	  14-­‐3-­‐3	  binding	   {Eiseler:2009kd}	  RIN1	   Inhibition	  of	  actin	  remodeling	  and	  cell	  motility	   {Ziegler:2011en}	  Cortractin	   Inhibition	  of	  actin	  remodeling	   {Eiseler:2010fz}	  
SNAIL	   Transcriptional	  de-­‐repression	  14-­‐3-­‐3	  binding	  Mediation	  of	  adherens-­‐junction	  formation	  	  
{Du:2010kx}	  
OSBP	   Attenuation	  OSBP	  Golgi	  localisation	  and	  promotes	  Golgi	  fragmentation	   {Nhek:2010ht}	  IFNAR1	   Phosphorylation	  within	  degron	  promotes	  degradation	  in	  CML	  cells	   (Bhattacharya	  et	  al.	  2011;	  H.	  Zheng	  et	  al.	  2011),	  Table	  1.3	  Key	  protein	  kinase	  D	  substrates	  and	  their	  functions	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The	   substrate	   requirement	   for	   PKD	   is	   dissimilar	   to	   that	   of	   PKC,	   with	   a	  high	   selectivity	   for	   leucine	   at	   the	   –5	   position	   (substrate	   consensus	  L/V/Ix(R/K)XX(S*/T*)	  (Nishikawa	  et	  al.	  1997)	  (Hutti	  et	  al.	  2004;	  Döppler	  et	  al.	  2005).	   A	   common	   feature	   amongst	   PKD	   substrates	   is	   that	   phosphorylation	   by	  PKD	  results	  in	  the	  creation	  of	  a	  14-­‐3-­‐3	  binding	  site	  which	  plays	  a	  crucial	  role	  in	  the	   translocation	   between	   cellular	   locations	   including	   the	   cytoplasm	   and	   the	  nucleus.	  	  Notably,	   PKD	   has	   been	   shown	   to	   phosphorylate	   class	   IIa	   histone	  deacetylases	  (HDACs),	  which	  includes	  HDAC4,	  HDAC5,	  HDAC7	  and	  HDAC9.	  Class	  IIa	   HDACs	   catalyse	   the	   removal	   of	   acetyl	   groups	   from	   lysine	   residues	   and	   are	  crucial	   transcriptional	   regulators	   (Martin	   et	   al.	   2007)	   (X.-­‐J.	   Yang	  &	  Seto	  2008).	  	  The	  acetylation	  of	  histones	  by	  histone	  acetyltransferases	  promotes	  transcription	  by	  relaxing	  chromatin	  structure,	  conversely,	  the	  removal	  of	  acetyl	  groups	  results	  in	  transcriptional	  repression.	  Specifically,	  class	  IIa	  HDACs	  are	  recruited	  to	  gene	  promoters	   by	   multiple	   transcription	   factors	   including	   MEF2,	   runt-­‐related	  transcription	   factor	   (RUNX)	   and	   calmodulin	   binding	   transcription	   activator	   2	  (CAMTA2)	  and	  function	  to	  repress	  these	  genes	  (Jensen	  et	  al.	  2009)	  (McKinsey	  et	  al.	   2001)	   (McKinsey	   et	   al.	   2002)	   (Taniuchi	   &	   Littman	   2004)	   (K.	   Song	   et	   al.	  2006b).	   The	   phosphorylation	   of	   class	   IIa	  HDACs	   results	   in	   14-­‐3-­‐3	   binding	   and	  their	   subsequent	   exportation	   from	   the	   nucleus	   to	   the	   cytoplasm	   thereby	   de-­‐repressing	   transcription.	   	   PKD	   mediated	   export	   of	   class	   IIa	   HDACs	   has	   been	  shown	   to	   be	   crucial	   in	   multiple	   cellular	   processes	   in	   various	   cell	   types.	   PKD	  mediated	   HDAC	   phosphorylation	   has	   been	   implicated	   in	   cardiac	   hypertrophy	  	  (Vega	  et	  al.	  2004)	  and	  within	  immune	  cell	  signaling	  (Dequiedt	  et	  al.	  2005)	  (Parra	  et	  al.	  2005)	  (Matthews	  et	  al.	  2006).	  	  Collectively,	  the	  PKD	  mediated	  phosphorylation	  and	  therefore	  regulation	  of	  class	  IIa	  HDACs	  serves	  as	  a	  molecular	  link	  that	  connect	  environmental	  stimuli	  to	  changes	  within	  the	  transcriptome.	  	  (Hausser	  et	  al.	  2005)	  (Hausser	  et	  al.	  2006)	  (Iglesias	  et	  al.	  2000)	  (Fugmann	  et	  al.	  2007)	  (Du	  et	  al.	  2010)	  (Eiseler	  et	  al.	  2009)	  (Eiseler	  et	  al.	  2010)	  (Nhek	  et	  al.	  2010)	  (Ziegler	  et	  al.	  2011)	  Additionally,	  as	  multiple	  substrates	  of	  PKD	  are	  fundamentally	  involved	  in	  cell	  migration	   pathways,	   including	  Hsp27,	   CREB,	   class	   IIa	  HDACs,	   PKD	   activity	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  Figure	  1.18	  PKD	  is	  implicated	  in	  multiple	  cellular	  processes	  Evidence	  exists	  to	  support	  the	  role	  of	  PKD	  in	  a	  large	  array	  of	  essential	  biological	  functions	  within	  normal	  and	  malignant	  cells.	  This	  includes	  (but	  is	  not	  limited	  to)	  cell	  survival	  during	  oxidative	  stress,	  inflammation	  including	  Cox-­‐2	  induction	  and	  IL-­‐8	   production,	   cell	   invasion,	   successful	   adaptive	   immunity,	   osteoclast	  differentiation	  and	  cell	  proliferation.	  It	  should	  be	  noted	  however	  that	  this	  figure	  is	   to	  give	  a	  broad	  overview	  of	  roles	  PKD	  has	  been	   implicated	   in	  and	  that	   these	  substrates	  are	  very	  dependent	  on	  the	  cell	  type,	  cellular	  localisation	  of	  PKD	  (and	  therefore	  its	  access	  to	  these	  substrates)	  and	  of	  course	  the	  isoform	  of	  PKD	  under	  study.	  
(Figure	  courtesy	  of	  S.A.Matthews)	  
1.6.6 Role	  of	  PKD	  in	  cancer	  development	  and	  progression	  	   Although	   no	   direct	   mutations	   of	   PKD	   isoforms	   in	   humans	   have	   been	  reported	  in	  the	  literature	  to	  lead	  to	  disease	  occurrence,	  PKD2	  was	  identified	  as	  one	   of	   the	   susceptible	   loci	   in	   a	   genome-­‐wide	   association	   study	   (GWAS)	   for	  chronic	  myeloid	  leukemia	  (CML)	  (Di	  Bernardo	  et	  al.	  2008).	  There	  is	  a	  wealth	  of	  literature	   reporting	   the	   dysregulation	   in	   the	   expression	   and	   activation	   of	   PKD	  isoforms	   in	   the	   development	   of	   cancer	   albeit	   with	   conflicting	   data,	   which	   are	  summarised	  below	  (Table	  1.4).	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  Cancer	  type	   Implication	   Reference	  	  	  	  Skin	  cancer	  
	  UVB	  activates	  keratinocyte	  PKD1	  Reduced	  papilloma	  formation	  in	  chemical	  induced	  carcinogenesis	  model	  	  PKD3	  found	  to	  mediate	  chemoresistance	  	  
	  (Arun	  et	  al.	  2010)	  	  (Rashel	  et	  al.	  2014)	  	  (J.	  Chen	  et	  al.	  2011)	  	  
	  	  	  	   	  BCR-­‐Abl+	  Leukemia	  
	  Tyrosine	  phosphorylated	  PKD2	  mediates	  BCR-­‐Abl	  induced	  NFκB	  activation	  	  Gabpα	  expression	  is	  required	  for	  development	  of	  BCR-­‐Abl	  induced	  CML	  and	  for	  HSC	  cell	  cycle	  entry	  	  Enhanced	  degradation	  of	  the	  IFNAR1	  from	  cell	  surface	  of	  CML	  cells	  	  
	  (Mihailovic	  et	  al.	  2004).	  	  	  (Bhattacharya	  et	  al.	  2011;	  H.	  Zheng	  et	  al.	  2011)	  
	  	  	  Colorectal	  
	  Combination	  of	  small	  molecule	  inhibitor	  of	  PKD	  (CRT101)	  with	  regorafenib	  reduces	  Hsp27	  phosphorylation	  in	  multiple	  colorectal	  cell	  lines	  	  CRT101	  compound	  inhibits	  tumour	  growth	  in	  vivo	  	  	  
	  (Wei,	  Chu,	  Wu,	  et	  al.	  2014b)	  	  	  (Wei,	  Chu,	  Wipf,	  et	  al.	  2014a)	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  Pancreatic	  
PKD2	  expression	  is	  upregulated	  and	  enhances	  invasion	  	  Novel	  small	  molecule	  inhibitor	  of	  PKD	  (CRT101)	  blocks	  pancreatic	  tumour	  cell	  growth	  in	  vitro	  and	  in	  vivo	  
	  Hypoxia	  activates	  PKD2	  in	  pancreatic	  cancer	  cells	  and	  knock	  down	  prevents	  angiogenesis	  and	  tumour	  growth	  
(Wille	  et	  al.	  2014)	  	  	  	  (Ochi	  et	  al.	  2011)	  	  (Harikumar	  et	  al.	  2010).	  	  	  	  (Azoitei	  et	  al.	  2010)	  
Breast	   Epigenetic	  silencing	  of	  PRKD1	  gene	  promoter	  is	  correlated	  with	  breast	  tumour	  invasiveness	  in	  patient	  sample	  	  
(Borges	  et	  al.	  2013)	  	  
Prostate	   Depletion	  of	  PKD3	  reduces	  prostate	  cancer	  proliferation	  in	  vivo	   (LaValle	  et	  al.	  2012).	  Table	  1.4	  Implications	  for	  PKD	  in	  multiple	  cancers	  
1.6.6.1 Potential	  role	  of	  PKD	  kinases	  within	  chronic	  myeloid	  leukemia	  	  	   As	   this	   thesis	   has	   a	   particular	   focus	   on	   exploring	   the	   role	   of	   PKD	   in	  chronic	  myeloid	  leukemia	  (CML),	  it	  requires	  a	  more	  detailed	  introduction.	  	  CML	   is	   a	   myeloproliferative	   neoplasm	   characterised	   by	   a	   dramatic	  increase	   in	   the	   infiltration	   of	   myeloid	   cells	   into	   the	   bone	   marrow,	   blood	   and	  peripheral	   tissues.	   CML	   is	   most	   frequently	   due	   to	   chromosomal	   translocation	  events	   that	   produce	   the	   Philadelphia	   chromosome,	   whereby	   a	   balanced	  translocation	   between	   the	   c-­‐abl	   gene	   on	   chromosome	   9	   and	   the	   Bcr	   gene	   on	  chromosome	  22	  occurs,	  designated	  as	  [t(9:22)].	  This	  results	  in	  the	  generation	  of	  the	   fusion	   oncoprotein	   Bcr-­‐Abl,	  which	   has	   constitutive	   tyrosine	   kinase	   activity	  (reviewed	  (Ahmed	  &	  Van	  Etten	  2013)).	  	  	   The	  expression	  of	  Bcr-­‐Abl	   in	  HSCs	   is	  central	   to	   the	  pathogenesis	  of	  CML	  and	   allows	   the	   cytokine	   independent	   proliferation	   of	   myeloid	   cells,	   whereby	  constitutive	   tyrosine	   kinase	   activity	   leads	   to	   dysregulation	   of	   key	   signalling	  pathways	  including	  STAT	  and	  NFκB	  pathways.	  This	  has	  multiple	  effects	  on	  CML	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cells	   including	   increased	   proliferation	   and	   increased	   cell	   survival.	   Bcr-­‐Abl	  tyrosine	  kinase	  inhibitors	  (TKIs),	  such	  as	  imatinib,	  are	  an	  effective	  treatment	  for	  CML	  cells	  but	   they	  are	  not	  a	   ‘cure’	  since	  they	   fail	   to	  eradicate	  all	  Bcr-­‐Abl+	  cells	  and	  have	  little	  effect	  on	  leukemic	  stem	  cells	  (LSCs)	  that	  drive	  disease	  recurrence	  	  (Y.	  Chen	  &	  S.	  Li	  2013).	  	  Furthermore,	  drug	  resistance	  to	  TKIs	  is	  becoming	  a	  more	  frequent	   occurrence	   resulting	   in	   blast	   crisis	   in	   patients	   with	   CML.	   As	   such,	  combinational	  therapy	  strategies	  are	  a	  particular	  focus	  of	  drug	  research,	  as	  more	  effective	   treatments	   are	   needed	   to	   target	   circulating	   LSCs	   (O'Hare	   et	   al.	   2011)	  (Graham	  2002)	   (Copland	   2006).	   	   As	   a	   result,	   further	   research	   is	   required	   into	  alternative	  therapies	  that	  actively	  target	  LSCs.	  One	  such	  therapy	  includes	  the	  use	  of	   interferon	   alpha	   (IFNα)	   either	   alone	   or	   in	   combination	   with	   existing	   TKIs.	  IFNα	   therapy	   has	   been	   previously	   used	  with	   success	   in	   a	   small	   subset	   of	   CML	  patients	   with	   data	   implicating	   IFNα	   induces	   CML	   cells	   to	   undergo	   terminal	  differentiation	  (Angstreich	  et	  al.	  2005).	  	  This	  is	  significant	  as	  it	  allows	  a	  window	  of	  opportunity	  for	  combinational	  therapy	  in	  sensitized	  cells	  with	  the	  potential	  to	  promote	  the	  eradication	  of	  LSCs.	  	  In	  regard	  to	  PKD	  expression	  in	  CML	  cells,	  PKD2	  is	  dominantly	  expressed	  in	   both	   the	  K562	  CML	   cell	   line	   but	   also	   in	   CML	  patient	   samples.	  However,	   the	  extent	   of	   IFNα	   signalling	   is	   limited	   by	   receptor	   induced	   ubiquitination	   and	  subsequent	   degradation	   of	   the	   IFNAR1/IFNAR2	   complex	   from	   the	   cell	   surface	  (Kumar	   et	   al.	   2003)	   (Kumar	   et	   al.	   2007).	   It	   has	   been	   shown	   this	   process	   of	  receptor	   down-­‐regulation	   is	   dysregulated	   in	   Bcr-­‐Abl+	   cells	  whereby	   CML	   cells	  express	  very	  low	  levels	  of	  IFNAR1,	  rendering	  them	  insensitive	  to	  IFNα	  therapy.	  Interestingly,	   PKD2	   has	   been	   implicated	   in	   this	   process	   whereby	   Bcr-­‐Abl	   has	  been	  shown	  to	  directly	  phosphorylate	  PKD2	  on	  a	  tyrosine	  site	  (Tyr	  438)	  within	  nthe	  PH	  domain	  causing	  constitutive	  activity	  of	  PKD	  in	  CML	  cells.	  Furthermore,	  PKD2	  has	  been	  directly	  linked	  to	  the	  degradation	  of	  IFNAR1	  by	  studies	  showing	  PKD2	  phosphorylates	  key	  serine	  residues	  (Ser535)	  on	   the	   intracellular	  domain	  of	   	   (degron)	   IFNAR1,	   tagging	   it	   for	   E3	   ligase	   ubiquitination,	   degradation	   and	  removal	   from	   the	   cell	   surface	   (Bhattacharya	   et	   al.	   2011;	  H.	   Zheng	   et	   al.	   2011),	  depicted	  in	  Figure	  1.19.	  Previous	  studies	  have	  also	  implicated	  a	  role	  for	  PKD2	  in	  NFκB	  signalling,	  which	  is	  constitutively	  active	  in	  Bcr-­‐Abl+	  CML	  cells	  (Mihailovic	  et	   al.	   2004).	  Here,	   PKD2	  was	   elucidated	   to	   play	   a	   significant	   role	   as	   a	   docking	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protein,	   as	   a	   result	   of	   tyrosine	   phosphorylation	   within	   the	   PH	   domain,	   rather	  than	  as	  a	  direct	  consequence	  of	  its	  kinase	  activity.	  	  
Constitutive  
	  Figure	  1.19	  PKD2	  is	  implicated	  in	  the	  degradation	  of	  the	  IFNα/β	  receptor	  on	  CML	  cells	  Bcr-­‐Abl	   oncoprotein	   activity	   leads	   to	   the	   dysregulation	   of	   multiple	   normal	  cellular	   processes.	   Bcr-­‐Abl	   oncoprotein	   has	   been	   shown	   to	   constitutively	  phosphorylate	  PKD2	  on	  tyrosine	  438.	  PKD2	  then	  goes	  on	  to	  phosphorylate	  a	  key	  serine	   residue	  on	   IFNAR1	  degron	   leading	   to	   it	   being	   tagged	   for	  ubiquitination,	  subsequent	  degradation	  and	  therefore	  removal	  from	  the	  cell	  surface.	  	  	   Furthermore,	  two	  recent	  studies	  have	  shed	  some	  light	  into	  PKD2	  role	  for	  CML	   in	  vivo.	  The	  first	  of	  which	  demonstrated	  that	  PKD2	  was	  a	  mediator	  of	  Bcr-­‐Abl	  transformation	  in	  CML	  via	  GA	  binding	  protein	  (GABP),	  in	  which	  knockdown	  or	   inhibition	   of	   PKD2	   resulted	   in	   increased	   CML	   cell	   death.	   (Z.-­‐F.	   Yang	   et	   al.	  2013).	  Additionally,	  the	  same	  groups	  have	  also	  demonstrated	  that	  loss	  of	  PKD2	  catalytic	   activity	   in	   BCR-­‐Abl	   induced	   CML	   cells	   protect	   mice	   from	   the	  development	  of	  CML	  in	  vivo	  (CML	  abstract	  unpublished	  data).	  	  	  
1.6.7 PKD	  isoform	  specific	  transgenic	  animals	  	  	   The	  first	  study	  to	  harness	  transgenic	  mouse	  models	  to	  address	  the	  role	  of	  PKD	   kinases,	   specifically	   in	   T	   cell	   function	   in	   vivo,	   was	   published	   in	   2003	  (Marklund	   et	   al.	   2003).	   Germ-­‐line	   deletion	   of	   PKD1	   has	   been	   shown	   to	   be	  embryonic	   lethal	   in	   studies	   investigating	   establishing	   the	   role	   of	   PKD1	   in	  pathological	   cardiac	   remodeling,	   embryonic	   lethality	   was	   overcome	   by	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conditional	   deletion	   of	   PKD1	   catalytic	   domain	   in	   cardiomyocytes	   specifically	  (Fielitz	   et	   al.	   2008).	   Additionally,	   homozygous	   disruption	   of	   the	   key	   PKC	  phosphorylation	   sites	   of	   PKD1	   (Ser744-­‐748)	   (PKD1SS/AA	  mice)	   also	   resulted	   in	  embryonic	   lethality	   (Matthews	   et	   al.	   2010).	   In	   contrast,	   transgenic	   mice	  generated	  with	  homozygous	  mutations	  in	  PKD2	  activation	  loop	  (Ser707-­‐Ser711),	  deemed	  catalytic	  knock-­‐in	  PKD2SS/AA	  mice,	  but	  also	  PKD2	  gene-­‐trap	  (PKD2GT/GT)	  mice	   with	   deletion	   of	   the	   catalytic	   domain,	   of	   PKD2	   were	   born	   at	   Mendelian	  frequency	   and	   indistinguishable	   from	   wild	   type	   littermates	   (Matthews	   et	   al.	  2010).	   The	   generation	   of	   isoform	   specific	   targeted	   transgenic	   mouse	   models	  demonstrates	  a	  clear	  non-­‐redundant	  role	  for	  intact	  PKD1	  catalytic	  activity	  during	  normal	  murine	  embryogenesis.	  	  The	   generation	   of	   PKD	   transgenic	   animals	   specifically	   lacking	   catalytic	  activity	  is	  significant	  as	  it	  permits	  investigation	  of	  the	  roles	  performed	  by	  specific	  isoform	  of	  PKD	  catalytic	  function	  but	  does	  not	  disturb	  any	  scaffolding	  functions.	  	  An	   overview	   of	   the	   current	   knowledge	   of	   existing	   isoform	   specific	   PKD	  transgenic	  mouse	  models	  and	  their	  known	  phenotypes	  are	  shown	  in	  Table	  1.5.	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Mutant	  allele	   Tissue	  specificity	  and	  description	   Phenotype	   Reference	  	  PKD1flox	  	  
	  Germline	  deletion	  (CAG-­‐Cre)	  	  Conditional	  deletion	  (alpha	  Myosin	  heavy	  chain	  (MHC)-­‐cre)	  in	  cardiomyocytes	  	  
	  Embryonic	  lethal	  	  Decreased	  heart	  hypertrophy	  in	  response	  to	  cardiac	  stress	  
	  (Fielitz	  et	  al.	  2008)	  
	  PKD1SS/AA	  KI	   	  Targeted	  knock	  in	  to	  generate	  kinase	  dead	  PKD1	  Ser744/748	  allele	  
	  Embryonic	  lethal	  (E9.5)	   	  (Matthews	  et	  al.	  2010)	  
	  PKD2SS/AA	  KI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  Targeted	  knock	  in	  to	  generate	  kinase	  dead	  PKD2	  Ser707/711	  allele	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  Reduced	  TCR	  stimulated	  cytokine	  production	  by	  CD4+	  and	  CD8+	  T	  cells	  in	  vitro	  	  Reduced	  T-­‐cell	  dependent	  antibody	  responses	  using	  immunisation	  model	  Enlarged	  thymus,	  spleen	  and	  lymph	  nodes	  when	  crossed	  to	  TCR-­‐Tg	  mice	  (OT	  I	  and	  OT	  II)	  	  
	  (Matthews	  et	  al.	  2010)	  	  	  	  	  	  	  (Navarro	   et	  al.	  2012)	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Table	  1.5	  Isoform	  specific	  PKD	  transgenic	  animal	  models	  and	  their	  phenotypes	  	  	  	  
	  	  PKD2SS/AA	  KI	  
	  Targeted	  knock	  in	  to	  generate	  kinase	  dead	  PKD2	  Ser707/711	  allele	  
	  Dispensable	  for	  integrin	  mediated	  adhesion	  and	  lymph	  node	  homing	  in	  lymphocytes.	  
	  (Matthews	  et	  al.	  2012)	  	  
	  PKD2GT/GT	   	  Gene	  trap	  deletion	  of	  PKD2	  catalytic	  domain	  by	  retroviral	  insertion	  into	  intron	  15.	  
	  Similar	  hyper	  cellularity	  when	  crossed	  to	  TCR-­‐Tg	  mice	  as	  observed	  in	  PKD2SS/AA	  KI	  	  
(Navarro	  et	  al.	  2012)	  
	  PKD3GT/GT	   	  Gene	  trap	  deletion	  of	  PKD3	  by	  retroviral	  insertion	  between	  exon	  1-­‐2.	  
	  Mice	  are	  viable	  albeit	  with	  reduced	  Mendelian	  frequency.	  	  	  Decreased	  vertebral	  trabecular	  bone	  volume	  and	  thickness	  
	  Unpublished	  data	  (S.Matthews)	  	  (Rogers	  et	  al.	  2005)	  	   	  	  PKD3KO/KO	   Bal-­‐Cre	  mediated	  excision	  resulting	  in	  loss	  of	  protein	  function	  by	  generation	  of	  frame	  shift	  mutation	  
Potentially	  embryonic	  lethal,	  no	  homozygous	  live	  born.	  
Unpublished	  data	  (S.Matthews)	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1.6.8 Pharmacological	  inhibition	  of	  PKD	  	  
1.6.8.1 Older	  generation	  inhibitors	  used	  to	  target	  PKD	  	   Foundational	  research	  attempting	  to	   tease	  apart	  PKC	  and	  PKD	  functions	  and	   downstream	   targets	   began	   with	   the	   development	   of	   a	   staurosporin	  derivative	   that	   potently	   blocked	   Ca2+	   dependent	   PKC	   isoforms	   including	   PKCα	  and	   PKCβ1	   but	   also	   PKD	   (Gschwendt,	   dieterich,	   et	   al.	   1996b).	   	   The	   Go6976	  compound	   arose	   from	   previous	   studies	   identifying	   that	   indolocarbazoles,	  including	   the	  microbial	   alkaloid	   staurosporin,	   potently	   inhibited	   PKC	   isoforms	  which	   were	   at	   the	   time	   a	   particular	   focus	   during	   phorbol	   ester	   induced	  tumorigenesis	  research	  (Martiny-­‐Baron	  et	  al.	  1993).	  The	  development	  of	  Go6976	  lead	  to	  a	  host	  of	  publications	  attempting	  to	  define	  the	  distinct	  functions	  of	  PKD	  that	  were	  independent	  from	  those	  previously	  attributed	  to	  PKC	  isoforms.	  Many	  of	  these	  studies	  were	  achieved	  by	  comparing	  the	  effects	  of	  Go6976	  with	  Go6983,	  also	  a	  derivative	   from	  staurosporin	   that	   acted	  as	  a	  pan-­‐PKC	   inhibitor,	  potently	  blocking	  all	  isoforms	  of	  PKC	  but	  importantly	  not	  PKD.	  Multiple	  studies	  have	  since	  used	   Go6976	   to	   assess	   the	   role	   of	   PKD	   in	   different	   cells	   and	   their	   biological	  processes.	   Go6976	   inhibited	   LPS	   induced	   production	   of	   inducible	   nitric	   oxide	  synthase	   (iNOS)	   and	   TNFα,	   ultimately	   protecting	   neurons	   from	   microglia	  mediated	  cytotoxicity.	  However,	  Go676	  has	  significant	  off	  target	  effects	  including	  inhibition	  of	  janus	  kinases	  (JAKs)	  (Grandage	  et	  al.	  2006).	  	  1-­‐Naphthyl	   PP1	   (1-­‐NA-­‐PP1),	   a	   pyrazolopyrimidine	   that	   was	   originally	  designed	  for	  inhibition	  of	  mutant	  src	  kinase	  (Bishop	  et	  al.	  1999)	   	  has	  also	  been	  shown	   to	   be	   a	   potent	   pan	   PKD	   inhibitor,	   with	   little	   effect	   on	   PKC	   isoforms	  (Tandon	  et	  al.	  2013).	  However,	  although	  there	  is	  little	  effect	  on	  PKC	  isoforms	  this	  compound	   also	   has	   major	   off	   targets	   effects	   at	   the	   concentration	   required	   to	  cause	   PKD	   inhibition	   including	   >50%	   inhibition	   of	   Src,	   Lck,	   CSK,	   RIP2,	   p38α	  MAPK	  and	  CK1δ	  (Bain	  et	  al.	  2007).	  	  Although	  these	  studies	  provided	  early	  insights	  into	  the	  many	  roles	  of	  PKD	  isoforms,	  they	  have	  provided	  somewhat	  conflicting	  data	  as	  to	  the	  true	  roles	  for	  PKD	   in	   many	   different	   cell	   lines.	   The	   ability	   to	   dissect	   and	   understand	   true	  biological	   functions	   of	   PKD	   is	   also	   complicated	   by	   lack	   of	   selectivity	   in	  widely	  used	  PKC/PKD	  inhibitors.	   In	  more	  recent	  years,	  small	  molecular	  protein	  kinase	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inhibitors	  have	  been	  widely	  developed	  and	  used	  in	  research	  to	  elucidate	  cellular	  signaling	  pathways.	  As	  such,	  small	  molecule	  inhibitors	  are	  frequently	  the	  focus	  of	  research	   into	   the	   generation	   of	   therapeutic	   agents	   including	   anti-­‐cancer	  therapies.	  The	   first	   report	   of	   a	   potent	   and	   specific	   inhibitor	   of	   PKD	  was	   identified	  from	  National	   Institute	  of	  Health	  (NIH)	  small	  molecule	  repository	   library	  using	  human	   PKD1	   for	   high	   throughput	   screening	   assays	   (HTS).	   The	   resulting	  compound,	   CID755673,	   demonstrated	   potent	   ability	   to	   suppress	   all	   3	   PKD	  isoforms,	  with	  no	   apparent	   preference	   (IC50:	   	   0.182nM,	   280nM	  and	  227nM	   for	  PKD1,	   PKD2	   and	   PKD3	   respectively)	   (Sharlow	   et	   al.	   2008).	   CID755673	   was	  demonstrated	  to	  not	  only	  be	  a	  potent	  pan-­‐PKD	  inhibitor	  but	  also	  highly	  selective,	  without	  any	  inhibition	  of	  PKC	  isoforms	  in	   in	  vitro	  kinase	  assays.	  Significantly,	   it	  was	  not	  ATP	  competitive,	  like	  all	  other	  previously	  described	  PKD	  inhibitors.	  This	  is	  advantageous	  as	   the	  ATP	  binding	  pocket	   is	  highly	  conserved	  between	  kinase	  families,	   often	   resulting	   in	  multiple	   off-­‐target	   effects,	  making	   it	   difficult	   to	   find	  selective	  compounds.	  	  The	  development	  of	  non-­‐competitive	  ATP	  inhibitors	  offers	  the	  possibility	   to	  overcome	  these	  difficulties.	   	   In	  contrast,	  non-­‐ATP	  competitive	  inhibition	   exert	   their	   effects	   by	   causing	   a	   conformational	   shift	   resulting	   in	   the	  kinase	   being	   unable	   to	   function	   rather	   than	   competing	   with	   high	   levels	   of	  intracellular	   ATP.	   	   Multiple	   analogues	   developed	   from	   CID755673	   were	  developed	   to	   improve	   potency,	   this	   notably	   included	   kb	   NB-­‐142-­‐70,	   which	  demonstrated	  a	  7	  fold	  increase	  in	  potency	  for	  PKD	  isoforms	  (IC50	  values	  are	  28.3,	  58.7	  and	  53.2	  nM	  for	  PKD1,	  2	  and	  3	  respectively).	  This	  analogue	  has	  been	  shown	  to	   inhibit	   cell	   migration	   and	   invasion	   in	   a	   prostate	   cancer	   cell	   line	   (LaValle,	  Bravo-­‐Altamirano,	  et	  al.	  2010a).	  However,	  additional	  studies	  have	  shown	  kb	  NB-­‐142-­‐70	  has	  poor	  aqueous	  solubility	  and	  is	  rapidly	  metabolised	  in	  mice	  (J.	  Guo	  et	  al.	  2013).	  	  In	  addition	  to	  CID755673	  and	   its	  analogues,	  another	  potent	   inhibitor	  of	  PKD	  was	  developed	  through	  further	  HTSs,	  however	  it	  was	  shown	  to	  have	  large	  off	   target	   effects	   (Meredith,	   Ardayfio,	   et	   al.	   2010a).	   The	   attempt	   to	   reduce	   off	  target	  effects	  led	  to	  the	  development	  of	  bipyridyl,	  BPKDi	  (2'-­‐(cyclohexylamino)-­‐6-­‐(piperazin-­‐1-­‐yl)-­‐[2,4'-­‐bipyridine]-­‐4-­‐	  carboxamide)	  (Monovich	  et	  al.	  2010).	  The	  BPKDi	  compound	  was	  generated	  at	  the	  same	  time	  as	  the	  Novartis	  12a	  compound	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  Figure	  1.20	  Chemical	  structures	  of	  older	  generation	  inhibitors	  of	  PKD	  (A)	  GO6976	  (B)	  CID75563	  (C)	  kb	  NB-­‐142-­‐70	  analogue	  (D)	  BPKDi/12a	  (E)	  1-­‐NA-­‐PP1.	  	  	  
Taken	   from	   (LaValle,	   George,	   et	   al.	   2010b)	   (Monovich	   et	   al.	   2010);	   (Meredith,	  Beattie,	  et	  al.	  2010b)	  (Grandage	  et	  al.	  2006).	  	  	  	  
1.6.8.2 Novel	  small	  molecule	  inhibitors	  of	  PKD	  	  	   In	  order	  to	  improve	  drug	  target	  specificity,	  cancer	  research	  technologies	  (CRT)	   have	   expanded	   studies	   for	   the	   development	   of	   new	   generation	   PKD	  inhibitors	   with	   such	   properties	   via	   further	   HTS	   studies.	   This	   resulted	   in	   the	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successful	   generation	   of	   two	   lead	   compounds:	   CRT0066101	   and	   CRT0066051.	  Both	  chemical	  structures	  are	  shown	  in	  Figure	  1.21.	  	  CRT0066101	  is	  a	  pyrazine	  benzamide,	  which	  is	  structurally	  distinct	  from	  CID75563	   It	   has	   had	   significant	   success	   in	   being	   the	   first	   PKD	   inhibitor	   to	  demonstrate	   good	   bioavailability	   in	   vivo	   (Harikumar	   et	   al.	   2010).	   Significantly,	  oral	   gavage	   of	   this	   compound	   led	   to	   reduction	   in	   tumour	   size	   in	   two	   separate	  pancreatic	   cancer	   models	   (Harikumar	   et	   al.	   2010).	   	   In	   addition	   to	   this	   study,	  three	   other	   studies	   investigating	   the	   therapeutic	   potential	   of	   the	   CRT0066101	  compound	  have	  been	  published,	  all	  of	  which	  demonstrated	  promising	  results	  for	  potential	  use	  of	  CRT0066101	  for	  treatment	  of	  CML,	  colorectal	  and	  glioblastoma	  tumors,	  in	  both	  in	  vitro	  and	  in	  vivo	  settings	  (Z.-­‐F.	  Yang	  et	  al.	  2013;	  Bernhart	  et	  al.	  2013;	  Wei,	  Chu,	  Wipf,	  et	  al.	  2014a).	  	  The	  CRT0066051compound	  has	  to	  our	  knowledge	  has	  only	  been	  cited	  in	  one	   study	   demonstrating	   its	   potential	   therapeutic	   use	   in	   the	   inhibition	   of	  vascular	  endothelial	  growth	   factor	  (VEGF)	   induced	  migration,	  proliferation	  and	  
in	  vitro	  angiogenesis	  (Evans	  et	  al.	  2010).	  	  Both	   past	   and	   present	   compounds	   used	   to	   target	   PKD,	   IC50s	   and	   the	  known	  off-­‐target	  effects	  are	  summarised	  in	  Table	  1.6.	  	  	  
!CRT0066101! CRT0066051!
A! B!
	  Figure	  1.21	  Chemical	  structures	  of	  new	  generation	  inhibitors	  of	  PKD	  	  (A)	  CRT0066101	  (B)	  CRT0066051.	  









Go6976	   PKCα	   (2.3nM)	  PKCβ1	  (6.2nM)	  PKD1	  PKD2	  PKD3	  	  
JAK2	  (5nM)	  JAK3	  (30nM)	  TrkA	  (130nM)	  TrkB	  (370nM)	  	  
(Gschwendt,	  Dieterich,	  et	  al.	  1996a)	  (Grandage	  et	  al.	  2006)	  
CID755673	   PKD1	  (0.182nM)	  PKD2	  (280nM)	  PKD3	  (227nM)	  
GSK3β	  MAPKAPK2	  CK18δ	  MK2	  ERK1	  	  	  




PKD1	  (28.3nM)	  PKD2	  (58.7nM)	  PKD3	  (53.2nM)	  
	   (LaValle	  et	  al.	  2012).	  {	  (LaValle,	  Bravo-­‐Altamirano,	  et	  al.	  2010a).	  	  
1-­‐NA-­‐PP1	   PKD1	  (154.6nM)	  PKD2	  (133.4nM)	  PKD3	  (109.4nM)	  
	   (Tandon	  et	  al.	  2013)	  (Bain	  et	  al.	  2007)	  
IKK-­‐16	   PKD1	  (153.9nM)	  PKD2	  (115.0nM)	  PKD3	  (99.47nM)	  
	   (Tandon	  et	  al.	  2013)	  
BPKDi/12a	   PKD1	  (1nM)	  PKD2	  PKD3	  
	   (Monovich	  et	  al.	  2010).	  (Meredith,	  Ardayfio,	  et	  al.	  2010a).	  (Meredith,	  Beattie,	  et	  al.	  2010b).	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CRT0066101	   PKD1	  (1nM)	  PKD2	  (2.5nM)	  PKD3	  (2nM)	  
	   {Harikumar:2010bz}	  (Z.-­‐F.	   Yang	   et	   al.	   2013;	  Bernhart	  et	  al.	  2013;	  Wei,	  Chu,	  Wipf,	  et	  al.	  2014a)	  	  
CRT0066051	   PKD1	  (1nM)	  PKD2	  (2.5nM)	  PKD3(1.5nM)	  
	   {Evans:2010dt}	  
Table	  1.6	  Inhibitors	  used	  to	  target	  PKD	  	  
1.6.9 Role	  of	  PKD	  enzymes	  in	  immune	  system	  	  
1.6.9.1 Innate	  immune	  cells	  	  	   In	   regard	   to	   the	   activation	   of	   PKD	   enzymes	   in	   cells	   from	   the	   myeloid	  lineage	  and	  innate	  arm	  of	  the	  immune	  system	  the	  literature	  is	  somewhat	  limited	  and	  conflicting.	  However,	  studies	  have	  pointed	  to	  a	  clear	  and	  conserved	  role	  for	  PKD	  kinases	   in	   innate	   immunity	  whereby	   studies	   in	  C.	   elegans	   lacking	  DFK-­‐2A	  (homologue	  of	  PKD)	  were	  hypersensitive	  to	  death	  from	  bacterial	  pathogens	  (Ren	  et	   al.	   2009).	   This	   is	   significant	   as	   the	   study	   directly	   links	   DAG	   mediated	  signalling,	  specifically	   involving	  PKD	  to	  innate	   immunity.	  At	  present,	  no	  studies	  have	   yet	   been	   published	   investigating	   the	   role	   of	   PKD	   kinases	   in	   the	  development	  of	  myeloid	  cells	  within	  the	  bone	  marrow	  or	  the	  effect	  of	  loss	  of	  PKD	  catalytic	   activity	   on	   the	   population	   of	   myeloid	   cells	   within	   peripheral	   tissues.	  Although	   there	   is	   data	   implicating	   a	   role	   for	   PKD	   within	   myeloid	   effector	  functions	   in	   which	   PKD1	   has	   been	   implicated	   in	   PRR	   signaling	   within	  macrophages,	  DCs	  and	  mast	  cells.	  	  Involvement	  of	  PKD	  kinases	  in	  response	  to	  PPR	  or	  TLR	  ligation	  was	  first	  highlighted	  whereby	   treatment	   of	  microglia	   cells	  with	   dual	   PKC/PKD	   inhibitor	  GO6976	  was	  shown	  to	  significantly	  reduce	  TNFα	  production	  in	  response	  to	  LPS	  (Jeohn	  et	  al.	  2002).	  	  Subsequently,	  another	  study	  implicated	  PKD1	  to	  be	  involved	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in	  TLR5	  activation	   in	  response	  to	  bacterial	   flagellin	   in	  HEK293	  cells	  expressing	  TLR5	  constructs	  (Ivison	  et	  al.	  2007).	  PKD1	  activation	  in	  response	  to	  PAM3CSK4,	  a	   TLR1/2	   agonist	   has	   also	   been	   shown	   in	   bone	   marrow	   derived	   mast	   cells	  (BMDMCs),	  additionally	  treatment	  with	  GO6976	  resulted	  in	  reduced	  expression	  of	   the	   chemokine	  CCL2	  mRNA	   transcript	  whereas	  other	  PKC	   inhibitors	  did	  not	  (Murphy	   et	   al.	   2007).	   Within	   mast	   cells,	   the	   overexpression	   of	   PKD	   led	   to	  enhanced	  production	   of	   IL-­‐13	   and	  TNFα	   after	   FceRI	   stimulation,	   although	   it	   is	  not	  clear	  what	  PKD	  isoform	  is	  under	  study	  (Yamashita	  et	  al.	  2010).	  	  Specifically,	  PKD1	  has	  implicated	  in	  pathogenic	  DNA	  sensing	  via	  the	  TLR9	  signalling	   pathway	   in	   BMDMOs	   (J.-­‐E.	   Park	   et	   al.	   2008).	   Pharmacological	  inhibition	  of	  PKD	  with	  Go6976	  significantly	   reduced	  proinflammatory	  cytokine	  production	   including	   TNFα,	   IL-­‐6,	   and	   IL-­‐12p40	   but	   also	   reduced	   IL-­‐10	  production.	   Additional	   studies	   also	   concluded	   that	   PKD1	   was	   required	   for	  MyD88	  mediated	   TLR	   signaling	   within	  macrophages	   and	   DCs	   (J.-­‐E.	   Park	   et	   al.	  2009b).	  	  More	   recently,	  both	  PKD1	  and	  PKD2	  have	  been	  reported	   to	  be	   required	  for	  the	  production	  of	  chemokines	  including	  CXCL8	  (IL-­‐8)	  and	  CCL20	  in	  response	  to	  TLR2,	  TLR4	  and	  TLR5	  in	  epithelial	  cells	  (Steiner	  et	  al.	  2010).	  	  
1.6.9.2 Adaptive	  immune	  cells	  	   A	   wealth	   of	   studies	   has	   established	   a	   prominent	   role	   for	   PKD	   kinases	  within	  the	  adaptive	  immune	  system	  including	  T	  and	  B	  lymphocytes.	  In	  regard	  to	  isoform	  expression,	  T	  and	  B	  lymphocytes	  selectively	  express	  PKD2.	  Upon	  antigen	  receptor	  engagement	  via	  the	  TCR	  the	  accumulation	  of	  DAG	  rapidly	  recruits	  PKD	  from	   the	   cytosol	   to	   the	   immunological	   synapse	   (Spitaler,	   Emslie,	   Wood	   &	  Cantrell	  2006b).	  	  	  Although	  studies	  have	  shown	  that	  PKD2	  participates	  in	  the	  IL-­‐2	  promoter	  regulation	  within	  Jurkat	  T	  cells	  (Irie	  et	  al.	  2006)	  PKD	  is	  not	  directly	  activated	  by	  IL-­‐2	  (Matthews	  et	  al.	  2000)Within	  B	  lymphocytes	  PKD	  activation	  is	  essential	  for	  class	  IIa	  HDAC	  phosphorylation	  after	  BCR	  ligation	  (Matthews	  et	  al.	  2006).	  	  Analysis	  of	  T	  and	  B	  cell	  development	  within	  catalytically	   in-­‐active	  PKD2	  transgenic	   animals	   has	   been	   shown	   to	   be	   normal.	   However,	   PKD2	   was	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highlighted	   to	   have	   a	   particular	   role	   in	   T	   cell	   effector	   function	   in	  which	   PKD2	  deficient	  mice	  are	  unable	  to	  efficiently	  produce	  key	  pro-­‐inflammatory	  cytokines	  such	  as	  IL-­‐2	  and	  IFNγ.	  Unsurprisingly,	  in	  vivo	  experiments	  went	  on	  to	  show	  that	  PKD2	  deficient	  mice	  displayed	  a	  reduced	  immune	  response	  after	  immunisation,	  presumably	  due	  to	  significantly	  reduced	  production	  of	  IL-­‐2	  and	  IFNγ	  (Matthews	  et	  al.	  2010).	  Further	  analysis	  has	  demonstrated	  lack	  of	  effector	  function	  by	  PKD2	  null	   T	   lymphocytes	   is	   cell	   intrinsic	   and	   not	   due	   to	   abnormal	   thymocyte	  development	  (Navarro	  et	  al.	  2012).	  	  Although	  the	  PKD	  family	  has	  been	  implicated	  in	  regulating	  the	  activity	  of	  β1	   integrins	   in	   T	   lymphocytes	   (Medeiros	   et	   al.	   2005),	   in	   vivo	   analysis	   of	   T	  lymphocyte	  homing	  to	  lymphoid	  tissues	  is	  not	  affected	  within	  	  PKD2	  catalytically	  inactive	  mice	  (Matthews	  et	  al.	  2012),	  demonstrating	  that	  PKD2	  does	  not	  play	  a	  key	  role	  in	  integrin	  receptor	  expression	  or	  integrin	  mediated	  adhesion	  in	  vivo.	  More	  recent	  studies	  have	  taken	  a	  wider	  approach	  and	  examined	  the	  effect	  of	  loss	  of	  PKD2	  on	  the	  phosphoproteome	  in	  CD8+	  CTLs,	  which	  display	  high	  levels	  of	  basal	  PKD	  activity,	  allowing	  insight	  into	  the	  role	  of	  PKD2	  including	  the	  positive	  and	   negative	   regulation	   of	   cell	   signalling	   networks	   within	   effector	   T	   cells	  (Navarro,	  Goebel,	   et	  al.	  2014b).	   	   Significantly,	  phosphoproteomics	   in	   this	   study	  revealed	  that	  PKD2	  regulates	  approximately	  5%	  of	  the	  phosphoproteome	  in	  CTL,	  whether	  directly	  or	  indirectly.	  Additionally,	  studies	  have	  also	  demonstrated	  that	  PKD2	   acts	   as	   a	   ultrasensitive	   digital	   amplifier	   of	   TCR	   signaling	   that	   mediates	  cellular	   responses	   within	   CD8+	   CTLs	   (Navarro,	   Feijoo	   Carnero,	   et	   al.	   2014a).	  Finally,	   the	   role	   of	   PKD2	   has	   also	   been	   addressed	   in	   multiple	   experimental	  disease	  models	  highlighting	  key	  roles	  for	  PKD2	  activity	  within	  CD8+	  CTLs	  during	  the	   immune	  response	  to	  Listeria	  Monocytogenes	  yet	  conversely	   lack	  of	  PKD2	   in	  CD8+	   CTLs	   has	   been	   shown	   to	   be	   protective	   within	   the	   development	   of	  autoimmune	  diabetes	  (Navarro,	  Feijoo	  Carnero,	  et	  al.	  2014a).	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1.7 Aims	  	  	   The	   aims	  of	   this	   thesis	  were	   to	   investigate	   for	   the	   requirement	   and	   role	   of	  catalytic	   activity	   of	   PKD	   kinases	   in	   the	  mammalian	   immune	   system,	   including	  cells	   from	   both	   the	   innate	   and	   adaptive	   branches.	   	   Specifically,	   we	   wished	   to	  answer	  the	  following	  research	  questions:	  	   1) Are	  novel	  small	  molecule	  inhibitors	  of	  PKD	  indeed	  specific	  for	  PKD	  and	  do	  they	  share	  significant	  off	  target	  effects?	  2) 	  Which	  isoforms	  of	  PKD	  are	  predominantly	  expressed	  in	  primary	  myeloid	  cells?	  	  3) Do	  TLR	   agonists	   activate	   PKD	   kinases	   in	  myeloid	   cells	   and	   does	   loss	   of	  PKD	  catalytic	  activity	  affect	  effector	  functions	  of	  myeloid	  cells	  4) Is	  PKD2	  catalytic	  activity	  required	  for	  normal	  myeloid	  cell	  development	  in	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  who	  performed	  cell	   sorting	   and	   	   finally	   Dr.	   George	   Ramsay	  who	   helped	   performed	   analysis	   of	  lymphocyte	  populations	  within	  the	  small	  intestine	  and	  provided	  much	  assistance	  during	  the	  colitis	  model.	  	  	  
2.2 Materials	  	  	  	   All	  materials	  used	  were	  of	   the	  highest	  quality	  available.	  Unless	  otherwise	  stated,	   all	   chemicals	   were	   provided	   by	   Sigmal-­‐Aldrich	   (Poole,	   Dorset,	   UK)	   or	  VWR	   (Lutterworth,	   Leicestershire,	   UK).	   	   All	   solutions	   were	   prepared	   using	  deionised	   water	   (MilliQ	   system,	   Millipore)	   and	   where	   appropriate	   solutions	  were	   autoclaved	   at	   120°C,	   15psi	   for	   20	   min.	   All	   cell	   culture	   media	   including	  Roswell	   Park	   Memorial	   Institute	   (RMPI),	   Dulbecco’s	   Modified	   Eagle	   Medium	  (DMEM)	  and	  Iscoves	  Modified	  Dulbecco's	  Medium	  (IMDM)	  were	  purchased	  from	  Invitrogen-­‐	  Life	   technologies	  (Paisley,	  Glasgow,	  UK).	   	  Fetal	  Bovine	  Serum	  (FBS)	  was	  purchased	  from	  Labtech	  International	  Ltd	  (FB-­‐1090/500).	  Sodium	  Dodecyl	  sulphate-­‐polyacrylamide	  gel	  electrophoresis	   	  (SDS-­‐PAGE)	  cell	  modules	  and	  pre-­‐cast	   gradient	   gels	   were	   purchased	   from	   Invitrogen	   Life	   Technologies.	   	   All	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oligonucleotides	  were	   purchased	   from	  MWG-­‐Biotech	  UK	   Ltd.	   (Peartree	  Bridge,	  Milton	  Keynes,	  Bucks,	  UK),	  sequences	  are	  shown	  in	  Appendix	  A.	  	  	  
2.3 Common	  Solutions	  	  Phosphate	  Buffered	  Saline	  (PBS)	  	   	   37mM	  NaCl	  	   	   	   	   	   	   2.7mM	  KCl	  	   	   	   	   	   	   4.3mM	  Na2HPO4	  	   	   	   	   	   	   1.2mM	  KH2PO4	  	  5x	  SDS	  sample	  	  buffer	   	   	   250mM	  Tris-­‐HCL	  pH	  6.8	  	   	   	   	   	   	   30%	  Glycerol	  	   	   	   	   	   	   10%	  SDS	  	   	   	   	   	   	   5%	  2β-­‐mercaptoethanol	  	   	   	   	   	   	   0.02%	  Bromophenol	  blue	  	  	  PBS-­‐Tween	  	   	   	   	   	   37mM	  NaCl	  	   	   	   	   	   	   2.7mM	  KCl	  	   	   	   	   	   	   4.3mM	  Na2HPO4	  	   	   	   	   	   	   1.2mM	  KH2PO4	  	   	   	   	   	   	   0.025%	  Tween	  20	  	  ACK	  lysing	  buffer	  (10x)	  pH	  7.2	   	   1.5M	  NH4Cl	  	   	   	   	   	   	   100mM	  KHC03	  	   	   	   	   	   	   10mM	  EDTA	  	  Tris-­‐borate-­‐EDTA	  (TBE)	  buffer	  	   	   89mM	  Tris-­‐Borate	  	   	   	   	   	   	   2mM	  EDTA	  pH	  8.3	  	  	  MES	  SDS	  running	  buffer	  	  (1x)	   	   50ml	  	  20X	  MES	  buffer	  	   	   	   	   	   	   	  950ml	  deionised	  water	  	  	   	   	   	   	   	   	  	  Transfer	  buffer	  (1x)	   	   	   	   50ml	  	  20x	  concentrated	  transfer	  buffer	  	   	   	   	   	   	   100ml	  methanol	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   850ml	  deionised	  water	  	  	  F	  lysis	  buffer	  	  	   	   	   	   10mM	  Tris-­‐HCl	  pH	  7.05	  	   	   	   	   	   	   50mM	  NaCl	  	  	   	   	   	   	   	   30mM	  Sodium	  pyrophosphate	  	  	   	   	   	   	   	   50mM	  NaF	  	   	   	   	   	   	   5µM	  ZnCl2	  	   	   	   	   	   	   10%	  (w/v)	  glycerol	  	   	   	   	   	   	   0.5%	  Triton-­‐x-­‐100	  	  Low	  salt	  lysis	  buffer	   	   	   	   50mM	  Tris-­‐HCl	  pH	  7.8	  	   	   	   	   	   	   150mM	  NaCl	  pH	  7.4	  	   	   	   	   	   	   10mM	  EDTA	  	   	   	   	   	   	   	  50mM	  NaF	  	   	   	   	   	   	   1%	  Triton-­‐x-­‐100	   	  	  NP-­‐40	  Lysis	  buffer	  	   	   	   	   50mM	  HEPES	  pH	  7.0	  	   	   	   	   	   	   250mM	  NaCl	  	   	   	   	   	   	   5mM	  EDTA	  	   	   	   	   	   	   5mM	  NaF	  	   	   	   	   	   	   0.5mM	  Na3VO4	  	   	   	   	   	   	   1%	  NP-­‐40	  	  	  Ear	  digestion	  buffer	  	   	   	   	   28nM	  NaCl	  	   	   	   	   	   	   55mM	  Tris/HCl	  pH	  8.0	  	   	   	   	   	   	   0.1%	  SDS	  	  Blood	  buffer	   	   	   	   	   Complete	  mouse	  media	  (RMPI)	  	   	   	   	   	   	   10mls	  1x	  ACK	  	  	   	   	   	   	   	   	  MACs	  buffer	  	   	   	   	   	   1xPBS	  	   	   	   	   	   	   1%	  FBS	  	   	   	   	   	   	   2mM	  EDTA	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  FACS	  buffer	   	   	   	   	   1xPBS	  	   	   	   	   	   	   1%	  FBS/BSA	  	   	   	   	   	   	   2mM	  EDTA	  	  
2.4 Animals	  	  
2.4.1 Maintenance	  of	  animal	  lines	  	   Animals	   in	   the	   transgenic	   animal	   unit	   have	   a	   14:	   10	   light	   cycle	   and	   are	  maintained	   on	   autoclaved	   RM3	   pelleted	   diet	   (SDS	   Diets,	   local	   agent	   DBM)	   ad	  libitum	   along	  with	   autoclaved	  water	   ad	   lib.	   Animals	   are	   housed	   in	   accordance	  with	   HO	   CoP,	   local	   WEC	   best	   practice	   guidance	   and	   project	   license	   authority	  Animals	   bred	   and	   maintained	   under	   specific	   pathogen	   free	   conditions	   in	   the	  Wellcome	  Trust	  Biocentre	  at	   the	  University	  of	  Dundee.	   	  The	  background	  strain	  for	  breeding	  is	  the	  C57Bl/6j	  jax	  supplied	  by	  Charles	  River	  UK,	  Manston,	  Kent.	  All	  animals	   were	   maintained	   in	   accordance	   with	   the	   UK	   Home	   Office	   Animals	  (Scientific	   Procedures)	   Act	   1986	   guidelines,	   under	   the	   license	   for	   the	   project	  (PPL	  60/3972	  and	  PPL	  70/8084).	  The	  genotypes	  of	  mice	  used	  within	  this	  thesis	  were	   as	   follows:	   wild	   type	   (WT),	   PKD1WT/KI,	   PKD2KI/KI,	   PKD1WT/KI	   x	   PKD2KI/KI	  double	   knock-­‐in,	   PKD2	   gene	   trap	   knock	   out	   mice	   (PKD2GT/GT)	   and	   RAG2KO/KO.	  	  The	   generation	   of	   PKD1	   and	   PKD2	   transgenic	   mice	   are	   thoroughly	   described	  within	  the	  following	  reference	  (Matthews	  et	  al.	  2010))	  	  
2.4.2 Biopsy	  of	  animals	  by	  ear	  notch	  	   Animals	  aged	  4	  weeks	  were	  biopsied	  by	  taking	  a	  small	  notch	  from	  the	  ear	  using	  a	  dermal	  punch.	  The	  notch	  served	  as	  both	  a	  source	  of	  DNA	  for	  genotyping	  and	  for	   identification	  of	   the	  animal.	  DNA	  was	  extracted	  from	  the	  ear	  notch	  and	  analysed	   using	   PCR.	   Animals	   within	   the	   PKD2KI/KI	   line	   were	   maintained	   by	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biopsy	   and	   genotyping	   of	   the	   first	   litter	   of	   a	   new	  mating,	   after	  which	   animals	  were	  presumed	  homozygous.	  	  	  
2.4.3 Genotyping	  of	  animals	  by	  PCR	  	  
2.4.3.1 Ear	  digest	  for	  DNA	  	   Ear	  notches	  were	  digested	  to	  obtain	  DNA	  by	  incubating	  with	  50µl	  of	  ear	  buffer	   and	   proteinase	   K	   (1mg/ml)	   (Sigma)	   and	   heated	   to	   55°C	   for	   9	   hrs.	  Proteinase	   K	   was	   then	   inactivated	   by	   addition	   of	   150µl	   of	   dH2O	   and	   boiling	  samples	  at	  100°C	  for	  10	  min.	  	  Ear	  digests	  were	  then	  centrifuged	  at	  250	  x	  g	  for	  1	  minute	   to	   collect	   debris	   and	   genomic	  DNA	  was	   stored	   at	   4°C	   short	   term	  and	   -­‐20°C	  long	  term.	  	  	  
2.4.3.2 Optimisation	  of	  PKD1	  genotyping	  assay	  	  Due	  to	  various	  problems	  with	  genotyping	  PKD1	  heterozygous	  mice	  via	  PCR,	  this	  assay	  was	  optimised.	  New	  primers	  were	  generated	  using	  ApE-­‐	  A	  plasmid	  editor	  software.	   Successful	   primers	  were	   subsequently	   validated	   using	   verifying	   PCR	  products	   using	   DNA	   sequencing	   by	   capillary	   electrophoresis	   (Lab901	  ScreenTape	  system).	   	  Verified	  sequence	  alignment	  of	   the	  PCR	  product	  with	   the	  relevant	  murine	   Prkd1	   gene	   region	   is	   shown	   in	   Appendix	   A.	   This	   service	   was	  provided	   by	   Genetics	   Core	   Services	   Unit,	   Ninewells	   Hospital,	   University	   of	  Dundee.	  Validated	  primers	  were	  purchased	  from	  MWG-­‐operon	  and	  reconstituted	  in	   nuclease	   free	   water	   at	   a	   concentration	   of	   100µM	   and	   diluted	   to	   10µM	   as	  required.	   All	   primers	  were	   stored	   at	   -­‐20°C	   and	   aliquoted	   to	   prevent	   repeated	  freeze	  thawing.	  	  Typical	  reaction	  mixture	  used	  to	  amplify	  genomic	  DNA	  from	  WT	  and	  PKD1WT/KI	  mice	  is	  shown	  in	  Table	  2.1	  and	  PCR	  conditions	  are	  shown	  in	  Table	  2.2	  respectively.	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   Reagent	   1	  x	  Volume	  10x	  Buffer	  (1x	  f.c)	   2.5µl	  25mM	  MgCl	  (2mM	  f.c)	   2µl	  10mM	  dNTPs	  (0.4mM	  f.c)	   1µl	  1:10	  Forward	  primer	  (10µM	  f.c)	   1µl	  1:10	  reverse	  primer	  (10µM	  f.c)	   1µl	  5u/µl	  Redtaq	  (1	  unit	  f.c)	   2.5µl	  H20	   13.5µl	  Genomic	  DNA	   2µl	  Table	  2.1	  A	  typical	  PCR	  reaction	  mixture	  used	  for	  genotyping	  WT	  and	  PKD1WT/KI	  mice	  	  	  
Step	   Temperature	   Time	   Cycles	  1.	  Initial	  denaturation	   95°c	   3	  min	   1	  
2.	  Denaturation	   95°C	   30	  seconds	   	  3.	  Annealing	   62°C	   45	  seconds	   34	  	  4.	  Extension	   72°C	   1	  minute	   	  5.	  Final	  extension	   72°C	   10	  min	   1	  Table	  2.2	  Reaction	  conditions	  and	  cycle	  used	  to	  amplify	  genomic	  DNA	  
2.4.3.3 Genotyping	  of	  PKD2KI/KI	  mice	  by	  PCR	  	   DNA	  obtained	  from	  ear	  notching	  from	  PKD2WT/WT	  and	  PKD2KI/KI	  mice	  was	  amplified	  using	  similar	  methodology	  to	  PKD1WT/KI	  genotyping.	  Reaction	  mixtures	  and	   PCR	   amplification	   cycles	   described	   below	   in	   Table	   2.3	   and	   Table	   2.4	  respectively.	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Step	   Temperature	   Time	   Cycles	  1.	  Initial	  denaturation	   95°c	   3	  min	   1	  
2.	  Denaturation	   95°C	   30	  seconds	   	  3.	  Annealing	   58°C	   45	  seconds	   34	  	  
Reagent	   1	  x	  Volume	  
10x	  Buffer	  (1x	  f.c)	   2.5µl	  
25mM	  MgCl2	  (2mM	  f.c)	   2µl	  
10mM	  dNTPs	  (0.4mM	  f.c)	   1µl	  
1:10	  Forward	  primer	  (10µM	  f.c)	   1µl	  
1:10	  reverse	  primer	  (10µM	  f.c)	   1µl	  
5u/µl	  Redtaq	  (1	  unit	  f.c)	   2.5µl	  
H20	   13.5µl	  
Genomic	  DNA	   2µl	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4.	  Extension	   72°C	   1	  min	   	  5.	  Final	  extension	   72°C	   10	  min	   1	  Table	   2.4	   Reaction	   conditions	   used	   to	   amplify	   genomic	   DNA	   from	   WT	   and	  PKD2KI/KI	  mice	  	  	  
2.4.4 Genotyping	  of	  OT	  II	  TCR	  transgenic	  mice	  by	  blood	  analysis	  	   Mice	   were	   blood	   biopsied	   at	   25	   days	   of	   age	   via	   tail	   bleeding.	   Blood	  samples	  were	  placed	  in	  500µl	  blood	  buffer.	  Red	  blood	  cells	  were	  lysed	  in	  1ml	  1x	  ACK	   buffer	   and	   incubated	   at	   room	   temperature	   until	   samples	   were	   no	   longer	  cloudy	  (30	  seconds	  to	  3	  min).	  Samples	  were	  then	  washed	  by	  adding	  2ml	  of	  PBS	  supplemented	  with	   1%	  FBS	  or	  BSA	   and	   spun	   at	   250	   x	  g	   for	   5	  min	   at	   4°C.	   The	  supernatant	   was	   then	   poured	   off	   and	   cells	   were	   stained	   with	   the	   following	  antibodies	  prepared	   in	  FACS	  buffer:	  CD4-­‐APC	  and	  Va2-­‐	  PE	  both	  used	  at	  1:200.	  Samples	  were	  stained	  for	  20	  min	  on	  ice	  in	  50µl	  staining	  buffer,	  washed	  with	  1ml	  FACS	  buffer,	  centrifuged	  at	  250	  x	  g	  for	  5	  min,	  resuspended	  in	  200µl	  	  FACS	  buffer	  and	  acquired	  on	  BD	  Verse.	  	  Samples	  were	  described	  as	  OT	  II	  positive	  if	  mice	  had	  a	  skewed	  CD4/CD8	  T	   cell	   ratio	   whereby	   80-­‐90%	   of	   lymphocytes	   are	   CD4+,	   additionally	   all	   CD4+	  lymphocytes	  were	  Vα2+	  (Figure	  2.1A).	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  Figure	  2.1	  Genotyping	  of	  OT	  II	  TCR	  transgenic	  mice	  by	  blood	  analysis	  using	  flow	  cytometry	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Homozygous	  OT	  II+	  lymphocytes	  double	  positive	  for	  surface	  staining	  of	  CD4	  (PE)	  and	  Vα2	  (APC).	  	  
2.5 Preperation	  of	  murine	  tissues	  	  	   Age	  (6-­‐12	  weeks	  of	  age	  unless	  otherwise	  indicated)	  and	  sex	  matched	  mice	  were	  sacrificed	  using	  CO2	  and	  various	  organs	  were	  harvested	  and	  prepared	  for	  use	   in	   downstream	   applications.	   All	   tissues	   were	   counted	   after	   preparation	  unless	  otherwise	  stated	  using	  either	  a	  hemocytometer	  or	  using	  the	  cell	  counting	  assay	  on	  a	  BD	  Verse.	  	  
2.5.1 Isolation	  of	  thymocytes	  	   Thymus	   was	   dissected	   and	   cleaned	   using	   cold	   DMEM	   media.	   Samples	  were	   mashed	   through	   cell	   strainers	   (70μm,	   BD)	   using	   the	   hard	   end	   of	   a	   5ml	  syringe	   (BD)	   to	   obtain	   single	   cell	   suspensions,	   strainers	  were	   flushed	   through	  with	   10ml	  DMEM	  media	   to	   ensure	  maximum	   collection	   of	   cells.	   Samples	  were	  centrifuged	  at	  250	  x	  g	  5	  min	  at	  4°C,	  resuspended	  in	  cold	  DMEM	  media	  and	  kept	  on	  ice	  until	  use.	  	  
2.5.2 Isolation	  of	  bone	  marrow	  cells	  	  	   Femurs	   and	   tibias	   were	   dissected	   and	   cleaned	   thoroughly	   to	   remove	  muscle	   using	   PBS	   and	   rinsing	   in	   70%	   ethanol.	   The	   end	   of	   each	   bone	   was	  removed	   and	   bone	  marrow	  was	   isolated	   by	   flushing	   through	   10ml	   sterile	   PBS	  with	  a	  23G	  needle.	  No	  red	  blood	  cell	  lysis	  was	  carried	  out	  when	  the	  resulting	  cell	  suspension	   for	  used	  within	  culture,	  as	   it	   is	  detrimental	   for	   isolation	  of	  myeloid	  progenitor	   cells	   thus	   lowering	   yield	   of	   differentiated	   cells	   throughout	   culture.	  However,	   for	   downstream	   application	   in	   flow	   cytometry	   red	   blood	   cells	   were	  lysed	   by	   incubation	   of	   samples	   with	   1	   x	   ACK	   buffer	   for	   2	   min	   at	   room	  temperature.	   Cells	   were	   then	   washed	   in	   10ml	   of	   complete	   mouse	   media	   and	  centrifuged	  at	  250	  x	  g	  for	  5	  minutes.	  	  
2.5.3 Isolation	  of	  splenocytes	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Spleens	  were	  dissected	  and	  placed	  between	  2	  pieces	  of	  sterile	  gauze	  in	  6-­‐well	  plates.	  Single	  cell	  suspensions	  were	  achieved	  by	  mashing	  tissues	  with	  5	  ml	  syringes	   into	   cold	   complete	   mouse	   media.	   Resulting	   cell	   suspensions	   were	  filtered	   through	   0.45μm	   filters	   (Partec,	   Milton	   Keynes,	   UK)	   into	   falcons	   and	  centrifuged	   for	   5	  min	   at	   250	   x	  g	   to	   pellet	   cells.	   Supernatant	  was	   removed	   and	  spleen	  preparations	  were	   red	  blood	  cell	   lysed	  using	  3ml	  1x	  ACK	  solution	   for	  2	  min	  at	  room	  temperature.	  Samples	  were	  then	  diluted	  with	  5ml	  RMPI	  media	  and	  centrifuged	  for	  5	  min	  at	  250	  x	  g	  at	  4°C.	  Red	  blood	  cell	  lysis	  step	  was	  performed	  until	  cell	  pellets	  were	  no	  longer	  red.	  At	  this	  point	  they	  were	  resuspended	  in	  10ml	  complete	  mouse	  media	  and	  kept	  on	  ice	  until	  use.	  	  
2.5.4 Isolation	  of	  cells	  from	  lymph	  nodes	  	  	   Lymph	  nodes	  including	  axillary,	   inguinal	  and	  mesenteric,	  were	  dissected	  and	   placed	   between	   2	   pieces	   of	   sterile	   gauze	   in	   6-­‐well	   plates.	   Single	   cell	  suspensions	   were	   achieved	   by	   mashing	   tissues	   with	   1	   ml	   syringes	   into	   cold	  complete	  mouse	  media.	  Resulting	  cell	  suspensions	  were	  filtered	  through	  0.45μm	  filters	  (Partec,	  Milton	  Keynes,	  UK)	  into	  falcons	  and	  centrifuged	  for	  5	  min	  at	  250	  x	  
g	  to	  pellet	  cells	  and	  resuspended	  in	  complete	  mouse	  media.	  	  	  
2.5.5 Preparation	  of	  blood	  	  	   Blood	  was	  obtained	  through	  cardiac	  puncture	  using	  1ml	  syringe	  with	  23G	  needle	   and	   collected	   in	  heparin	   tubes.	  Heparin	   tubes	  were	   inverted	  3	   times	   to	  prevent	   clotting	  of	  blood	   samples,	   and	  were	  kept	  on	   ice	  until	  use.	  100µl	   blood	  per	  stain,	  per	  mouse	  was	  pipetted	  into	  FACS	  tubes	  and	  1ml	  1	  x	  ACK	  solution	  was	  added	   to	   allow	   lysis	   of	   red	   blood	   cells.	   Samples	   were	   incubated	   at	   room	  temperature	   for	   2	   min	   and	   1ml	   RMPI	   media	   was	   added	   before	   centrifuging	  samples	  at	  250	  x	  g	  for	  5	  min	  at	  4°C.	  The	  red	  blood	  cell	  lysis	  step	  was	  repeated	  3	  times	   or	   until	   cell	   pellets	   were	   no	   longer	   red.	   Cells	   were	   kept	   on	   ice	   before	  proceeding	  to	  FACS	  staining.	  	  	  
	  	  
86	  
2.5.6 Isolation	  of	  lymphocytes	  from	  the	  small	  intestine	  	  	  
2.5.6.1 Isolation	  of	  intraepithelial	  lymphocytes	  (IELs)	  	   The	  small	  intestine	  from	  the	  proximal	  duodenum	  to	  terminal	  ileum	  were	  dissected	   free	   from	   the	  mesentery	  and	   removed.	   Small	   intestines	  were	   flushed	  with	   20ml	   cold	   1	   x	   PBS	   and	   cut	   longitudinally.	   Peyers	   patches	  were	   identified	  and	  excised.	   Intestines	  were	  then	  cut	   transversely	   into	  pieces	  of	  approximately	  5mm	   in	   length	   and	   placed	   in	   falcons	   containing	   50ml	   of	   RPMI	   media	  supplemented	  with	  10%	  FBS	  and	  1mM	  DTT	  per	  individual	  tissue.	  	  Samples	  were	  incubated	   for	   30	  min	  whilst	   shaking	   at	   room	   temperature.	   Samples	  were	   then	  centrifuged	   for	   5	   minutes	   at	   500	   x	   g	   at	   room	   temperature	   for	   5	   min.	   The	  supernatant	  was	   discarded	   and	   intestinal	   pieces	  were	   resuspended	   in	   10ml	   of	  RMPI	  media	  within	  50ml	  falcons.	  Samples	  were	  vortexed	  for	  3	  min.	  At	  this	  point,	  the	   resulting	   suspension	   was	   passed	   through	   a	   70μm	   cell	   strainer	   (Griener,	  Gloucestershire,	  UK)	  and	  supernatant	  was	  collected.	  Remaining	  intestinal	  pieces	  were	  placed	  in	  10ml	  RMPI	  media,	  vortexed	  for	  3	  min	  and	  passed	  through	  a	  70μm	  cell	  strainer.	  The	  resulting	  supernatant	  was	  centrifuged	  at	  500	  x	  g	   for	  5	  min	  at	  room	  temperature.	  Cells	   were	   then	   resuspended	   in	   40%	   Percoll	   (Sigma,	   Dorset,	   UK)	   and	  overlaid	   on	   80%	   Percoll	   and	   the	   gradient	   was	   centrifuged	   at	   700	   x	   g	   for	   30	  minutes	  at	  room	  temperature.	  Cells	  that	  lay	  at	  the	  40-­‐80%	  interface	  are	  the	  IEL,	  which	   were	   removed	   from	   the	   Percoll	   and	   washed	   with	   RMPI	   media	  supplemented	  with	  complete	  mouse	  media.	  	  	  	  
2.5.6.2 Isolation	  of	  cells	  within	  the	  lamina	  propria	  Once	   the	   intraepithelial	   layer	   had	   been	   extracted,	   the	   remaining	   small	  intestinal	   pieces	   were	   washed	   twice	   in	   PBS	   before	   extraction	   of	   the	   lamina	  propria	   lymphocyte	   layer.	   Pieces	  were	   placed	   in	   RMPI	   complete	  mouse	  media	  with	   collagenase	   D	   (0.5mg/ml)	   (Roche,	   West	   Sussex,	   UK)	   and	   DNAse	   I	  (100μg/ml)	  (Sigma).	  	  Samples	  were	  incubated	  at	  37°C	  for	  1	  hr	  and	  subsequently	  vortexed	   for	   3	   min	   before	   passing	   through	   70μm	   cell	   strainers.	   The	   resulting	  supernatant	  was	  then	  mixed	  with	  40%	  Percoll	  and	  centrifuged	  at	  700	  x	  g	  for	  30	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minutes	  at	   room	  temperature.	  Cells	  were	   then	   isolated	   from	  the	   lower	   layer	  of	  40%	   Percoll,	   placed	   in	   a	   fresh	   falcon.	   Samples	  were	   then	  washed	   in	   complete	  mouse	  media	  and	  centrifuged	  for	  5	  min	  at	  250	  x	  g	  at	  4°C.	  Cells	  were	  kept	  on	  ice	  until	  use.	  	  
2.5.7 CD4+	  T	  lymphocyte	  purification	  from	  primary	  cell	  suspensions	  	  	   In	  order	  to	  use	  a	  pure	  population	  of	  cells,	  murine	  tissues	  including	  spleen	  and	   multiple	   lymph	   nodes	   including	   axillary,	   inguinal	   and	   mesenteric	   lymph	  nodes	  were	  used	  as	  prepared.	  	  For	   positive	   selection	   of	   CD4+	   lymphocytes	   total	   cell	   suspension	   were	  mixed	   with	   CD4+	   magnetic	   beads	   (Miltenyi)	   according	   to	   manufacturers	  instructions.	  Briefly,	  cell	  preparations	  were	  centrifuged	  at	  250	  x	  g	  for	  10	  min,	  the	  supernatant	   was	   removed	   and	   10µl	   CD4	   magnetic	   beads	   +	   90µl	   MACs	   buffer	  (1xPBS/	   1%	   FBS/	   2mM	   EDTA)	   was	   added	   per	   107	  total	   cells,	   mixed	   well	   and	  incubated	   on	   ice	   for	   30	  min.	   Samples	   were	   washed	   in	   40ml	  MACs	   buffer	   and	  centrifuged	  for	  5	  min	  at	  250	  x	  g.	  Labeled	  cells	  were	  resuspended	  in	  MACs	  buffer	  and	   positively	   selected	   using	   magnetic	   separation	   using	   autoMACs	   machine	  (Miltenyi).	   	  Cells	  were	  counted	  and	  placed	  on	   ice	  until	  use.	   	  Purity	  of	  CD4	  cells	  after	  positive	  selection	  was	  checked	  by	  flow	  cytometry,	  purity	  was	  always	  >80%.	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  Figure	  2.2	  CD4+	  lymphocyte	  purity	  after	  magnetic	  purification	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CD4+	  T	  lymphocyte	  purity	  assessed	  by	  CD4	  surface	  staining	  by	  flow	  cytometry.	  	  
2.6 Cell	  culture	  	  
2.6.1 Culture	  of	  mammalian	  cell	  lines	  	  	  
2.6.1.1 RAW264.7	  macrophage	  cell	  line	  	   Cells	  were	  kindly	  obtained	   from	  Simon	  Arthur	   laboratory	  (Cell	  signaling	  and	   Immunology,	   University	   of	   Dundee).	   Cells	   were	   cultured	   in	   DMEM	  media	  (Invitrogen)	   supplemented	   with	   10%	   (v/v)	   heat-­‐inactivated	   FBS,	   50	   units/ml	  penicillin	   and	   50	   μg/ml	   streptomycin.	   Cells	  were	   cultured	   at	   37°C,	   5%	   CO2	   at	  90%	  humidity	  and	  maintained	  at	  70%	  confluence,	  according	  to	  ATCC	  guidelines.	  	  When	   70%	   cell	   confluence	   was	   reached,	   cells	   were	   scraped	   into	   suspension	  using	   a	   cell	   scraper	   and	   flushed	   to	   harvest.	   Cells	   were	   split	   into	   1:3	   or	   1:6	  suspensions	  with	  media	  refreshed	  every	  2	  days.	  	  	  	  
2.6.1.2 K562	  human	  CML	  cell	  line	  	   Cells	   were	   kindly	   obtained	   from	   David	   Meek	   laboratory	   (Division	   of	  Cancer	   Research,	   University	   of	   Dundee).	   Cells	   were	   cultured	   in	   RMPI	   media	  supplemented	  with	   10%	   (v/v)	   heat-­‐inactivated	   FBS,	   50	   units/ml	   penicillin,	   50	  μg/ml	   streptomycin	   and	   2mM	   l-­‐glutamine.	   	   Cells	  were	   cultured	   at	   37°C	   at	   5%	  CO2	   and	  maintained	   at	   1x106/ml	   and	   the	  media	  was	   renewed	   every	   2-­‐3	   days,	  according	  to	  ATCC.	  	  
2.6.1.3 Freezing	  of	  cell	  lines	  	   All	   cell	   lines	   were	   frozen	   at	   5x106	   or	   10x106	   total	   cells	   in	   cyrovials	  suspended	  in	  FBS	  with	  5%	  (v/v)	  DMSO	  (Sigma).	  Cells	  were	  frozen	  in	  Mr.	  Frosty	  containers	   at	   -­‐80°C	   for	   24	   hrs.	   Vials	   were	   then	   transferred	   to	   liquid	   nitrogen	  containers	  and	  stored	  in	  liquid	  nitrogen	  vapor	  phase.	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2.6.2 Primary	  cell	  culture	  	  
2.6.2.1 Bone	  marrow	  derived	  macrophages	  (BMDMs)	  	  	   Isolated	   bone	   marrow	   cells	   were	   resuspended	   in	   20ml	   DMEM	   media	  (Invitrogen)	   medium	   supplemented	   with	   10%	   (v/v)	   heat-­‐inactivated	   FBS	   ,	   50	  units/ml	   penicillin,	   50	   μg/ml	   streptomycin	   and	   further	   supplemented	   with	  10ng/ml	  macrophage-­‐colony	  stimulating	   factor	   (M-­‐CSF)	   (R&D	  systems,	  Oxford,	  UK).	  Cells	  were	  cultured	  for	  6	  days	  at	  37°C	  at	  5%	  CO2	  and	  were	  supplemented	  with	   fresh	  media	   containing	  M-­‐CSF	   on	   day	   3.	  Macrophages	  were	   harvested	   on	  day	  6	  of	  culture.	  	  
2.6.2.2 Bone	  marrow	  derived	  dendritic	  cells	  (BMDCs)	  	   Isolated	   bone	   marrow	   cells	   were	   resuspended	   at	   a	   cell	   density	   of	  1x107/ml.	   200μl	   (2x106	   total)	   of	   this	   suspension	   was	   added	   to	   the	   middle	   of	  	  non-­‐tissue	   treated	   10cm	   plates	   containing	   10ml	   of	   RPMI	  media	   supplemented	  with	   L-­‐glutamine	   (Invitrogen),	   10%	   (v/v)	   heat-­‐inactivated	   FBS,	   50	   units/ml	  penicillin	   (Sigma),	   50	   μg/ml	   streptomycin,	   50	   μM	   2-­‐βmercaptoethanol	   and	  10ng/ml	   granulocyte	   macrophage	   colony	   stimulating	   factor	   (GM-­‐CSF)	  (Peprotech,	  London,	  UK).	  Cells	  were	  cultured	  for	  10	  days	  at	  37°C	  at	  5%	  CO2	  and	  given	  fresh	  media	  containing	  10ng/ml	  GM-­‐CSF	  on	  days	  3,	  6	  and	  8.	  BMDCs	  were	  harvested	  on	  day	  10	  of	  culture.	  	  
2.6.2.3 Harvesting	  adherent	  primary	  myeloid	  cells	  	  	   Unless	   otherwise	   stated,	   cells	   were	   harvested	   by	   aspirating	   media	   and	  incubating	   5ml	   sterile	   2mM	   EDTA/PBS	   @	   37°C	   for	   10	   min	   to	   loosen	   cell	  adhesions	  (Invitrogen).	  Cells	  were	  then	  flushed	  up	  and	  down	  repeatedly	  using	  a	  pipette	  aid	  to	  harvest,	  centrifuged	  for	  5	  min	  at	  250	  x	  g.	  Cells	  were	  then	  counted	  using	  a	  hemocytometer	  and	  resuspended	  at	  required	  density	  in	  6,	  12	  or	  24-­‐well	  non-­‐TC	  treated	  plates	  (BD).	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2.7 Stimulation	  and	  inhibiton	  of	  various	  cells	  	  	  
2.7.1 Cell	  lines	  	  	  
2.7.1.1 RAW264.7	  macrophage	  cell	  line	  	   Cells	  were	  harvested	  by	  gentle	  cell	  scraping,	  counted	  and	  resuspended	  at	  required	  density.	  For	  protein	  samples	  cells	  were	  plated	  at	  either	  5x106/ml	  in	  12-­‐well	   tissue	   culture	   plates,	   or	   2.5x106/ml	   in	   2ml	   in	   6-­‐well	   tissue	   culture	   plates	  and	  allowed	  to	  settle	  for	  3	  hr	  before	  stimulation.	  For	  cytokine	  analysis	  cells	  were	  plated	  at	  1x106/ml	  in	  2ml	  per	  well.	  For	  phospho-­‐flow	  analysis	  cells	  were	  plated	  at	  0.5x106/ml	  the	  night	  before	  and	  stimulated	  the	  following	  morning.	  	  
2.7.1.2 K562	  CML	  cell	  line	  	   Cells	  were	  harvested,	   counted	  and	  resuspended	  at	   required	  density.	  For	  protein	   samples	   cells	   were	   plated	   at	   either	   5x106/ml	   or	   7x106/ml	   in	   12-­‐well	  tissue	   culture	   plates	   and	   allowed	   to	   settle	   for	   3	   hr	   before	   stimulation.	   For	  phospho-­‐flow	   and	   cell	   cycle	   analysis	   cells	   were	   plated	   at	   0.2x106/ml	   or	  0.5x106/ml	  the	  night	  before	  and	  stimulated	  the	  next	  morning.	  	  	  
2.7.2 Primary	  cells	  	  
2.7.2.1 Lymph	  node	  cells	  	   Lymph	  nodes	  were	  dissected	  and	  prepared	  as	  previously	  described.	  Cells	  were	  resuspended	  to	  5x106/ml	  and	  plated	  in	  12-­‐	  or	  24-­‐well	  tissue	  culture	  plates.	  Cells	  were	  allowed	  to	  settle	  for	  4	  hrs	  at	  37°C	  at	  5%	  CO2	  before	  stimulation.	  	  
2.7.2.2 BMDMs	  and	  BMDCs	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For	  protein	  analysis	  cells	  were	  seeded	  at	  either	  5x106/ml	  or	  7x106/ml	  in	  12-­‐well	   non-­‐tissue	   cultured	   plates	   (BD)	   and	   allowed	   to	   settle	   for	   4	   hr	   before	  stimulation.	   For	   flow	   cytometry	   and	   cytokine	   analysis	   cells	   were	   plated	   at	  2x106/ml	  in	  2ml	  in	  6-­‐well	  non-­‐tissue	  culture	  treated	  plates	  (BD)	  and	  starved	  of	  M-­‐CSF	  and	  GM-­‐CSF	  overnight	  before	  stimulation.	  	  
2.7.2.3 Co-­‐culture	  of	  CD4+	  OT	  II+	  T	  cells	  with	  OVA-­‐loaded	  BMDCs	  	   BMDCs	   were	   generated	   in	   vitro	   as	   previously	   described	   from	   WT	   and	  PKD2KI/KI	  bone	  marrow.	   BMDCs	  were	   then	   counted	   and	   resuspended	   complete	  mouse	  medium	   supplement	  with	   GM-­‐CSF	   (10ng/ml)	   at	   2x106	  cells	   per	  ml	   and	  stimulated	  with	  or	  without	  LPS	  (100ng/ml)	  overnight.	  Cells	  were	  harvested	  the	  following	  morning	  with	  4mM	  EDTA	  in	  1xPBS	  and	  loaded	  with	  1μM	  OVA-­‐peptide,	  which	  encompasses	  an	  allergenic	  and	  antigenic	  epitope	  of	  the	  ovalbumin	  protein	  a	   	   I-­‐A(d)	   MHC	   class	   II	   protein	   (peptide	   sequence	   	   -­‐	   SQAVHAAHAEINEAGR)	  (Anaspec,	  Fremont,	  California,	  USA)	  and	  incubated	  for	  90	  min.	  BMDCs	  were	  then	  harvested,	  counted	  and	  resuspended	  at	  0.2x106	  cells	  per	  ml.	   	  BMDCs	  were	  then	  mixed	   1:10	   with	   purified	   CD4+	   T	   lymphocytes	   obtained	   from	   OT	   II+	   mice	   as	  previously	  described	  and	  co-­‐cultured	  for	   in	  24-­‐well	  plates.	  Samples	  were	  taken	  every	   24	   hours	   for	   flow	   cytometry	   analysis	   and	   supernatant	  was	   obtained	   for	  downstream	  ELISA	  application.	  	  
2.8 Detection	  of	  protein	  by	  immunoblotting	  	  	  




Cell	  type	   Lysis	  buffer	   Cell	  density	  
Bone	  marrow	  derived	  dendritic	  
	  cells	  
Low	  salt	  lysis	  buffer	   70x106/ml	  
Bone	  marrow	  derived	  
	  macrophages	  
	  
NP-­‐40	  lysis	  buffer	   70x106/ml	  
RAW264.7	  cell	  line	   Np-­‐40	  lysis	  buffer	   50-­‐70x106/ml	  
K562	  human	  CML	  cell	  line	   Low	   salt	   or	   RIPA	  buffer	   50-­‐70x106/ml	  
T	  lymphocytes	   F	  lysis	  buffer	   100x106/ml	  
Spleen	  lymphocyte	  preparations	   F	  lysis	  buffer	   100x106/ml	  
Lymph	  node	  lymphocyte	  
	  preparations	  
F	  lysis	  buffer	   100x106/ml	  







Solvent	   Inhibition	  of	  
Leupeptin	   5mg/ml	   2µg/ml	   Water	   Cysteine	   and	   serine	  proteases	  
PMSF	   100mM	   1mM	   Isopropanol	   Serine	  proteases	  
Pepstatin	  
A	  
1mg/ml	   1µg/ml	   Methanol	   Aspartic	  proteases	  
Na3VO4	   200mM	   1mM	   Water	   Phosphotases	  Table	  2.6	  Protease	  inhibitors	  used	  in	  cell	  lysis	  buffers	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2.8.2 Lysis	  of	  cells	  for	  protein	  immunoblotting	  	  	  
2.8.2.1 Suspension	  cells	  	  	   After	   treatment	   cells	   were	   harvested	   into	   1.5ml	   eppendorfs	   and	  centrifuged	  for	  5	  min	  at	  250	  x	  g	  at	  4°C.	  Cell	  pellets	  were	  then	  washed	  in	  1ml	  ice	  cold	  PBS	  and	  centrifuged	  again	  for	  5	  min	  at	  250	  x	  g.	   	  Samples	  were	  then	  either	  snap	   frozen	   in	   liquid	   nitrogen	   or	   lysed	   in	   appropriate	   volume	   of	   chosen	   lysis	  buffer	  and	  protease	  inhibitors	  as	  described	  in	  for	  30	  min	  on	  ice	  with	  occasional	  vortexing.	   Samples	   were	   then	   centrifuged	   for	   20	   min	   at	   500	   x	   g	   	   at	   4°C.	   The	  supernatant	  was	  removed	  carefully	  to	  avoid	  disrupting	  the	  pellet	  and	  placed	  in	  fresh	   eppendorfs.	   1	   x	   laemelli	   buffer	   supplemented	   with	   1:20	   2β-­‐mercaptoethanol	  was	  finally	  added	  and	  samples	  were	  boiled	  for	  10	  min	  at	  100°C.	  Samples	  were	  subsequently	  stored	  at	  -­‐20°C	  until	  use. 	  




2.8.3 Resolution	   of	   protein	   samples	   on	   SDS	   polyacrylamide	   gel	  
electrophoresis	  	  	   For	  western	  blotting,	  30µl	  of	   sample	   for	  1.5mm	  10	  well	  pre-­‐cast	  4-­‐12%	  gradient	  gels	  (Life	  technologies)	  or	  15µl	  of	  sample	  for	  1.0mm	  12	  well	  pre-­‐cast	  4-­‐12%	  gels.	  For	  each	  gel	  5µl	  of	  molecular	  weight	  seeblue®	  prestained	  marker	  (Life	  technologies)	   was	   loaded.	   Pre-­‐cast	   gels	   were	   run	   with	   1X	   MES	   buffer	   (Life	  technologies)	   using	   .	   Gels	   were	   then	   electrophoresed	   at	   150V	   for	   80-­‐100	  min	  depending	  on	  protein	  size.	  Proteins	  were	  then	  transferred	  onto	  PVDF	  membrane	  (Millipore,	  Seltham,	  UK)	  	  	  
2.8.4 Transfer	  of	  proteins	  onto	  PVDF	  membrane	  for	  immunoblotting	  	  	   Invitrogen	   life	   technologies	   transfer	   cell	  modules	  were	   used	   to	   transfer	  proteins	  from	  the	  SDS-­‐PAGE	  gel	  onto	  polyvinylidene	  fluoride	  (PVDF)	  membrane	  (Merek,	  Millipore).	  All	  materials	  were	  pre-­‐soaked	  in	  transfer	  buffer	  (Invitrogen	  -­‐	  life	   technologies)	   prior	   to	   assembly	   of	   transfer	   module.	   The	   transfer	   module	  comprised	  of	  2	  sponges,	  2	  x	  8cm	  by	  8cm	  3mm	  Whatman	  filter	  paper	  (Sigma),	  the	  SDS	  page	  gel,	   one	  7.5cm	  by	  8cm	  PVDF	  membrane	   (pre-­‐activated	  by	   soaking	   in	  100%	  methanol	  for	  5	  min),	  2	  x	  8cm	  by	  8cm	  Whatman	  filter	  paper	  and	  2	  further	  sponges.	   	   The	  module	  was	   then	   filled	  with	   transfer	   buffer.	   	   The	   proteins	  were	  transferred	  at	  35V	  for	  1-­‐2	  hr	  depending	  on	  protein	  size.	  	  	  
2.8.5 Western	  blot	  antibodies	  and	  conditions	  	  	   Following	  transfer	  of	  proteins	  onto	  PVDF	  membrane	  protein	  loading	  was	  checked	  by	  staining	  the	  membrane	  with	  Ponceau	  solution	  (Sigma)	  for	  5	  min	  and	  washed	  in	  de-­‐ionised	  water.	  Membranes	  were	  then	  blocked	  with	  5%	  (w/v)	  dried	  milk	   (Marvel)	   in	   PBS-­‐Tween	  buffer	   for	   1	   hr	   on	   a	   shaker	   at	   room	   temperature.	  	  Membranes	  were	  then	  incubated	  with	  primary	  antibody	  diluted	  1:100	  or	  1:500	  in	   either	   5%	   dried	   milk/PBS-­‐Tween	   or	   2%	   BSA/	   PBS-­‐Tween	   as	   described	   in	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tables	   (Table	   2.7	   and	  Table	   2.8).	   	   Unbound	  primary	   antibody	  was	   removed	  by	  washing	   the	   membrane	   with	   PBS-­‐Tween	   for	   3x	   5	   min	   shaking,	   after	   which	  membranes	   were	   then	   incubated	   with	   appropriate	   species	   horseradish	  peroxidase	   (HRP)	   conjugated	   secondary	   antibody	   (company)	   diluted	   either	  1:10,000	  or	  1:5000	   in	   either	  3%	  dried	  milk	   in	  PBS-­‐Tween	  or	  PBS-­‐Tween	  only.	  Various	  antibodies	  used	  to	  detect	  both	  endogenous	  and	  phosphorylated	  proteins	  are	  described	  in	  Table	  2.7.	  Specific	  antibodies	  used	  to	  detect	  PKD	  isoforms,	  both	  endogenous	  and	  phosphorylated	  are	  detailed	  in	  Table	  2.8	  	  
Antibody	   Species	  	   Company	   Order	  
number	  
Pan-­‐AKT	   Rabbit	   Cell	  Signaling	  Technologies	   9272S	  
Phospho-­‐	  AKT	  (473)	   Rabbit	   Cell	  Signaling	  Technologies	   9272S	  
β-­‐Tubulin	   Mouse	   Santa	  Cruz	   SC	  5274	  
Phospho	  p.38	  
	  (T180/Y204)	  
Mouse	   Cell	  Signaling	  Technologies	   9216S	  
Phospho	  ERK1/2	  
(T202/Y204)	  
Mouse	   Cell	  Signaling	  Technologies	   9106S	  
Total	  ERK1/2	  
(P44/p42)	  
Mouse	   Cell	  Signaling	  Technologies	   9102S	  
Phospho	  HDAC	  4-­‐5-­‐7	  
	  
Rabbit	   Cell	  Signaling	  Technologies	   3424S	  
Iκβα	  (NFKB)	   Mouse	   Cell	  Signaling	  Technologies	   9247S	  
p-­‐105	  NFκB	  
Ser933	  site	  	  
Rabbit	   Cell	  Signaling	  Technologies	  	   4806S	  
Phospho-­‐STAT3	  (XP)	   Rabbit	   Cell	  Signaling	  Technologies	   9145S	  
Phospho-­‐STAT5	  (XP)	   Rabbit	  	   Cell	  Signaling	  Technologies	   4322S	  
Phospho-­‐S6	  
(Ribosomal)	  
Rabbit	   Cell	  Signaling	  Technologies	   2211S	  




Antibody	   Species	   Isoform	  
specificity	  	  





Rabbit	   PKD1	  PKD2	   Raised	  in	  house	   N/A	  
Phospho	  PKD	  	  
Serine	  744/748	  
	  
Rabbit	   PKD1	  PKD2	  PKD3	  
Cell	   Signaling	  Technology	   2054S	  
Phospho	  PKD	  
Tyrosine	  643	  	  
	  
Rabbit	   PKD1	  PKD2	  	  
	  Abcam	   AB59415	  
PKD	  total	   Rabbit	   PKD1	  PKD2	  PKD3	  
	  Raised	  in	  house	   N/A	  
PKD2	  total	   Rabbit	   PKD2	  	   Calbiochem	  (Merck	  Millipore)	   ST1042	  
PKD3	  total	   Rabbit	   PKD3	  	   Bethyl	   A300-­‐319A	  
Table	  2.8	  Antibodies	  used	  to	  detect	  PKD	  isoforms	  by	  western	  blotting	  	  	  
2.9 	  Flow	  cytometry	  	  Flow	   cytometric	   data	   was	   obtained	   using	   either	   an	   LSR	   II	   Fortessa,	   Canto	   or	  Verse	   (BD).	   All	   flow	   cytometry	   data	   was	   analysed	   using	   FlowJo	   data	   analysis	  (Tree	  star	  inc).	  	  	  
2.9.1 Flow	  cytometry	  solutions	  	  	  FACS	  buffer	   	   	   	   	   1	  x	  PBS	  	  	   	   	   	   	   	   2%	  FBS/BSA	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   2mM	  EDTA	  	  Fixation	  and	  permeabilisation	  buffers	  	   (eBioscience)	  	  
2.9.2 Determination	  of	  cell	  number	  by	  flow	  cytometry	  	   Murine	  tissues	  were	  prepared	  as	  stated	  and	  their	  cell	  number	  determined	  by	  making	  a	  1:10	  dilution.	  Live/dead	  cells	  were	  counted	  	  by	  adding	  500µl	  of	  	  PBS	  supplemented	  with	   50µg/ml	  DAPI	   and	   analysis	   of	   cell	   populations	   by	   forward	  light	  scatter	  (FSC)	  and	  side	  scatter	  (SSC)	  identifying	  live	  cells	  as	  a	  DAPI	  negative	  population.	   Cell	   counting	   was	   performed	   on	   BD	   FACS	   Verse	   and	   cells	   per	   ml	  number	  was	  achieved	  by	  the	  following	  calculation:	  	  
 
 	  	  Cells/volume	  *	  1000	  	  	  	  Total	  cell	  number	  per	  tissue	  was	  then	  achieved	  by	  the	  following	  calculation:	  	   	  	   	   Cells	  per	  ml	  *	  dilution	  factor	  *	  total	  volume	  	  
    
2.9.3 Compensation	  controls	  	  	   All	  flow	  cytometry	  experiments,	  unless	  stated	  otherwise,	  were	  performed	  with	   compensation	   controls	   to	   correct	   for	   spectral	   overlap	   in	  multi-­‐colour	   and	  multi-­‐parameter	   experiments.	   	   This	   included	   a	   no	   stain	   control	   and	   single	  stained	   samples	   for	   all	   fluorophores	   used	   in	   the	   experiment.	   With	   the	   use	   of	  tandem	   dyes	   the	   same	   antibody	   was	   used	   for	   compensation	   as	   used	   in	   the	  experiment.	   Where	   non-­‐tandem	   dyes	   were	   used	   compensation	   controls	   were	  picked	  to	  ensure	  a	  negative	  and	  positive	  population	  was	  present	   in	   the	  stained	  control.	  For	   intracellular	  staining,	   including	  phospho-­‐flow,	  compensations	  were	  also	   fixated	   and	   permeabilised	   to	   ensure	   the	   same	   FSC	   and	   SSC	   profiles	   as	  experimental	  samples.	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2.9.4 Surface	  staining	  	  	   To	  pellet	  cells	  samples	  were	  placed	  in	  FACS	  tubes	  (BD)	  and	  spun	  down	  at	  250	  x	  g	  in	  a	  chilled	  4°C	  centrifuge.	  The	  supernatant	  was	  poured	  off	  and	  samples	  were	  resuspended	  in	  Fc	  blocking	  solution	  (eBioscience),	  this	  step	  is	  necessary	  to	  block	   the	  binding	  of	   antibodies	   to	   the	  FcγR	  present	  on	   cell	   surfaces	  which	   can	  result	   in	  non-­‐specific	  antibody	  binding.	   	  All	   samples	  were	   incubated	  with	  FcγR	  antibody	   for	   20	   min	   on	   ice	   prior	   to	   staining.	   Surface	   staining	   was	   performed	  using	  the	  relevant	  antibodies	  at	  previously	  determined	  saturating	  concentration	  as	  described	   in	   table	   (Table	  2.9	  and	  Table	  2.9).	   Staining	  was	  performed	   for	  20	  min	   on	   ice	   in	   the	   dark.	   Cells	  were	  washed	   in	   FACS	   buffer	   and	   resuspended	   in	  FACS	  buffer	  before	  acquisition	  on	  stated	  flow	  cytometer.	  A	  minimum	  of	  10,000	  events	  were	  collected	  and	  stored	  un-­‐gated	  after	  which	  the	  data	  was	  analysed	  on	  FlowJo.	   Live	   cells	   were	   gated	   by	   FSC/SSC	   profiles	   and	   live	   cells	   were	   further	  confirmed	  by	  being	  DAPI	  negative.	  	  
2.9.5 Detection	  of	  Treg	  populations	  by	  intracellular	  flow	  cytometry	  	   Age	   and	   sex	   matched	   mice	   were	   sacrificed	   at	   6-­‐8	   weeks	   of	   age	   unless	  otherwise	   stated.	   Tissues	  were	   dissected	   and	   prepared	   as	   described,	   5-­‐10x106	  cells	  were	  used	  per	  mouse	  per	  tissue	  and	  centrifuged	  at	  250	  x	  g	  for	  5	  min	  at	  4°C.	  5x106	  cells	  were	  used	  per	  tissue	  for	  compensation	  controls.	  Samples	  were	  FcγR	  blocked	  (eBioscience)	  1:70	  for	  20	  min	  on	  ice.	  Samples	  were	  then	  surface	  stained	  for	  CD4-­‐PE-­‐CY7,	  CD25	  –APC-­‐CY7	  or	  CD25	  -­‐PerCPCy5.5,	  and	  CD103-­‐PE	  for	  30	  min	  on	   ice	   concealed	   from	   light.	   Samples	   were	   washed	   in	   1ml	   FACS	   buffer	   and	  centrifuged	   at	   250	   x	   g	   for	   5	   min	   at	   4°C.	   Samples	   were	   then	   resuspended	  fixation/permeabilisation	  buffer	  (FoxP3	  specific	  buffer	  in	  kit	  -­‐	  eBioscience)	  and	  incubated	   at	   4°C	   overnight	   or	   for	   1	   hr	   at	   room	   temperature.	   Samples	   were	  centrifuged	   at	   250	  x	  g	   for	   5	  min	   and	   supernatant	  was	   removed.	   Samples	  were	  vortexed	  and	  resuspended	  in	  100µl	  1x	  permeabilisation	  buffer	  (provided	  in	  kit)	  with	  FoxP3-­‐APC	  antibody	  diluted	  1:100.	  Cells	  were	  stained	  with	  FoxP3	  antibody	  for	  45	  min	  at	  4°C	  in	  the	  dark.	  Samples	  were	  washed	  in	  2ml	  1x	  permeabilisation	  buffer	  and	  centrifuged	  at	  250	  x	  g	  for	  5	  min.	  Supernatant	  was	  removed,	  samples	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were	  vortexed,	   resuspended	   into	  300µl	  FACS	  buffer	  and	  acquired	  on	  either	  BD	  Canto	  or	  BD	  Fortessa.	  	  
	  
2.9.6 Analysis	  of	  phospho-­‐proteins	  by	  flow	  cytometry	  	   For	  analysis	  of	  phospho	  proteins	  by	  flow	  cytometry	  cells	  were	  plated	  and	  settled	   overnight.	   After	   stimulation	   all	   reagents	   were	   kept	   on	   ice	   unless	  otherwise	  stated.	  Unless	  otherwise	  stated	  all	  experiments	  contained	  a	  negative	  unstimulated	   control	   and	   a	   positive	   control.	   Depending	   on	   the	   experiment	   1-­‐5x106	  cells	  were	  used	  per	  sample.	  For	  adherent	  cells	  the	  media	  was	  immediately	  aspirated	  and	  cells	  were	  placed	  in	  200µl	  of	  cold	  IC	  fixation	  buffer	  supplemented	  with	   various	   protease	   inhibitors	   including	   leupeptin,	   pepstatin	   and	   sodium	  orthovanadate.	   	   Cells	  were	   then	   harvested	   by	   vigorous	   pipetting.	   Cell	   scraping	  was	  never	  used	  during	  phospho	  flow	  analysis	  as	  it	  affects	  the	  cells	  FSC	  and	  SSC	  profiles	  dramatically.	  For	  cell	   suspensions	  1:1	  volume	  of	  cold	   IC	   fixation	  buffer	  was	  directly	  added	  to	  the	  media	  and	  cells	  were	  harvested	  into	  FACS	  tubes.	  Cells	  were	  fixed	  for	  20	  min	  on	  ice.	  	  	  
2.9.6.1 Analysis	   of	   phospho	   PKD	   (p.	   SER916)	   and	   phospho	   ERK1/2	   (p.	  
ERK1/2)	  	  	   After	   cells	   were	   fixed	   cells	   were	   centrifuged,	   the	   supernatant	   removed	  and	   1ml	   ice-­‐cold	   90%	   methanol	   was	   added	   whilst	   vortexing.	   Samples	   were	  permeabilised	   for	   30	  min	   on	   ice	   and	  washed	   twice	  with	   2ml	   FACS	   buffer	   and	  centrifuged	  at	  250	  x	  g	  for	  5	  min	  at	  4°C.	  Samples	  were	  FcγR	  (blocked	  for	  20	  min	  on	  ice	  and	  stained	  with	  either	  both	  p-­‐SER916	  rabbit	  antibody	  used	  at	  1:1000	  and	  p-­‐ERK	  mouse	   antibody	   1:200	   for	   30	  min	   at	   room	   temperature.	   Samples	   were	  washed	  twice	  with	  FACS	  buffer	  and	  centrifuged	  at	  250	  x	  g	  for	  5	  min.	  Secondary	  antibodies	   including	   anti-­‐rabbit	   Alexafluor	   488	   and	   anti-­‐mouse	  Alexafluor	   647	  both	   used	   at	   1:500	   for	   30	  min	   at	   room	   temperature	   and	   concealed	   from	   light.	  Finally	   cells	   were	   washed	   twice	   with	   FACS	   buffer	   and	   acquired	   on	   either	   BD	  Fortessa	  or	  BD	  Canto.	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2.9.6.2 Analysis	  of	  phospho	  STAT5	  	  	   After	   cells	   were	   fixed	   cells	   were	   washed	   with	   2ml	   FACS	   buffer	   and	  centrifuged	  at	  250	  x	  g	  for	  5	  min	  at	  4°C.	  The	  supernatant	  was	  discarded	  and	  1ml	  ice	   cold	   1:1	   acetone:	   methanol	   solution	   was	   added	   whilst	   vortexing.	   Samples	  were	  either	  permeabilised	  for	  30	  min	  on	  ice	  or	  overnight	  at	  -­‐20°C.	  Samples	  were	  washed	   twice	   with	   4ml	   1xPBS	   5%	   FBS.	   Samples	   were	   FcγR	   blocked	   with	  CD16/32	  antibody	   (Biolegend)	   for	  20	  min	  at	   room	  temperature.	  Samples	  were	  then	   stained	  with	  pSTAT5-­‐	  PE	   antibody	   (BD)	  used	   at	   1:50	   for	  30	  min	   at	   room	  temperature	  and	  concealed	  from	  light.	  Finally	  samples	  were	  washed	  twice	  with	  2ml	  1xPBS	  5%	  FBS	  and	  acquired	  on	  BD	  Canto.	  	  	  
2.9.7 	  Analysis	   of	   IFNAR1	   surface	   and	   intracellular	   expression	   in	   K562	  
CML	  cells	  	   Chronic	  myeloid	   leukemia	   cells	   are	  documented	  within	   the	   literature	   to	  display	  abnormal	  amounts	  of	  intracellular	  expression	  of	  the	  IFN-­‐α	  receptor	  due	  to	  enhanced	  down-­‐regulation	  from	  the	  cell	  surface.	  To	  analyse	  the	  effects	  of	  PKD	  inhibitors	   on	   the	   up-­‐regulation	   of	   the	   IFN-­‐	  α	   receptor	  both	  surface	  staining	  and	  
intracellular	  staining	  was	  performed.	  	  
2.9.7.1 Surface	  	  	   5x106	   cells	   were	   treated	   and	   centrifuged	   for	   5	   min	   at	   250	   x	   g	   at	   4°C.	  Samples	   were	   then	   FcRγ	   blocked	   for	   20	   min	   and	   stained	   with	   an	   anti-­‐IFN-­‐α	  receptor	   human	   rabbit	  monoclonal	   (Abcam,	   Cambridge,UK)	   for	   30	  min	   on	   ice.	  Samples	   were	   washed	   in	   1ml	   FACS	   buffer	   and	   centrifuged.	   Cells	   were	   then	  stained	  with	  1:500	  anti-­‐rabbit	  AlexaFluor	  488	   for	  30	  min	  at	  room	  temperature	  concealed	  from	  light.	  Finally	  cells	  were	  washed	  in	  2ml	  FACS	  buffer	  and	  acquired	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on	  BD	  Canto.	  Either	  20µg/ml	  DAPI	  or	  ToPRO(Invitrogen,	  Life	  Technologies)	  was	  added	  to	  discriminate	  between	  live/dead	  cells.	  	  	  
2.9.7.2 Intracellular	  	  For	   intracellular	   detection	   5x106	  cells	   were	   centrifuged	   at	   250	   x	   g	   and	  resuspended	   in	   200µl	   of	   IC	   fixation	   buffer	   (eBioscience)	   for	   20	   min	   at	   room	  temperature.	   Cells	   were	   washed	   in	   2ml	   FACS	   buffer,	   cells	   pelleted	   and	  resuspended	   in	   1x	   permeabilisation	   (eBioscience)	   buffer	   supplemented	   with	  FcγR	  block	   (eBioscience)	  and	   incubated	   for	  20	  min	  at	   room	  temperature.	  Anti-­‐human	   IFN-­‐α	  receptor	  antibody	  was	  diluted	  1:30	   in	  1x	  permeabilisation	  buffer	  and	   100µl	   was	   added	   per	   sample	   and	   stained	   for	   30	   min	   to	   1	   hr	   at	   room	  temperature.	  Cells	  were	  washed	  and	  resuspended	  in	  1:500	  anti-­‐rabbit	  Alexafluor	  488	  (Invitrogen	  Life	  Techonologies)	  and	  stained	  for	  30	  min	  at	  room	  temperature	  concealed	  from	  light.	  Samples	  were	  washed	  in	  2ml	  FACS	  buffer	  and	  acquired	  on	  BD	  Canto.	  	  
2.9.8 Analysis	  of	  cell	  cycle	  by	  propidium	  iodide	  	   K562	   cells	   were	   harvested,	   their	   cell	   number	   determined	   and	  resuspended	   at	   required	   density.	   For	   cell	   cycle	   analysis,	   cells	   were	   plated	   at	  0.2x106/ml	   in	  24-­‐well	   tissue	   culture	   treated	  plates	   and	   incubated	  overnight	   to	  ensure	   cells	   were	   actively	   cycling	   after	   seeding.	   Cells	   were	   then	   treated	   with	  increasing	  concentrations	  of	  PKD	  inhibitors,	  DMSO	  was	  used	  as	  a	  vehicle	  control	  and	   media	   only	   samples	   were	   including	   as	   negative	   controls.	   Cell	   cycle	   was	  analysed	  at	   the	   following	   time	  points;	   2,	   4,	   6,	   7	   and	  8	  hr.	  After	   treatment	   cells	  were	  harvested	  into	  FACS	  tubes	  and	  centrifuged	  at	  250	  x	  g	  for	  5	  min	  at	  4°C.	  The	  supernatant	  was	   poured	   off	   and	   cells	  were	   gently	   resuspended	   by	   flicking	   the	  bottom	  of	   the	   tubes.	   Cells	  were	   suspended	   in	  1ml	   ice	   cold	  70%	  ethanol	  whilst	  gently	  vortexing	  to	  prevent	  clumping	  of	  cells.	  Cells	  were	  fixed	  for	  at	  least	  30	  min	  room	  temperature	  or	  stored	  at	   -­‐20°C	   for	  up	   to	  4	  weeks.	  Cells	  were	  adjusted	  to	  5x106/ml	  and	  washed	  in	  twice	  in	  1x	  PBS	  +	  1%	  v/v	  FBS.	  Cells	  were	  then	  pelleted	  and	   resuspended	   in	   300-­‐500µl	   staining	   buffer	   which	   consisted	   50µg/ml	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propidium	  iodide	  (company)	  and	  50µg/ml	  ribonuclease	  A	   in	  1x	  PBS	  +	  1%	  FBS.	  	  Cells	  were	  incubated	  at	  room	  temperature	  and	  concealed	  from	  light	  for	  20	  min	  before	  acquisition	  on	  BD	  Canto.	  	  	  
2.9.9 Flow	  cytometry	  antibodies	  and	  their	  conjugates	  	  
Antibody	   Clone	   Fluorophore	   Company	  CD4	   RM45	   PE-­‐Cy7	   Biolegend	  	  	  CD4	   RM45	   PE	   Biolegend	  	  CD4	  	   H129.19	   FITC	   BD	  CD8α	   53.6.7	   APC-­‐	  Cy7	   eBioscience	  CD8α	   53.6.7	   PerCP	  Cy5.5	   eBioscience	  CD8β	   eBioH35-­‐17.2	   APC	   eBioscience	  CD11b	  	   M170	  	   APC	   Biolegend	  	  CD11b	  (Integrin	  αM)	  	  	   M170	  	   PerCP	  Cy5.5	   Biolegend	  	  CD11c	  (Integrin	  αX)	   HL3	   Pe-­‐Cy7	   BD	  	  CD16/CD32	  (Fc	  receptor	  γ	  block)	   93	   N/A	   Biolegend	  CD19	   6D5	   APC-­‐Cy7	   Biolegend	  	  
CD19	  	   6D5	   FITC	   Biolegend	  CD21	   7G6	   FITC	   BD	  
CD23	  (FcεRII)	   B2B4	   PE	   BD	  CD25	  (IL-­‐2Rα)	   PC61	   APC-­‐Cy7	   Biolegend	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CD25	  (IL-­‐2Rα)	   PC61	   PerCP-­‐Cy5.5	   Biolegend	  	  CD40	   312.3	   PE-­‐Cy7	   Biolegend	  CD44	   IM7	   PE	   BD	  CD45	   30F11	   APC-­‐Cy7	   Biolegend	  CD45	   30F11	   APC	   Biolegend	  CD45	   30F11	   PE-­‐Cy7	   Biolegend	  CD45	   30F11	   PerCP	  Cy5.5	   Biolegend	  CD45	   30F11	   PE	   eBioscience	  CD45	   30F11	   FITC	   eBioscience	  CD69	   H1.273	   PE	   eBioscience	  CD45R	   RA3-­‐632	   PE-­‐Cy7	   Biolegend	  	  




Antibody	   Clone	   Fluorophore	   Company	  B220	   RA3-­‐632	   PerCP-­‐CY5.5	   Biolegend	  	  B220	   RA3-­‐632	   PE	   eBioscience	  B220	   RA3-­‐632	   FITC	   BD	  B220	   RA3-­‐632	   APC	   eBioscience	  F4/80	  	   BM8	   PE	   Biolegend	  FoxP3	  	   FJK16S	   APC	   eBioscience	  Ly6-­‐C	   1G7.G10	   APC	   Miltenyi	  Biotec	  Ly6-­‐G	   RD6-­‐85C	   FITC	   eBioscience	  	  GL-­‐7	  (Ly-­‐77)	   GL-­‐7	  	   FITC	   BD	  	  MHC	  class	  II	  (I-­‐A/I-­‐E)	   M5/114.15.2	   APC-­‐Cy7	   Biolegend	  	  p-­‐STAT5	  	   47	   PE	   BD	  PhospFlow	  	  Siglec-­‐H	  	   eBio440c	   FITC	   eBioscience	  TCR	  αβ	   H57-­‐597	   APC	   BD	  TCR	  αβ	   H57-­‐597	   PE	   eBioscience	  TCR	  αβ	   H57-­‐597	   PerCP	  -­‐	  Cy5.5	  	   eBioscience	  TCRγδ	   GL3	   APC	   Biolegend	  TCRγδ	   GL3	   PE	   BD	  	  Thy1.1	   53.2.1	   APC	   Biolegend	  Table	  2.10	  List	  of	  non-­‐CD	  antibodies	  used	  and	  their	  conjugates	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2.10 	  Enzyme	  Linked	  Immunosorbant	  Assay	  (ELISA)	  
2.10.1 Reagents	  and	  solutions	  ELISA	  coating	  buffer	  	   	   	   	   1x	  PBS	  	  ELISA	  blocking	  and	  diluting	  buffer	   	   	   1xPBS	  	   	   	   	   	   	   	   2%	  BSA	  	  Wash	  buffer	  	   	   	   	   	   	   1xPBS-­‐Tween	  	  Substrate	  solution	  	   	   	   	   	   TMB	  solution	  (eBioscience)	  	  	  Stop	  solution	   	   	   	   	   	   1M	  H2SO4	  	  	  
2.10.2 ELISA	  procedure	  	  	  
2.10.2.1 Sample	  preparation	  	  After	   treatment	   cells	  were	   collected	   in	   2ml	   eppendorfs	   and	   centrifuged	  for	   5	   min	   at	   250	   x	   g	   at	   4°C.	   Supernatants	   were	   then	   transferred	   into	   fresh	  eppendorfs	  and	  stored	  in	  aliquots	  to	  prevent	  freeze	  thawing.	  	  	  
2.10.2.2 Sandwich	  ELISA	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  For	  analysis	  of	  cytokine	  production	  96-­‐well	  plates	  were	  coated	  with	  the	  antibodies	  described	  in	  Table	  2.11.	  All	  coating	  antibodies	  were	  used	  at	  1:1000	  as	  per	  manufacturers	   instructions	   in	  1x	  PBS	  and	  100µl	  was	  used	  per	  well	  coating	  immuno	   maxisorp	   96-­‐well	   flat-­‐bottomed	   plates	   (Thermo	   Scientific,	  Leicestershire,	   UK)	   and	   incubated	   at	   4°C	   overnight.	   Plates	  were	  washed	   three	  times	   in	   PBS-­‐Tween	   and	   non-­‐specific	   binding	  was	   removed	   by	   blocking	   plates	  with	  200µl	  2%	  BSA	  in	  PBS	  per	  well.	  Samples	  were	  mixed	  thoroughly	  and	  diluted	  in	  2%	  BSA/PBS-­‐Tween	  and	  specific	  cytokine	  standards	  were	  also	  plated.	  Plates	  were	   incubated	  overnight	   at	  4°C,	   after	  which	   they	  were	  washed	   in	  PBS-­‐Tween	  repeatedly.	   Cytokine	   specific	   biotin-­‐conjugated	   antibodies	   (same	   as	   primary	  antibody	   but	   biotin	   conjugated)	  were	   diluted	   1:1000	  with	   2%BSA/PBS-­‐Tween	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and	   incubated	  at	   room	  temperature	   for	  2	  hr	   rocking.	  Plates	  were	   then	  washed	  three	   times	   in	   PBS-­‐Tween	   and	   incubated	   with	   anti	   Avidin-­‐HRP	   (eBioscience)	  diluted	  in	  2%BSA/PBS-­‐Tween	  1:1000	  for	  1	  hr	  at	  room	  temperature	  with	  gentle	  rocking.	  Plates	  were	  then	  washed	  a	  final	  5	  times	  in	  PBS-­‐Tween	  and	  100µl	  1xTMB	  substrate	  (eBioscience)	  was	  used	  per	  well	  for	  detection.	  Plates	  were	  allowed	  to	  develop	   for	   5-­‐10	   min	   until	   standards	   were	   developed	   to	   a	   similar	   level	   to	  experimental	  samples.	  The	  reaction	  was	  stopped	  using	  50µl	   	  2M	  sulphuric	  acid	  per	  well,	  initiating	  a	  colour	  change	  from	  blue	  to	  yellow.	  Plates	  were	  then	  read	  at	  450nm	  on	  microplate	  spectrometer.	  Cytokine	  production	  was	  determined	  using	  the	  relevant	  recombinant	  mouse	  cytokine	  standard	  curve.	  	  
2.10.2.3 ELISA	  antibodies	  	  	  
Capture	  antibody	   Clone	   Dilution	   Company	  
IFN-­‐γ	   AN-­‐18	   1:1000	   eBioscience	  
TNF-­‐α	   1F3F3D4	   1:1000	   eBioscience	  
IL-­‐2	   78071	   1:1000	   Biolegend	  
IL-­‐6	   MP5-­‐20F3	   1:1000	   eBioscience	  
IL-­‐10	   JES5-­‐16E3	   1:1000	   eBioscience	  
IL-­‐12p40	  subunit	   C15.6	   1:1000	   Biolegend	  Table	  2.11	  Capture	  antibodies	  used	  in	  ELISA	  assays	  
2.10.2.4 Cytokine	  standards	  	  	  	  	  	  	  	  	  	  	  	  	  	  Murine	   TNF-­‐α,	   IFN-­‐γ,	   IL-­‐6	   and	   IL-­‐10	   standards	   were	   purchased	   from	  eBioscience.	   Murine	   IL-­‐2	   and	   IL-­‐12p40	   standards	   were	   purchased	   from	  Biolegend.	   All	   standards	   were	   stored	   and	   used	   according	   to	   manufactures	  instructions,	  standards	  were	  always	  used	  fresh	  and	  diluted	   in	  1%	  BSA/PBS.	  To	  create	  a	  standard	  curve	  standards	  were	  diluted	  two	  fold.	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2.11 	  	  In	  vivo	  colitis	  model	  
2.11.1 	  Cell	  sorting	  for	  naïve	  T	  cells	  and	  Treg	  populations	  	  	   Spleens	  from	  age	  and	  sex	  matched	  WT	  and	  PKD2	  KI/KI	  mice	  were	  dissected	  and	   prepared	   as	   previously	   described.	   Cells	   were	   then	   purified	   for	   CD4+	  lymphocytes	   using	   a	   CD4	   isolation	   kit	   (Miltenyi)	   according	   to	   manufacturers	  instructions.	  Briefly,	  cell	  number	  was	  determined	  and	  cells	  were	  centrifuged	  for	  10	  min	  at	  300	  x	  g.	   400µl	  MACs	  buffer	   	  +	  100µl	  of	  biotin	  antibody	   cocktail	  was	  added	  per	  107	  cells,	  mixed	  well	  and	  incubated	  for	  5	  min	  at	  4°C.	  	  Next	  300µl	  MACs	  buffer	  plus	  200µl	  of	  anti-­‐biotin	  beads	  were	  added,	  mixed	  well	  and	  incubated	  for	  10	  min	   at	   4°C.	   Cells	   were	   then	   sorted	   using	   an	   autoMACs	  machine	   (Miltenyi)	  using	   depletion.	   Cell	   number	   was	   determined	   and	   cells	   were	   Fc	   blocked	   1:70	  before	   staining	   with	   the	   following	   antibody	   cocktail;	   CD4-­‐PerCP-­‐Cy5.5,	   CD25-­‐APC,	   CD45RB-­‐FITC,	   all	   diluted	   1:100	   in	   hanks	   buffered	   salt	   solution	   (HBSS)	  supplemented	  with	  1%	  FBS.	  	  Cells	  were	  stained	  for	  20	  min	  on	  ice	  and	  washed	  in	  4ml	   HBSS	   before	   centrifuging	   at	   250	   x	   g	   at	   4°	   C	   for	   5	   min.	   Cells	   were	   finally	  resuspended	   in	  HBSS/1%	  FBS	  and	   filtered	   through	  50μm	   filcons	   (BD)	   into	  cell	  sorting	  tubes.	  	  Naïve	  T	  cells	  were	  sorted	  by	  definition	  of	  CD4+	  CD25-­‐	  CD45RB	  high	  whereas	   regulatory	   T	   cells	  were	   defined	   as	   CD4+	   CD25+	   CD45RB-­‐.	   Cells	  were	  collected	   into	  sterile	  RMPI	  media	  supplemented	  with	  20%FBS	  and	  50	  units/ml	  penicillin.	  	  
2.11.2 	  Intraperitoneal	  injection	  of	  lymphocytes	  into	  RAG2KO/KO	  	  hosts	  	   For	  this	  study	  20	  male	  homozygous	  RAG2KO/KO	  mice	  were	  used	  and	  split	  into	  4	  groups	  of	  n=	  5	  per	  group.	  Cells	  transferred	  into	  each	  group	  are	  detailed	  in	  table	  (Table	  5.1).	  All	  mice	  had	  body	  weight	  recorded	  on	  day	  0	  before	  cells	  were	  injected.	   Sorted	   cells	   were	   injected	   into	   the	   peritoneal	   cavity	   using	   29g	   1ml	  insulin	  needles	  (Terumo,	  Somerset,	  UK).	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2.11.3 	  Analysis	  of	  body	  weight	  	  	   Mice	   were	   weighed	   weekly	   until	   signs	   of	   illness	   appeared	   after	   which	  point	  they	  were	  then	  weighed	  and	  monitored	  daily.	  When	  mice	  lost	  20%	  of	  their	  total	  body	  weight	  they	  were	  sacrificed	  using	  CO2.	  	  	  
2.11.4 	  Generation	   of	   tissue	   sections	   and	   Hematoxylin	   and	   Eosin	   (HE)	  
staining	  	  	   Samples	  including	  sections	  of	  the	  mesenteric	  lymph	  nodes	  were	  taken	  ex-­‐vivo	   from	   age	   and	   sex	   matched	   mice	   and	   collected	   in	   10%	   neutral	   buffered	  formalin.	  Tissue	  samples	  were	  then	  embedded	  in	  paraffin	  blocks,	  sliced	  into	  4μm	  thick	   sections	   which	   were	   subsequently	   stained	   using	   Hematoxylin	   and	   Eosin	  (HE)	  and	  assessed	  microscopically	  by	  a	  pathologist.	  The	  University	  of	  Glasgow	  Veterinary	  Diagnostic	  Services	  kindly	  provided	  these	  services;	  pathologist	  Dr	  Francesco	  Marchesi	  assessed	  microphotographs.	  	  




Colitis	  scoring	  parameters	   Score	  
Histological	  changes	  
Epithelial	  hyperplasia	  and	  goblet	  cell	  depletion	  
Inflammatory	  cell	  infiltration	  within	  lamina	  propria	  
Presence	  of	  crypt	  abscesses	  
Mucosal	  erosion/	  ulceration	  
Submucosal	   to	   transmural	   inflammatory	   cell	  
infiltration	  
	  	  0	  =	  no	  changes	  1=	  mild	  2	  =	  moderate	  3	  =	  marked	  
PMNs	  infiltration	  
	  
Number	  of	  neutrophils	  	  
	  
	  0	  =	  absent	  1=	  low	  numbers	  2	  =	  moderate	  numbers	  3	  =	  large	  numbers	  
Extent	  of	  tissue	  affected	  
Extent	  of	  tissue	  involved	  with	  epithelial	  and	  
	  inflammatory	  changes	  	  
	  
	  0	  =	  no	  change	  1=	  <30%	  	  	  2	  =	  30-­‐60%	  	  	  3	  =	  >60%	  	  
	  	   Scores	   for	   all	   six	   parameters	   listed	   above	   were	   added	   to	   give	   a	   total	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inflammation	  score	  for	  each	  individual	  section	  of	  0–18.	  Finally,	  an	  overall	  colonic	  lesions	   score	   for	   each	  mouse	  was	   calculated	   as	   the	   average	   of	   the	   total	   scores	  from	  the	  sections	  of	  proximal	  and	  distal	  colon.	  	  
2.12 	  Real	  time	  -­‐	  quantitative	  PCR	  (RT-­‐	  qPCR)	  
2.12.1 	  RNA	  preparation,	  purification	  and	  quantification	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5x106	  cells	  were	  harvested	  and	  washed	  in	  1ml	  ice	  cold	  PBS,	  centrifuged	  for	   5	   min	   at	   250	   x	   g.	   Cell	   pellets	   were	   lysed	   in	   350µl	   RLT	   cell	   lysis	   buffer	  (Qiagen).	   Samples	   were	   then	   stored	   at	   -­‐80°C	   until	   further	   use.	   For	   RNA	  purification	  samples	  were	  first	  homogenized	  whereby	  samples	  were	  transferred	  into	   cell	   shredders	   (Qiagen)	   and	   centrifuged	   for	   1	   min	   at	   1300	   x	   g.	   Resulting	  lysates	  were	  prepared	  using	  RNA	  easy	  kit	  (Qiagen)	  according	  to	  manufacturers'	  instructions.	  RNA	  was	  eluted	   in	  50µl	  of	  RNase	   free	  water.	  The	  eluted	  RNA	  was	  stored	  at	  -­‐80°C	  until	  further	  use.	  	  1µl	   purified	   RNA	   was	   measured	   using	   a	   nanodrop	   (Thermo	   Scientific)	  according	  to	  manufactures	  instructions.	  Absorbance	  was	  between	  at	  260nm	  and	  280nm	  and	  RNA	  sample	  concentration	  was	  determined	  by	  Nano	  drop	  software.	  	  	  




Reagent	   1	  x	  Volume	  Nuclease-­‐free	  water	   10µl	  qScript	  reaction	  mix	  (5x)	   4µl	  qScript	   Reverse	  Transcriptase	   1µl	  RNA	   5µl	  Total	  volume	   15µl	  Table	  2.12	  cDNA	  reaction	  master	  mix	  	  	  
Step	   Temperature	   Time	   Cycles	  
1	   22°C	   5	  min	   1	  
2	   42°C	   30	  min	   1	  
3	   85°C	   5	  min	   1	  Table	  2.13	  cDNA	  amplification	  cycles	  	  
2.12.3 RT-­‐qPCR	  assay	  Quantitative	   PCR	   was	   performed	   in	   384	   well-­‐plate	   format	   (Bio-­‐Rad,	  Hertfordshire,	   UK)	   using	   SYBR	   Green	   based	   detection	   (Takara,	   Saint-­‐Germain-­‐en-­‐Laye,	  France)	  in	  a	  Bio-­‐Rad	  CFX384	  thermo	  cycler.	  	  Each	  reaction	  comprised	  of	  14μl	   reaction	   containing	   6μl	   of	   diluted	   template	   cDNA	   (15ng	   per	   well),	   0.5μl	  (10μM)	   sense	   primer	   and	   0.5μl	   (10μM)	   antisense	   primer,	   7μl	   of	   SYBR	   Green	  supermix.	  Samples	  were	  heated	  to	  95°C	  for	  30	  seconds	  and	  then	  underwent	  49	  cycles	  of	  95°C	  for	  1	  second	  and	  60°C	  for	  25	  seconds.	  This	  was	  followed	  by	  95°C	  for	  1	  min,	  65°C	  for	  1	  min	  then	  0.5°C	   increments	  every	  5	  seconds	  to	  calculate	  a	  melt	   curve.	   Each	   reaction	   was	   performed	   in	   duplicate.	   CD45	   was	   used	   for	  normalisation	  and	  relative	  mRNA	  levels	  calculated	  using	  the	  following	  equation:	  	  Relative	  mRNA	  expression=	  2^(Ct,	  CD45	  –	  Ct,	  GOI)	  
	  	  
112	  	   Where	   2	   is	   primer	   efficiency,	   Ct	   is	   the	   threshold	   cycle,	   CD45	   is	   the	  reference	  gene	  and	  GOI	  of	  gene	  of	  interest.	  	  	   	   	   	   	  	  
2.13 	  Statistical	  methods	  and	  analysis	  	  	   All	  quantified	  data	  was	  processed	  in	  Microsoft	  Excel	  (Mac	  2011).	  Statistical	  evaluation	  was	  performed	  in	  Prism	  5	  (Mac	  OS	  X).	  	  Prism	  was	  used	  to	  generate	  all	  bar	   and	   line	   graphs,	   dot	   plots	   and	   column	   graphs.	   Unless	   otherwise	   stated	  statistical	  tests	  used	  to	  determine	  significant	  differences	  were	  unpaired	  students	  T-­‐test	  or	  where	  indicated	  one-­‐way	  ANOVA	  with	  post-­‐hoc	  Dunnet	  test	  or	  two-­‐way	  ANOVA	   with	   Bonferroni	   post-­‐hoc	   test.	   Differences	   were	   considered	   significant	  when	  p≤	  0.05.	  	  For	   annotation	   purposes	   the	   following	   convention	   was	   used	   for	  significance:	   ns	  =	  p>0.05	  	  *	  	  =	  p≤	  0.05	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  **	  =	  p≤0.01	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ***	  =	  p≤0.001	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ****	  =	  p≤0.0001	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3 Charaterisation	   of	   new	   generation	   small	  
molecule	   pharmacological	   inhibitors	   of	   the	  
PKD	  family	  
3.1 Introduction	  	   The	   PKD	   family	   has	   been	   implicated	   in	  multiple	   biological	   pathways	   and	  cellular	  processes	  including	  angiogenesis,	  proliferation,	  cell	  survival,	  cell	  motility	  and	  within	  various	  inflammatory	  pathways	  all	  of	  which	  are	  intricately	  linked	  to	  development	  and	  progression	  of	  cancer,	  and	  targeting	  PKD	  family	  members	  has	  become	   a	   particular	   focus	   for	   potential	   therapeutic	   target	   in	   cancer	   therapy	  through	   drug	   development.	   Within	   the	   current	   literature	   the	   focus	   on	   the	  therapeutic	   use	   of	   inhibition	   of	   PKD	   has	   focused	   largely	   on	   therapeutic	   use	   of	  PKD	  inhibition	  within	  pancreatic	  and	  prostate	  cancer	  cell	  lines	  (Wille	  et	  al.	  2014)	  (Ochi	  et	  al.	  2011)	  (Harikumar	  et	  al.	  2010)	  (LaValle	  et	  al.	  2012).	  	  Previous	  inhibitors	  of	  PKD	  have	  had	  limited	  success	  in	  vivo	  largely	  due	  to	  poor	   bioavailability	   and	   numerous	   off	   target	   effects.	   New	   and	   highly	   specific	  small	  molecule	  inhibitors	  of	  PKD	  have	  since	  been	  developed	  and	  one	  compound	  has	   shown	   significant	   promise	   in	   an	   in	  vivo	  model	   of	   pancreatic	   cancer	   due	   to	  improvements	   in	   bioavailability	   (Harikumar	   et	   al.	   2010).	   Significantly	   this	  potentially	  allows	  the	  movement	  of	  PKD	  inhibitors	  into	  clinical	  trials	  for	  the	  first	  time.	  However,	  more	   knowledge	   is	   required	   to	   determine	   the	   potential	   effects	  these	  inhibitors	  may	  have	  on	  the	  immune	  system	  if	  they	  are	  to	  be	  used	  as	  anti-­‐cancer	  drugs.	  	  Accordingly,	   this	   chapter	  describes	  data	  exploring	   the	   specificity	  of	  novel	  small	  molecule	  inhibitors	  of	  PKD	  derived	  through	  the	  use	  of	  in	  vitro	  kinase	  assay	  screening.	  This	  screening	  process	  importantly	  also	  revealed	  off	  target	  effects	  on	  other	  kinases	  demonstrated	  by	  all	  three	  compounds.	  Additionally,	  we	  wished	  to	  address	   if	  pharmacological	   inhibition	  of	  PKD	  with	  these	  novel	   inhibitors	  would	  correspond	  with	  data	  within	  the	   literature	  obtained	  by	  knockdown	  of	  PKD	  and	  indeed	  data	   observed	   from	  PKD	   transgenic	  mice.	   	   In	   regard	   to	   the	   therapeutic	  potential	   of	   using	   novel	   compounds	   to	   target	   PKD	   within	   malignant	   cells,	   we	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chose	  to	  direct	  our	  studies	  towards	  examining	  the	  effects	  of	  these	  compounds	  on	  chronic	  myeloid	   leukemia	  (CML)	  cells	  as	  PKD2	  has	  been	  specifically	   implicated	  in	   development	   and/or	   progression	   of	   CML,	   therefore	   potentially	   opening	   the	  exciting	  avenue	  for	  combinational	  therapies	  within	  CML	  via	  PKD	  inhibition.	  	  	  	  
3.2 	  Results	  	  
3.2.1 Characterisation	   of	   novel	   small	  molecule	   inhibitors	   of	   PKD	   via	   in	  
vitro	  kinase	  screen	  analysis	  	  	   Kinase	   inhibitors	   are	   powerful	   tools	   for	   the	   dissection	   of	   intricate	  signaling	  pathways,	  as	  well	  as	  being	  a	  strong	  focus	  of	  therapeutic	  interest	  within	  disease	  settings	  such	  as	  cancer	  and	  autoimmunity.	   In	   the	  past	  10	  years	   the	  U.S	  Food	   and	   Drug	   Administration	   (FDA)	   have	   approved	   15	   small	   molecular	  inhibitors	   and	   five	   anti-­‐kinase	   antibodies	   for	   therapeutic	   use	   (Grant	   2009).	  However,	   as	   many	   kinase	   inhibitors	   target	   the	   highly	   conserved	   ATP	   binding	  pocket,	  many	   inhibitors	   act	   on	  multiple	   kinases.	   As	   such,	   off	   target	   effects	   can	  often	  skew	  results	  and	  make	  the	  process	  of	  attributing	  an	  effect	  to	  a	  single	  kinase	  difficult.	  	  	  	   With	  the	  development	  of	  new,	  more	  specific	  small	  molecule	  inhibitors	  of	  PKD	  we	  first	  sought	  to	  validate	  the	  specificity	  of	  these	  inhibitors	  for	  PKD	  and	  to	  assess	   off	   target	   effects	   on	   other	   kinases.	   To	   achieve	   this,	   inhibitors	   were	  screened	   using	   in	   vitro	   kinase	   assays	   against	   a	   panel	   of	   124	   protein	   kinases,	  including	  PKC	  isoforms	  (PKCα,	  PKCγ	  and	  PKCζ)	  and	  other	  CaMK	  family	  members.	  This	   is	   an	   important	   control	   as	   older	   PKD	   inhibitors	   have	   been	   shown	   also	   to	  target	   PKC	   activity	   (Gschwendt,	  Dieterich,	   et	   al.	   1996a)	   (Grandage	   et	   al.	   2006)	  (Meredith,	   Ardayfio,	   et	   al.	   2010a).The	   protocol	   used,	   and	   substrate	   peptide	  sequences	  for	  assessing	   in	  vitro	  kinase	  activity	  have	  been	  described	  previously,	  samples	   were	   measured	   in	   duplicate	   (Bain	   et	   al.	   2007).	   In	   order	   to	   remain	  consistent	  with	  the	  literature,	  a	  cut-­‐off	  point	  of	  less	  than	  20%	  remaining	  activity	  was	   chosen	   to	   define	   significant	   off	   target	   effects	   on	   other	   kinases	   (Bain	   et	   al.	  2003).	  	  Full	  kinase	  screens	  of	  all	  three	  compounds	  can	  be	  see	  in	  Appendix	  B.	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  Figure	  3.1	  Kinase	  profile	  report	  for	  Novartis	  12a	  compound	  screen	  at	  1μM	  5	  out	  of	  124	  kinases	  screened	  were	  reduced	  ≤	  20%	  remaining	  activity	   in	  an	   in	  




Kinase	   12a	  1μM	  
%	  Activity	  remaining	  
PKD1	   5	  
MINK1	   13	  
DRYK3	   14	  
NUAK1	   17	  
CAMK1	   20	  Table	  3.1	  Kinase	  profile	  report	  for	  Novartis	  12a	  compound	  screen	  at	  1μM	  5	   out	   of	   124	   kinases	   included	   in	   in	   vitro	   kinase	   assay	   are	   reduced	   to	   ≤	   20%	  remaining	  activity	  with	  1μM.	  of	  12a	  compound.	  	  	   Additionally,	   the	   12a	   compound	   was	   also	   screened	   at	   a	   higher	  concentration	   of	   10μM.	   As	   can	   be	   seen	   in	   Table	   3.2	   this	   greatly	   increased	   the	  occurrence	   of	   off	   target	   effects	   with	   25/124	   kinases	   significantly	   inhibited	  (≤20%	   remaining	   activity).	   Furthermore,	   this	   did	   not	   only	   increase	   off	   target	  effects	   it	   also	   produced	   greater	   inhibition	   of	   5	   kinases	   other	   than	   PKD	   at	   this	  concentration	  including	  CAMK1,	  MINK1,	  RSK1,	  PKBb	  and	  ERK8.	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Kinase	   12a	  10μM	  
%	  Activity	  remaining	  
CAMK1	   2	  
MINK1	   2	  
RSK1	   2	  
PKBb	   3	  
ERK8	   4	  
PKD1	   5	  
PHK	   5	  
ERK2	   6	  
MNK2	   6	  
MNK1	   7	  
DYRK3	   7	  
BRSK2	   8	  
Lck	   9	  
SmMLCK	   10	  
MARK4	   10	  
ERK1	   10	  
DYRK2	   10	  
CDK2-­‐Cyclin	  A	   11	  
TSSK1	   12	  
MARK3	   15	  
MKK6	   16	  
CK1	   18	  
PRK2	   19	  
AMPK	   20	  



















Kinase	   CRT0066101	  1μM	  
%	  Activity	  
remaining	  
DYRK3	   2	  
CLK2	   3	  
PIM3	   3	  
PIM1	   5	  
ERK8	   9	  
PKD1	   11	  
SIK2	   14	  
CDK9-­‐cyclin	  T1	   15	  
CDK2-­‐cyclin	  A	   16	  
PHK	   17	  Table	  3.3	  Kinase	  profile	  for	  CRT0066101	  compound	  screen	  at	  1μM	  6	  out	  of	  124	  kinases	  screened	  were	  reduced	  to	  less	  than	  20%	  remaining	  activity	  in	  an	  in	  vitro	  kinase	  assay	  using	  a	  single	  dose	  of	  1μM	  CRT101	  compound.	  	  	  











MINK1" MAP4K3" PKD1" MAP4K5" BRK" GCK" 	  Figure	  3.3	  Kinase	  profile	  for	  CRT051	  compound	  at	  2.5μM	  6	  out	  of	  124	  kinases	  screened	  were	  reduced	  to	  less	  than	  20%	  remaining	  activity	  in	  an	  in	  vitro	  kinase	  assay	  using	  a	  single	  dose	  of	  2.5μM	  CRT051	  compound.	  	  	  
Kinase	   CRT051	  2.5μM	  
%	  Activity	  remaining	  
GCK	   3	  
BRK	   5	  
MAP4K5	   5	  
PKD1	   8	  
MAP4K3	   11	  
MINK1	   12	  Table	  3.4	  Kinase	  profile	  for	  CRT051	  compound	  at	  2.5	  μM	  	  6	  out	  of	  124	  kinases	  screened	  were	  reduced	  to	  less	  than	  20%	  remaining	  activity	  in	  an	  in	  vitro	  kinase	  assay	  using	  a	  single	  dose	  of	  2.5μM	  CRT051	  compound.	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3.2.2 Comparative	  analysis	  of	  off	  target	  effects	  of	  current	  PKD	  inhibitors	  	  	   In	   order	   to	   distinguish	   between	   specific	   PKD	   inhibition	   and	   off	   target	  effects	   frequently	   found	  with	  small	  molecule	   inhibitors	  we	  compared	  off	   target	  effects	  seen	  with	  new	  compounds	  12a,	  CRT101	  and	  CRT051.	  	  	  	  
	  Figure	  3.4	  Comparative	  analyses	  of	  novel	  small	  molecular	  inhibitors	  of	  PKD	  and	  common	  off	  target	  effects	  Shown	  are	  the	  protein	  kinases	  that	  are	  inhibited	  by	  >80%	  by	  indicated	  inhibitors	  in	  in	  vitro	  activity	  assays	  using	  purified	  kinases.	  	   Using	  the	  kinase	  screen	  data	  obtained,	  we	  were	  able	  to	  compare	  specific	  kinase	   inhibition	  by	  our	  three	  novel	  PKD	  inhibitors	  as	  well	  as	  older	  generation	  inhibitors	  such	  as	  1-­‐NA-­‐PP1.	  As	  illustrated	  in	  Figure	  3.4,	  although	  each	  inhibitor	  does	  display	  off	   target	  effects	  on	  other	  kinases	   inhibition	  of	  PKD	   isoforms	  was	  the	   only	   common	   target	   of	   all	   4	   inhibitors.	   With	   these	   data	   we	   are	   able	   to	  confidently	  conclude	  that	  the	  effects	  seen	  with	  by	  all	  three	  PKD	  novel	  inhibitors	  are	  highly	  likely	  to	  be	  due	  to	  specific	  PKD	  inhibition	  and	  not	  to	  off	  target	  effects	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on	   other	   kinases.	   	   In	   conclusion,	   these	   data	   demonstrate	   that	   inhibition	   of	   all	  three	  PKD	  isoforms	  is	  shown	  to	  be	  a	  common	  trait	  amongst	  the	  4	  small	  molecule	  inhibitors.	  	  
3.2.3 Pharmacological	  inhibition	  of	  PKD	  using	  new	  generation	  inhibitors	  
reduce	  cytokine	  production	  in	  murine	  T	  lymphocytes	  	   Having	  demonstrated	   that	   the	   three	  novel	   small	  molecule	   inhibitors	  are	  indeed	  highly	  specific	  for	  PKD	  and	  they	  do	  not	  share	  any	  of	  the	  same	  off-­‐target	  effects,	   we	   next	   wanted	   to	   investigate	   if	   PKD	   inhibitors	   lead	   to	   biological	  consequences	   that	   would	   be	   expected	   from	   the	   loss	   of	   PKD	   activity.	   It	   has	  previously	   been	   shown	   that	   lack	   of	   PKD2	   catalytic	   activity	   in	   T	   lymphocytes	  leads	  to	  significantly	  reduced	  cytokine	  production	  in	  vitro	  after	  TCR	  engagement	  (Matthews	   et	   al.	   2010).	   Therefore	   we	   hypothesised	   that	   pharmacological	  inhibition	  of	  PKD	  should	  also	  led	  to	  reduced	  cytokine	  production	  from	  murine	  T	  lymphocytes	  after	  TCR	  triggering.	  To	  achieve	  this,	  T	  lymphocytes	  obtained	  from	  WT	  murine	  lymph	  nodes	  were	  pretreated	  with	  increasing	  concentrations	  of	  12a,	  CRT101	  and	  CRT051	  for	  1	  hour	  before	  TCR	  triggering	  using	  anti-­‐CD3.	  As	  can	  be	  seen	  in	  Figure	  3.5A-­‐B,	  treatment	  of	  T	  lymphocytes	  with	  the	  12a	  compound	  lead	  to	  a	  3	  fold	  reduction	  in	  the	  production	  of	  key	  cytokines	  including	  IFN-­‐γ	  and	  IL-­‐2	  after	   24	   hours	   after	   TCR	   triggering.	   	   Results	  with	   the	   CRT101	   compound	   also	  lead	  to	  a	  significant	  reduction	  of	  both	  IL-­‐2	  and	  IFNγ	  in	  a	  more	  dose	  dependent	  manner	  (Figure	  3.5C-­‐D).	  The	  highest	  concentration	  used	  (5μM)	  of	  CRT101	  lead	  to	   a	   5-­‐fold	   reduction	   of	   IL-­‐2	   and	   a	   3	   fold	   reduction	   in	   production	   of	   IFNγ.	   	   .	  	  Finally,	   we	   observed	   the	   same	   results	   with	   CRT051,	   with	   a	   significant	   dose-­‐dependent	   reduction	   in	   cytokine	  production	   (Figure	  3.5E-­‐F);	   10-­‐fold	   reduction	  in	  IL-­‐2	  and	  31-­‐fold	  reduction	  in	  IFNγ	  respectively.	  	  Importantly,	   this	   was	   not	   simply	   due	   to	   toxicity	   of	   increasing	  concentrations	  of	  12a,	  CRT101	  and	  CRT051	  as	  minimal	  cell	  death	  was	  observed	  by	   propidium	   iodide	   (PI)	   staining	   when	   compared	   to	   DMSO	   vehicle	   controls	  (data	  not	  shown).	   	  Collectively,	  these	  data	  show	  that	  PKD	  inhibition	  mimics	  the	  biological	  effects	  observed	  by	  previously	  published	  data.	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CRT051 	  Figure	  3.5	  Effects	  of	  PKD	  inhibition	  on	  murine	  T	  cell	  cytokine	  production	  Production	  of	   IFN-­‐γ	  and	   IL-­‐2	  within	   the	  supernatant	  of	  WT	  T	  cells	  assessed	  by	  ELISA	   after	   pretreatment	   for	   1	   hour	   with	   increasing	   doses	   of	   compounds	   as	  indicated	  (A)	  12a	  (B)	  CRT101	  and	  (C)	  CRT051	  24	  hours	  after	  TCR	  triggering	  via	  αCD3	  (500ng/ml).	  *=	  p≤	  0.05,	  **	  =	  p≤0.01,	  ***	  =	  p≤0.001	  compared	  with	  DMSO	  vehicle	   treated	   controls	   by	   one-­‐way	   ANOVA	   with	   post-­‐hoc	   Dunnetts	   test.	  (Representative	   experiment	   from	   2	   independent	   experiments,	   error	   bars	  represent	  SEM	  from	  technical	  replicates	  from	  one	  experiment).	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3.2.4 Exploring	  the	  use	  of	  PKD	  inhibitors	  in	  CML	  	  	   As	   discussed	   within	   the	   introduction,	   CML	   is	   a	   myeloproliferative	  disorder	   that	   occurs	   most	   frequently	   as	   a	   result	   chromosomal	   translocation	  events	   resulting	   in	   the	   formation	   of	   the	   oncoprotein	   Bcr-­‐Abl,	   which	   has	  constitutive	  tyrosine	  kinase	  activity.	  This	  leads	  to	  the	  dysregulation	  of	  numerous	  signaling	   pathways,	   such	   as	   PI3K/AKT/mTOR,	   RAS/RAF/MEK/ERK	   and	  JAK/STAT/	   (Holyoake	   &	   Helgason	   2015).	   	   Unregulated	   activity	   of	   these	  pathways	   supports	   the	   cytokine	   independent	   drive	   of	   cell	   survival	   and	   cell	  proliferation	   of	   CML	   cells	   and	   promotes	   disease	   progression.	   One	   therapeutic	  approach	   is	   to	   examine	   and	   target	   these	   dysregulated	   intracellular	   signaling	  pathways	   that	   are	   caused	   by	   Bcr-­‐Abl	   oncogene	   in	   order	   to	   uncover	   novel	  therapeutic	   targets.	   	   Current	   therapies	   involving	   TKIs	   including	   imatinib	  experience	  significant	   levels	  of	  drug	   resistance	  and	  although	  TKIs	  have	  proved	  highly	   successful	   within	   the	   clinic,	   they	   do	   not	   eradicate	   LSCs,	   therefore	   TKI	  therapy	   is	  a	   lifelong	  treatment	  and	   for	   this	  reason,	  new	  therapeutic	   targets	  are	  required	  (O'Hare	  et	  al.	  2011)	  (Graham	  2002)	  (Copland	  2006).	  Involvement	   of	   PKD2	   in	   numerous	   aspects	   of	   intracellular	   signaling	  pathways	  within	  CML,	  including	  direct	  phosphorylation	  of	  PKD2	  via	  Bcr-­‐Abl	  has	  been	  demonstrated	  previously.	   PKD2	  has	   also	  been	   shown	   to	  be	   the	  dominant	  isoform	  expressed	   in	  Bcr-­‐Abl+	  LAMA85	  human	  CML	  cells,	   in	   this	  context	  PKD2	  displayed	  constitutive	  tyrosine	  phosphorylation	  within	  the	  pleckstrin	  homology	  domain	   (PH)	   and	  mediates	   Bcr-­‐Abl	   induced	  NF-­‐κB	   activation	   (Mihailovic	   et	   al.	  2004).	  	  More	  recently,	  studies	  have	  uncovered	  a	  role	  for	  PKD2	  in	  the	  constitutive	  degradation	   and	   subsequent	   removal	   of	   the	   IFNAR1	   from	   Bcr-­‐Abl+	   CML	   cell	  surface.	  	  This	  is	  significant	  as	  interferon	  alpha	  (IFNα)	  therapy	  has	  been	  shown	  to	  be	   curative	   in	   a	   small	   subset	   of	   patients.	   This	   development	   has	   generated	  interest	  in	  using	  multi-­‐targeted	  therapies	  for	  CML	  to	  reintroduce	  more	  efficient	  IFNα	   therapy	   in	   combination	   with	   TKIs	   therapy	   (Kujawski	   &	   Talpaz	   2007).	  Accordingly,	   we	   sought	   to	   ask	   the	   following	   questions;	   what	   role(s)	   do	   PKD	  enzymes	  play	  in	  CML	  signaling	  pathways?	  Do	  human	  CML	  cells	  display	  basal	  PKD	  activity?	   	   Does	   pharmacological	   inhibition	   of	   PKD	   affect	   cell	   cycle	   progression,	  up-­‐regulation	  of	  the	  IFNAR1	  or	  p.	  STAT5	  levels	  in	  CML	  cells?	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  To	  address	  these	  questions	  we	  chose	  to	  use	  the	  human	  K562	  Bcr-­‐Abl+	  CML	  cell	  line	  as	  they	  provided	  a	  useful	  starting	  point	  displaying	  several	  characteristics	  of	  those	  seen	  in	  CML	  patients	  such	  as	  low	  surface	  expression	  of	  the	  IFNAR1	  chain	  yet	   high	   amounts	   of	   this	   receptor	   are	   found	   intracellularly	   (Figure	  3.6A).	   	   It	   is	  important	   to	   mention	   that	   we	   chose	   to	   assess	   IFNAR1	   expression	   via	   flow	  cytometry	  due	   to	   the	   ability	   to	  quantitatively	  detect	   surface	   expression,	   rather	  than	   simply	   detect	   protein	   degradation	   via	   western	   blotting.	   The	   Bcr-­‐Abl	  oncogene	  promotes	   the	  activation	  of	  multiple	  signaling	  pathways	   including	   the	  constitutive	  phosphorylation	  of	  STAT5.	  In	  this	  context	  constitutive	  p.	  STAT5	  has	  been	   shown	   in	  multiple	   studies	   be	   a	   critical	   component	   in	   the	  maintenance	   of	  CML	  cells	  (Gesbert	  &	  Griffin	  2000)	  (Hoelbl	  et	  al.	  2010)	  (Anon	  2011;	  Hantschel	  et	  al.	   2012).	   	  Within	   the	  K562	   cell	   line	  we	  observed	  high	   levels	   of	   constitutive	  p.	  STAT5	   (Tyrosine	   694	   site)	   activity	   within	   cell	   culture	   by	   phospho-­‐flow	  cytometry	   (Figure	   3.6B).Comparing	   the	   p.	   STAT5	   levels	   to	   another	   non	   CML	  human	   malignant	   B	   cell	   line	   (Raji),	   we	   saw	   high	   levels	   of	   p.	   STAT5	   in	  unstimulated	  K562	  cells	  which	  was	  completely	  absent	  in	  the	  Raji	  cell	  line	  (Figure	  3.6C),	   supporting	   the	   use	   of	   the	   human	   K562	   CML	   cell	   line	   as	   an	   appropriate	  model	  for	  human	  CML.	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  Figure	  3.6	  K562	  human	  CML	  line	  display	  common	  characteristics	  of	  CML	  cells	  (A)	  Representative	   flow	  cytometry	  of	  surface	  and	  intracellular	  IFNAR1	  in	  K562	  cell	   line	   (n=3).	   (B)	   Flow	   cytometry	   of	   intracellular	   constitutive	   p.	   STAT5	  (tyrosine	   694	   site)	   activity	   in	   culture	  with	   no	   cell	   stimulation,	   4	   hours	   and	   24	  hours	   after	   passage	   of	   cells	   in	   culture	   (n=2).	   (C)	   Western	   blot	   of	   p.	   STAT5	  (Tyr694)	  and	  β-­‐tubulin	  as	  equal	  loading	  control	  of	  K562	  cell	  lysates	  and	  Raji	  cell	  lysates	   unstimulated	   or	   treatment	   with	   pervanadate	   (10nM)	   for	   10	   minutes.	  Data	  obtained	  from	  2	  independent	  experiments.	  	  	  	  	  








	  Figure	  3.7	  PKD2	  isoform	  is	  expressed	  in	  human	  K562	  CML	  cell	  line	  Western	   blot	   of	   WT	   murine	   spleen	   sample	   and	   K562	   CML	   cell	   line	   lysates	  detecting	   PKD2	   with	   PKD2	   specific	   antibody	   (Calbiochem)	   with	   β-­‐tubulin	   as	  loading	  control	  (n=2).	  	  	  	  In	  regard	  to	  activity	  of	  PKD,	  CML	  cells	  have	  been	  shown	  to	  display	  constitutive	  tyrosine	  phosphorylation	  (tyrosine	  438)	  within	  the	  pleckstrin	  homology	  domain	  (PH)	   directly	  mediated	   by	   the	  Bcr-­‐Abl	   oncoprotein.	   This	   phosphorylation	   does	  not	   lead	   to	   the	   activation	  of	   PKD	  and	   rather	   has	   been	  described	   as	   potentially	  serving	   as	   a	   docking	   site	   for	   the	  mediation	   of	   signaling	   complexes	   rather	   than	  directly	   activating	   NF-­‐κB	   (Mihailovic	   et	   al.	   2004).	   Other	   reports	   also	  demonstrate	   constitutive	   p.	   SER916	   activity	   within	   CML	   cells,	   including	   K562	  cells,	   furthermore	   this	   basal	   activity	   was	   severely	   reduced	   upon	   treatment	   of	  K562	   cells	  with	   the	   CRT101	   compound	   (Z.-­‐F.	   Yang	   et	   al.	   2013).	   	  We	   therefore	  assessed	   PKD	   activity	   in	   K562	   cells	   via	   flow	   cytometry	   to	   examine	   p.	   SER916	  levels	  after	  treatment	  of	  unstimulated	  cells	  with	  5μM	  of	  PKD	  inhibitors	  including	  12a,	  CRT101	  and	  CRT051.	  	  As	  can	  be	  seen	  in	  Figure	  3.8,	  we	  did	  not	  observe	  any	  reduction	  in	  the	  level	  of	  p.	  SER916	  upon	  treatment	  with	  12a,	  CRT101	  or	  CRT051	  demonstrating	   that	   K562	   had	   no	   detectable	   levels	   of	   PKD	   activity,	   certainly	  within	  the	  autophosphorylation	  site	  of	  SER916.	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  Figure	   3.8	   K562	   CML	   cells	   do	   not	   display	   any	   basal	   PKD	   phosphorylation	   on	  SER916	  site	  Assessment	   of	   basal	   intracellular	   p.	   SER916	   levels	   within	   K562	   CML	   cells	  detected	  by	  flow	  cytometry	  in	  unstimulated	  cells	  treated	  with	  DMSO	  as	  a	  vehicle	  control	   or	   treated	  with	   5μM	  of	   PKD	   inhibitors	   12a,	   CRT101	   and	  CRT051	   for	   1	  hour.	  Data	  is	  representative	  of	  3	  independent	  experiments.	  	  	  	  	   To	  assess	  the	  activation	  of	  PKD	  in	  K562	  CML	  cells	  we	  next	  used	  phorbol	  ester	  (PdBu)	  to	  induce	  the	  activation	  of	  PKD,	  which	  was	  upregulated	  in	  a	  similar	  fashion	   to	   that	   seen	   in	   T	   lymphocytes	   in	   published	   data.	   	   Strong	   PKD	   activity,	  indicated	  by	  p.	  SER916	  within	  autophosphorylation	   loop,	  was	  seen	  15	  minutes	  after	  stimulation,	  peaking	  at	  30	  minutes	  and	  beginning	  to	  decline	  at	  60	  minutes	  when	   assessed	   by	   flow	   cytometry	   (Figure	   3.9A).	   This	   was	   also	   seen	   using	  western	  blot	  analysis	  (Figure	  3.9B).	  	  Interestingly,	   pervanadate	   was	   a	   weak	   inducer	   of	   PKD	   activity	   (p.	  SER916),	  which	  we	  first	  used	  as	  a	  positive	  control	  (data	  not	  shown),	  possibly	  a	  further	   indication	  of	   lack	  of	  basal	  PKD	  activity	  as	  pervanadate	   is	   a	   irreversible	  protein	   phosphatase	   inhibitor	   which	   upon	   application	   to	   cells	   prevents	  dephosphorylation	   therefore	   serving	   as	   a	   strong	   positive	   control	   within	  phosphorylation	  experiments.	   In	  regard	  to	  this,	  any	  basal	  PKD	  phosphorylation	  within	  K562	  cells	   should	  accumulate	  with	   treatment	  of	  pervanadate,	  which	  we	  did	  not	  observe.	  As	  pervanadate	  was	  a	  poor	  positive	  control	  we	  used	  PdBu	  in	  all	  subsequent	  experiments	  within	  K562	  CML	  cells.	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  Figure	   3.11	   PKD	   inhibitors	   reduced	   induction	   of	   p.SER916	   after	   PdBu	  stimulation	  in	  K562	  cells	  	  MFI	  of	  p.	  SER916	  within	  K562	  cells	  after	  treatment	  with	  increasing	  doses	  of	  (A)	  12a	   (B)	   CRT101	   and	   (C)	   CRT051.	   Data	   obtained	   and	   combined	   from	   two	  independent	  experiments.	  	  	   These	  experiments	  were	  also	  expanded	  to	  combine	  p.	  ERK1/2	  staining	  as	  a	  positive	  control	  of	  successful	  cell	  stimulation.	  As	  can	  be	  seen	  in	  Figure	  3.12A-­‐B,	  all	   three	  PKD	   inhibitors	  used	  at	  5μM	   for	  1	  hour	   robustly	  prevented	  p.	   SER916	  PKD	  activity	  yet	  p.	  ERK1/2	  activation	   in	   response	   to	  phorbol	   ester	   stimulation	  remained	   intact.	   Although	   it	   should	   be	   noted	   that	   treatment	   with	   CRT051	  compound	   did	   reduced	   p.ERK1/2	   levels	   this	   is	   most	   likely	   due	   to	   off	   target	  effects	  present	  with	  this	  compound,	  however	  p.ERK1/2	  levels	  still	  demonstrated	  that	   cells	   had	   successfully	   been	   stimulated	   with	   phorbol	   ester.	   This	   is	   also	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demonstrated	   in	   Figure	   3.12C	  whereby	   activation	   of	   p.SER916	  was	   blocked	   in	  K562	  CML	  cells	  but	  key	  PKC	  transphosphorylation	  sites	  remained	  functional.	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  Figure	  3.12	  PKD	  inhibitors	  block	  PKD	  autophosphorylation	  in	  K562	  cells	  but	  do	  not	  inhibit	  phosphorylation	  of	  key	  PKC	  sites	  on	  PKD	  Phospho-­‐flow	  cytometry	  analysis	  of	  p.	  SER916	  and	  p.	  ERK1/2	  in	  K562	  cells	  pre-­‐treated	  with	  5μM	  12a,	  CRT101	  and	  CRT051	  for	  1	  hour	  before	  stimulation	  with	  PdBu	  (200nM)	  for:	  (A)	  30	  minutes	  (B)	  60	  minutes.	  (C)	  Western	  blot	  of	  P.SER916	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and	   p.SER744/748	   in	   K562	   cells.	   Data	   is	   representative	   of	   3	   independent	  	  experiments	  performed	  in	  duplicate.	  	  	   Collectively,	   these	   results	   demonstrate	   that	   12a,	   CRT101	   and	   CRT051	  compounds	   efficiently	   inhibit	   the	   activation	   of	   PKD,	   specifically	   the	  autophosphorylation	   site	   p.	   SER916,	   in	   a	   dose	   dependent	   manner,	   which	   is	  detectable	  by	  both	  phospho-­‐flow	   cytometry	   and	  western	  blotting.	   Importantly,	  key	  PKC-­‐mediated	   transphorylation	  sites	   (p.	  SER744/748)	  remained	   functional	  indicating	  these	  compounds	  do	  not	  affect	  up-­‐stream	  PKC	  signaling.	  	  	  	  	  
3.2.4.2 Pharmacological	   inhibition	  of	  PKD	   in	  K562	  CML	  cells	   causes	   cell	  
cycle	  arrest	  	   Consistent	  with	  previously	  published	  data	  assessing	  toxicity	  of	  CRT101	  in	  K562	  CML	  cells	  (Z.-­‐F.	  Yang	  et	  al.	  2013),	  unpublished	  data	  from	  our	  group	  agrees	  	  that	   all	   3	   PKD	   inhibitors,	   12a,	   CRT101	   and	   CRT051	   were	   toxic	   in	   increasing	  concentrations	   to	   K562	   CML	   cells..	   	   This	   was	   assessed	   using	   PI	   staining	   after	  incubation	  with	   increasing	  doses	  of	   inhibitors	   for	  24	  hours.	   From	   this	   analysis	  IC50’s	  were	   obtained;	   12a	   IC50	   26.4±1.5μM,	   CRT101	   IC50	  7.3	   ±	   0.7μM,	   CRT051	  4.0±0.4μM.	  Significant	  cellular	  cytotoxicity	  was	  also	  noted	  in	  other	  experiments	  with	   the	   inclusion	   of	   live/dead	   dye	   including	   DAPI	   and	   PI	   staining	   in	   flow	  cytometry	   experiments	   using	   PKD	   inhibitors.	   In	   order	   to	   investigate	   the	  mechanism	   of	   cellular	   cytotoxicity	   we	   performed	   cell	   cycle	   analysis	   using	   PI	  staining	   in	   K562	   CML	   cells	   under	   increasing	   concentrations	   of	   PKD	   inhibitors.	  	  Optimisation	   of	   these	   experiments	   lead	   us	   to	   exclude	   CRT051	   from	   cell	   cycle	  studies	   due	   to	   the	   rapid	   cell	   death	   observed	   (within	   5	   hours)	   after	   incubation	  with	  the	  inhibitor,	  most	  likely	  due	  to	  off	  target	  inhibition	  of	  constitutive	  p.	  STAT5	  signaling	  that	  exists	  within	  these	  cells,	  which	  is	  discussed	  later	  in	  this	  chapter.	  To	  ensure	  cells	  were	   indeed	  undergoing	  normal	  cell	  cycle	  activity,	  K562	  cells	  were	  plated	  12	  hours	  before	  treatment.	  	  Cell	  cycle	  analysis	  was	  performed	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  Figure	  3.13	  Cell	  cycle	  analysis	  of	  K562	  CML	  cells	  under	  increasing	  concentrations	  of	  Novartis	  12a	  (A)	  Representative	  histograms	  of	  cell	  cycle	  analysis	  performed	  by	  PI	  staining	  7	  hours	   after	   treatment	   with	   either	   DMSO	   as	   vehicle	   control	   or	   5.0μM	   12a	  compound.	   Average	  %	   of	   cells	   in	   each	   stage	   of	   cell	   cycle	  with	   SD	   is	   displayed	  (n=3)	  (B)	  Combined	  data	  showing	  %	  cells	  in	  G1	  after	  treatment	  with	  media	  only,	  DMSO	  or	   increasing	   concentrations	  of	  12a	   compound	   (1.0μM,	  2.5μM	  or	  5.0μM.	  (C)	  %	  cells	  in	  S	  phase	  (D)	  %	  cells	  in	  G2	  phase.	  Flow	  cytometry	  software	  that	  uses	  an	   algorithm	   to	  fit	  Gaussian	   curves	   to	   each	   phase	   was	   used,	   since	   it	  is	   more	  objective	  than	  setting	  markers	  by	  eye.	  **	  =	  p≤0.01	  analysed	  by	  one-­‐way	  ANOVA	  with	  post	  hoc	  Dunnet	  test.	  Data	  obtained	  from	  3	  independent	  experiments.	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3.2.4.3 Analysis	   of	   the	   role	   of	   PKD	   in	   constitutive	   p.	   STAT5	  
phosphorylation	  in	  CML	  cells	  	  	   As	   all	   three	   novel	   PKD	   inhibitors	   cause	   toxicity	   at	   increasing	   doses	   and	  cause	   cell	   cycle	   arrest,	   we	   wanted	   to	   investigate	   underlying	  mechanisms.	   The	  transcription	   factor	   STAT5	  has	   been	   shown	   to	   be	   an	   essential	  mediator	   of	   the	  pathogenesis	   and	   survival	   of	   CML	   cells.	   CML	   cells	   including	   the	   K562	   cell	   line	  have	   constitutively	   active	   and	   phosphorylated	   STAT5,	   which	   drives	   the	  transcription	  of	  multiple	  key	  survival	  genes	  such	  as	  BCL-­‐x,	  and	  cyclin	  D	  (Hoelbl	  et	   al.	   2010).	   Although	   there	   is	   published	   literature	   that	   PKD	   inhibitor	   CRT101	  causes	  cell	  cycle	  arrest	  in	  K562	  and	  human	  patient	  CML	  cells,	  no	  mechanism	  to	  explain	  the	  resulting	  cell	  death	  has	  yet	  been	  elucidated	  (Z.-­‐F.	  Yang	  et	  al.	  2013).	  Therefore,	  we	  decided	   to	  address	   if	   the	  pharmacological	   inhibition	  of	  PKD	  had	  any	  effect	  on	  the	  level	  of	  constitutive	  p.	  STAT5	  in	  CML	  cells.	  To	  achieve	  this	  we	  used	   phospho-­‐flow	   cytometry	   with	   p.	   STAT5	   staining	   after	   incubation	   with	  increasing	  concentration	  of	  PKD	  inhibitors.	  	  Analysis	  of	  p.	  STAT5	  activity	  in	  K562	  CML	  cells	  after	  treatment	  with	  increasing	  concentrations	  of	  12a	  compound	  had	  no	   effect	   on	   p.	   STAT5	   activity	  within	   4	   hours	   treatment,	  which	  was	   similar	   to	  DMSO	  vehicle	   controls	   (Figure	  3.15A-­‐C).	  Conversely,	   treatment	  with	   increasing	  concentrations	   of	   CRT051	   compound	   resulted	   in	   a	   significant	   reduction	   of	   p.	  STAT5	  levels	  within	  K562	  CML	  cells	  at	  4	  hours,	  shown	  by	  phospho-­‐flow	  (Figure	  3.15D)	  and	  by	  western	  blot	  (Figure	  3.15E).	  These	  data	  are	  also	  shown	  plotted	  as	  MFI	  values	  in	  Figure	  3.16.	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Figure	  3.15	  Assessing	  effects	  of	  PKD	  inhibitors	  on	  constitutive	  p.	  STAT5	  activity	  in	  K562	  CML	  cells	  (A)	   Representative	   histogram	   of	   intracellular	   p.	   STAT5	   levels	   in	   K562	   cells	  assessed	   by	   flow	   cytometry	   after	   treatment	   of	   cells	   with	   increasing	  concentrations	   of	   PKD	   inhibitors	   12a,	   CRT101	   and	   CRT051	   for	   4	   hours.	  Combined	  data	   showing	   analysis	   of	  %	  K562	   cells	   positive	   for	  p.	   STAT5	  after	  4	  hours	   with	   increasing	   doses	   of	   (B)	   12a.	   (C)	   CRT101	   and	   (D)	   CRT051.	   	   (E)	  Western	  blot	   of	   p.	   STAT5	   activity	   in	  K562	   cells	   after	   treatment	  with	  5μM	  PKD	  inhibitors	  for	  4	  hours.	  ***	  =	  p≤0.001	  analysed	  by	  one-­‐way	  ANOVA	  with	  post	  hoc	  Dunnet	  test.	  Data	  obtained	  from	  two	  independent	  experiments.	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  Figure	   3.16	   p.STAT5	   levels	   shown	   as	   MFI	   4	   hours	   after	   treatment	   with	   PKD	  inhibitors	  	  Combined	  MFI	  data	   of	   p.STAT5	   staining	   in	  K562	   cells	   after	   4	  hours	   treatment	  increasing	  concentration	  of	  PKD	  inhibitors	  including	  (A)	  12a	  (B)	  CRT101	  and	  (C)	  CRT051.	  Data	  obtained	  from	  2	  independent	  experiments.	  	  	  Consequently,	   we	   extended	   our	   time	   point	   to	   24	   hours,	   excluding	   the	   12a	  compound	   from	   our	   studies	   and	   instead	   focusing	   on	   newer	   CRT	   compounds.	  Preliminary	  data	  of	  K562	  cells	  after	  24	  hours	  with	   increasing	  doses	  of	  CRT101	  compound	  we	   noticed	   subtle	   increases	   in	   p.	   STAT5	   in	   K562	   CML	   treated	   cells	  (Figure	   3.17A-­‐B)	   with	   increasing	   concentrations	   when	   compared	   to	   DMSO	  treated	   controls.	   As	   expected	   from	   initial	   4	   hour	   time	   points	   with	   CRT051	  compound,	   the	   number	   of	   cells	   positive	   for	   p.	   STAT5	   was	   severely	   decreased	  with	  higher	  concentrations	  of	  CRT051	  including	  5μM	  and	  10μM	  (Figure	  3.17C)	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  Figure	  3.17	  Analysis	  of	  p.	  STAT5	  activity	  after	  treatment	  with	  increasing	  doses	  of	  PKD	  inhibitors	  for	  24	  hours	  (A)	  Flow	  cytometry	  of	  p.	  STAT5	  activity	  in	  K562	  CML	  cells	  after	  treatment	  with	  increasing	   doses	   of	   PKD	   inhibitors	   CRT101	   and	   CRT051	   for	   24	   hours.	  %	   cells	  pSTAT5+	  after	  24	  hour	  incubation	  with	  increasing	  concentrations	  of	  (B)	  CRT101	  and	   (C)	   CRT051.	   (D)	   MFI	   p.STAT5	   levels	   after	   treatment	   with	   CRT101	   for	   24	  hours.	   (E)	   MFI	   p.STAT4	   levels	   after	   treatment	   with	   CRT051	   for	   24	   hours.	  Preliminary	  data	  showing	  data	  from	  1	  independent	  experiment.	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3.2.4.4 Pharmacological	  inhibition	  of	  PKD	  promotes	  the	  up-­‐regulation	  of	  
the	  IFNAR1	  on	  the	  cell	  surface	  of	  CML	  cells	  	   Data	   published	   by	   Zhang	   et	   al	   have	   demonstrated	   that	   knockdown	   of	  PKD2	   resulted	   in	   the	   increase	   of	   the	   IFNAR1	   on	   the	   cell	   surface	   of	   CML	   cells,	  offering	   the	   potential	   therapeutic	   advantage	   to	   sensitise	   CML	   cells	   to	   IFNα	  therapy.	   This	   is	   of	   particular	   significance	   in	   the	   case	   of	   patients	   who	   have	  developed	   drug	   resistance	   to	   TKIs	   and	   require	   further	   treatment	   options.	  Moveover,	   there	   is	   evidence	   that	   IFNα	   therapy	   can	   sensitise	   LSCs	   that	   are	  resistant	   to	   conventional	   TKI	   therapy	   and	   contribute	   to	   disease	   regression	  (Kujawski	   &	   Talpaz	   2007).	   We	   wanted	   to	   investigate	   if	   pharmacological	  inhibition	   of	   PKD	   with	   small	   molecular	   inhibitors	   also	   replicated	   results	   seen	  with	   knockdown	   of	   PKD.	   To	   achieve	   this	   we	   used	   12a,	   CRT101	   and	   CRT051	  compounds	   in	   increasing	   concentrations	   for	   18	   hours	   using	   flow	   cytometry	   to	  assess	   cell	   surface	   expression	   of	   IFNAR1	   on	   K562	   CML	   cells.	   We	   also	  incorporated	  the	  use	  of	  a	   live/dead	  dye	  in	  these	  experiments	  to	  assess	  IFNAR1	  on	   live	   cells	   only.	   12a,	   CRT101	   and	   CRT051	   had	   modest	   effects	   on	   the	   up-­‐regulation	   of	   IFNAR1	   at	   higher	   doses	   including	   2.5μM	   and	   5μM	   compared	   to	  DMSO	  vehicle	  controls	  (Figure	  3.18A-­‐C).	  	  This	  was	  particularly	  difficult	  to	  assess	  due	  to	  high	  levels	  of	  toxicity	  at	  higher	  doses	  of	  PKD	  inhibitors	  at	  later	  time	  points	  including	  24	  and	  48	  hours	  (data	  not	  shown).	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  Figure	   3.19	  Analysis	   of	   IFNAR	  up-­‐regulation	   on	   cell	   surface	   of	  K562	  CML	   cells	  after	  pharmacological	  inhibition	  of	  PKD	  Analysis	   of	   IFNAR1	   expression	   on	   the	   cell	   surface	   by	   flow	   cytometry	   of	   K562	  cells	   after	   treatment	   with	   increasing	   concentrations	   of	   PKD	   inhibitors,	   graphs	  show	  MFI	  (A)	  12a	  (B)	  CRT101	  (C)	  CRT051.	  *=	  p≤	  0.05,	  **	  =	  p≤0.01,	  ***	  =	  p≤0.001	  compared	   with	   DMSO	   treated	   controls	   by	   one-­‐way	   ANOVA	   with	   post-­‐hoc	  Dunnetts	  test.	  Combined	  data	  from	  3	  independent	  experiments.	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3.3 	  Discussion	  	  	   The	   data	   in	   this	   chapter	   explore	   the	   specificity	   and	   biological	   effects	   of	  novel	  small	  molecule	  inhibitors	  of	  PKD.	   	  Our	  results	  show	  that	  compounds	  12a,	  CRT101	  and	  CRT051	  are	  indeed	  specific	  for	  PKD	  and	  although	  individually	  they	  display	  off	   target	  effects	  on	  other	  kinases	   they	  comparatively	  do	  not	  share	  any	  off-­‐target	   effects.	   	   Importantly,	   all	   three	   inhibitors	   did	   not	   inhibit	   the	   in	   vitro	  kinase	  activity	  of	  multiple	  PKC	  isoforms	  including	  PKCα,	  PKCγ	  and	  PKCζ.	  	  This	  is	  significant,	  as	  it	  distinguishes	  these	  newer	  inhibitors	  from	  previous	  reports	  using	  dual	   PKC/PKD	   inhibitors	   such	   as	   Go6976	   allowing	  more	   selective	   targeting	   of	  PKD	   and	   its	   downstream	   substrates	   despite	   the	   fact	   that	   significant	   off	   target	  effects	   remain.	   	   Furthermore,	   our	   comparative	   analysis	   of	   data	   obtained	   from	  our	   in	   vitro	   kinase	   analysis	   in	   combination	  with	   published	   data	   illustrate	   that	  although	  each	  compound	  display	  individual	  off	  target	  effects	  they	  are	  not	  shared	  between	   all	   three	   compounds.	   These	   results	   subsequently	   allowed	   us	   to	  confidently	   explore	   the	   effect	   of	   pharmacological	   inhibition	   of	   PKD	   with	   the	  rationale	   that	   any	   biological	   effects	   observed	   should	   be	   shared	   between	   the	  three	  compounds	  and	  to	  allows	  us	  to	  reliably	  describe	  it	  as	  a	  consequence	  of	  PKD	  inhibition	  specifically.	  	  Our	  subsequent	  studies	  detailed	  the	  characteristics	  of	  PKD	  inhibition	  that	  compounds	   12a,	   CRT101	   and	   CRT051	   demonstrated	  within	   primary	  murine	   T	  lymphocytes	  and	  malignant	  myeloid	  cells	  including	  human	  K562	  CML	  cells.	  Pharmacological	   inhibition	   of	   PKD	   within	   murine	   T	   lymphocytes	  demonstrated	   that	   catalytic	   activity	   of	   PKD	   after	   TCR	   ligation	   is	   essential	   for	  IFNγ	  and	  IL-­‐2	  production	  in	  agreement	  with	  previous	  reports	  showing	  impaired	  cytokine	   production	   in	   PKD2KI/KI	   animals	   lacking	   specifically	   PKD2	   catalytic	  activity	   (Matthews	   et	   al.	   2010).	   Previous	   reports	   within	   the	   literature	   have	  further	   revealed	   that	   PKD	   catalytic	   activity	   is	   required	   downstream	   of	   TCR	  ligation	   for	   the	   recruitment	   of	   RNA	   polymerase	   II	   (Pol	   II)	   to	   the	   IFNγ	  transcriptional	  start	  site	  (Navarro,	  Feijoo	  Carnero,	  et	  al.	  2014a).	  	  To	  determine	  if	  is	   the	   case	   in	   regard	   to	   the	   effect	   pharmacological	   inhibition	   of	   PKD	   on	   the	  recruitment	  of	  Pol	   II	   to	   the	   IFNγ	  and	   IL-­‐2	   start	   sites	   could	  be	   examined	   in	   the	  future.	  	  The	  implication	  of	  PKD	  kinases	  within	  cytokine	  production	  is	  not	  limited	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to	  TCR	  induced	  cytokine	  production	  as	  studies	  using	  pharmacological	  inhibition	  or	  knockdown	  of	  PKD	  in	  prostate	  cancer	  cell	   lines	  and	  epithelial	  cell	   lines	  have	  also	   reported	   a	   reduction	   in	   the	   production	   of	   IL-­‐6	   and	   IL-­‐8	   (LaValle,	   Bravo-­‐Altamirano,	  et	  al.	  2010a;	  Hao	  et	  al.	  2009).	  Previous	   reports	   within	   the	   literature	   implicate	   a	   role	   for	   PKD	   within	  multiple	  aspects	  of	  including	  CML	  development	  and	  CML	  cell	  survival	  (Mihailovic	  et	   al.	   2004)	   (Z.-­‐F.	   Yang	   et	   al.	   2013)	   (Bhattacharya	   et	   al.	   2011;	   H.	   Zheng	   et	   al.	  2011).	   Additionally,	   PKD2	   has	   been	   shown	   to	   be	   expressed	   within	   K562	   Bcr-­‐Abl+	  CML	  cell	  line,	  in	  agreement	  with	  our	  data.	  	  However,	  one	  discrepancy	  within	  these	  results	  are	  reports	  also	  describe	  constitutive	  PKD	  activity	  (p.SER916	  site)	  after	   direct	   phosphorylation	   by	   the	   Bcr-­‐Abl	   oncoprotein,	   which	   we	   do	   not	  observe	  either	  by	  western	  blot	  or	  more	  sensitive	  methods	  such	  as	  phospho-­‐flow	  cytometry.	   	  This	   is	   in	  contrast	  to	  data	  previously	  published	  and	  data	  generated	  within	   our	   lab	   that	   demonstrates	   high	   basal	   activity	   of	   PKD	   (p.	   SER916)	   in	  murine	   T	   lymphocytes	   (Matthews	   et	   al.	   2010)	   and	   within	   primary	   murine	  myeloid	   cells	   (discussed	   within	   the	   chapter	   4).	   	   Although	   one	   study	   has	  demonstrated	  that	  Bcr-­‐Abl	  phosphorylation	  the	  tyrosine	  residues	  within	  the	  PH	  domain	   of	   PKD	   rather	   than	   inducing	   p.	   SER916	   autophosphorylation	   sites	  (Mihailovic	   et	   al.	   2004).	   To	   determine	   if	   PKD	   inhibitors	   block	   tyrosine	  phosphorylation	   in	   K562	   CML	   cells	   could	   be	   addressed	   in	   the	   future	   by	   using	  immunoprecipitation	   techniques	   to	   purify	   PKD2	   and	   assess	   tyrosine	  phosphorylation.	   	   Although	   constitutive	   activity	   is	   absent	   in	   our	   experiments,	  PKD	  was	  strongly	  induced	  within	  K562	  cells	  in	  response	  to	  phorbol	  ester.	  The	   lack	   of	   constitutive	   activity	   of	   PKD	   within	   K562	   Bcr-­‐Abl+	   CML	   cells	  made	  it	  difficult	  to	  address	  potency	  of	  these	  inhibitors	  to	  block	  PKD.	  Therefore	  to	  overcome	  this,	  we	  assessed	  the	  ability	  of	  PKD	  inhibitor	  compounds	  12a,	  CRT101	  and	  CRT051	  to	  block	  phorbol	  ester	  induced	  activation,	  a	  potent	  activator	  of	  PKD.	  The	  pharmacological	   inhibition	  of	  PKD	  demonstrated	   that,	  within	  human	  K562	  CML	   cells,	   all	   three	   small	   molecule	   inhibitors	   of	   PKD	   potently	   block	   PKD	  activation	   in	   response	   to	   phorbol	   ester,	   in	   a	   dose	   dependent	   manner.	  	  Importantly,	   key	   PKC	   mediated	   transphorylation	   sites	   were	   unaffected	   by	   all	  three	  compounds.	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Previous	   reports	   on	   PKD2	   in	   CML	   cells	   have	   found	   that	   knockdown	   or	  pharmacological	   inhibition	   of	   PKD	   (with	   the	   CRT101	   compound)	   led	   to	  inhibition	  of	  cell	  cycle	  progression,	  with	  a	  significant	  reduction	  in	  cells	  within	  S	  phase	  (Z.-­‐F.	  Yang	  et	  al.	  2013).	  	  Our	  data	  displays	  discrepancy	  with	  these	  results,	  in	   which	   treatment	   of	   cells	   with	   the	   CRT101	   compound	   led	   to	   a	   significant	  increase	  in	  the	  number	  of	  cells	  in	  S	  phase.	  This	  conflict	  in	  data	  may	  be	  due	  to	  two	  possibilities.	   Firstly,	   the	   Yang	   et	   al	   study	   does	   not	   give	   a	   time	   point	   used	   for	  treatment	  with	  CRT101	  although	  cell	  cycle	  analysis	  is	  frequently	  analysed	  at	  24	  hour	   time	   points,	   however	   our	   analysis	   was	   performed	   at	   7	   hours	   as	   we	   had	  previously	   observed	   significant	   cell	   death.	   Secondly,	   studies	   within	   cell	   lines	  such	  as	   the	  K562	  CML	  cell	   line	  must	  be	  approached	  with	  caution	  due	   to	  clonal	  variation	   between	   different	   laboratories	   as	   a	   result	   of	   the	   acquisition	   of	  mutations	   over	   time	   due	   to	   repeated	   passaging.	   Furthermore,	   based	   on	   the	  kinase	   profiling	   data,	   it	   is	   plausible	   that	   effects	   we	   observed	   within	   cell	   cycle	  analysis	  after	  inhibition	  of	  PKD	  in	  K562	  CML	  cells	  with	  CRT101	  is	  in	  part	  due	  to	  its	  inhibition	  on	  CDK9	  and	  CDK2	  which	  are	  known	  to	  be	  a	  regulators	  of	  S-­‐phase	  entry	  via	  the	  binding	  of	  cyclin	  A	  (McDonald	  2005)	  (Hu	  et	  al.	  2001).	  	  	  	   Although	   K562	   CML	   cells	   and	   indeed	   CML	   patient	   cells	   are	   known	   to	  express	  constitutive	  phosphorylation	  of	  p.	  STAT5	  no	  studies	  have	  yet	  examined	  the	  effect	  of	  PKD	   inhibition	  upon	  p.	  STAT5	  within	  CML	  cells.	  Treatment	  within	  CML	   cells	   12a,	   CRT101	   and	   CRT051	   compounds	   revealed	   inconsistent	   results	  between	   compounds	   in	  which	  12a	  had	  no	   effect,	   CRT101	   subtly	   increased	  and	  CRT051	   profoundly	   decreased	   p.	   STAT5	   levels,	   it	   is	   highly	   plausible	   that	  discrepancies	   are	   most	   likely	   to	   be	   off	   target	   effects	   displayed	   by	   individual	  compounds.	   Referring	   to	   data	   obtained	   within	   in	   vitro	   kinase	   screen	   analysis	  offers	  potential	   insights	   into	   results	   in	   regard	   to	   the	   increase	   in	  pSTAT5	   levels	  upon	  treatment	  with	  CRT101.	  Notably,	  PIM1	  and	  PIM3	  kinases	  are	  significantly	  reduced	  within	  the	  kinase	  screening	  profile	  for	  CRT101.	   	  PIM1	  has	  been	  shown	  to	   be	   involved	   the	   negative	   feedback	   loop	   for	   p.	   STAT5	   levels,	   whereby	   PIM1	  phosphorylates	  and	  activates	  suppressors	  of	  cytokine	  signaling	  (SOCs)	  proteins	  which	  act	  to	  suppress	  p.	  STAT5	  signaling.	  Additionally,	  the	  2-­‐(4-­‐aminopyridin-­‐2-­‐yl)	  phenol	  moiety	  in	  CRT101	  is	  also	  present	  in	  small	  molecule	  inhibitors	  of	  PIM1	  
	  	  
148	  




4 Exploring	   the	   expression	   and	   function	   of	   PKD	  
isoforms	  in	  primary	  myeloid	  cells	  	  
4.1 Introduction	  	   In	   the	   previous	   chapter	   I	   have	   introduced	   novel	   data	   characterising	   the	  specificity	   of	   three	   novel	   small	  molecule	   inhibitors	   of	   PKD	   and	   their	   biological	  effects	  within	   T	   lymphocytes	   and	   a	   CML	   cell	   line.	   As	  we	   established	   the	   PKD2	  isoform	   was	   indeed	   expressed	   in	   human	   K562	   CML	   cells,	   we	   also	   wished	   to	  address	  PKD	  isoform	  expression	  in	  primary	  murine	  myeloid	  cells,	  including	  DCs	  and	  macrophages.	   In	   regard	   to	   expression	  within	  different	   lineages	  of	   immune	  cells	   the	   PKD2	   isoform	   is	   known	   to	   be	   predominantly	   expressed	   in	   T	   and	   B	  lymphocytes	   in	   the	   adaptive	   immune	   system,	   moreover,	   PKD2	   is	   selectively	  activated	  after	  TCR	  triggering	  with	  cognate	  antigen	  and	  rapidly	  translocate	  from	  the	   cytoplasm	   to	   the	   plasma	   membrane	   within	   the	   immunological	   synapse	  (Matthews	  et	  al.	  2010)	  (Spitaler,	  Emslie,	  Wood	  &	  Cantrell	  2006b).	  	  Within	  cells	  of	  the	  innate	  immune	  system	  specific	  PKD	  isoform	  expression	  remains	   largely	   unaddressed,	   although	   PKD1	   is	   reported	   to	   be	   the	   dominant	  isoform	  expressed	  within	  mast	  cells	  (Murphy	  et	  al.	  2007).	  Previous	  investigation	  into	   PKD	   isoform	   expression	   has	   been	   problematic	   due	   to	   the	   high	   level	   of	  homology	  between	   family	  members	   leading	   to	   a	   lack	  of	   antibodies	   that	  do	  not	  cross-­‐react	  .	  To	  overcome	  this	  problem,	  we	  largely	  focused	  on	  the	  use	  of	  isoform	  specific	   PKD	   transgenic	   animal	   models.	   Additionally,	   a	   global	   aim	   within	   this	  thesis	  was	  to	  focus	  on	  the	  use	  of	  isoform	  specific	  kinase	  dead	  mice	  to	  investigate	  the	   true	   biological	   functions	   of	   PKD	   kinases.	   The	   justification	   to	   use	   a	  catalytically	  in-­‐active	  kinase	  transgenic	  model	  rather	  than	  a	  total	  protein	  knock-­‐out	  was	   that	   they	   represent	   a	  more	   accurate	   tool	   to	  directly	   assess	   the	   role	  of	  PKD	   kinase	   activity	   by	   examining	   a	   direct	   consequence	   of	   loss	   of	  phosphorylating	  ability	  and	  therefore	  the	  effect	  on	  the	  regulation	  of	  downstream	  substrates,	   rather	   than	   affect	   potential	   scaffolding	   functions.	   As	   such,	   it	   is	  important	  to	  emphasise	  that	  the	  only	  PKD	  knockout	  cells	  used	  in	  this	  thesis	  were	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PKD2KO/KO,	  which	  served	  as	  controls	  for	  isoform	  expression	  experiments	  and	  to	  confirm	  antibody	   specificity.	   It	   is	   also	   important	   to	  note	   that	   as	  well	   as	   loss	  of	  PKD	  activity	  upon	   stimulation	  of	   cells	  with	  PKD	  activating	   factors,	   catalytically	  inactive	  mutant	  cells	  have	  also	   lost	  basal	  kinase	  activity	  which	  may	  also	  play	  a	  significant	  role	  in	  cellular	  processes.	  In	   addition	   to	   isoform	   expression,	   we	   also	   wished	   to	   utilise	   PKD	  transgenic	   animal	   models	   to	   investigate	   the	   consequence	   of	   loss	   of	   isoform	  specific	  PKD	  catalytic	  activity	  on	  myeloid	  cell	  development	  in	  vivo.	  At	  present,	  no	  studies	   have	   yet	   established	   the	   requirement	   for	   PKD	   catalytic	   activity	   in	   the	  development	   of	  myeloid	   cells	  within	   the	  bone	  marrow	  or	  peripheral	   lymphoid	  tissues	   such	   as	   the	   spleen.	   In	   regard	   to	   the	   adaptive	   immune	   system,	  previous	  reports	   have	   shown	   that	   loss	   of	   PKD2	   catalytic	   activity	   has	   been	   shown	   to	   be	  dispensable	  for	  the	  development	  of	  T	  and	  B-­‐lymphocytes	  in	  vivo	  (Matthews	  et	  al.	  2010).	  	  Although	   the	   loss	   of	   PKD2	   catalytic	   activity	   has	   been	   shown	   be	  dispensable	  for	  T	  cell	  development	  it	  has	  been	  shown	  to	  be	  required	  for	  normal	  T	   cell	   effector	   functions	   such	   as	   cytokine	   production	   including	   IL-­‐2	   and	   IFNγ,	  which	   has	   direct	   consequences	   on	   the	   immune	   response	   in	   vivo.	   Immunised	  PKD2KI/KI	  mice	   displayed	   significantly	   reduced	   humoral	   responses,	   presumably	  due	   to	   abhorrent	   T	   cell	   response	   caused	   by	   reduced	   production	   of	   effector	  cytokines.	   More	   recent	   evidence	   has	   also	   highlighted	   a	   role	   for	   PKD2	   activity	  within	  the	  immune	  response	  in	  vivo	  whereby	  loss	  of	  PKD2	  activity	  in	  CD8+	  CTL	  results	   in	  an	   impaired	   response	   to	  Listeria	  Monocytogenes	   (L.	  Monocytogenes),	  yet	   loss	   of	   PKD2	   catalytic	   activity	   was	   protective	   in	   a	   model	   of	   autoimmune	  diabetes	  (Navarro,	  Feijoo	  Carnero,	  et	  al.	  2014a).	  Are	  PKD	  kinases	  also	  required	  for	   normal	   effector	   responses	   on	   innate	   immune	   cells?	   The	   evidence	   for	   this	  question	  within	  the	  literature	  is	  limited,	  however,	  studies	  within	  C.elegans	  have	  pointed	   to	   a	   clear	   and	   conserved	   role	   for	   PKD	   kinases	   in	   innate	   immunity	  whereby	  animals	  lacking	  the	  DFK-­‐2A	  homologue	  of	  PKD	  were	  hypersensitive	  to	  death	  from	  bacterial	  pathogens	  (Ren	  et	  al.	  2009).	  In	  the	  context	  of	  activation	  of	  PKD	  downstream	  of	  PRR	  ligation,	  previous	  reports	  include	  activation	  of	  PKD	  via	  TLR1/2	  in	  BMDCs	  (Murphy	  et	  al.	  2007),	  and	  TLR9	  in	  murine	  macrophages	  (J.-­‐E.	  Park	   et	   al.	   2008).	   	   Further	   studies	   also	   reported	   requirement	   for	   PKD1	   in	   all	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MyD88	  mediated	  TLR	  signalling	  within	  a	  macrophage	  cell	  line	  and	  BMDCs	  (J.-­‐E.	  Park	  et	  al.	  2009b).	  	  	  Despite	   providing	   insight	   into	   the	   potential	   role	   of	   PKD	   and	   their	  downstream	  substrates	  in	  innate	  immunity,	  significant	  limitations	  to	  these	  past	  studies	   exist	   as	   they	   are	   often	   performed	   in	   cell	   lines	   using	   overexpression	  techniques	  and	  assessed	  using	  non-­‐specific	  dual	  PKC/PKD	  inhibitors.	  Therefore,	  much	   of	   this	   research	   needs	   to	   be	   validated	   in	   primary	   cells	   and	   in	   vivo	   to	  ascertain	  the	  true	  contribution	  of	  PKD	  kinases	  to	  these	  processes.	  	  	  Accordingly,	   within	   this	   chapter	   I	   will	   present	   data	   exploring	   if	   PKD	  kinases	  play	   a	   true	  physiological	   role	   in	   normal	  myeloid	   cell	   development	   and	  function	   including:	   PKD	   isoform	   expression	   within	   primary	   myeloid	   cells,	   the	  effect	   of	   loss	   of	   catalytic	   activity	   in	  myeloid	   cell	   development	  within	   the	   bone	  marrow	   and	  myeloid	   cell	   populations	  within	   the	   spleen	   and	   finally	   the	   role	   of	  PKD	  catalytic	  activity	  within	  effector	  function	  of	  primary	  myeloid	  cells.	  	  	  
4.2 	  Results	  	  
4.2.1 Exploring	  PKD	  isoform	  expression	  in	  primary	  myeloid	  cells	  	  	   PKD	  isoform	  expression	  has	  been	  examined	  in	  both	  murine	  T	  and	  B	  cells	  (Matthews	   et	   al.	   2010)	   (Matthews	   et	   al.	   2006),	   with	   PKD2	   preferentially	  expressed	   in	   these	   cell	   types,	   however,	   no	   studies	   have	   specifically	   addressed	  isoform	  expression	   in	  cells	  within	  the	   innate	   immune	  system,	  although,	  studies	  have	  concluded	   that	  PKD2	   is	   the	  main	   isoform	  expressed	   in	   two	  CML	  cell	   lines	  (Mihailovic	  et	  al.	  2004).	  Additional	   insights	   into	  PKD	   isoform	  expression	  at	   the	  mRNA	   level	   can	   be	   assessed	   by	   using	   data	   from	   the	   immunological	   genome	  project	   (Immgen),	   whereby	   gene	   expressional	   profiles	   are	   generated	   from	  different	  immune	  cells	  by	  RNA-­‐sequencing	  (Ilumina).	  PKD	  expression	  in	  multiple	  immune	   cells	  within	   the	   adaptive	   immune	   system	   (assessed	  ex-­‐vivo)	   including	  CD19+	  B	  lymphocytes,	  CD4+	  and	  CD8+	  T	  lymphocytes	  can	  be	  seen	  in	  Figure	  4.1.	  These	   data	   agree	   with	   literature	   which	   demonstrates	   that	   PKD2	   is	   selectively	  and	  dominantly	  expressed	  within	   lymphoid	   tissue	  and	   indeed	  adaptive	   cells	  of	  the	   immune	   system	   (Matthews	   et	   al.	   2010).	   In	   regard	   to	   myeloid	   cells,	   RNA-­‐
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sequencing	   data	   from	   Immgen	   reveal	   dominant	   expression	   of	   PKD	   in	   splenic	  DCs,	  yet	  comparable	  levels	  of	  PKD1	  and	  PKD2	  expression	  in	  splenic	  neutrophils	  (Figure	  4.2).	  	   	  
	  Figure	   4.1	   PKD	   RNA	   isoform	   expression	   in	   CD19+	   B	   lymphocytes,	   CD4+	   and	  CD8+	  T	  lymphocytes.	  	  RNA	   sequencing	   data	   showing	   analysis	   of	   exons	   of	   PKD1,	   PKD2	   and	   PKD3	  isoforms	   found	   within	   either	   CD19+	   B	   lymphocytes,	   CD4	   and	   CD8+	   T	  lymphocytes	  
Data	  obtained	  from	  www.immgen.com	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  Figure	  4.2	  RNA	  sequencing	  data	  displaying	  PKD	  isoform	  expression	   in	  multiple	  immune	  cells.	  	  
Data	  obtained	  from	  www.immgen.com	  	  
	   To	  begin	  to	  assess	  protein	  expression	  of	  PKD	  isoforms	  within	  cells	  of	  the	  innate	   immune	   system,	   including	   DCs	   and	   macrophages.	   As	   DCs	   and	  macrophages	   are	   small	   populations	   within	   murine	   tissues	   we	   therefore	   first	  expanded	   these	   cell	   populations	   in	   vitro	   using	   previously	   described	   methods,	  allowing	   for	   generation	   of	   larger	   cell	   numbers	   of	   a	   more	   homogenous	   cell	  population.	   Bone	  marrow	   derived	  macrophages	   (BMDMOs)	   and	   bone	  marrow	  derived	   dendritic	   cells	   (BMDCs)	   were	   expanded	   in	   vitro	   after	   bone	   marrow	  isolation	   using	   GM-­‐CSF	   (P	   Matheu	   et	   al.	   2008)	   and	   M-­‐CSF	   (Manzanero	   2011)	  respectively	  and	  cultured	  for	  the	  indicated	  time.	  	  In	   order	   to	   accurately	   assess	   which	   isoforms	   of	   PKD	   are	   expressed	   in	  primary	  myeloid	   cells	  we	  used	   isoform	  specific	   kinase	   inactive	   (KI)	  or	   isoform	  specific	   knock	   out	   (KO)	   cells	   generated	   from	   various	   PKD	   isoform	   specific	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transgenic	  animals.	  This	  included	  cells	  generated	  from	  the	  bone	  marrow	  of	  wild	  type	   (WT),	   PKD1	   kinase	   inactive	   heterozygous	   (PKD1WT/KI	   )	   (as	   homozygous	  mutation	   is	   embryonic	   lethal),	   PKD2	   kinase	   inactive	   homozygous	   (PKD2KI/KI	   ),	  double	  kinase-­‐inactive	  cross	  mice	  (PKD1WT/KI	  x	  PKD2KI/KI	  	  )	  and	  finally	  PKD2	  gene	  trap	  knock	  out	  (PKD2KO/KO).	  The	  generation	  of	  double-­‐kinase	  dead	  mice	  was	  to	  assess	  any	  significant	  activity	  of	  PKD3	  by	  depletion	  of	  the	  pool	  of	  inducible	  PKD1	  and	  PKD2	  isoforms.	  Furthermore,	  PKD3	  has	  been	  shown	  to	  have	  extremely	  low	  abundance	  in	  T	  lymphocytes	  (Matthews	  et	  al.	  2010).	  Firstly,	   before	   using	   in	   vitro	   generated	   cells	   to	   examine	   PKD	   isoform	  expression	   we	   wanted	   to	   address	   if	   BMDC	   and	   BMDMO	   generated	   from	   all	  transgenic	  PKD	  mice	  were	  phenotypically	  comparable	  to	  cells	  derived	  from	  WT	  bone	   marrow.	   	   This	   analysis	   addresses	   two	   fundamental	   questions.	   Firstly,	   is	  specific	   PKD	   isoform	   activity	   required	   during	   the	   generation	   and	   expansion	   of	  myeloid	  cell	   in	  vitro?	  And	  secondary,	  are	  myeloid	  cells	  generated	   from	   isoform	  specific	   PKD	   bone	   marrow	   comparable	   to	   reliably	   determine	   PKD	   isoform	  expression.	  	  By	  the	  end	  of	  the	  culture	  period	  WT	  BMDC	  typically	  express	  high	  levels	  of	  CD11c	   and	   MHC	   class	   II,	   which	   is	   frequently	   used	   for	   phenotyping	   BMDCs	  generated	   in	   vitro	   (Inaba	   et	   al.	   2009).	   Our	   data	   demonstrates	   that	   BMDCs	  generated	   from	  the	  bone	  marrow	  of	  various	  PKD	   transgenic	  mice	  all	  displayed	  comparable	   levels	   CD11c	   and	   MHC	   class	   II	   to	   WT	   BMDCs	   (Figure	   4.3A).	  Microscopically,	  BMDCs	  generated	  from	  PKD	  mutant	  mice	  were	  morphologically	  comparable	   to	  WT	  BMDCs	   (data	  not	   shown).	  Additionally,	   analysis	  of	   total	   cell	  number	   (x106)	   from	  both	   the	  bone	  marrow	  on	  day	  0	  and	   total	   cell	  number	  by	  day	  10	  of	  culture	  from	  all	  PKD	  transgenic	  mice	  were	  comparable	  to	  WT	  counts	  (Figure	   4.3B-­‐C).	   These	   data	   importantly	   demonstrates	   that	   PKD1	   and	   PKD2	  catalytic	   activity,	   or	   indeed	   in	   the	   case	   of	   loss	   of	   PKD2	   protein	   in	   the	   case	   of	  PKD2KO/KO	  cells,	   is	   dispensable	   for	   the	   development	   or	   expansion	   of	   BMDCs	   in	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  Figure	  4.3	  Generation	  and	  phenotypical	  analysis	  of	  murine	  BMDCs	  generated	  in	  
vitro	  from	  WT	  and	  PKD	  mutant	  mice	  (A)	  Flow	  cytometry	  analysis	  of	  CD11c	  and	  MHC	  class	  II	  surface	  expression	  on	  live	  cells	   within	   BMDC	   on	   day	   10	   of	   culture	   generated	   from	  WT	   and	   PKD	  mutant	  bone	  marrow	  as	  indicated	  (n=3).	  (B)	  Total	  cell	  number	  (x106)	  from	  day	  0	  bone	  marrow	  (n=3).	  (C)	  Total	  number	  (x106)	  of	  BMDC	  generated	  by	  day	  10	  of	  culture.	  Error	  bars	  represent	  SEM	  (n=3	  biological	  experiments	  9	  mice	  total).	  	  	   Using	   the	   same	   experimental	   approach,	   we	   moved	   on	   to	   validate	   and	  phenotype	  BMDMOs	  generated	   from	  the	  bone	  marrow	  of	  PKD	  transgenic	  mice.	  	  In	   contrast	   to	  BMDCs,	  BMDMO	  phenotypically	   express	  F4/80	  and	  CD11b	  upon	  the	   cell	   surface	   after	   the	   culture	   period	   (X.	   Zhang,	   Goncalves,	   et	   al.	   2001a).	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  Figure	  4.4	  Generation	  and	  phenotypical	  analysis	  of	  murine	  BMDMO	  generated	  in	  
vitro	  from	  WT	  and	  PKD	  mutant	  mice	  	  (A)	   Representative	   flow	   cytometry	   analysis	   of	   F4/80	   and	   CD11b	   surface	  expression	  on	  day	  6	  of	  culture	  in	  BMDMOs	  generated	  from	  WT	  and	  PKD	  mutant	  mice	  as	  indicated	  (B)	  Total	  cell	  number	  (x106)	  from	  day	  0	  bone	  marrow	  before	  BMDMO	  generation	  (n=3).	  (C)	  Total	  number	  (x106)	  of	  BMDMO	  generated	  by	  day	  6	  of	  culture.	  (n=2	  biological	  experiments	  7	  mice	  total).	  	  	   After	   phenotypic	   validation	   of	   in	   vitro	   differentiated	   primary	   myeloid	  cells	   we	   sought	   to	   determine	   PKD	   isoform	   expression.	   In	   order	   to	   identify	  isoforms	   by	   western	   blot,	   two	   phospho-­‐specific	   antibodies	   against	   PKD	   were	  strategically	   used.	   Briefly,	   p.	   SER916	   antibody	   recognises	   the	   p.	   SER916	   site	  within	  the	  autophosphorylation	  loop	  of	  PKD1	  and	  PKD2	  isoforms	  but	  not	  PKD3	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(as	   it	   lacks	   an	   autophosphorylation	   domain).	   The	   p.	   SER744/748	   antibody	   in	  contrast	   recognises	   PKD1,	   PKD2	   and	   PKD3	   indistinguishably	   as	   it	   recognises	  trans-­‐phosphorylation	  residues	  SER744/748	  within	  the	  catalytic	  domain	  of	  PKD,	  which	  are	  conserved	  sites	  shared	  by	  all	  three	  isoforms.	  	  Using	   a	   combination	   of	   these	   antibodies,	   cells	   that	   lack	   either	   catalytic	  activity	  of	  PKD1WT/KI,	  PKD2KI/KI	  or	  by	  depleting	  the	  PKD	  pool	  even	  further	  by	  use	  of	   PKD1WT/KI	   x	   PKD2KI/KI	   mice	   we	   confirmed	   that	   PKD2	   was	   the	   dominant	  isoform	  expressed	   in	  primary	  murine	  BMDC	  by	  western	  blot	  (Figure	  4.5A).	  We	  achieved	   this	   by	   treatment	   of	   cells	   with	   pervanadate,	   a	   strong	   phosphatase	  inhibitor,	  to	  induce	  maximal	  phosphorylation	  of	  all	  present	  PKD	  isoforms.	  It	  was	  clear	  that	  heterozygous	  mutation	  of	  PKD1	  catalytic	  activity	  had	  little	  effect	  on	  the	  level	  of	  p.	  SER916	  and	  p.	  SER744/748,	  indicating	  that	  PKD1	  is	  expressed	  in	  low	  levels.	  However	  homozygous	  mutation	  of	  PKD2	  within	  the	  catalytic	  domain	   led	  to	   a	   dramatic	   reduction	   in	   the	   signal	   of	   both	   p.	   SER916	   and	   p.	   SER744/748,	  which	   was	   also	   true	   within	   double	   knock-­‐in	  mice	   PKD1WT/KI	  x	   PKD2KI/KI.	   	   Any	  detectable	   expression	   of	   PKD3	   would	   be	   observed	   in	   these	   cells	   with	   the	   p.	  SER744/748	  antibody,	  which	  we	  could	  not	  detect.	  As	  catalytic	  activity	  is	  severely	  reduced	  rather	  than	  absolutely	  abolished	  in	  PKD2KI/KI	  mice,	  we	  included	  BMDCs	  generated	   from	   PKD2KO/KO	   bone	   marrow	   as	   an	   additional	   control.	   Within	  PKD2KO/KO	  BMDCs	  we	  could	  not	  detect	  any	  p.	  SER916	  signal	  and	  very	  low	  levels	  of	  p.	  SER744/748,	  in	  agreement	  with	  PKD2KI/KI	  cells.	  Finally,	  p.	  ERK1/2	  was	  used	  within	   these	   experiments	   as	   a	   positive	   control	   of	   successful	   cell	   stimulation,	  which	  was	  evident	  in	  all	  stimulated	  samples.	  We	   went	   on	   to	   expand	   these	   experiments	   to	   assess	   PKD	   isoform	  expression	  in	  a	  single	  cell	  based	  assay	  using	  phospho-­‐flow	  cytometry	  as	  a	  more	  sensitive	   and	   quantitative	   approach	   to	   detect	   p.	   SER916	   levels	   in	   BMDC.	   To	  achieve	   strong	   phosphorylation	   of	   all	   PKD	   isoforms	   we	   stimulated	   cells	   with	  phorbol	  ester	   for	  30	  minutes.	  As	  can	  be	  seen	   in	  Figure	  4.5B,	  PKD1WT/KI	  	  BMDCs	  had	  comparable	  levels	  of	  p.	  SER916	  activation	  in	  response	  to	  phorbol	  ester	  when	  compared	  to	  WT	  cells.	   In	  contrast,	  when	  we	  compared	  PKD2KI/KI	  BMDCs	   to	  WT	  BMDCs	  we	  observed	  an	  almost	  2-­‐fold	  reduction	   in	   the	   level	  of	  p.	  SER916	  upon	  treatment	  with	  phorbol	  ester.	  Furthermore,	  PKD1WT/KI	  x	  PKD2KI/KI	  and	  PKD2KO/KO	  BMDCs	   displayed	   a	   2-­‐fold	   and	   3-­‐fold	   reduction	   respectively	   in	   the	   level	   of	   p.	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SER916	  in	  response	  to	  phorbol	  ester	  when	  compared	  to	  WT	  BMDC.	  	  Importantly,	  all	   cells	   displayed	   successful	   activation	   as	   demonstrated	   by	   p.	   ERK1/2	   levels,	  which	   we	   co-­‐stained	   for	   as	   a	   positive	   control	   of	   successful	   cell	   stimulation,	  although	  p.	  ERK1/2	  levels	  were	  reduced	  in	  PKD1WT/KI	  x	  PKD2KI/KI	  	  and	  PKD2KO/KO	  BMDCs.	  	  It	  is	  also	  worthwhile	  mentioning	  that	  data	  from	  western	  blots	  identifying	  isoform	  expression	  of	  PKD	  in	  BMDCs	  also	  demonstrated	  that	  PKD	  has	  high	  basal	  phosphorylation	   within	   the	   p.	   SER916	   site	   in	   unstimulated	   samples.	   	   This	  observation	  is	  consistent	  with	  previous	  reports	  of	  high	  basal	  phosphorylation	  of	  PKD	  in	  other	  immune	  cells	  including	  CD8+	  CTLs	  (Matthews	  et	  al.	  2010).	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  Figure	  4.6	  PKD2	  is	  the	  dominant	  isoform	  expressed	  in	  primary	  BMDMOS	  Western	  blot	  analysis	  of	  primary	  BMDMOs	  generated	  from	  WT	  and	  PKD	  mutant	  mice	  as	  indicated	  treated	  with	  pervanadate	  (10nM)	  for	  10	  minutes	  for	  detection	  of	   p.	   SER916,	   p.	   SER744/748	   and	   β-­‐tubulin.	   Representative	   data	   from	   2	  independent	  	  experiments,	  n=2	  mice	  per	  genotype.	  	  	  Using	   the	   same	  experimental	   approach,	  we	  also	   confirmed	   that	  PKD2	  was	  also	  the	  dominant	  isoform	  expressed	  in	  BMDMO	  with	  western	  blotting	  (Figure	  4.6A).	  Unfortunately	   attempts	   to	   reproduce	   this	   result	   using	   phospho-­‐flow	   were	  unsuccessful,	   possibly	   due	   to	   differences	   in	   the	   required	   fixation	   and	  permeabilisation	   process	   of	   BMDMO	   compared	   to	   BMDC.	   However,	   it	   is	   clear	  from	   western	   blot	   data	   that	   PKD2	   is	   indeed	   the	   dominant	   isoform	   in	   similar	  respect	   to	  BMDC	  where	  we	  only	  observe	  a	   reduction	   in	   the	   level	   of	  p.	   SER916	  signal	   in	   BMDMOs	   that	   have	   either	   lost	   PKD2	   catalytic	   activity	   (PKD2KI/KI	  and	  PKD1WT/KI	  x	  PKD2KI/KI)	  or	  indeed	  in	  PKD2KO/KO	  mice.	  	  	  	   During	   our	   studies	   two	   separate	   companies	   have	   generated	   new	   and	  more	  specific	  total	  PKD2	  antibodies	  and	  we	  sought	  to	  validate	  the	  specificity	  of	  these	   antibodies.	   To	   achieve	   this	   we	   took	   a	   similar	   approach	   to	   previous	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  Figure	   4.7	   PKD2	   expression	   in	   various	   myeloid	   cells	   using	   PKD2	   specific	  antibody	  that	  differentially	  recognises	  PKD2	  only.	  Western	   blot	   analysis	   of	   untreated	  WT	   splenocytes	   and	  WT	   and	   PKD	   mutant	  BMDMOs	  and	  BMDCs	  as	  indicated	  for	  detection	  of	  PKD2	  and	  β-­‐tubulin.	  Western	  blot	  representative	  of	  2	  independent	  experiments.	  	  	  	   Collectively	   these	   data	   demonstrate	   for	   the	   first	   time	   that	   PKD2	   is	   the	  dominant	   isoform	   expressed	   in	   both	   primary	   myeloid	   cells	   including	   murine	  BMDCs	  and	  BMDMO,	   in	  agreement	  with	  data	  published	   from	  adaptive	   immune	  cells.	   Additionally,	   these	   data	   also	   demonstrate	   that	   both	   PKD1	   and	   PKD3	  isoforms	  are	  expressed	  at	  very	   low	  levels	   in	  murine	  myeloid	  cells.	   Importantly,	  these	  data	  demonstrates	  that	  abundance	  of	  the	  protein	  level	  of	  distinct	  isoforms	  of	   PKD	   do	   not	   increase	   after	   introducing	   loss	   of	   function	   mutations	   into	   one	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isoform	   in	  a	   compensatory	  manner.	  For	  example,	  we	  do	  not	   see	  an	   increase	   in	  the	  abundance	  of	  PKD1	  or	  PKD3	  in	  both	  PKD2KI/KI	  and	  PKD2KO/KO	  cells.	  	  	   Having	   addressed	   isoform	  expression	   in	   primary	  myeloid	   cells,	  we	  next	  sought	   to	   explore	   the	   kinetics	   of	   PKD	   activity	   in	   response	   to	   various	   stimuli	  including	  TLR	   activation.	   To	   assess	   this,	  we	   sought	   to	  make	   further	   use	   of	   the	  phospho-­‐flow	  cytometry	  techniques	  that	  were	  used	  to	  assess	  isoform	  expression	  in	  primary	  myeloid	  cells	  as	  this	  provides	  higher	  sensitivity	  over	  western	  blotting	  and	  has	  the	  ability	  to	  assess	  PKD	  activity	  at	  a	  single	  cell	  level.	  This	  approach	  has	  been	   successfully	   used	   to	   analyse	   the	   activity	   of	   PKD	   in	   mature	   T	   cells	   in	  response	  to	  TCR	  engagement	  (Navarro	  et	  al.	  2012).	  The	  advantage	  of	  assessment	  of	   PKD	   activity	   via	   phospho-­‐flow	   cytometry	   was	   highlighted	   in	   recent	  publications	  whereby	  studies	  have	  shown	  that	  depending	  on	  the	  context	  of	  cell	  stimuli,	   e.g.	   phorbol	   ester	   activates	   the	   total	   cellular	   pool	   of	   PKD2,	  whereas	   in	  response	  to	  TCR	  ligation	  only	  some	  cells	  activate	  PKD,	  differences	   in	  activation	  kinetics	   of	   PKD	   can	   be	   seen,	   which	   are	   indistinguishable	   via	   conventional	  western	   blotting.	   We	   therefore	   sought	   to	   apply	   this	   technique	   to	   assess	   PKD	  activation	  in	  myeloid	  cells	  
4.2.2 Assessing	   PKD	   activity	   by	   p.	   SER916	   phospho-­‐flow	   is	   specific	   for	  
PKD	  	   Before	   routinely	   using	   p.	   SER916	   antibody	   during	   a	   series	   of	   phospho-­‐flow	  experiments	  we	   sought	   to	   confirm	   that	   this	   antibody	   specifically	  detected	  changes	  in	  PKD	  activity.	   	  In	  particular,	  we	  also	  wished	  to	  assess	  this	  in	  primary	  myeloid	   cells,	   which	   are	   notoriously	   auto-­‐fluorescent	   when	   used	   during	   flow	  cytometry	  or	  microscopy.	  	  To	   validate	   the	   use	   of	   p.	   SER916,	  we	   used	   BMDCs	   generated	   from	  WT,	  PKD2KI/KI	   and	   PKD2KO/KO	   	   bone	   marrow,	   unstimulated	   and	   stimulated	   with	  phorbol	   ester	   for	   30	   minutes	   (Figure	   4.8A),	   p.ERK1/2	   was	   used	   a	   positive	  control.	  It	  can	  be	  seen	  that	  WT	  BMDC	  stimulated	  with	  phorbol	  ester	  have	  a	  clear	  shift	   demonstrating	   increase	   of	   p.	   SER916	   levels,	   in	   contrast,	   	   p.SER916	   levels	  within	   PKD2KI/KI	   and	   PKD2KO/KO	   	   BMDCs	   remained	   unchanged	   in	   stimulated	  samples	  despite	  strong	  p.ERK1/2	  activation.	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  Figure	   4.8	   p.	   SER916	   PKD	   antibody	   effectively	   detects	   activation	   of	   PKD	   using	  phospho	  flow	  in	  primary	  BMDC.	  	  Phospho	  flow	  analysis	  of	  p.	  SER916	  PKD	  and	  p.	  ERK1/2	  in	  BMDC	  generated	  from	  WT	  and	  PKD	  mutant	  mice	  unstimulated	  and	  stimulated	  with	  PdBu	  (200nM)	  for	  30	  minutes.	  Representative	  flow	  data	  shown	  from	  2	  independent	  experiments.	  	  	  
4.2.3 Basal	  activity,	  activation	  and	  inhibition	  of	  PKD	  in	  myeloid	  cells	  	  	   During	   initial	   experiments	   investigating	   PKD	   activity	   and	   regulation	   in	  myeloid	   cells	   it	  became	  apparent	   that	  primary	  myeloid	   cells	  displayed	  obvious	  basal	  PKD	  activity.	  We	  began	   to	   characterise	   this	  basal	   activity	  within	  myeloid	  cells	  using	  a	  murine	  macrophage	  cell	   line,	  RAW264.7	  cells,	  using	  phospho-­‐flow	  cytometry.	   	   Treatment	   of	   RAW264.7	   cells	   with	   phorbol	   ester	   for	   30	   minutes	  	  induced	   an	   increase	   in	   p.SER916	   levels	   whereas	   treatment	   of	   RAW264.7	   cells	  with	  PKD	  inhibitor	  12a	  compound	  led	  to	  an	  obvious	  reduction	  when	  compared	  to	  untreated	  samples	  (Figure	  4.9A).	  	  We	  also	  confirmed	  specificity	  of	  p.	  ERK1/2	  staining	  in	  RAW264.7	  by	  treatment	  of	  RAW264.7	  cells	  with	  MEK	  (MKK1;	  MAPK	  kinase)	   inhibitor	   PD184352,	   which	   selectively	   suppresses	   the	   ERK	   pathway	  (Mody	  et	  al.	  2001).	  As	  can	  be	  seen	  in	  Figure	  4.9B,	  RAW264.7	  cells	  treated	  with	  1μM	  PD184352	  displayed	  obvious	  reductions	  in	  the	  level	  of	  p.	  ERK1/2,	  whereas	  cells	   treated	  with	  phorbol	  ester	  had	   increased	  p.ERK1/2	  activity.	   	  Additionally,	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the	  reduction	  of	  basal	  p.SER916	  levels	  was	  not	  limited	  to	   	  one	  PKD	  inhibitor	  as	  treatment	   of	   unstimulated	   RAW264.7	   cells	   with	   all	   three	   PKD	   inhibitor	  compounds	  including	  12a,	  CRT101	  and	  CRT051	  for	  1	  hour	  led	  to	  a	  reduction	  in	  detectable	   levels	  of	  p.	  SER916	  (Figure	  4.9C).	  PKD	  inhibitor	  compounds	  and	  the	  MAPK	   inhibitor	   were	   subsequently	   used	   in	   all	   phospho-­‐flow	   experiments	   as	  controls.	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  Figure	  4.9	  Basal	  PKD	  and	  p.	  ERK1/2	  phosphorylation	  in	  RAW264.7	  macrophages	  (A)	  Flow	  cytometry	  of	  p.	  SER916	  PKD	  activity	  in	  cells	  treated	  with	  5μM	  12a	  for	  1	  hour	  or	  stimulated	  with	  PdBu	  (200nM)	  for	  30	  minutes	  (B)	  Flow	  cytometry	  of	  p.	  ERK1/2	   in	   cells	   treated	   with	   MAPK	   inhibitor	   PD184352	   (1μM)	   for	   1	   hour	   or	  stimulated	  with	  PdBu	  for	  30	  minutes	  (C)	  Flow	  cytometry	  assessing	  p.	  SER916	  in	  unstimulated	  cells	  treated	  with	  5μM	  of	  PKD	  inhibitors	  12a,	  CRT101	  and	  CRT051	  for	  1	  hour.	  Representative	  flow	  cytometry	  data	  from	  3	  independent	  experiments.	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Following	  this,	  we	  also	  wanted	  to	  assess	  basal	  phosphorylation	  levels	  of	  PKD	  in	  primary	   myeloid	   cells	   including	   BMDCs.	   This	   was	   achieved	   using	   a	   two-­‐fold	  approach,	   firstly	  by	  comparing	  unstimulated	  WT	  BMDCs	  with	  PKD2KI/KI	  BMDCs	  then	  secondly	  by	  using	  pharmacological	  inhibition	  of	  PKD	  in	  WT	  BMDCs.	  As	  can	  be	   seen	   in	   Figure	   4.10A,	   unstimulated	   PKD2KI/KI	   BMDCs	   show	   an	   obvious	  reduction	  in	  the	  level	  of	  p.	  SER916	  when	  compared	  to	  WT	  BMDCs.	  This	  change	  in	  basal	   activity	   is	   comparable	   to	  WT	  BMDC	   treated	  with	   5μM	  of	   CRT051,	  which	  blocks	  p.	  SER916	  activity	  (Figure	  4.10B).	  












	  	  Figure	  4.10	  Basal	  PKD	  activity	  in	  primary	  BMDCs	  (A)	   Detection	   of	   intracellular	   p.	   SER916	   by	   flow	   cytometry	   in	   non-­‐stimulated	  (N/S)	  WT	  BMDC	  and	  PKD2KI/KI	  BMDCs.	   (B)	  Detection	  of	   intracellular	  p.	  SER916	  by	   flow	  cytometry	  of	  WT	  BMDCs	  non-­‐stimulated	  (N/S)	  and	  WT	  BMDCs	  treated	  with	   5μM	   CRT051	   PKD	   inhibitor	   for	   1	   hour.	   Representative	   data	   from	   three	  independent	  experiments.	  	   Following	   the	  observation	   that	   the	  macrophage	  cell	   line	  RAW264.7	  cells	  had	  basal	  PKD	  activity	  we	  went	  on	   to	   investigate	   the	  activation	  and	  kinetics	  of	  PKD	   activation	   in	   these	   cells.	   Firstly	   we	   examined	   activation	   of	   PKD	   after	  stimulation	   with	   phorbol	   ester.	   Upon	   stimulation	   we	   saw	   strong	   activation	   of	  PKD	  (p.SER916)	  at	  15	  minute	  time	  point,	  this	  strong	  activation	  was	  maintained	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at	  45	  minutes	  stimulation	  (Figure	  4.11A).	  We	  also	  observed	  robust	  activation	  of	  p.ERK1/2.	  	  After	   confirming	   we	   could	   accurately	   assess	   activation	   of	   PKD	   via	   p.	  SER916	  in	  RAW264.7	  macrophages	  we	  moved	  on	  to	  assess	  the	  efficiency	  of	  PKD	  inhibitors	   to	   block	   the	   induction	   of	   phorbol	   ester	   induced	   PKD	   activation.	  	  RAW264.7	   cells	   treated	   with	   phorbol	   ester	   from	   15-­‐45	   minutes	   show	   strong	  activation	   of	   PKD	   p.	   SER916	   which	   correlated	   with	   an	   increased	   in	   levels	   of	  p.ERK1/2	   levels	   (Figure	   4.11A).	   	   In	   contrast,	   RAW264.7	   cells	   pretreated	   with	  5μM	  of	  12a,	  CRT101	  or	  CRT051	  for	  1	  hour	  fail	  to	  strongly	  induce	  p.SER916	  levels	  upon	   phorbol	   ester	   treatment	   	   yet	   p.ERK1/2	   activation	   remains	   intact	   (Figure	  4.11B).	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  Figure	  4.11	  Activation	  and	  inhibition	  of	  PKD	  activity	  in	  RAW264.7	  macrophages	  using	  small	  molecule	  inhibitors	  of	  PKD.	  	  (A)	   Detection	   of	   intracellular	   p.	   SER916	   PKD	   activity	   by	   flow	   cytometry	   in	  RAW264.7	   macrophages	   with	   PdBu	   (200nm)	   for	   indicated	   time	   points,	   p.	  ERK1/2	   was	   used	   as	   an	   indication	   of	   successful	   activation	   of	   cell	   signalling	  pathways	  (n=3).	   (B)	  Flow	  cytometry	  analysis	  of	  p.	  SER916	  PKD	  and	  p.	  ERK1/2	  activity	   after	   pre-­‐treatment	   of	   cells	   for	   1	   hour	   with	   5μM	   of	   PKD	   inhibitor	  compounds	  12a,	  CRT101	  and	  CRT051	  before	  30	  minute	  stimulation	  with	  PdBu	  (200nM),	  DMSO	  was	  used	  as	  a	  vehicle	  control	  (n=3).	  	  	   Collectively,	  these	  data	  demonstrates	  that	  various	  myeloid	  cells	  including	  RAW264.7	  cell	  line	  and	  primary	  BMDCs	  display	  high	  levels	  of	  basal	  PKD	  activity	  as	  assessed	  by	  level	  of	  P.SER916.	  This	  basal	  activity	  can	  be	  removed	  by	  mutation	  of	   the	   serine	   residues	   within	   PKD2,	   as	   demonstrated	   with	   PKD2KI/KI	   cells	   but	  pharmacological	   inhibition	   of	   PKD	   by	   three	   different	   compounds	   also	   has	   a	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similar	  effect.	  Additionally,	  we	  did	  note	  some	  off	   target	  effects	  of	  all	   three	  PKD	  compounds	   in	   regard	   to	   ERK1/2	   signalling	   pathways	   highlighting	   that	   caution	  should	  be	  used	  with	  these	  compounds.	  	  	  	  	  	  
4.2.3.1 Assessing	  activation	  of	  PKD	  by	  TLR	  ligation	  	   After	  establishing	  tools	  to	  accurately	  and	  confidently	  identify	  activation	  of	  PKD	  within	  myeloid	   cells,	  we	   sought	   to	   address	   PKD	   activation	   in	   response	   to	  PRR	   ligation.	   Additionally,	   we	   also	   wanted	   to	   address	   the	   role	   of	   PKD	   in	   the	  effector	  functions	  of	  myeloid	  cells	   including	  cytokine	  production.	   	  As	  discussed,	  previous	  reports	  have	  implicated	  PKD	  within	  innate	  immune	  cells	  including	  PKD	  activation	   downstream	   of	   various	   PRRs	   including	   TLRs	   that	   use	   the	   adaptor	  protein	  Myd88	  within	  myeloid	   cells	   but	   also	   epithelial	   cells	   (Ren	   et	   al.	   2009).	  (Ivison	  et	  al.	  2007)	  (J.-­‐E.	  Park	  et	  al.	  2008)	  (Murphy	  et	  al.	  2007)	  Steiner:2010gm}.	  The	   emerging	   evidence	   that	   PKD	   isoforms	   are	   involved	   in	   inflammatory	  signaling	  and	  cytokine	  production	  in	  innate	  immune	  cells	  led	  us	  to	  address	  these	  observations	   with	   PKD	   transgenic	   animals	   but	   also	   with	   more	   specific	  pharmacological	  inhibitors	  for	  PKD.	  To	   begin	   to	   address	   this,	   we	   assessed	   if	   PKD	   becomes	   activated	   in	  response	   to	  TLR4	   ligation	  by	   lipopolysaccharide	   (LPS)	  within	  RAW264.76	  cells	  largely	   due	   to	   the	   ease	   of	   generation	   of	   larger	   cell	   numbers	   during	   culture,	   in	  contrast	   to	   lower	   cell	   numbers	   generated	   by	   generating	   cells	   in	   vitro	   from	  murine	  bone	  marrow.	  	  Stimulation	  of	  RAW264.7	  cells	  with	  LPS	  for	  indicated	  time	  points	  led	  to	  a	  slight	  increase	  in	  PKD	  activation	  when	  assessed	  by	  p.	  SER916	  flow	  cytometry.	   	   p.ERK1/2,	   levels	   were	   used	   as	   a	   positive	   control	   within	   these	  experiments	  as	  p.ERK1/2	  is	  known	  to	  be	  activated	  downstream	  of	  TLR4	  ligation	  (Weinstein	  et	  al.	  1992).	  Indeed	  within	  our	  experiments	  LPS	  resulted	  in	  activation	  of	  p.ERK1.2	  (Figure	  4.12A).	  	  Furthermore,	   increasing	  dose	  of	  LPS	  (100ng/ml	  -­‐	  1μg/ml)	  did	  enable	  us	  to	   see	   a	   stronger	   PKD	   activation	  when	   assessed	   by	   p.	   SER916	   flow	   cytometry	  (data	  not	  shown).	  These	  results	  were	  comparable	  upon	  western	  blot	  analysis	  of	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p.	   SER916	   and	   p.ERK1/2,	   although	   high	   basal	   levels	   of	   p.SER916	   within	  RAW264.7	  cells	  make	  western	  data	  more	  difficult	  to	  assess	  (Figure	  4.12).	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Figure	   4.13	   TLR3	   TLR4	   and	   TLR9	   ligation	   does	   not	   strongly	   activate	   PKD	   in	  primary	  BMDCs	  (A)	  Western	   blot	   of	  WT	  BMDCs	   stimulated	  with	   LPS	   (100ng/ml)	   for	   indicated	  time	   points	   and	   blotted	   for	   p.	   SER916	   and	   β-­‐tubulin,	   10-­‐minute	   pervanadate	  (10nM)	   stimulation	   was	   used	   as	   a	   positive	   control.	   (B)	   Assessment	   of	  intracellular	  p.	  SER916	  by	   flow	  cytometry	   in	  WT	  BMDCs	  after	  stimulation	  with	  PdBu	   (200nM)	   and	   LPS	   (100ng/ml)	   for	   30	   minutes.	   (C)	   Western	   blot	   of	   WT	  BMDCs	  stimulated	  with	  LPS	  (100n/ml),	  poly	  I:C	  (50μg/ml)	  and	  CPG	  (1μM)	  for	  30	  minutes	   and	   blotted	   for	   P.SER916	   and	   β-­‐tubulin.	   (D)	   Flow	   cytometry	   of	  intracellular	  p.	  SER916	   in	  WT	  BMDCs	  stimulated	  LPS	  (100ng/ml)	   for	   indicated	  time	  points.	  Data	  is	  representative	  of	  3	  independent	  experiments.	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  Figure	   4.14	   Zymosan	   activates	   PKD	   in	   Raw264.7	   macrophages	   and	   primary	  BMDMOs	  (A)	   Western	   blots	   of	   Raw264.7	   macrophages	   stimulated	   with	   zymosan	  (200mg/ml)	  for	  indicated	  time	  points	  and	  blotted	  for	  p.	  SER916,	  p.	  SER744/748,	  p.HDAC	  (4-­‐5-­‐7),	  p.ERK1/2	  and	  β-­‐tubulin	  (n=2).	  (B)	  Representative	  Western	  blots	  of	  WT	  BMDMOs	  stimulated	  with	  zymosan	  (200mg/ml)	  for	  indicated	  time	  points	  and	  blotted	  for	  p.	  SER916,	  p.	  HDAC	  (4-­‐5-­‐7),	  p.	  ERK1/2	  and	  β-­‐tubulin.	  Preliminary	  data	   is	   from	   one	   independent	   experiment.	  Cell	   lysates	   kindly	  provided	  by	  Vicky	  
McGuire,	  University	  of	  Dundee.	  	  	  	   Collectively,	  these	  data	  reveals	  the	  surprising	  result	  of	  poor	  activation	  of	  PKD	   by	   TLR4	   ligation	   in	   both	   the	  macrophage	   cell	   line	   RAW264.7	   but	   also	   in	  primary	   BMDCs,	   by	   both	   assessed	   by	   western	   blotting	   but	   also	   with	   more	  sensitive	   methods	   including	   phospho-­‐flow	   cytometry.	   Furthermore,	   TLR3	   or	  TLR9	  ligation	  within	  RAW264.7	  cells	  did	  not	  result	  in	  a	  strong	  induction	  of	  PKD.	  	  Interestingly	  however,	  preliminary	  data	   suggest	   robust	  activation	  of	  PKD	  upon	  stimulation	  with	  zymosan,	  which	  activates	  the	  C-­‐type	  lectin	  Dectin-­‐1	  and	  TLR2.	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4.2.4 Pharmacological	   inhibition	  of	  PKD	  reduces	  cytokine	  production	  in	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  Figure	   4.16	   PKD	   inhibitors	   reduce	   LPS	   induced	   IL-­‐6	   production	   in	   RAW264.7	  cells	  Analysis	  of	  IL-­‐6	  production	  by	  RAW264.7	  macrophages	  by	  ELISA	  in	  cells	  treated	  with	   increasing	   concentrations	   of	   (A)	   12a	   (B)	   CRT101	   and	   (C)	   CRT051	   and	  stimulated	   with	   LPS	   (500ng/ml).	   *p≤0.05,	   **	   p≤0.005	   analysed	   by	   one-­‐way	  ANOVA	  with	  Dunnett	  post-­‐hoc	  test.	  Error	  bars	  represent	  SD	  (Representative	  data	  of	  3	  independent	  biological	  experiments).	  	  	   Collectively,	  these	  data	  reveals	  that	  the	  pharmacological	  inhibition	  of	  PKD	  by	   three	   structurally	   distinct	   compounds	   results	   in	   significantly	   reduced	  cytokine	   production,	   including	   IL-­‐10	   and	   IL-­‐6,	   in	   response	   to	   LPS	   in	  RAW264.7macrophages.	  In	  agreement	  with	  data	  shown	  in	  the	  previous	  chapter,	  pharmacological	   inhibition	   of	   primary	   T-­‐	   lymphocytes	   also	   demonstrated	  significantly	  reduced	  cytokine	  production,	   including	  IL-­‐2	  and	  IFN-­‐γ	  in	  response	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to	   TCR	   stimulation,	   signifying	   a	   general	   role	   for	   PKD	   mediated	   cytokine	  production	  downstream	  of	  multiple	  immune	  receptors.	  	  	  	  
4.2.5 Analysis	  of	  myeloid	  cell	  development	  in	  PKD2KI/KI	  mice	  	  	   In	   regard	   to	   murine	   mature	   lymphocyte	   development,	   loss	   of	   PKD2	  catalytic	  activity	  is	  dispensable	  for	  normal	  B	  and	  T	  cell	  development	  in	  the	  bone	  marrow	   and	   thymus	   respectively	   (Matthews	   et	   al.	   2010).	   In	   regard	   to	   PKD	  isoform	   expression	   in	   murine	   myeloid	   cells,	   within	   this	   chapter	   we	   have	  demonstrated	  that	  comparable	  to	  cells	  from	  the	  adaptive	  immune	  system,	  PKD2	  is	   also	   dominantly	   expressed	   in	   innate	   immune	   cells	   including	   DCs	   and	  macrophages.	  Although	  we	  observed	  no	  differences	  within	  the	  phenotype	  of	  cells	  from	  the	  culture	  of	  both	  BMDCs	  and	  BMDMO’s	  from	  PKD2KI/KI	  in	  vitro	  we	  wished	  to	  address	  if	  loss	  of	  PKD2	  catalytic	  activity	  had	  any	  effect	  on	  the	  development	  of	  myeloid	   cells	   in	   PKD2KI/KI	   mice	   within	   the	   bone	   marrow,	   or	   indeed	   with	  subsequent	  homing	  to	  peripheral	  lymphoid	  tissues	  such	  as	  the	  spleen.	  To	  address	  this	  we	  assessed	  two	  major	  DC	  populations	  found	  within	  the	  bone	  marrow	   and	   spleen	   including	   cDCs	   and	   pDCs,	   which	   can	   be	   assessed	   by	  expression	   of	   cell	   specific	   markers.	   	   As	   previously	   discussed,	   the	   term	   cDCs	  largely	  refers	  to	  all	  other	  DC	  subsets	  that	  are	  not	  pDCs.	  cDCs	  have	  an	  enhanced	  ability	   to	   sense	   infection	   and	   tissue	   injury	   and	   largely	   function	   to	   capture,	  process	  and	  present	  environmental	  antigen,	  whether	  pathogenic	  or	  self-­‐antigen,	  to	  promote	  an	  immune	  response	  or	  tolerance	  respectively,	  to	  T	  cells.	  In	  contrast,	  pDCs	   represent	   a	   small	   subsets	   of	   DCs	   that	   play	   a	   significant	   role	   in	   anti-­‐viral	  immunity,	   largely	   due	   to	   the	   presence	   of	   endosomal	   TLR7	   and	   TLR9	   for	  detection	  of	  foreign	  nucleic	  acid,	  as	  well	  as	  their	  ability	  to	  produce	  large	  amounts	  of	   type	   I	   IFN,	   including	   IFNα	   and	   IFNβ.	   	   In	   regard	   to	   development	   within	   the	  bone	   marrow,	   different	   groups	   have	   uncovered	   evidence	   that	   both	   cDCs	   and	  pDCs	  in	  mice	  arise	  from	  a	  clonogenic	  precursor	  and	  differentiate	  within	  the	  bone	  marrow	  under	   instruction	  of	   specific	   cytokines	   and	   transcription	   factors.	  After	  differentiation,	  cDCs	  and	  pDCs	  migrate	  from	  the	  bone	  marrow	  to	  the	  periphery.	  Additionally,	  the	  role	  of	  PKD	  catalytic	  activity	  for	  the	  development	  of	  neutrophils	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remains	  unaddressed	  within	  the	  literature	  therefore	  we	  assessed	  neutrophil	  and	  macrophage	   development	   in	   vivo	   within	   the	   bone	   marrow	   and	   subsequent	  population	  of	  these	  myeloid	  subsets	  within	  the	  spleen	  of	  PKD2KI/KI	  mice.	  	  	  	  
4.2.5.1 Analysis	   of	   the	   development	   of	   conventional	   and	   plasmacytoid	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  Figure	  4.17	  Analysis	  of	  tissue	  size	  in	  PKD2KI/KI	  mice	  Total	  cell	  number	  (x106)	  obtained	  from	  age	  and	  sex	  matched	  WT	  and	  PKD2KI/KI	  mice;	   (A)	   Bone	   marrow	   (B)	   Spleen.	   Error	   bars	   represent	   SD	   (data	   of	   3	  independent	  biological	  experiments	  n=	  9	  mice	  per	  group).	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Next,	   we	   assessed	   the	   development	   of	   cDC	   and	   pDC	   subsets	  within	   the	  bone	  marrow	  of	  PKD2KI/KI	  ex-­‐vivo.	  cDCs	  were	  defined	  as	  CD11chigh	  Siglec-­‐Hlow	  and	  	  pDCs	  were	  defined	  as	  CD11chighSiglec-­‐Hhigh	  and	  MHC	  class	  IIlow.	   	  Figure	  4.18A-­‐B,	  shows	  development	  of	  both	  cDCs	  and	  pDCs	  within	  the	  bone	  marrow	  of	  PKD2KI/KI	  mice	  were	  normal	  when	  compared	  to	  WT	  mice	  with	  no	  significant	  changes	  in	  the	  %	   frequency	   of	   either	   cell	   subset.	   Furthermore,	   MHC	   class	   II	   expression	   on	  PKD2KI/KI	  pDCs	  was	  also	  comparable	  to	  WT	  pDCs	  (Figure	  4.18C).	  	  The	  cDC	  subset	  can	  also	  be	  further	  divided	  into	  two	  populations	  including	  CD4+	  cDCs	  and	  CD8+	  cDCs,	  both	  of	  which	  carry	  out	  unique	  functions	  within	  the	  immune	   system.	   CD4+	   cDC	   have	   been	   shown	   to	   have	   strong	   tendencies	   to	  activate	  CD4+	  T	  cells	  (Allenspach	  et	  al.	  2008)	  (Mount	  et	  al.	  2008),	  whereas	  CD8+	  cDCs	   are	  well	   known	   for	   their	   ability	   to	  perform	  cross	  presentation	  of	   antigen	  which	   is	   important	   in	   anti-­‐viral	   immune	   responses	   but	   for	   maintenance	   of	  tolerance	   towards	   self	   (Haan	   et	   al.	   2000)	   (Schliehe	   et	   al.	   2011).	   We	   assessed	  these	   populations	   in	   the	   bone	   marrow	   of	   PKD2KI/KI	   mice	   and	   observed	   no	  significant	   difference	   in	   the	  %	   frequency	   of	   either	   CD4+	   or	   CD8+	   cDC	   subsets	  (Figure	  4.18D-­‐E).	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  Figure	   4.18	   Conventional	   and	   plasmacytoid	   DC	   subsets	   are	   normal	   within	   the	  bone	  marrow	  of	  PKD2KI/KI	  mice	  (A)	  Representative	  dot	  plots	  showing	  cDC	  and	  pDC	  subsets	  within	  the	  spleen	  of	  WT	  and	  PKD2KI/KI	  mice	  shown	  by	  Siglec-­‐H	  and	  CD11c	  surface	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  Combined	  data	  showing	  %	  frequency	  of	  cDCs	  and	  pDC	  (C)	  Overlayed	  representative	  histogram	  of	  WT	  and	  PKD2KI/KI	  pDCs	  showing	  expressing	  of	  MHC	  class	  II	  on	  the	  cell	  surface	  (D)	  Representative	  dot	  plots	  showing	  CD4+	  and	  CD8+	  cDC	  subpopulations	  (gated	  on	   CD11c)	  within	   bone	  marrow	   of	  WT	   and	   PKD2KI/KI	  mice.	   (E)	   Combined	   data	  showing	  %	   frequency	  of	  CD4+	   cDCs	   and	  CD8+	   cDCs.	   	   Error	  bars	   represent	   SD.	  Data	  is	  from	  3	  independent	  biological	  experiments,	  n=8	  mice	  per	  genotype.	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After	  confirming	  that	  the	  development	  of	  DC	  subsets	  within	  the	  bone	  marrow	  of	  PKD2KI/KI	   mice	   were	   comparable	   to	   WT	   mice	   we	   sought	   to	   assess	   these	  populations	   within	   the	   spleen.	   This	   offered	   insight	   into	   the	   requirement	   for	  PKD2	   catalytic	   activity	   for	   normal	   migration	   of	   these	   subsets	   from	   the	   bone	  marrow	  to	  peripheral	  lymphoid	  tissues.	  Figure	  4.19A-­‐B	  shows	  that	  both	  cDC	  and	  pDC	   %	   frequencies	   within	   the	   spleen	   of	   PKD2KI/KI	   mice	   were	   normal	   when	  compared	  with	  WT	  mice.	   It	   is	  known	   that	  pDCs	  upon	  migration	   from	  the	  bone	  marrow	  into	  the	  periphery	  upregulate	  surface	  expression	  of	  MHC	  class	  II.	   	  This	  process	  is	  also	  normal	  in	  PKD2KI/KI	  pDCs	  when	  compared	  to	  WT	  pDCs	  within	  the	  spleen	   (Figure	   4.19C).	   Additionally,	   we	   assessed	   CD4+	   and	   CD8+	   cDC	   subsets	  within	   the	   spleen	   and	   found	   no	   difference	   in	   the	   %	   frequencies	   of	   these	  populations	  in	  PKD2KI/KI	  mice	  when	  compared	  to	  WT	  mice	  (Figure	  4.19D-­‐E).	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  Figure	   4.19	   Conventional	   and	   plasmacytoid	   DC	   subsets	   are	   normal	   within	   the	  spleen	  of	  PKD2KI/KI	  mice	  (A)	  Representative	  dot	  plots	  showing	  cDC	  and	  pDC	  subsets	  within	  the	  spleen	  of	  WT	  and	  PKD2KI/KI	  mice	  shown	  by	  Siglec-­‐H	  and	  CD11c	  surface	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  %	  frequency	  of	  cDCs	  and	  pDC	  (C)	  Representative	  histogram	  of	  WT	  and	  PKD2KI/KI	  pDCs	  showing	  expressing	   of	   MHC	   class	   II	   on	   the	   cell	   surface	   (D)	   Representative	   dot	   plots	  showing	   CD4+	   and	   CD8+	   cDC	   subpopulations	   (gated	   on	   CD11c)	   within	   bone	  marrow	  of	  WT	  and	  PKD2KI/KI	  mice.	  (E)	  Combined	  data	  showing	  %	  Frequency	  of	  CD4+	   cDCs	   and	   CD8+	   cDCs.	   Error	   bars	   represent	   SD.	   Data	   obtained	   from	   3	  independent	  biological	  experiments	  n=	  8	  mice	  per	  genotype.	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Collectively,	  these	  data	  reveals	  no	  obvious	  requirement	  for	  PKD2	  catalytic	  activity	   within	   the	   development	   or	   differentiation	   of	   two	   major	   DC	   subsets,	  including	  cDCS	  (both	  CD4+	  and	  CD8+	  subsets)	  and	  pDCs	  within	  the	  bone	  marrow	  but	  also	  in	  regard	  to	  their	  migration	  and	  maintenance	  within	  the	  spleen.	  	  	  
4.2.5.2 Analysis	   of	   macrophage	   and	   neutrophil	   population	   in	   PKD2KI/KI	  
mice	  	   In	  addition	  to	  DC	  development	  within	  the	  bone	  marrow,	  other	  cells	  of	  the	  myeloid	  lineage	  also	  develop	  and	  differentiate	  from	  the	  bone	  marrow	  including	  neutrophils	   and	   macrophages.	   After	   demonstrating	   that	   major	   DC	   subset	  development	  within	   the	  bone	  marrow	  of	  PKD2KI/KI	  is	  normal	  we	  also	  sought	   to	  address	   neutrophil	   and	  macrophage	  populations.	   	   To	   assess	   this	  we	  used	   flow	  cytometry,	  neutrophils	  were	  defined	  as	  Ly6Ghigh	  CD11b+	  and	  macrophages	  were	  defined	  as	  Ly6Glow	  CD11b+	  F4/80+.	  As	  can	  be	  seen	  in	  Figure	  4.20A-­‐B,	  assessment	  of	   both	   neutrophil	   and	   macrophage	   populations	   within	   the	   bone	   marrow	   of	  PKD2KI/KI	  mice	  revealed	  no	  differences	  when	  compared	  to	  WT	  mice.	  	  














































	  Figure	  4.20	  Macrophage	  and	  neutrophil	  populations	  are	  normal	  within	  the	  bone	  marrow	  of	  PKD2KI/KI	  mice	  (A)	   Representative	   dot	   plots	   showing	  macrophage	   and	   neutrophil	   populations	  with	   the	   bone	  marrow	   of	  WT	   and	   PKD2KI/KI	   mice	   shown	   by	   Ly6G	   and	   CD11b	  surface	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	   SD.	   (B)	   Combined	   data	   showing	   %	   frequency	   of	   neutrophils	   and	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macrophages	   Data	   is	   pooled	   from	   3	   independent	   experiments	   n=	   7	   mice	   per	  genotype.	  	  	   Neutrophil	   and	  macrophages	  populations	  within	   the	   spleen	  of	  PKD2KI/KI	  mice	  were	  also	  assessed	  and	  no	  differences	  in	  these	  populations	  when	  compared	  to	  WT	  mice	  were	  seen	  (Figure	  4.21).	  	  	  	  


















































4.2.6 Analysis	   of	   myeloid	   cell	   development	   in	   PKD1WT/KI	   x	   PKD2KI/KI	  	  







































	  Figure	  4.22	  Analysis	  of	  tissue	  size	  in	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  Total	  cell	  number	  (x106)	  obtained	  from	  age	  and	  sex	  matched	  WT	  and	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  of;	  (A)	  Bone	  marrow	  (B)	  Spleen.	  Error	  bars	  represent	  SD.	  Data	  combined	  from	  3	  independent	  experiments	  n=	  9	  mice	  per	  group.	  	  	  
4.2.6.1 Analysis	   of	   development	   of	   conventional	   and	   plasmacytoid	   DC	  
populations	  in	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  	  	   Overall	   assessment	   of	   cDC	   and	  pDC	   subset	   populations	  within	   the	   bone	  marrow	  of	  PKD1WT/KI	  x	  PKD2KI/KI	  revealed	  no	  differences	  when	  compared	  to	  WT	  mice	   (Figure	   4.23A-­‐C).	   Additionally,	   CD4+	   and	   CD8α+	   cDC	   populations	   were	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unaffected	   within	   the	   bone	   marrow	   of	   PKD1WT/KI	   x	   PKD2KI/KI	   	   	   mice	   (Figure	  4.23B).	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  Figure	   4.23	   Conventional	   and	   plasmacytoid	   DCs	   within	   bone	   marrow	   of	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  are	  normal	  (A)	   Representative	   dot	   plots	   showing	   cDC	   and	   pDC	   subsets	   within	   the	   bone	  marrow	   of	  WT	   and	   PKD1WT/KI	   x	   PKD2KI/KI	  mice	   shown	   by	   Siglec-­‐H	   and	   CD11c	  surface	  expression	  by	  flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	   SD.	   (B)	   Representative	   dot	   plots	   showing	   CD4+	   and	   CD8+	   cDC	  subpopulations	   (gated	   on	   CD11c)	  within	   bone	  marrow	  of	  WT	   and	  PKD1WT/KI	  x	  PKD2KI/KI	  mice.	  (C)	  Combined	  data	  showing	  %	  frequency	  of	  cDCs	  and	  pDC	  (D)	  %	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  Figure	   4.24	   Conventional	   and	   plasmacytoid	   DC	   subsets	   are	   normal	   within	   the	  spleen	  of	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  (A)	   Dot	   plots	   showing	   cDC	   and	   pDC	   subsets	   within	   the	   spleen	   of	   WT	   and	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  shown	  by	  Siglec-­‐H	  and	  CD11c	  surface	  expression	  by	  flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  Dot	  plots	  showing	  CD4+	  and	  CD8+	  cDC	  subpopulations	  (gated	  on	  CD11c)	  within	  spleen	  of	  WT	   and	   PKD1WT/KI	   xPKD2KI/KI	  mice.	   (C)	  %	   Frequency	   of	   cDCs	   and	   pDC	   (D)	  %	  frequency	   of	   CD4+	   and	   CD8+	   cDC	   Error	   bars	   represent	   SD.	   Data	   from	   3	  independent	  experiments	  n=8	  mice	  per	  genotype.	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4.2.6.2 Analysis	   of	   the	   development	   of	   macrophage	   and	   neutrophil	  






























































	  Figure	  4.25	  Macrophage	  and	  neutrophil	  populations	  are	  normal	  within	  the	  bone	  marrow	  of	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  (A)	   Representative	   dot	   plots	   showing	  macrophage	   and	   neutrophil	   populations	  with	   the	  bone	  marrow	  of	  WT	  and	  PKD1WT/KI	   	   x	  PKD2KI/KI	  mice	   shown	  by	  Ly6G	  and	  CD11b	  surface	  expression	  by	  flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  Combined	  data	  showing	  %	  frequency	  of	  neutrophils	  and	  macrophages	   Error	   bars	   represent	   SD.	   Data	   from	   3	   independent	   experiments	  n=8	  mice	  per	  genotype.	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  Figure	   4.26	   Macrophage	   and	   neutrophil	   populations	   are	   normal	   within	   the	  spleen	  of	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  (A)	   Representative	   dot	   plots	   showing	  macrophage	   and	   neutrophil	   populations	  with	   the	   spleen	   of	   WT	   and	   PKD1WT/KI	   	   x	   PKD2KI/KI	  mice	   shown	   by	   Ly6G	   and	  CD11b	   surface	   expression	   by	   flow	   cytometry.	   Numbers	   represent	   average	   %	  frequency	  and	  SD.	  (B)	  Combined	  data	  showing	  %	  frequency	  of	  neutrophils	  and	  macrophages.	   Error	   bars	   represent	   SD.	   Data	   from	   3	   independent	   experiments	  n=8	  mice	  per	  genotype.	  	  
4.2.7 	  Investigating	   the	   loss	   of	   PKD2	   catalytic	   activity	   on	   effector	  
functions	  of	  BMDCs	  in	  vitro	  	   Having	   established	   PKD2	   is	   the	   dominant	   isoform	   expressed	   in	   BMDCs	  yet	  loss	  of	  catalytic	  activity	  of	  PKD	  is	  dispensable	  for	  the	  development	  of	  various	  myeloid	  cells	   in	  vivo	  we	  sought	   to	  address	   the	  role	  of	  PKD2	  catalytic	  activity	   in	  effector	  functions	  of	  these	  cells.	  Within	  T	  lymphocytes	  although	  the	  loss	  of	  PKD2	  catalytic	  activity	  did	  not	  affect	  T	  cell	  development,	  multiple	  studies	  have	  shown	  that	  PKD2	  catalytic	  activity	  is	  essential	  for	  normal	  T	  lymphocyte	  function	  in	  vitro	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and	   in	   vivo	   (Matthews	   et	   al.	   2010)	   (Navarro	   et	   al.	   2012)	   (Navarro,	   Feijoo	  Carnero,	  et	  al.	  2014a).	  Although	  we	  have	  demonstrated	  that	  PKD	  is	  not	  strongly	  activated	  by	  LPS	  stimulation;	  LPS	  induces	  the	  activation	  of	  multiple	  downstream	  effector	   functions	   within	   BMDCs	   including	   the	   upregulation	   of	   key	   surface	  molecules	  and	  the	  production	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  IL-­‐6	  and	  IL-­‐12p40.	   	   Previous	   studies	   have	   implicated	   PKD	   in	   integrin	   expression	   and	  recycling	   (Medeiros	   et	   al.	   2005),	   in	   contrast	   PKD2	   has	   been	   shown	   to	   be	  dispensable	   for	   normal	   lymphocyte	   homing	   in	   vivo	   (Matthews	   et	   al.	   2012),	  however	  the	  role	  of	  PKD2	  catalytic	  activity	  for	  the	  expression	  of	  key	  integrins	  on	  the	   cell	   surface	   of	   BMDCs	   remains	   unaddressed.	   Integrin	   expression	   upon	  BMDCs	  is	  essential	  during	  antigen	  presentation	  is	  known	  to	  be	  crucial	  for	  normal	  T	   cell	   activation.	   PKD2KI/KI	   BMDCs	   expressed	   comparable	   levels	   of	   multiple	  integrins	  including	  CD11c,	  CD11b,	  CD11a,	  CD18	  as	  well	  as	  normal	  levels	  of	  MHC	  class	  II	  when	  compared	  to	  WT	  BMDC	  (Figure	  4.27A).	  	  	  To	   assess	   if	   PKD2	   catalytic	   activity	   was	   required	   for	   BMDC	   effector	  function	  we	  stimulated	  WT	  and	  PKD2KI/KI	  BMDCs	  with	  LPS	  for	  24	  hours.	  As	  can	  seen	   in	   Figure	   4.27B-­‐E,	   upregulation	   of	   key	   costimulatory	  molecules	   upon	   the	  cell	   surface	   of	   PKD2KI/KI	   BMDCs	   were	   significantly	   higher	   than	   WT	   BMDCs.	  	  Additionally,	   assessment	   of	   cytokine	   production	   revealed	   comparable	   levels	   of	  IL-­‐6	   production	   by	   PKD2KI/KI	   BMDCs	   however	   IL-­‐12p40	   production	   was	  significantly	  increased	  (Figure	  4.27F-­‐G).	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+ +- - LPS 	  Figure	   4.27	   Analysis	   of	   integrin	   expression	   and	   LPS	   induced	   activation	   of	  PKD2KI/KI	  BMDCs	  (A)	  Flow	  cytometry	  of	  integrin	  expression	  upon	  the	  surface	  of	  WT	  and	  PKD2KI/KI	  BMDCs	   including	   CD11c,	   CD11b,	   CD11a,	   CD18	   and	   MHC	   class	   II.	   (B)	  Representative	   histograms	   of	   upregulation	   of	   costimulatory	   molecules	   on	   cell	  surface	   of	   WT	   and	   PKD2KI/KI	   BMDCs	   after	   24	   hours	   stimulation	   with	   LPS	  (100ng/ml).	  Geo	  MFI	   of	   costimulatory	  molecules	   including	   (C)	  CD80	   (D)	  CD86	  and	   (E)	  CD40.	   	  ELISA	  analysis	  of	   cytokine	  production	  after	  activation	  with	  LPS	  (100ng/ml	  24	  hours)	  (F)	  IL-­‐6	  production	  (pg/ml)	  and	  (G)	  IL-­‐12p40	  production	  (pg/ml).	   (C-­‐G	   is	  pooled	  data	   from	  3	   independent	   experiments	  n=	  9	  mice	   total)	  Error	  bars	  represent	  SEM.	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4.2.8 PKD2KI/KI	   BMDCs	   can	   activate	   T	   lymphocytes	   using	   an	   in	   vitro	  
activation	  model	  	   As	  we	  had	   observed	   an	   overactive	   phenotype	   upon	   activating	   PKD2KI/KI	  BMDCs	  with	  LPS	  we	  next	  sought	  to	  address	  if	  these	  alterations	  were	  biologically	  significant.	   One	   way	   to	   address	   this	   was	   to	   examine	   the	   ability	   of	   PKD2KI/KI	  BMDCs	  to	  activate	  T	  lymphocytes.	  To	  do	  this	  we	  chose	  to	  use	  the	  TCR	  transgenic	  OT	  II+	  system,	  a	  well-­‐characterised	  model	  to	  study	  DC	  mediated	  T	  cell	  activation	  
in	  vitro	  in	  which	  T	  cells	   from	  OT	  II+	   transgenic	  mice	  express	  a	  TCR	  specific	   for	  chicken	   ovalbumin	   (Sheng	   et	   al.	   2008).	   To	   assess	   the	   functionality	   of	   BMDCs	  lacking	  PKD2	  catalytic	  activity	  BMDCs	  generated	  in	  vitro	  from	  WT	  and	  PKD2KI/KI	  mice	   were	   untreated	   or	   stimulated	   with	   LPS	   overnight	   to	   promote	   activation.	  	  BMDCs	  were	  then	  loaded	  with	  OVA	  peptide	  and	  co-­‐cultured	  (1:10)	  with	  naïve	  OT	  II+	  CD4+	  T	  cells	  for	  4	  days.	  T	  cell	  activation	  by	  peptide	  loaded	  WT	  and	  PKD2KI/KI	  DCs	  was	  assessed	  by	  flow	  cytometry	  every	  24	  hours.	  Commonly	  used	  activation	  markers	   to	   assess	   T	   cell	   activation	   include	   CD44,	   CD69,	   CD62L	   and	   CD25	   (IL-­‐2Rα)	   (Shipkova	   &	   Wieland	   2012).	   	   As	   can	   be	   seen	   in	   Figure	   4.28A-­‐E,	   T	   cell	  activation	   by	   peptide	   loaded	   PKD2KI/KI	   BMDCs	   were	   comparable	   to	   peptide	  loaded	   WT	   BMDCs	   when	   we	   assessed	   CD44,	   CD69,	   CD62L	   and	   CD25	  upregulation	  on	  T	  cell	  surface.	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Day 1 Day 4Day 3Day 2 Day 1 Day 4Day 3Day 2
Day 1 Day 4Day 3Day 2 Day 1 Day 4Day 3Day 2 	  Figure	   4.28	   Analysis	   of	   OT	   II+	   T	   cell	   activation	   from	   WT	   and	   PKD2KI/KI	   OVA	  loaded	  BMDCs	  Analysis	   of	  OT	   II+	  T	   cell	   activation	   cell	   surface	  markers	   including	  CD44,	  CD69,	  CD62L	   and	   CD25	   (IL-­‐2R)	   (A)	   Representative	   histograms	   of	   OT	   II+	   T	   cells	  activation	   markers	   assessed	   by	   flow	   cytometry	   after	   co-­‐culture	   for	   indicated	  time	  point	  with	  OVA-­‐peptide	  loaded	  (1μM)	  WT	  and	  PKD2KI/KI	  BMDCs	  stimulated	  with	   LPS	   (100ng/ml)	   overnight.	   MFI	   of	   	   (A)	   CD44	   expression	   (C)	   CD69	   (D)	  CD62L	   and	   (D)	   CD25	   (IL-­‐2R).	   Representative	   data	   of	   two	   independent	  experiments	  with	  5	  mice	  total	  per	  genotype	  assessed.	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Additionally,	   we	   also	   cytokine	   production	   by	   activated	   T	   cells	   by	  harvesting	  supernatant	  every	  24	  hours	  and	  assessed	  IL-­‐2	  and	  IFNγ	  production,	  which	  are	  abundantly	  produced	   in	   response	   to	  TCR	   ligation.	  As	   can	  be	   seen	   in	  Figure	  4.29A,	  IL-­‐2	  production	  by	  OT	  II+	  T	  cells	  co-­‐cultured	  with	  peptide-­‐loaded	  PKD2KI/KI	   	  BMDCs	   was	   comparable	   to	   WT	   BMDCs	   at	   all	   indicated	   time	   points.	  However,	   when	   we	   assessed	   IFNγ	   production	   OT	   II+	   T	   cells	   that	   were	   co-­‐cultured	  with	  peptide-­‐loaded	  PKD2KI/KI	  BMDCs	  produced	  significantly	  more	  IFN-­‐γ	  by	  day	  3	  and	  day	  4	  (Figure	  4.29B).	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  Figure	  4.29	  Cytokine	  production	  by	  OT	  II+	  CD4+	  T	  cells	  after	  co-­‐culture	  with	  WT	  and	  PKD2KI/KI	  	  BMDCs	  	  Cytokine	  production	  of	  IL-­‐2	  (A)	  and	  IFNγ	  	  (B)	  by	  sandwich	  ELISA	  after	  co-­‐culture	  of	  naïve	  OT	   II+	  CD4+	  T	  cells	  with	  unstimulated	  or	  LPS	  (100ng/ml)	   treated	  WT	  and	  PKD2KI/KI	  BMDCs	  loaded	  with	  OVA-­‐peptide	  (1μM)	  over	  indicated	  time	  points.	  ****	  p≤0.0001	  analysed	  by	  two-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐hoc	  test.	   	  IL-­‐2	  data	  combined	  data	   from	  2	   independent	  experiments.	   IFNγ	  data	   is	  preliminary	  from	  one	  independent	  experiment.	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Collectively,	  these	  data	  reveal	  a	  potential	  regulatory	  role	  for	  PKD2	  catalytic	  activity	  after	  activation	  by	  LPS,	  as	  demonstrated	  with	  heightened	  upregulation	  of	  key	  costimulatory	  markers	  and	  with	  heightened	  production	  of	  proinflammatory	  cytokine	   IL-­‐12p40.	  These	  differences	  did	  not	  generally	   impact	  on	   the	  ability	  of	  PKD2KI/KI	  BMDCs	  to	  perform	  antigen	  presentation	  or	  T	  lymphocyte	  activation	  in	  an	   in	   vitro	   model	   although	   did	   we	   did	   observed	   significantly	   higher	   IFNγ	  production	  by	  day	  3	  and	  day	  4	  of	  co-­‐culture.	  
4.3 	  Discussion	  	  	   The	  aim	  of	  this	  chapter	  was	  to	  explore	  the	  importance	  of	  PKD	  isoforms	  in	  the	  development	   and	  effector	   functions	  of	  myeloid	   cells.	   Previous	   studies	  have	  reported	   that	   PKD1	   is	   required	   for	   successful	   signaling	   downstream	   of	   TLRs	  utilising	   the	   Myd88	   dependent	   pathway	   within	   both	   RAW264.7	   cells	   and	  primary	  BMDMOs	  (J.-­‐E.	  Park	  et	  al.	  2009b).	   	  One	  discrepancy	  within	  our	  results	  when	   compared	   to	   the	   current	   literature	   is	   that	   we	   observe	   that	   PKD2	   is	   the	  predominant	   isoform	   expressed	  within	   primary	  BMDMOs	   and	  BMDCs.	   	   This	   is	  consistent	   with	   RNA-­‐sequencing	   data	   from	   Immgen	   that	   report	   that	   PKD2	   is	  predominantly	  expressed	  in	  various	  innate	  immune	  cells.	   	  In	  general	  within	  the	  mammalian	  immune	  system	  PKD2	  appears	  to	  be	  selectively	  and	  predominantly	  expressed	   (Matthews	   et	   al.	   2010).	   	   To	   determine	   if	   PKD1	   is	   predominantly	  expressed	   in	   mast	   cells	   as	   previously	   reported	   (Murphy	   et	   al.	   2007),	   the	  generation	  of	  bone	  marrow	  derived	  mast	  cells	   from	  PKD	  transgenic	  mice	  could	  be	   carried	   out	   in	   the	   future.	   The	   successful	   generation	   of	   both	   BMDCs	   and	  BMDMO	  from	  PKD1	  and	  PKD2	  transgenic	  mice	  demonstrated	  that	  these	  isoforms	  are	  not	  required	  for	  the	  normal	  expansion	  of	  these	  cell	  subsets	  in	  vitro.	  	  Previous	   studies	   have	   reported	   high	   basal	   phosphorylation	   within	   T	  lymphocytes,	  which	  was	  also	  the	  case	  for	  BMDMOs	  and	  BMDCs	  (Navarro,	  Goebel,	  et	   al.	   2014b).	   Importantly,	   we	   observed	   a	   reduction	   of	   basal	   PKD	   activity	  demonstrated	   in	   in	   both	   PKD2KI/KI	   and	   PKD2KO/KO	   cells	   or	   through	  pharmacological	  inhibition	  of	  PKD.	  One	  possible	  reason	  for	  the	  high	  level	  of	  basal	  PKD	  activity	  could	  be	  due	  to	  intracellular	  reactive	  oxygen	  species	  (ROS),	  that	  is	  expressed	  in	  high	  levels	  within	  macrophages	  and	  DCs	  (Y.	  Zhang	  et	  al.	  2013)	  (Del	  Prete	  et	  al.	  2008).	   In	  particular	   it	   is	  known	   that	   the	  generation	  of	  BMDCs	  with	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GM-­‐CSF	  results	  in	  phenotype	  of	  DC	  comparable	  to	  that	  of	  TNFα	  and	  inducible	  NO	  synthase-­‐producing	   (TIP)	   DC,	   which	   has	   high	   abundance	   of	   ROS	   (Sheng	   et	   al.	  2010;	  Matsue	   et	   al.	   2003).	   Interesting,	  mitochondrial-­‐derived	  ROS	   is	   known	   to	  promote	   DAG	   generation	   and	   subsequent	   recruitment	   and	   activation	   of	   PKD	  (Cowell,	  Döppler,	  et	  al.	  2009a).	  	  	  Previous	  studies	  have	  demonstrated	  the	  activation	  of	  PKD	  downstream	  of	  MyD88	  dependent	  TLR	  activation	  and	  for	  the	  successful	  production	  of	  cytokines	  including	   IL-­‐6	   and	   IL-­‐12p40	  within	   various	  myeloid	   cells	   as	   well	   as	   epithelial	  cells	   (J.-­‐E.	   Park	   et	   al.	   2008)	   (Yamashita	   et	   al.	   2010)	   (Murphy	   et	   al.	   2007)	   (J.-­‐E.	  Park	   et	   al.	   2009b)	   (Steiner	   et	   al.	   2010).	   In	   contrast	   to	   previously	   published	  literature,	   we	   did	   not	   detect	   any	   strong	   activation	   of	   PKD	   by	   TLR	   stimulation	  including	   TLR4	   or	   TLR9	   in	   either	   RAW264.7	   macrophage	   cell	   line	   or	   BMDCs.	  	  Interestingly,	  our	  preliminary	  data	  indicates	  that	  zymosan	  is	  a	  strong	  inducer	  of	  PKD	   in	   myeloid	   cells.	   Stimulation	   with	   zymosan	   is	   known	   to	   trigger	   ROS	  production	   (Goodridge	  et	   al.	   2007)	  and	   induce	   intracellular	  Ca2+	   flux	  mediated	  by	   PLCγ	   (Xu	   et	   al.	   2009),	   both	   of	   which	   have	   been	   shown	   to	   activate	   PKD	  however	   not	   within	   a	   myeloid	   cell	   context.	   Furthermore,	   zymosan	   extracts	  activate	   TLR2	   in	   cooperation	  with	   dectin-­‐1.	   Future	   studies	  will	   be	   required	   to	  address	   the	  mechanism	  of	  PKD	  activation	   in	   response	   to	   zymosan.	  One	  way	   to	  approach	  this	  would	  be	  to	  strategically	  compare	  zymosan	  stimulated	  cells	  with	  depleted	  zymosan,	  which	  solely	  activates	  dectin-­‐1,	  and	  TLR2	  only	  agonists	  such	  as	   PAM2CSK4.	   Furthermore,	   it	   would	   be	   interesting	   to	   assess	   if	   cytokine	  production	   in	   cells	   lacking	  PKD2KI/KI	  	   cells	   in	   response	   to	   zymosan	   stimulation.	  Investigation	   into	   the	   effect	   of	   the	   loss	   of	   PKD2	   catalytic	   activity	   within	   anti-­‐fungal	  immunity	  using	  in	  an	  in	  vivo	  infection	  model	  such	  as	  Pneumocytsis	  carinii	  and	   Crpytococcus	   neoformans	   infection,	   could	   be	   carried	   out	   in	   the	   future	  (Nakamura	  et	  al.	  2007).	  	  Although	  within	  our	  studies	  LPS	  stimulation	  did	  not	   strongly	   induce	  PKD	  activity	   the	   pharmacological	   inhibition	   of	   PKD	   in	   RAW264.7	   cells	   led	   to	   a	  significant	   decrease	   in	   IL-­‐10	   and	   IL-­‐6	   production	   after	   LPS	   stimulation.	  	  	  Previous	   studies	   have	   demonstrated	   that	   reduced	   IFNγ	   production	   in	   T	  lymphocytes	   is	   due	   to	   reduced	   recruitment	   of	   RNA	   Pol	   II	   to	   the	   IFNγ	  transcriptional	  start	  site	  (Navarro,	  Feijoo	  Carnero,	  et	  al.	  2014a).	   	  Future	  studies	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could	  assess	  the	  recruitment	  of	  RNA	  Pol	  II	  to	  transcriptional	  start	  site	  of	  IL-­‐6	  and	  IL-­‐10	  after	  pharmacological	  inhibition	  of	  PKD	  in	  RAW264.7	  cells	  to	  assess	  if	  this	  is	  the	  mechanism	  behind	  reduction	  in	  cytokine	  production	  by	  these	  cells.	  	  Previous	  studies	  have	  demonstrated	  that	   loss	  of	  PKD2	  catalytic	  activity	   is	  dispensable	  for	  T	  and	  B	  lymphocyte	  development	  in	  vivo,	  the	  role	  of	  PKD	  kinases	  remains	   unaddressed	   within	   myeloid	   cell	   development	   in	   vivo.	   Our	   data	  demonstrates	   for	   the	   first	   time	   that	   both	   PKD1	   and	   PKD2	   catalytic	   activity	   is	  dispensable	   for	   the	   development	   of	   multiple	   innate	   immune	   cells	   within	   the	  bone	  marrow	   including	   cDC,	   CD4+	   and	   CD8α+	   cDC	   subsets,	   pDCs,	   neutrophils	  and	  macrophages.	  Furthermore,	   the	  population	  of	   these	  subsets	  was	  normal	   in	  peripheral	  lymphoid	  tissue	  including	  the	  spleen.	  Although	   previous	   studies	   have	   attempted	   to	   address	   the	   role	   of	   PKD	  kinases	  in	  the	  effector	  functions	  in	  myeloid	  cells	  including	  primary	  BMDMOs	  and	  BMDCs,	   these	   studies	   frequently	   address	   the	   role	   of	   PKD	   via	   knockdown	   or	  pharmacological	   inhibition	   with	   poor	   specificity	   PKD	   inhibitors	   such	   as	   the	  Go6976	  compound.	  	  These	   data	   suggests	   although	   PKD	   may	   not	   be	   activated	   in	   response	   to	  TLR4	  stimulation	  with	  LPS,	  PKD2	  may	  be	  involved	  in	  the	  negative	  regulation	  of	  this	   response	   in	  vitro	  as	   indicated	   by	   our	   data	   in	  which	   loss	   of	   PKD2	   catalytic	  activity	   led	   to	   the	   overactive	   response	   of	   BMDCs	   to	   LPS	   stimulation.	   Previous	  studies	   have	   implicated	   a	   role	   for	   PKD	   in	   activation	   of	   the	   deubiquitinase	  A20	  (also	   know	   as	   TNFα	   induced	   protein	   (TNFAIP3)),	   although	   these	   studies	  were	  performed	  using	   transfection	  of	  A20	   and	  PKD	   into	   a	   beta	   islet	   cell	   line	   (βTC3)	  and	   it	   was	   not	   clear	   which	   isoform	   was	   used	   (Liuwantara	   et	   al.	   2006).	  	  Assessment	   of	  whether	   the	   over	   activation	   status	  we	   see	  within	   the	   PKD2KI/KI	  BMDCs	   affected	   T	   lymphocyte	   activation	   using	   an	   in-­‐in	   vitro	   activation	  model	  that	   demonstrate	   that	   T	   cell	   activation	   was	   normal,	   as	   indicated	   by	   normal	  activation	  markers	  such	  as	  CD69,	  CD44,	  CD62L	  and	  CD25.	  However,	  we	  did	  note	  significantly	  increased	  production	  IFNγ	  by	  day	  3	  and	  day	  4	  by	  T	  cells	  stimulated	  with	  activated	  PKD2KI/KI	  BMDCs	  compared	  to	  activated	  WT	  BMDCs.	  One	  caveat	  of	  this	  T	  cell	  activation	  model	   is	  the	   inability	  to	  distinguish	  between	  DC	  produced	  IFNγ	   and	   T	   lymphocyte	   produced	   IFNγ.	   	   One	   way	   to	   overcome	   this	   problem	  would	   be	   to	   use	   intracellular	   cytokine	   staining	   allowing	   identification	   of	   IFNγ	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produced	   by	   T	   cells	   only.	   Interestingly,	   studies	   investigating	  mice	   lacking	   A20	  specifically	   within	   DCs	   develop	   autoimmunity	   characterised	   by	   increased	  conversion	   of	   CD4+	   naïve	   T	   cells	   into	   Th1	   phenotype	   in	   which	   Th1	   cells	  produced	  significantly	  more	  IFNγ	  as	  well	  as	  increased	  generation	  of	  plasma	  cells	  (Kool	  et	  al.	  2011).	  	  	  Future	   studies	   could	   investigate	   if	   that	   PKD	   mediates	   anti-­‐inflammatory	  responses	   within	   innate	   immune	   cells	   after	   PRR	   ligation	   and	   assess	   the	  regulation	  of	  A20	  within	  PKD2KI/KI	  BMDCs.	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5 	  Investigating	  the	  role	  of	  PKD2	  catalytic	  activity	  
in	   gut	   homeostasis,	   regulatory	   T	   cells	   and	  
colitis	  	  
5.1 	  Introduction	  	   In	  the	  previous	  chapters,	  I	  have	  taken	  a	  particular	  focus	  on	  the	  role	  of	  PKD	  kinases,	   more	   specifically	   the	   PKD2	   isoform,	   in	   the	   development	   and	   effector	  functions	  of	  myeloid	   cells	   in	  vitro	   and	   in	  vivo.	   	  Within	   the	  mammalian	   immune	  system	  it	  is	  well	  established	  that	  thymocytes	  and	  peripheral	  T	  lymphocytes	  also	  predominantly	  express	  PKD2	  which	  is	  selectively	  activated	  after	  TCR	  activation	  (Matthews	   et	   al.	   2000;	   Matthews	   et	   al.	   2010;	   Navarro,	   Feijoo	   Carnero,	   et	   al.	  2014a;	  Spitaler,	  Emslie,	  Wood	  &	  Cantrell	  2006b).	  TCR	  signaling	   is	  known	  to	  be	  essential	   for	   both	   T	   cell	   development	   within	   the	   thymus	   and	   controlling	   the	  function	   of	   effector	   T	   cells	   during	   a	   successful	   adaptive	   immune	   response	  (Smith-­‐Garvin	  et	  al.	  2009).	  Equally	  important	  is	  the	  role	  of	  TCR	  signaling	  in	  the	  process	  of	  deletion	  of	  self-­‐reactive	  T	  cells,	  known	  as	  central	  tolerance	  (reviewed	  Mathis	   &	   Benoist	   2004),	   	   although	   this	   is	   not	   completely	   effective	   as	  demonstrated	   by	   presence	   of	   self-­‐reactive	   T	   cells	   within	   the	   periphery	  (Bouneaud	  et	  al.	  2000).	  	  Therefore,	  T	  cell	  tolerance	  within	  the	  periphery	  must	  be	  maintained	   by	   additional	   mechanisms,	   these	   include	   induction	   of	   Tregs	  (reviewed	  extensively	  (Josefowicz	  et	  al.	  2012))	  and	  T	  cell	  clonal	  anergy,	  a	  state	  of	  T	  cell	  unresponsiveness	  induced	  by	  TCR	  stimulation	  that	  occurs	  in	  the	  absence	  of	  co-­‐stimulation	  (Schwartz	  2003)	  (Appleman	  &	  Boussiotis	  2003).	  	  DAG	   signaling	   is	   an	   essential	   component	   of	   downstream	   TCR	   signaling	  events	  as	  demonstrated	  by	   loss	  of	  DGKs	  (DAG	  kinases),	  such	  as	  DGKα	  or	  DGKζ,	  which	   results	   in	   reduction	   in	   normal	   peripheral	   T	   cells	   (R.	   Guo	   et	   al.	   2008).	  Furthermore,	  it	  has	  also	  been	  shown	  that	  loss	  of	  DGKα	  or	  DGKζ	  led	  to	  enhanced	  T	  cell	  activation	  and	  prevents	  induction	  of	  anergy	  (Riese	  et	  al.	  2011)	  (Olenchock	  et	  al.	  2006).	  	  	  PKD	  family	  members	  are	  key	  receptors	  and	  secondary	  messengers	  of	  DAG	  and	  integrates	  signals	  from	  DAG	  and	  PKC	  (Q.	  J.	  Wang	  2006).	  In	  this	  context,	  PKD2	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in	  T	   lymphocytes	  has	  been	  shown	  to	  be	  required	   for	   IL-­‐2	  and	   IFNγ	  production	  after	  TCR	  triggering,	  highlighting	  an	  essential	  function	  of	  PKD2	  in	  effector	  T	  cell	  responses	   and	   humoural	   immune	   responses	   in	   vivo	   (Matthews	   et	   al.	   2010).	  Studies	   attempting	   to	   address	   lack	   of	   T	   cell	   effector	   function	  went	   on	   to	   show	  that	  although	  PKD2	  catalytic	  activity	   is	  not	  required	  for	  normal	  T	  cell	  selection	  (shown	   by	   transcriptome	   analysis),	   but	   rather	   PKD2	   null	   T	   cells	   are	   simply	  unable	  to	  switch	  to	  effector	  T	  cell	  status	  in	  response	  to	  TCR	  stimulation	  (Navarro	  et	   al.	   2012).	  However,	   it	   is	   clear	   that	   in	   this	   context	   PKD2	   also	   plays	   a	   role	   in	  negative	   regulation	   of	   T	   cell	   proliferation	   both	   PKD2KI/KI	   or	   PKD2KO/KO	   mice	  crossed	   onto	   both	   the	   TCR-­‐transgenic	   OTI	   and	   OTII	   strains	   (which	   select	   for	  CD8+	  and	  CD4+	  T	  cells	  respectively)	  had	  striking	  hypercellularity	  of	  thymus	  and	  as	   a	   consequence	   of	   these	   mice	   also	   displayed	   splenomegaly	   and	   lymphoid	  hyperplasia.	  	  Subsequent	  studies	  have	  defined	  PKD2	  as	  a	  digital	  amplifier	  in	  TCR	  mediated	   signalling,	   and	   was	   shown	   to	   be	   required	   for	   normal	   CD8+	   CTLs	   in	  response	   to	   L.Monocytogenes	   however	   lack	   of	   PKD2	   was	   protective	   in	   an	  autoimmune	   model	   of	   diabetes	   (Navarro,	   Feijoo	   Carnero,	   et	   al.	   2014a)	  Furthermore,	   	   recent	   studies	   have	   taken	   a	   wider	   approach	   to	   assess	  phosphoproteomics	  within	  PKD2KO/KO	  CD8+	  CTLs	  (Navarro,	  Goebel,	  et	  al.	  2014b).	  The	   main	   proteins	   affected	   by	   loss	   of	   PKD2	   included	   those	   involved	   in	  transcription,	   cell	   cycle,	   RNA	   processing,	   chromosomal	   organisation.	  Additionally,	  novel	  substrates	  of	  PKD2	  identified	  in	  CTLs	  included	  the	  E3	  ligase	  C-­‐Cbl	   and	   the	   tyrosine	   protein	   phosphatase	   non	   receptor	   type	   22	   (Ptpn22),	  which	   is	   known	   to	   be	   crucial	   for	   the	   TCR	   to	   discriminate	   between	   strong	   and	  weak	  peptides	  (Salmond	  et	  al.	  2014).	  	  	  The	   development	   of	   Tregs	   has	   been	   shown	   to	   absolutely	   require	   TCR	  signalling	  within	  the	  thymus	  where	  CD4+	  T	  cells	  with	  self	  reactive	  TCRs	  respond	  strongly	  to	  self	  antigen	  resulting	  in	  the	  upregulation	  of	  the	  FoxP3	  transcription	  factor	   and	   development	   into	   nTreg	   (reviewed	   extensively	   (Hsieh	   et	   al.	   2012)).	  More	  recently	  the	  role	  of	  TCR	  signaling	  has	  been	  addressed	  in	  Tregs,	  which	  arise	  from	  CD4+	  T	   cells	  within	   the	   periphery.	  Here,	   TCR	   signaling	  was	   shown	   to	   be	  required	   for	   suppressive	   capacity	   of	   Tregs	   where	   loss	   of	   TCR	   signaling	   in	  peripheral	   Tregs	   resulted	   in	   the	   development	   of	   severe	   autoimmunity	   and	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moribund	   by	   day	   13,	   highlighting	   the	   requirement	   for	   TCR	   signaling	   for	   Treg	  function	  within	  the	  periphery	  in	  vivo	  (Levine	  et	  al.	  2014).	  In	   this	   chapter	   I	   will	   present	   our	   analysis	   on	   the	   effect	   of	   loss	   of	   PKD2	  catalytic	  activity	  in	  gut	  associated	  tissues	  and	  lymphocyte	  populations.	  Although	  there	  is	  abundant	  information	  available	  about	  the	  role	  PKD2	  plays	  in	  CD8+	  and	  CD4+	   T	   cell	   subsets,	   it	   is	   unknown	   if	   PKD2	   catalytic	   activity	   may	   play	   in	   the	  induction	  of	   the	  development	  of	  Tregs,	   their	  maintenance	  within	   the	  periphery	  or	   their	   effector	   function.	   To	   understand	   whether	   PKD2	   catalytic	   activity	   is	  required	   for	   Treg	   development,	  we	   decided	   to	   assess	   Treg	   populations	  within	  the	   tissues	   of	   PKD2KI/KI	  mice.	   Furthermore,	   we	   addressed	   if	   functionality	   was	  impaired	  in	  PKD2	  KI/KI	  Tregs	  by	  using	  a	  well-­‐characterised	  T	  cell	  transfer	  colitis	  model	  to	  address	  if	  any	  changes	  observed	  were	  due	  to	  cell	  intrinsic	  or	  extrinsic	  mechanisms	  in	  an	  in	  vivo	  model.	  	  
5.2 	  Results	  	  
5.2.1 PKD2	  KI	  mice	  display	  enlarged	  mucosal	  associated	  tissues	  

















































































	  	  Figure	   5.1	   PKD2	   KI/KI	   mice	   display	   significantly	   enlarged	   mesenteric	   lymph	  nodes	  but	  display	  normal	  non-­‐GALT	  associated	  tissue	  size	  (A)	  Representative	   images	  depicting	  mesenteric	   lymph	  nodes	  ex	  vivo	   from	  WT	  and	   PKD2KI/KI	   	   mice.	   (B)	   Representative	   images	   depicting	   excised	   mesenteric	  lymph	  nodes	  from	  age	  and	  sex	  matched	  WT	  and	  PKD2	  KI/KI	  mice.	  (C)	  Mesenteric	  lymph	   node	   live	   total	   cell	   counts	   (x106	  )	   from	   aged	   and	   sex	  matched	  WT	   and	  PKD2KI/KI	  mice	  	  (D)	  Combined	  inguinal/axillary	  lymph	  nodes	  live	  total	  cell	  counts	  (x106)	  (	   (E)	  Combined	  spleen	   live	   total	  cell	  counts	  (x106	  )	  Error	  bars	  represent	  SD.	   Data	   obtained	   from	   4	   independent	   experiments,	   n=15	   mice	   total).	   ****	   =	  p≤0.0001	  analysed	  by	  students	  t	  test.	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Next,	   we	   wanted	   to	   explore	   if	   PKD2KI/KI	   mice	   displaying	   enlarged	  mesenteric	   lymph	   nodes	   displayed	   any	   associated	   histopathology.	   To	   achieve	  this,	   samples	   including	   sections	   of	   the	  mesenteric	   lymph	   nodes	  were	   taken	   ex	  
vivo	   from	   age	   and	   sex	   matched	  WT	   and	   PKD2KI/KI	   mice	   and	   collected	   in	   10%	  neutral	   buffered	   formalin.	   Tissue	   samples	   were	   then	   embedded	   in	   paraffin	  blocks,	   sliced	   into	   4-­‐μm	   thick	   sections	  which	  were	   subsequently	   stained	   using	  Hematoxylin	   and	   Eosin	   (HE)	   and	   assessed	   microscopically	   by	   a	   pathologist.	  
These	   services	   were	   kindly	   provided	   by	   the	   University	   of	   Glasgow	   Veterinary	  
Diagnostic	  Services,	  microphotographs	  were	  assessed	  by	  pathologist	  Dr	  Francesco	  







	  Figure	   5.2	  Histological	   features	   of	  WT	   and	  PKD2KI/KI	  murine	  mesenteric	   lymph	  nodes	  (A)	  Histological	  sections	  of	  mesenteric	   lymph	  node	   from	  WT	  mice	  stained	  with	  HE	  (10x	  magnification.	  Blue	  arrows	   indicate	  cortical	   lymphoid	   follicles	  without	  well	   developed	   germinal	   centres	   (B)	  Histological	   sections	  of	  mesenteric	   lymph	  node	   sections	   from	   PKD2KI/KI	  mice	   stained	   with	   HE	   (10x	   magnification).	   Blue	  arrows	  indicate	  cortical	  lymphoid	  follicle	  with	  expanded	  germinal	  centres,	  which	  are	  characterised	  by	  a	  slightly	  irregular	  architecture.	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We	   also	   wanted	   to	   assess	   lymphocyte	   populations	   within	   the	   enlarged	   mLN	  tissue	  of	  PKD2KI/KI	  mice.	  As	  we	  had	  observed	  an	  expansion	  of	  germinal	   centres	  within	   the	  mLN	  of	  PKD2KI/KI	  mice,	  we	  decided	   to	   explore	  any	   changes	   in	  B	   cell	  populations	   ex	   vivo	   by	   flow	   cytometry.	   	   	   As	   can	   be	   seen	   in	   Figure	   5.3A-­‐B,	   we	  observed	  a	  significant	  increase	  in	  the	  %	  frequency	  and	  total	  cell	  number	  (x106)	  of	   B	   lymphocytes	   (CD19+	   B220+)	   within	   the	   mLNs	   of	   PKD2KI/KI	   mice	   when	  compared	  to	  WT	  mice.	   	  To	  explore	  potential	  reasons	  behind	  enlarged	  germinal	  centres	  and	  significantly	  increase	  B	  cells	  within	  the	  mLN	  we	  also	  stained	  B	  cells	  for	   GL-­‐7	   (also	   known	   as	   Ly-­‐77),	   which	   is	   a	   well-­‐known	   marker	   of	   germinal	  center	   B	   cells	   (Laszlo	   et	   al.	   1993).	   This	   revealed	   no	   difference	   in	   the	   surface	  expression	  of	  GL-­‐7	  on	  PKD2KI/KI	  B	  cells	  when	  compared	  with	  WT	  B	  cells	  within	  the	  mLN	  (Figure	  5.3D-­‐E)	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  Figure	  5.3	  B	  lymphocytes	  are	  increased	  within	  mLN	  tissue	  of	  PKD2	  KI/KI	  mice	  (A)	  Dot	  plots	  showing	  live	  B	  cells	  populations	  within	  mLN	  of	  WT	  and	  PKD2KI/KI	  mice	   by	   CD19	   and	   B220	   surface	   expression	   by	   flow	   cytometry.	   Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  %	  frequency	  of	   live	  B	  cells	  (CD19+	  B220+)	   within	   mLN	   (C)	   Total	   cell	   number	   	   (x106)	   of	   B	   cells	   within	   mLN.	   (D)	  Histogram	   showing	   GL-­‐7	   surface	   marker	   expression	   on	   B	   cells	   (gated	   on	   live	  CD19+	  B220+	  lymphocytes).	  (E)	  %	  of	  live	  B	  cells	  	  (CD19+	  B220+)	  expressing	  GL-­‐7	  surface	  marker.	   	  Error	  bars	   represent	  SD.	  Data	  obtained	   from	  4	   independent	  experiments,	  n=12	  mice	  per	  genotype.	  **	  =	  p≤0.01	  analysed	  by	  students	  t	  test.	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We	  also	  examined	  T	  cell	  populations	  within	  the	  mLN	  of	  WT	  and	  PKD2KI/KI	  mice	   including	   TCRαβ+	   and	   TCRγδ+	   cells	   but	   also	   TCRαβ+	   CD4+	   and	   TCRαβ+	  CD8+	  lymphocytes.	  As	  can	  be	  seen	  in	  Figure	  5.4A-­‐B,	  the	  %	  frequency	  of	  TCRαβ+	  and	  TCRγδ+	  T	  cell	  subsets	  within	  the	  mLN	  of	  PKD2KI/KI	  mice	  was	  comparable	  to	  WT	   mice.	   Although	   when	   we	   compare	   total	   cell	   number	   of	   these	   subsets,	   all	  populations	  with	  PKD2KI/KI	  mice	  are	   inherently	   increased	  due	   to	   the	   significant	  increase	  we	  observe	  with	  the	  total	  cellularity	  of	  the	  mLN	  tissue.	  	  	  




























































































5.2.1.2 Peyers	  patches	  	   During	  assessment	  of	  ex	  vivo	   tissues	   it	  was	  observed	   that	   in	   addition	  of	  enlarged	   mesenteric	   lymph	   nodes	   Peyers	   patches	   found	   within	   the	   small	  intestine	  were	  also	  visibly	  larger	  within	  PKD2KI/KI	  mice	  Figure	  5.5.	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B





	  Figure	  5.5	  Peyers	  patches	  are	  enlarged	  in	  PKD2KI/KI	  mice	  (A)	  Representative	   images	   of	   Peyer’s	   patches	  within	   the	   small	   intestine	   of	  WT	  and	  PKD2KI/KI	  mice	  ex	  vivo	  indicated	  by	  white	  boxes.	  (B)	  Excised	  small	  intestine	  and	   presence	   of	   Peyer’s	   patches	   in	  WT	   and	   PKD2KI/KI	  mice	   indicated	   by	  white	  boxes.	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Following	  this	  observation	  we	  wanted	  to	  investigate	  the	  potential	  reason	  behind	  increased	  size	  of	  GALT	  tissues.	  Importantly,	  we	  also	  wanted	  to	  address	  if	  these	  were	  indeed	  enlarged	  Peyers	  patches,	  containing	  immune	  cell	  subsets,	  and	  were	   not	   for	   example	   intestinal	   polyps.	   Furthermore,	   we	   also	   wanted	   to	  investigate	   if	   the	   enlarged	   PPs	   in	   PKD2KI/KI	  mice	   displayed	   any	   histopathology	  associated	   with	   the	   increase	   in	   tissue	   size.	   To	   achieve	   this,	   samples	   including	  sections	  of	  the	  transverse	  small	  intestine	  containing	  Peyers	  patches	  were	  taken	  








WT! PKD2KI/KI!! 	  Figure	  5.6	  Histological	  features	  of	  WT	  and	  PKD2KI/KI	  mice	  Peyers	  patches	  within	  the	  small	  intestine	  (A)	   Comparison	   of	   sectioned	  WT	   and	   PKD2	   KI	   small	   intestine	   Peyers	   patches	  (4x)	  stained	  with	  H+E,	   images	  show	  germinal	  centres	   indicated	  by	  blue	  arrows	  (4x).	   (B)	   Sectioned	   WT	   Peyers	   patches	   show	   follicular	   structures	   with	   small	  germinal	  centres	  (4x).	  (C)	  PKD2	  KI	  small	  intestine	  Peyers	  patches	  show	  follicular	  structures	  with	  slightly	  expanded	  germinal	  centres.	  	  	   To	   study	   the	   effect	   of	   loss	   of	   PKD2	   catalytic	   activity	   on	   lymphocytes	  within	  GALT	  tissues	  PPs	  were	  isolated	  from	  age	  and	  sex	  matched	  WT	  and	  PKD2	  KI/KI	   mice	   and	   lymphocyte	   populations	   were	   assessed	   using	   flow	   cytometry.	  Although	  PPs	  were	  visibly	   larger	   simply	  by	  eye,	   it	  was	  difficult	   to	   get	   accurate	  cell	   numbers	   from	   these	   tissues,	   as	   they	   are	   notoriously	   difficult	   to	   remove	   in	  one	  piece	  from	  the	  small	  intestinal	  tract	  due	  to	  their	  small	  size.	  However,	  it	  was	  possible	  to	  prepare	  samples	  for	  flow	  cytometry.	  Analysis	  of	  B	  cell	  populations	  via	  CD19+	  B220+	  surface	  marker	  staining	  revealed	  that	  frequency	  of	  B	  cells	  within	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PKD2	  KI/KI	  PPs	  were	  not	   significantly	  different	   from	  WT	   tissue	   (Figure	  5.7A-­‐B).	  Additional	  staining	  of	  B	  cells	  with	  GL-­‐7,	  revealed	  significantly	  higher	  expression	  of	  this	  cell	  surface	  marker	  on	  B	  cells	  within	  PKD2KI/KI	  PPs	  (Figure	  5.7C-­‐D).	  	  These	  results	  collectively	  show	  that	  loss	  of	  PKD2	  catalytic	  activity	  leads	  to	  an	  apparent	  increase	   in	   PP	   tissue	   size	   and	   that	   germinal	   centers	   within	   these	   tissues	   are	  moderately	  expanded	  with	  activated	  B	  cells	  expressing	  significantly	  more	  GL-­‐7	  (2	  fold	  increase).	  	  This	  indicates	  that	  B	  cells	  within	  PKD2	  KI/KI	  may	  potentially	  be	  more	   activate	   or	   possibly	   over	   responding	   to	   antigen	   (whether	   food	   proteins,	  commensal	  bacteria	  or	  pathogenic	  bacteria).	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A WT PKD2 KI/KI
B220C WT PKD2 KI/KI





























































	  	  Figure	   5.7	   B	   cells	   within	   Peyers	   patches	   of	   PKD2	   KI/KI	   mice	   have	   increased	  expression	  of	  GL-­‐7	  	  (A)	  Representative	  dot	  plots	  showing	  live	  B	  cells	  populations	  within	  PPs	  of	  WT	  and	   PKD2	   KI	   mice	   by	   CD19	   and	   B220	   surface	   marker	   expression	   by	   Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD	  (B)	  Combined	  data	  showing%	  Frequency	  of	   live	  B	  cells	   in	  PPs	  (C)	  Histogram	  showing	  GL-­‐7	  surface	  marker	  expression	  on	  B	  cells	  (gated	  on	  live	  CD19+	  B220+	  lymphocytes)	  (D)	  %	  B	  cells	  positive	  for	  GL-­‐7	  expression.	  Error	  bars	  represent	  SD.	  Data	  obtained	  from	  3	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independent	  experiments,	  n=	  9	  mice	  per	  genotype.	  ****	  =	  p≤0.0001	  analysed	  by	  students	  t	  test.	  In	  regard	  to	  T	  cell	  populations	  within	  PPs	  the	  frequency	  of	  T	  cell	  subsets	  within	  this	  tissue	  were	  grossly	  normal.	  	  Analysis	  of	  TCRαβ+T	  cells	  within	  PPs	  of	  PKD2KI/KI	   mice	   were	   not	   significantly	   different	   to	   WT,	   representative	   Flow	  cytometry	  dot	  plots	  are	  shown	  in	  Figure	  5.8A	  and	  %	  frequency	  of	  cells	  is	  shown	  in	  Figure	  5.8C.	  In	  contrast,	  %	  frequency	  of	  TCRγδ+	  population	  was	  significantly	  decreased	  within	   PPs	   of	   PKD2	   KI/KI,	   as	   indicated	   in	   representative	   dot	   plots	   in	  Figure	  5.8A	  and	  %	  frequency	  in	  Figure	  5.8C.	  	  These	   data	   importantly	   demonstrates	   that	   enlarged	   PP	   tissue	   within	  PKD2KI/KI	  mice	  were	  indeed	  PPs	  rather	  than	  the	  presence	  of	  intestinal	  polyps	  as	  they	   contained	   cell	   subsets,	   including	   B	   cells	   and	   typical	   T	   cell	   subsets,	   that	  would	  be	  expected	  of	  gut	  associated	  lymphoid	  tissue.	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  Figure	  5.8	  T	  cell	  populations	  within	  enlarged	  PPs	  of	  PKD2KI/KI	  mice	  (A)	  Representative	  dot	  plots	   showing	   live	  T	   cell	   subsets	  within	  PPs	  of	  WT	  and	  PKD2KI/KI	   mice	   by	   TCRαβ	   and	   TCRγδ	   surface	   expression	   by	   Flow	   cytometry.	  Numbers	   represent	   average	  %	   frequency	   and	   SD	   (B)	   Dot	   plots	   showing	   CD4+	  and	   CD8+	   populations	   (gated	   on	   TCRαβ+	   T	   cells)	   in	   PPs	   of	  WT	   and	   PKD2KI/KI	  mice.	   (C)%	   frequency	  of	  T	   cell	   subsets	   in	  PPs	  of	  WT	  and	  PKD2KI/KI	  mice.	  Error	  bars	  represent	  SD.	  Data	  obtained	  from	  2	  independent	  experiments	  n=	  3	  mice	  per	  WT	  group	  and	  4	  mice	  per	  PKDKI/KI	  group.	  **	  =	  p≤0.01	  analysed	  by	  students	  t	  test.	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5.3 	  PKD2KI/KI	   mice	   have	   increased	   abundance	   of	   Tregs	   in	  
multiple	  tissues	  	  	   Although	   the	   role	   of	   PKD2	   has	   been	   explored	   in	   regard	   to	   lymphocyte	  development	   and	   function,	   including	   both	   B	   and	   T	   cells,	   the	   potential	   role	   for	  PKD2	  in	  the	  development	  of	  natural	  and	  induced	  regulatory	  T	  cells	  subsets	  has	  remained	  unaddressed.	   	   It	   is	  known	  that	  TCR	  signaling	   is	  essential	   for	  not	  only	  the	  development	  of	  nTreg	  cells	  within	  the	  thymus,	  but	  is	  also	  intricately	  required	  for	   the	   development	   of	   Tregs	   and	   their	   suppressive	   function	   within	   the	  periphery	  to	  maintain	  tolerance	  and	  homeostasis	  (Levine	  et	  al.	  2014)	  (Hsieh	  et	  al.	  2012).	  Tregs	  are	  also	  produced	  in	  response	  to	  environmental	  cues	  within	  the	  periphery;	   strong	   inducers	   of	   Treg	   include	   the	   presence	   of	   cognate	   antigen	  alongside	   TGF-­‐β	   and	   IL-­‐10	   and	   lack	   of	   co-­‐stimulation	   (Bilate	   &	   Lafaille	   2012)	  (Hsieh	   et	   al.	   2012).	  Tregs	  have	  become	  a	   large	   area	  of	   therapeutic	   exploration	  due	   to	   their	  potent	   the	   suppressive	   capacities	  and	  potential	  use	   in	  a	  variety	  of	  autoimmune	  diseases.	  This	  is	  significant	  as	  if	  PKD	  inhibitors	  are	  to	  be	  used	  in	  the	  clinic	  it	  is	  imperative	  to	  understand	  the	  potential	  role	  of	  PKD2	  catalytic	  activity	  within	  cells	  of	  the	  immune	  system.	  	  
5.3.1 	  Tregs	  within	   the	   spleen	   and	  mesenteric	   lymph	  node	  of	   PKD2KI/KI	  

































































































	  Figure	  5.9	   Induced	  Tregs	  are	   significantly	   increased	   in	   the	  spleen	  of	  PKD2	  KI/KI	  mice	  	  (A)	   Representative	   dot	   plots	   showing	   induced	   Treg	   (Treg)	   populations	   within	  spleen	   of	   WT,	   PKD1WT/KI	   and	   PKD2KI/KI	   mice	   by	   CD4	   surface	   expression	   and	  intracellular	  FoxP3	  expression	  by	  Flow	  cytometry.	  Numbers	   represent	   average	  %	   frequency	  and	  SD.	   (B)	  Combined	  data	  showing	  %	   frequency	  of	  CD4+	  CD25+	  FoxP3+	   Tregs	   within	   the	   spleen	   (C)	   Total	   cell	   number	   (x106)	   of	   CD4+	   CD25+	  FoxP3+	  Treg	  within	   the	  spleen.	   (D)	  Mean	   fluorescence	   intensity	   (MFI)	  of	  CD25	  expression	  on	  CD4+	  FoxP3+	   gated	   lymphocytes.	   Error	   bars	   represent	   SD.	  Data	  obtained	  from	  5	  independent	  experiments	  n=	  25	  WT	  mice,	  4	  PKD1WT/KI	  mice	  and	  25	  PKD2KI/KI	  mice.	  ****	  =	  p≤0.0001	  analysed	  by	  students	  t	  test.	  	  	  We	   next	   assessed	   the	   number	   of	   CD4+CD25+	   FoxP3+	   Tregs	   within	   the	  mLNs	  of	  WT	  and	  PKD2KI/KI	  mice.	  	  As	  can	  be	  seen	  in	  Figure	  5.10A,	  %	  frequency	  of	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Treg	  populations	   are	   also	   significantly	   increased	   (1.3-­‐fold)	  within	   the	  mLNs	  of	  PKD2KI/KI	  mice,	  although	  this	  increase	  is	  more	  modest	  than	  that	  observed	  in	  the	  spleen,	   it	   is	   statistically	   significant.	   Furthermore,	  when	   taking	   into	   account	   the	  increased	   size	   of	   mLN	   tissue	   itself	   within	   PKD2KI/KI	   mice	   and	   assessed	   total	  number	  of	  Tregs	  we	  observed	  a	  3.4	  fold	  increase	  (Figure	  5.10D).	  	  These	  data	  shows	  that	  the	  increase	  in	  Tregs	  subsets	  observed	  in	  PKD2KI/KI	  mice	  is	  not	  limited	  to	  one	  lymphoid	  site	  but	  rather	  a	  general	  increase	  in	  the	  total	  number	   of	   Tregs	   within	   PKD2KI/KI	   mice.	   This	   phenotype	   is	   therefore	   unlikely	  simply	  homing	  or	  migratory	  problem	  in	  which	  Tregs	  within	  PKD2KI/KI	  mice	  are	  unable	  to	  migrate	  between	  tissues	  and	  lymphoid	  sites.	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  Figure	  5.10	  Tregs	  are	  increased	  in	  the	  mesenteric	  lymph	  nodes	  of	  PKD2	  KI/KI	  mice	  (A)	  Representative	  dot	  plots	  showing	  Treg	  populations	  within	  mesenteric	  lymph	  nodes	   of	   WT	   and	   PKD2KI/KI	   mice	   by	   CD4	   surface	   expression	   and	   intracellular	  FoxP3	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	   SD.	   (B)	   Histogram	   showing	   overlayed	   expression	   of	   FoxP3	   in	   WT	   and	  PKD2KI/KI	  CD4+	  gated	   lymphocytes	  (C)	  Combined	  data	  showing	  %	  frequency	  of	  CD4+	   CD25+	   FoxP3+	   Tregs	  within	  mLN	   (D)	   Total	   cell	   number	   (x106)	   of	   CD4+	  CD25+	  FoxP3+	  Treg	  within	  mLN.	  Error	  bars	  represent	  SD.	  Data	  obtained	  from	  4	  independent	   experiments	   n=	   12	   mice	   per	   genotype.	   	   **	   =	   p≤0.01	   and	   	   ****	   =	  p≤0.0001	  analysed	  by	  students	  t	  test.	  	  	  
5.3.2 Thymus	  	  	   After	  examining	  the	  presence	  of	   increased	  Tregs	   in	  tissues	   including	  the	  mesenteric	  lymph	  nodes,	  Peyers	  patches,	  spleen	  and	  inguinal	  and	  axillary	  lymph	  nodes	   of	   PKD2KI/KI	   mice,	   we	   wanted	   to	   address	   if	   this	   difference	   was	   due	   to	  increased	  output	  of	  precursors	  of	  peripheral	  Tregs	  (nTregs)	  within	  the	  thymus.	  	  nTregs	   are	   developed	   after	   TCR	   activation	   via	   recognition	   of	   cognate	   self-­‐
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peptide,	   presented	   by	  medullary	   thymic	   epithelial	   cells	   (mTEC)	   and	  medullary	  thymic	  DCs	  that	  express	  the	  autoimmune	  regulator	  (AIRE)	  (Nomura	  &	  Sakaguchi	  2007)	  (Gallegos	  &	  Bevan	  2004).	  	  Strength	  of	  TCR	  signal	  is	  also	  known	  to	  be	  key	  within	   this	   stage	   to	   determine	   cell	   death	   versus	   development	   of	   nTreg	   (Bour-­‐Jordan	  &	  Bluestone	  2009).	  To	   assess	   if	   increased	   abundance	   of	   peripheral	   Tregs	   in	   PKD2KI/KI	  mice	  was	  indeed	  a	  result	  of	  increased	  output	  of	  Treg	  subsets,	  thymi	  from	  age	  and	  sex	  matched	   mice	   were	   prepared	   and	   assessed	   for	   Treg	   populations	   via	   Flow	  cytometry.	  CD4	  and	  CD25	  surface	  marker	  expression	  were	  used	   to	  define	  Treg	  populations	  as	  well	  as	  intracellular	  staining	  for	  FoxP3.	  These	  data	  demonstrated	  that	   the	   frequency	   of	   nTreg	   cells	   within	   the	   thymus	   were	   normal,	   shown	   by	  assessing	   CD4+	   FoxP3+	   populations	   (Figure	   5.11A).	   This	   was	   clearly	  demonstrated	  by	  both	  the	  percentage	  frequency	  and	  total	  number	  (x106)	  of	  CD4+	  CD25+	   FoxP3+	   cells	   in	   thymus	   of	   PKD2KI/KI	   mice	   compared	   to	   age	   and	   sex	  matched	  WT	  controls	  (Figure	  5.11B-­‐C)	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  Figure	  5.11	  nTregs	  within	  the	  thymus	  of	  PKD2	  KI/KI	  mice	  are	  normal	  (A)	   Representative	   dot	   plots	   showing	   natural	   Treg	   (nTreg)	   populations	  within	  thymus	   of	  WT	   and	  PKD2KI/KI	  mice	   by	  CD4	   surface	   expression	   and	   intracellular	  FoxP3	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  %	  frequency	  of	  CD4+FoxP3+	  T	  cells	  within	  the	  thymus	  (C)	  Combined	  data	  showing	  total	  cell	  number	  (x106)	  of	  CD4+	  CD25+	  FoxP3+	  nTregs	  in	  thymus.	  Error	   bars	   represent	   SD.	   Data	   obtained	   from	   3	   independent	   experiments,	   n=7	  mice	  per	  genotype.	  	  	   Furthermore,	   assessment	   of	   T	   cell	   subsets	   within	   the	   thymus	   of	   PKD2	  KI/KI	  mice	  revealed	  no	  differences	  in	  %	  frequency	  of	  TCRαβ+,	  TCRγδ+,	  TCRαβ+	  CD4+	   or	   TCRαβ+	   CD8+	   (Figure	   5.12A-­‐D).	   	   These	   data	   are	   consistent	   with	  previous	  publications	  in	  which	  loss	  of	  PKD2	  catalytic	  activity	  did	  not	  affect	  T	  cell	  development	  in	  vivo	  (Matthews	  et	  al.	  2010).	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  Figure	  5.12	  T	  cell	  subsets	  are	  normal	  within	  the	  thymus	  of	  PKD2	  KI/KI	  mice	  (A)	   Representative	   dot	   plots	   showing	   live	   T	   cell	   subsets	  within	   thymus	   of	  WT	  and	  PKD2	  KI/KI	  mice	  by	  TCRαβ	  and	  TCRγδ	  surface	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD	  (B)	  Combined	  data	  showing%	  frequency	   of	   TCRαβ+	   and	   TCRγδ+	   cell	   subsets	   (C)	   Representative	   dot	   plots	  showing	  CD4+	  and	  CD8+	  populations	  (gated	  on	  TCRαβ+	  T	  cells)	  of	  WT	  and	  PKD2	  KI/KI	   mice.	   (D)	   Combined	   data	   showing	   %	   frequency	   of	   TCRαβ+	   CD4+	   and	  TCRαβ+	  CD8+	   subsets.	   Data	   obtained	   from	   two	   independent	   experiments,	   n=2	  mice	  per	  genotype.	  	  	   Collectively,	   these	  results	  demonstrate	   that	  although	  T	  cell	  development	  is	   clearly	   intact	   in	   PKDKI/KI	  mice	  within	   normal	   T	   lymphocyte	   output	   from	   the	  thymus,	   significant	   changes	   are	   observed	   when	   T	   lymphocytes	   populate	   the	  periphery	   with	   an	   obvious	   increase	   in	   the	   number	   of	   Tregs	   within	   multiple	  lymphoid	  tissues.	  	  As	  discussed	  previously,	  HDAC	  has	  been	  implicated	  in	  governing	  the	  both	  the	   development	   of	   Tregs	   but	   also	   their	   suppressive	   capabilities	   (reviewed	   (L.	  Wang	   et	   al.	   2009))	   .	   Class	   IIa	   HDACs	   including	   HDAC7	   and	   HDAC9	   have	   been	  shown	  to	  be	  expressed	  in	  CD4+	  FoxP3+	  T	  cells	  	  (Dequiedt	  et	  al.	  2003)	  	  (Fontenot	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et	  al.	  2005)).	  Furthermore,	  the	  treatment	  of	  mice	  with	  HDAC	  inhibitors	  (HDACi)	  has	  been	  shown	  to	  boost	  the	  number	  of	  Tregs	  within	  multiple	  lymphoid	  tissues	  (Tao	   et	   al.	   2007).	   This	   has	   been	   shown	   to	   be	   due	   to	   increased	   stability	   of	   the	  FoxP3	  protein	  HDAC9	  has	  been	  shown	  to	  directly	  acetylate	  FoxP3	  and	  promote	  its	  subsequent	  degradation	  (van	  Loosdregt	  et	  al.	  2010)	  (de	  Zoeten	  et	  al.	  2010)..	  In	   human	   Tregs,	   FoxP3	   has	   been	   shown	   to	   form	   a	   complex	   with	   histone	  acetyltransferase	  (TIP60)	  and	  with	  HDAC7	  which	  functions	  as	  a	  transcriptional	  repressor	  (B.	  Li	  et	  al.	  2007).	  Importantly,	  PKD	  has	  been	  shown	  to	  regulate	  class	  IIa	   HDACs	   in	   multiple	   cells	   including	   B	   and	   T	   lymphocytes	   downstream	   of	  antigen	   receptor	   ligation	   via	   the	  BCR	   and	  TCR	   respectively	   (Parra	   et	   al.	   2005)	  (Matthews	  et	  al.	  2006).	  HDAC7	  which	  is	  structurally	  similar	  to	  HDAC9,	  is	  highly	  expressed	  in	  the	  thymus	  and	  is	  essential	  for	  normal	  T	  cell	  development	  from	  the	  double	  negative	  3	  stage	  (DN3)	  in	  which	  deletion	  of	  HDAC7	  using	  an	  Lck	  specific	  Cre	  results	  in	  a	  defect	  in	  the	  ability	  of	  thymocytes	  to	  undergo	  positive	  selection	  (Dequiedt	  et	  al.	  2003)	  (Kasler	  et	  al.	  2011).	  	  As	   such,	   we	   hypothesised	   that	   the	   increase	   in	   Tregs	   we	   observe	   in	  peripheral	   tissues	   of	   PKD2KI/KI	   mice	   may	   be	   caused	   by	   dysregulated	   FoxP3	  protein	  degradation,	  mediated	  via	  a	  PKD-­‐HDAC	  pathway.	  Within	  the	  lab	  HDAC7	  vav-­‐cre	   (HDAC7-­‐/-­‐)	  mice	   are	   available.	   These	  mice	   display	   a	   similar	   phenotype	  observed	  in	  Lck-­‐Cre	  HDAC7	  mice	  in	  which	  there	  is	  a	  developmental	  block	  at	  the	  DN3	   stage	   within	   thymocyte	   differentiation	   during	   positive	   selection	  (unpublished	  data,	  S.Matthews).	   	  More	  recently,	  the	  exportation	  of	  HDAC7	  from	  the	  nucleus	  as	  been	  shown	  to	  be	  required	  for	  the	  upregulation	  of	  CD25	  (IL-­‐2Rα)	  on	  CD8+	  CTLs	  (Navarro	  et	  al.	  2011).	  Hence	   the	  nuclear	  exclusion	  of	  HDAC7	  by	  phosphorylation	  and	  exportation	  to	  the	  cytoplasm	  favours	  the	  expression	  of	  the	  CD25	   receptor	   on	   lymphocyte	   cell	   surface.	   As	   shown	   throughout	   this	   chapter,	  CD25	   is	   constitutively	   highly	   expressed	   on	   the	   surface	   of	   Tregs.	  We	   therefore	  sought	   to	  address	   the	  development	  of	  Tregs	  within	   the	   thymus	  and	  peripheral	  lymphoid	  organs	  such	  as	  spleen	  and	  lymph	  nodes	  of	  HDAC7-­‐/-­‐	  mice.	  	  As	   can	   be	   seen	   in	   Figure	   5.13A-­‐B,	   %	   frequency	   of	   nTregs	   within	   the	  thymus	  of	  HDAC7-­‐/-­‐	  mice	  was	   significantly	   reduced	   (6-­‐fold)	  when	  compared	   to	  WT	  mice.	  Interestingly	  however	  the	  %	  frequency	  of	  Tregs	  within	  the	  peripheral	  tissues	   of	   HDAC7-­‐/-­‐	   were	   normal	   (Figure	   5.13E-­‐G).	   Furthermore,	   we	   also	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assessed	  level	  of	  FoxP3	  expression	  within	  CD4+	  CD25+	  gated	  cells	  from	  WT	  and	  HDAC7-­‐/-­‐	  within	   the	   spleen	   and	   observed	   no	   difference	   from	  WT	  mice	   (Figure	  5.13D-­‐E).	  This	  was	  also	  the	  case	   for	  other	   lymphoid	  tissues	   including	  mLN	  and	  lymph	  nodes	  (Figure	  5.13F-­‐G).	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  Figure	   5.13	   Exploring	   Treg	   populations	   within	   lymphoid	   tissues	   of	   HDAC7-­‐/-­‐	  mice	  (A)	  Representative	   dot	   plots	   showing	   nTreg	   populations	  within	   thymus	   of	  WT	  and	  HDAC7-­‐/-­‐	  mice	  by	  CD4	  surface	  expression	  and	  intracellular	  FoxP3	  expression	  by	   Flow	   cytometry.	   Numbers	   represent	   average	   %	   frequency	   and	   SD.	   (B)	  Combined	   data	   showing	   %	   frequency	   of	   nTregs	   within	   the	   thymus.	   (C)	  Representative	   dot	   plots	   showing	   Treg	   populations	   within	   spleen	   of	   WT	   and	  HDAC7-­‐/-­‐	  mice.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (D)	  Histogram	  overlaying	  FoxP3	  expression	  within	  CD4+	  CD25+	  gated	  lymphocytes	  in	  WT	  and	  HDAC7-­‐/-­‐	   mice.	   (E-­‐G)	   Combined	   data	   showing	   %	   Frequency	   of	   CD4+	   CD25+	  FoxP3+	   Tregs	   within	   spleen,	   mLN	   and	   inguinal/axillary	   (In/Ax)	   respectively.	  Data	  obtained	  from	  two	  independent	  experiments,	  n=4	  mice	  per	  genotype.	  **	  =	  p≤0.01	  analysed	  by	  student’s	  t	  tests.	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   Collectively	  these	  data	  revealed	  that	  a	  PKD	  regulated	  HDAC7	  mechanism	  is	   unlikely	   to	   be	   involved	   in	   the	   regulation	   of	   FoxP3	   protein	   stability	   and	  therefore	  does	  not	  explain	  the	  increase	  in	  Tregs	  observed	  in	  PKD2KI/KI	  mice.	  	  
5.3.3 	  CD103+	  population	  of	  Tregs	  is	  increased	  within	  PKD2	  KI/KI	  mice	  	  	   In	   order	   to	   explore	   possible	   explanations	   to	   account	   for	   increased	  abundance	  of	  Treg	  populations	  within	  the	  periphery	  of	  PKD2KI/KI	  mice	  yet	  lack	  of	  increased	   output	   from	   the	   thymus	   we	   assessed	   known	  memory	   markers	   that	  indicate	  if	  Tregs	  are	  activated	  or	  indeed	  memory	  effector	  Tregs.	   	  CD103	  (αEβ7)	  is	   an	   integrin	   highly	   expressed	   in	   mucosal	   sites	   that	   binds	   E-­‐cadherin,	   and	   is	  widely	  expressed	  on	  epithelial	  cells	  (but	  not	  on	  the	  endothelium).	  In	  contrast	  to	  well-­‐defined	   homing	   receptors,	   CD103	   is	   thought	   to	   retain	   expressing	  lymphocytes	  at	  the	  epithelial	  surface	  rather	  than	  assist	  in	  the	  extravasation	  of	  T	  cells	  from	  tissues.	  	  In	  regard	  to	  expression,	  CD103	  is	  expressed	  at	  high	  levels	  on	  IELs,	   tolergenic	  DC	   subsets	  within	   gastrointestinal	   sites,	   CD8+	  CTLs	  within	   the	  lung	  and	  more	  recently	  a	  unique	  subset	  of	   functionally	  distinct	  Tregs	  (Schön	  et	  al.	  1999)	  (Lehmann	  et	  al.	  2002)	  (Huehn	  et	  al.	  2004)	  (D.	  Zhao	  et	  al.	  2008).	  	  CD103	  function	  and	  expression	  on	  Tregs	  has	  been	  studied	  using	  multiple	  inflammatory	  and	  infection	  models	  both	  in	  vitro	  and	  in	  vivo.	  These	  studies	  have	  revealed	   CD103	   as	   an	   excellent	   marker	   for	   memory	   and	   activated	   Tregs	  (Lehmann	  et	  al.	  2002)	  (Huehn	  et	  al.	  2004)	  (Suffia	  et	  al.	  2005)	  (Banz	  et	  al.	  2003)	  (McHugh	  et	  al.	  2002).	  CD103+	  CD4+	  CD25+	  FoxP3+	  Tregs	  have	  been	  shown	  to	  be	  highly	   proliferative	   when	   compared	   to	   CD103-­‐	   Treg	   subsets.	   Furthermore,	  CD103+	  Treg	  population	  have	  been	  shown	  to	  be	  more	  potent	  suppressor	  within	  an	   experimental	   arthritis	  model	   than	  CD103-­‐	  Treg	   cells.	   For	   these	   reasons,	  we	  decided	   to	  assess	  expression	  of	  CD103	  on	   the	  cell	   surface	  of	  WT	  and	  PKD2KI/KI	  Tregs	  ex	  vivo,	  with	  the	  hypothesis	  that	  Tregs	  from	  PKD2KI/KI	  mice	  would	  display	  a	   more	   activated	   or	   memory	   phenotype,	   which	   would	   explain	   why	   they	   are	  increased	  in	  abundance	  within	  these	  tissues	  if	  they	  have	  become	  activated	  after	  antigen	  recognition	  and	  are	  subsequently	  proliferating.	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In	   agreement	   with	   previous	   experiments	   we	   observed	   a	   significant	   (2-­‐fold)	   increase	   in	  the	  abundance	  of	  CD4+	  CD25+	  FoxP3+	  Treg	  populations	  within	  the	  spleen	  of	  PKD2KI/KI	  when	  compared	  to	  WT	  controls	  (Figure	  5.14A-­‐B).	  Upon	  assessing	  surface	  expression	  of	  CD103	  on	  splenic	  Treg	  populations	  we	  observed	  that	   approximately	   3%	   of	   WT	   splenic	   Tregs	   expressed	   high	   levels	   of	   CD103	  whereas	   CD103+	   splenic	   Tregs	   in	   PKD2KI/KI	   mice	   were	   significantly	   increased	  with	   approximately	   10%	  of	   Tregs	   positive	   for	   CD103	   (Figure	   5.14C).	   This	  was	  also	  true	  for	  total	  cell	  numbers	  (Figure	  5.14D).	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  Figure	   5.14	   CD103+	   Treg	   populations	   are	   increased	   within	   the	   spleen	   of	  PKD2KI/KI	  mice	  (A)	  Representative	  dot	  plots	  showing	  Treg	  populations	  within	  spleen	  of	  WT	  and	  PKD2	  KI/KI	  mice	  by	  CD4	  surface	  expression	  and	  intracellular	  FoxP3	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  Combined	  data	   showing	  %	   frequency	   of	   CD4+FoxP3+CD25+	   Tregs	   within	   the	   spleen	   (C)	  Representative	  dot	  plots	  showing	  CD103	  expressing	  populations	  of	  Treg	  within	  spleen	  (Gated	  on	  CD4+	  population)	  (D)	  Combined	  data	  showing	  %	  frequency	  of	  CD4+	   FoxP3+	  CD103+	  Tregs	  within	   spleen.	  Data	   obtained	   from	  3	   independent	  experiments,	   n=9	   mice	   per	   genotype.	   ***	   =	   p≤0.001	   and	   	   ****	   =	   p≤0.0001	  analysed	  by	  students	  t	  test.	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   These	   data	   collectively	   suggests	   that	   the	   increase	   in	   Tregs	   we	   observe	  within	  peripheral	  lymphoid	  tissues	  of	  PKD2	  KI/KI	  mice	  are	  either	  activated	  Tregs	  or	  memory	  Tregs	  when	  compared	  to	  Treg	  populations	  within	  WT	  mice.	  	  We	  also	  assessed	  IL-­‐7R	  (CD127)	  expression	  on	  the	  cell	  surface	  of	  WT	  and	  PKD2	  KI/KI	  Tregs	  from	  the	  spleen	  and	  found	  no	  change	  in	  expression	  on	  the	  cell	  surface	  (data	  not	  shown).	  	  	  
5.3.4 Aging	  mice	  	  It	   is	   known	   that	   CD4+	   CD25+	   FoxP3+	   Treg	   populations	   accumulate	  with	  increase	  in	  age	  in	  various	  tissues	  in	  mice,	  including	  spleen	  and	  lymph	  nodes.	  We	  next	   to	   decided	   to	   assess	   if	   Treg	   populations	   within	   PKD2KI/KI	   mice	   increased	  with	  age	  when	  compared	  to	  age	  matched	  WT	  mice.	  	  	  We	  also	  wished	  to	  address	  if	  CD103+	   population	   of	   Tregs	   also	   expands	  with	   increase	   in	   age	   as	   observed	   in	  PKD2KI/KI	  mice	  between	  4-­‐8	  weeks	  of	  age.	  Mice	  used	  in	  this	  study	  were	  allowed	  to	  age	  to	  12	  months.	  	  Assessment	  of	  Tregs	  within	   spleen	  of	  PKD2KI/KI	   aged	  mice	   revealed	  a	  2-­‐fold	   increase	   (Figure	   5.15A-­‐B)	   when	   compared	   to	   WT	   mice	   of	   the	   same	   age.	  Although	  WT	  mice	  had	  an	  increase	  of	  Tregs	  within	  the	  spleen	  as	  expected	  with	  an	  increase	  in	  age,	  PKD2KI/KI	  mice	  still	  retained	  a	  2	  fold	  increase,	  suggesting	  the	  expanded	   pool	   observed	   in	   younger	  mice	   is	   retained	   as	   the	   difference	   in	   fold	  change	  remains	  constant	  between	  genotypes	  with	  age.	  	  Furthermore,	   CD103	   expression	   on	   Tregs	   displayed	   a	   4-­‐fold	   increase	   on	  PKD2KI/KI	  Tregs	  (Figure	  5.15C-­‐D).	  	  These	  data	  imply	  that	  not	  only	  is	  CD103	  found	  to	   be	   up	   regulated	   on	   the	   cell	   surface	   of	   Tregs	  within	   tissues	   of	   younger	  mice	  (between	   4-­‐8	  weeks),	   but	   that	   this	   up-­‐regulation	   continues	   over	   time	   in	   aging	  PKD2KI/KI	  mice.	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  Figure	  5.15	  CD103+	  Treg	  populations	  are	  increased	  in	  spleen	  of	  aged	  PKD2KI/KI	  mice	  	  (A)	  Representative	  dot	  plots	  showing	  Treg	  populations	  within	  spleen	  of	  aged	  WT	  and	   PKD2KI/KI	   mice	   by	   CD4	   surface	   expression	   and	   intracellular	   FoxP3	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	   %	   frequency	   of	   CD4+FoxP3+CD25+	   Tregs	   within	   the	   spleen	   (C)	  Representative	   dot	   plots	   showing	   CD103	   surface	   expression	   and	   intracellular	  Foxp3	  expression	  of	  Treg	  populations	  within	  spleen	  (Gated	  on	  CD4+	  population)	  (D)	  Combined	  data	  showing	  %	  frequency	  of	  CD4+	  FoxP3+	  CD103+	  Tregs	  within	  spleen.	  (E)	  Histogram	  showing	  CD103	  surface	  expression	  in	  CD4+	  FoxP3+	  Tregs	  within	  spleen	  of	  WT	  and	  PKD2KI/KI	  aged	  mice.	  	  Data	  obtained	  from	  1	  independent	  experiment,	  3	  WT	  mice	  and	  2	  PKD2KI/KI	  mice	  *	  	  =	  p≤	  0.05	  analysed	  by	  students	  t	  test.	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   In	   addition	   to	   the	   Tregs	   within	   the	   spleen,	   we	   also	   assessed	   Treg	  populations	   within	   the	   inguinal	   and	   axillary	   lymph	   nodes	   of	   aged	   mice.	   	   As	  expected,	  aged	  PKD2KI/KI	  mice	  displayed	  a	  significant	   increased	   in	  %	  frequency	  of	   CD4+	   CD25+	   FoxP3+	   populations	   (Figure	   5.16A-­‐B),	   again	   this	   increase	   was	  approximately	   2	   fold	   in	   agreement	   with	   data	   obtained	   from	   the	   spleen.	  Furthermore,	  analysis	  of	  CD103	  expression	  on	  PKD2KI/KI	  Tregs	  showed	  that	  this	  was	  also	  significantly	  increased	  (Figure	  5.16C-­‐D).	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PKD2 KI/KIGated on CD4+ FoxP3+WT
	  Figure	   5.16	   CD103+	   Treg	   populations	   are	   increased	   in	   inguinal	   and	   axillary	  lymph	  nodes	  of	  aged	  PKD2KI/KI	  mice.	  (A)	  Dot	  plots	  showing	  Treg	  populations	  within	  inguinal	  and	  axillary	  lymph	  nodes	  of	   aged	   WT	   and	   PKD2	   KI/KI	   mice	   by	   CD4	   surface	   expression	   and	   intracellular	  FoxP3	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	   SD.	   (B)	  %	   frequency	   of	   CD4+FoxP3+CD25+	  Tregs	  within	   the	   lymph	  nodes	  (C)	   Dot	   plots	   showing	   CD103	   surface	   expression	   and	   intracellular	   Foxp3	  expression	  of	  Treg	  populations	  within	  lymph	  nodes	  (Gated	  on	  CD4+	  population)	  (D)	  %	   frequency	   of	   CD4+	   FoxP3+	   CD103+	   Tregs	  within	   spleen.	   (E)	   Histogram	  showing	  CD103	  surface	  expression	  in	  CD4+	  FoxP3+	  Tregs	  within	  lymph	  nodes	  of	  WT	  and	  PKD2	  KI/KI	  aged	  mice.	  	  Data	  obtained	  from	  1	  independent	  experiment,	  n=	  3	  WT	  mice	  and	  2	  PKDKI/KI	  mice.	  *	  	  =	  p≤	  0.05	  analysed	  by	  students	  t	  test.	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5.4 Analysis	  of	  lymphocyte	  populations	  in	  the	  small	  intestine	  
of	  PKD2	  KI/KI	  mice	  	  	   After	   initially	   observing	   the	   increased	   lymphoid	   tissues,	   specifically	   the	  GALTs	   including	   the	   mLN	   and	   PPs,	   we	   decided	   to	   next	   assess	   lymphocyte	  populations	  within	   the	   small	   intestine	   in	  PKD2KI/KI	  mice.	  The	  mucosal	   immune	  system	  within	  the	  small	  intestine	  can	  be	  separated	  into	  two	  anatomically	  distinct	  layers,	   the	   lamnia	   propria	   and	   the	   intraepithelial	   layer,	   both	   of	   which	   are	  populated	   with	   distinct	   cell	   subsets.	   The	   lamina	   propria	   is	   characterised	   by	   a	  heterogeneous	   population	   of	   immune	   cells,	   including	   multiple	   innate	   immune	  cell	  subsets	  such	  as	  DC	  subsets,	  macrophages,	  eosinophils,	  neutrophils,	  and	  mast	  cells.	   Adaptive	   immune	   cells	   include	   IgA	   producing	  B	   cells	   and	  T	   cells	   (mostly	  CD4+),	   including	   CD4+	   Foxp3+	   Tregs	   (Extensively	   reviewed	   (Mowat	   &	   Agace	  2014))	   	   .	   In	   contrast,	   the	   intraepithelial	   layer	   contains	   a	   more	   homogenous	  population	  primarily	  consisting	  of	  T	  cells	  known	  as	   intraepithelial	   lymphocytes	  (IELs).	  PKD	  isoform	  expression	  within	  GALT	  tissues	  is	  largely	  unknown,	  however	  embryonic	   in	   situ	   hybridisation	   studies	   have	   demonstrated	   PKD2	   transcript	  levels	   within	   the	   mucosa	   of	   the	   intestine	   and	   the	   intestinal	   villi	   (Oster	   et	   al.	  2006).	  Recently,	  PKD1	  has	  been	  be	  implicated	  in	  mediating	  class	  IIa	  HDAC	  export	  within	   intestinal	   epithelial	   cells	   as	  well	   as	   promoting	   rapid	  migration	   of	   these	  cells	  (Sinnett-­‐Smith	  et	  al.	  2014)	  (Young	  et	  al.	  2012).	  	  	  	  	  As	   PKD2	   is	   the	   dominant	   isoform	   expressed	   by	   CD4+	   and	   CD8+	   T	  lymphocytes	   from	   the	   thymus	  and	   lymph	  node	   tissue	   it	   is	   plausible	   that	  PKD2	  will	  be	   selectively	  expressed	  within	  GALTs	  and	  within	   lymphocytes	   residing	   in	  the	   small	   intestine.	   	   However,	   the	   role	   of	   PKD2	   within	   the	   mucosal	   immune	  system	   and	   indeed	   if	   it	   plays	   a	   role	   in	   mucosal	   associated	   lymphocyte	  populations	  has	  not	  been	  addressed.	  	  	  
5.4.1 Intraepithelial	  lymphocytes	  	  	   As	   discussed	   within	   introduction,	   the	   intraepithelial	   epithelium	   of	  mammals	   within	   mucosal	   membranes	   found	   within	   the	   tissues	   such	   as	   the	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  Figure	   5.17	   Intraepithelial	   lymphocytes	   are	   increased	   in	   the	   small	   intestine	   of	  PKD2KI/KI	  mice	  	  Total	  live	  cell	  number	  (x106)	  of	  intraepithelial	  lymphocytes	  in	  WT	  and	  PKD2	  KI/KI	  intraepithelial	  layer	  of	  the	  small	  intestine	  determined	  by	  Flow	  Cytometry.	  (n=3)	  **	  =	  p≤0.01	  analysed	  by	  students	  t	  test.	  Error	  bars	  represent	  SD.	  (Data	  obtained	  from	   	   from	   3	   independent	   biological	   experiments	   n=9	   mice	   per	   genotype).	  Experiments	  were	  performed	  in	  collaboration	  with	  Mr.	  George	  Ramsay,	  Doreen	  Cantrell’s	  lab,	  University	  of	  Dundee.	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   We	   next	   assessed	   IEL	   populations	   within	   the	   small	   intestine	   via	   flow	  cytometry.	   	  We	  observed	  a	  significant	   increase	  (1.7	   fold)	   in	  the	  %	  frequency	   in	  TCRαβ+	   IELs	  within	   the	   intraepithelial	   layer	  of	   the	   small	   intestine	   in	  PKD2KI/KI	  mice	  when	  compared	   to	  WT	  mice.	   Interestingly,	  we	  also	  observed	  a	   significant	  reduction	   (1.5	   fold)	   in	   the	   %	   frequency	   of	   TCRγδ+	   IEL	   in	   the	   small	   intestine	  (Figure	   5.18A-­‐C).	   These	   data	   could	   suggest	   a	   potential	   role	   for	   PKD2	   catalytic	  activity	  in	  the	  maintenance	  of	  “normal”	  T	  cell	  subset	  population	  and	  homeostasis	  within	  the	  intraepithelial	  layer.	  These	  data	  also	  imply	  that	  loss	  of	  PKD2	  catalytic	  activity	  has	   led	   to	  a	   converted	   lymphocyte	  profile	  within	   the	  gut,	   either	  due	   to	  skewed	  differentiation,	  impaired	  homeostasis,	  and	  lymphocyte	  homing	  multiple	  mechanisms.	  	  Furthermore,	   these	   experiments	   revealed	   no	   difference	   in	   the	   %	  frequency	   of	   TCRαβ+	   CD4+	   IEL	   although	   there	   was	   a	   significant	   increase	   (2.6	  fold)	   in	   the	   %	   frequency	   of	   TCRαβ+	   CD8+	   IEL	   within	   the	   small	   intestine	   of	  PKD2KI/KI	  mice	  when	  compared	  to	  WT	  mice	  (Figure	  5.18D-­‐F).	  Although	   all	   IEL	  display	   an	   antigen	   experienced	  phenotype	   or	   activated	  phenotype,	  they	  can	  be	  further	  divided	  into	  two	  major	  subsets	  including	  natural	  IEL	  and	  inducible	  IEL,	  which	  are	  defined	  by	  the	  mechanism,	  in	  which	  they	  were	  activated	   and	   the	   unique	   surface	  markers	   they	   display.	   Natural	   IEL	   have	   been	  described	  as	  a	   regulatory	   subset	   required	   to	  maintain	  gut	  epithelium	   integrity.	  These	   subsets	   are	   defined	   as	   either	   TCRαβ+	  CD8αα-­‐/+	   or	   TCRγδ+	   CD8αα-­‐/+	   and	  importantly	  do	  not	  express	  CD4	  or	  CD8αβ.	  Inducible	  IEL	  are	  either	  TCRαβ+	  CD4+	  CD8αα-­‐/+	  	  or	  TCRαβ+	  CD8αβ+	  CD8αα-­‐/+	  ,	  furthermore	  we	  were	  also	  able	  to	  analyse	  TCRαβ+	   CD8αβ+	   and	   TCRαβ+	   CD8αα+	   .	   Interestingly,	   we	   also	   observed	   a	  significant	   increase	   in	   the	  %	  frequency	  of	  TCRαβ+	  CD8αβ+	   inducible	   IEL	  subset	  (Figure	   5.18G-­‐I)	   and	   a	   concurrent	   significant	   decrease	   in	   the	   %	   frequency	   of	  TCRαβ+	  CD8αβ-­‐	  CD8αα+	  natural	  IEL	  subset.	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  Figure	  5.18	  Analysis	  of	  specific	  T	  lymphocyte	  subsets	  in	  the	  intraepithelial	  layer	  of	  small	  intestine	  of	  PKD2KI/KI	  	  (A)	   Representative	   dot	   plots	   showing	   live	   CD45+	   TCRαβ+	   and	   TCRγδ+	  populations	   of	   WT	   and	   PKD2	   KI/KI	   mice	   within	   IEL	   layer	   by	   Flow	   cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  Combined	  data	  showing	  %	  frequency	   of	   TCRαβ+	   subsets	   within	   IEL	   layer	   (C)	   %	   frequency	   of	   TCRγδ+	  subsets	  within	  IEL	  layer	  (D)	  Dot	  plots	  showing	  live	  CD45+	  TCRαβ+	  CD4+,	  CD45+	  TCRαβ+	  CD8α+	  and	  TCRαβ+CD4+	  CD8α+	  double	  positive	  populations	  of	  WT	  and	  PKD2	   KI/KI	   mice.	   (E)	   %	   Frequency	   of	   CD45+	   TCRαβ+	   CD4+	   populations	   (F)	  Combined	  data	  showing	  %	  frequency	  of	  CD45+	  TCRαβ+	  CD8α+	  populations	  (G)	  Dot	  plots	  showing	  live	  CD45+	  TCRαβ+	  CD8αβ	  and	  CD45+	  TCRαβ+	  CD8αα+	  T	  cell	  subsets	   of	   WT	   and	   PKD2	   KI/KI	   mice	   within	   IEL.	   (H)	   %	   Frequency	   of	   CD45+	  TCRαβ+	   CD8αβ+	   (I)	   Combined	   data	   showing	   %	   Frequency	   of	   CD45+	   TCRαβ+	  CD8αα+	   T	   cell	   subsets.	   Error	   bars	   represent	   SD.	   Data	   obtained	   from	   3	  independent	   experiments,	   n=13	   mice	   per	   genotype.	   ***	   =	   p≤0.001	   and	   ****	   =	  p≤0.0001	   analysed	   by	   students	   t	   test.	   Experiments	   were	   performed	   in	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collaboration	   with	   Mr.	   George	   Ramsay,	   Doreen	   Cantrell’s	   lab,	   University	   of	  Dundee.	  	  	  	  
5.4.2 Lamina	  Propria	  	  	   In	   contrast	   to	   the	   intraepithelial	   layer,	   which	   mainly	   consists	   of	   T	  lymphocytes,	  the	  lamina	  propria	  layer	  (LP)	  layer	  within	  the	  small	  intestine	  is	  far	  more	   heterogeneous	   containing	   a	   variety	   of	   immune	   cell	   subsets	   including	   B	  cells,	  T	  cells,	  macrophages	  and	  dendritic	  cells.	   	  We	  next	  assessed	   if	   lymphocyte	  populations	   including	  B	   cells	   and	  T	   cell	   subsets	  were	   affected	  by	   loss	   of	   PKD2	  catalytic	  activity.	  	  The	  %	  frequency	  of	  B	  cells	  (B220+)	  and	  TCRαβ+	  within	  the	  LP	  layer	   of	   PKD2	   KI/KI	  mice	  were	  normal	  when	   compared	   to	   age	   and	   sex	  matched	  WT	  mice	  (Figure	  5.19A-­‐C).	  A	  more	  detailed	  analysis	  of	  T	  cell	  subsets	  within	  the	  LP	   layer	   revealed	   no	   significant	   changes	   within	   PKD2	   KI/KI	   	   mice	   including	   %	  frequency	   of	   TCRαβ+	   CD4+,	   TCRαβ+	   CD8α+	   and	   TCRαβ+	   CD4+	   CD8α+	   double	  positive	  populations	  (Figure	  5.19D-­‐G).	  These	  data	  were	   in	  contrast	   to	  dramatic	  differences	  observed	  within	  the	  intraepithelial	  layer	  of	  PKD2	  KI/KI	  mice	  indicating	  that	   PKD2	   may	   play	   a	   selective	   role	   in	   this	   layer	   of	   the	   gut	   and	   perhaps	   not	  within	  the	  LP	  layer.	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  Figure	   5.19	   B	   cells	   and	   T	   cell	   subsets	  within	   lamnia	   propria	   layer	   are	   normal	  within	  the	  small	  intestine	  of	  PKD2KI/KI	  mice	  (A)	   Representative	   dot	   plots	   showing	   live	   CD45+	   B220+	   and	   TCRαβ	   +	  populations	  of	  WT	  and	  PKD2	  KI/KI	  mice	  within	  lamnia	  propria	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  Combined	  data	  showing	  %	  frequency	  of	  B220+	  subsets	  within	  IEL	  layer	  (C)	  %	  frequency	  of	  TCRαβ	  +	  subsets	  within	  IEL	  layer	  (D)	  Dot	  plots	  showing	  live	  CD45+	  TCRαβ+	  CD4+,	  CD45+	  TCRαβ+	  CD8α+	   and	  TCRαβ+CD4+	  CD8α+	  double	   positive	   populations	   of	  WT	   and	  PKD2	  KI/KI	  mice.	  (E)	  %	  Frequency	  of	  CD45+	  TCRαβ+	  CD4+	  populations	  (F)	  %	  frequency	  of	  CD45+	  TCRαβ+	  CD8α+	  populations	  (G)	  Dot	  plots	  showing	  live	  CD45+	  TCRαβ+	  CD8αβ	   and	   CD45+	   TCRαβ+	   CD8αα+	   T	   cell	   subsets	   of	  WT	   and	   PKD2	   KI/KI	  mice	  within	   IEL.	   (H)	   %	   Frequency	   of	   CD45+	   TCRαβ+	   CD8αβ+	   (I)	   %	   Frequency	   of	  CD45+	   TCRαβ+	   CD8αα+	   T	   cell	   subsets.	   Data	   obtained	   from	   3	   independent	  experiments,	   n=5	   WT	   mice	   and	   6	   PKD2KI/KI	  mice	   per	   genotype.	   	   Experiments	  were	  performed	  in	  collaboration	  with	  Mr.	  George	  Ramsay,	  Doreen	  Cantrell’s	  lab,	  University	  of	  Dundee.	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5.4.3 Analysis	   of	   Tregs	   within	   the	   IEL	   and	   lamina	   propria	   of	   PKD2KI/KI	  


























































	  Figure	  5.20	  Treg	  populations	  are	  increased	  in	  the	  intraepithelial	  layer	  within	  the	  small	  intestine	  of	  PKD2KI/KI	  mice	  	  (A)	   Representative	   dot	   plots	   showing	   Treg	   populations	   in	   the	   intraepithelial	  layer	  within	   small	   intestine	   of	  WT	   and	   PKD2	   KI/KI	  mice	   shown	   by	   CD4	   surface	  expression	   and	   intracellular	   FoxP3	   expression	   by	   Flow	   cytometry.	   Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  %	  frequency	  of	  CD4+FoxP3+	  Tregs	  within	  the	  intraepithelial	  layer	  of	  the	  small	  intestine	  (C)	  Total	  number	  (x10^6)	  of	  CD4+FoxP3+	   Tregs	   within	   the	   intraepithelial	   layer	   of	   the	   small	   intestine	   Data	  obtained	   from	   two	   independent	   experiments,	   n=3	   mice	   per	   genotype.	   **	   =	  p≤0.01	  analysed	  by	  students	  t	  test.	  Experiments	  were	  performed	  in	  collaboration	  with	  Mr.	  George	  Ramsay,	  Doreen	  Cantrell’s	  lab,	  University	  of	  Dundee.	  	  	   We	  were	  also	  able	  to	  assess	  CD4+	  FoxP3+	  Tregs	  within	  the	  LP	  layer	  of	  the	  small	   intestine	   in	   PKD2KI/KI	   mice,	   although	   unfortunately	   we	   were	   unable	   to	  gather	  a	  large	  cohort	  for	  this	  due	  to	  difficulties	  obtaining	  preparations	  of	  the	  LP	  layer.	   	   In	  successful	   samples	  we	  observed	  a	   trend	   in	   the	   increase	   (3-­‐fold)	  of	  %	  frequency	  of	  CD4+	  FoxP3+	  Tregs	  within	  the	  LP	  of	  PKD2KI/KI	  mice	  (Figure	  5.21A-­‐B).	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  Figure	  5.21	  Tregs	  within	  lamnia	  propria	  layer	  of	  small	  intestine	  of	  PKD2KI/KI	  mice	  (A)	   Representative	   dot	   plots	   showing	   Treg	   populations	   in	   the	   lamnia	   propria	  layer	   within	   small	   intestine	   of	  WT	   and	   PKD2KI/KI	   mice	   shown	   by	   CD4	   surface	  expression	   and	   intracellular	   FoxP3	   expression	   by	   Flow	   cytometry.	   Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  Combined	  data	  showing	  %	  frequency	  of	   CD4+FoxP3+	   Tregs	   within	   the	   lamnia	   propria.	   Data	   obtained	   from	   2	  independent	  experiments,	  n=3	  mice	  per	  genotype.	  Experiments	  were	  performed	  in	   collaboration	   with	   Mr.	   George	   Ramsay,	   Doreen	   Cantrell’s	   lab,	   University	   of	  Dundee.	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5.5 	  In	  vivo	  colitis	  model	  	  	   Inflammatory	   bowel	   diseases	   (IBD)	   can	   be	   separated	   into	   two	   clinically	  defined	  forms	  of	  chronic	  inflammatory	  conditions	  including	  Crohn’s	  disease	  (CD)	  and	   ulcerative	   colitis	   (UC),	   although	   characteristically	   different	   both	   diseases	  involve	  chronic	  inflammation	  that	  affects	  the	  gastrointestinal	  tract.	  The	  etiology	  of	   IBD	   is	   thought	   to	   be	   multifaceted	   involving	   a	   genetic	   basis,	   environmental	  factors,	  microbiota	  within	  the	  gastrointestinal	  tract	  and	  a	  dysregulated	  immune	  system	   although	   exact	   mechanisms	   remains	   largely	   unknown	   (Reviewed	  extensively	  (Kaser	  et	  al.	  2010)).	  	  	  Studies	   investigating	   the	   mechanisms	   of	   IBDs	   have	   exploded	   in	   recent	  years	  due	  to	  increased	  availability	  of	  multiple	  animal	  models	  to	  study	  intestinal	  inflammation	   (Reviewed	   (Ostanin	   et	   al.	   2008)).	   	   Data	   obtained	   from	   multiple	  studies	  have	  demonstrated	  chronic	  gut	   inflammation	   is	   the	   result	  of	  a	   immune	  dysregulation.	   Specifically	   T	   cells	   have	   been	   shown	   to	   be	   involved	   in	   both	  protective	  and	  pathogenic	  roles	  in	  gut	  inflammation	  (Reviewed	  (Powrie	  1995)).	  	  As	  such,	  the	  T	  cell	  transfer	  model	  of	  chronic	  colitis	  has	  become	  widely	  used	  as	  an	  appropriate	  animal	  model	  to	  study	  early	  immune	  events	  during	  the	  development	  of	  colitis	  (Powrie	  et	  al.	  1993)	  (Asseman	  et	  al.	  1999)	  (Read	  et	  al.	  2006)	  (Uhlig	  et	  al.	  2006).	  This	  model	  is	  based	  upon	  the	  disruption	  of	  T	  cell	  homeostasis	  initiated	  by	  the	  transfer	  of	  naïve	  CD4+	  CD45Rbhi	  T	  cells	  from	  WT	  mice	  into	  a	  synergic	  host	  resulting	  in	  intestinal	  inflammation.	  Importantly,	  this	  model	  allows	  the	  study	  of	  cytokine	   levels	   within	   distinct	   sections	   of	   the	   small	   intestine	   involved	   in	   the	  pathogenesis	   of	   disease,	   in	   contrast	   to	   spontaneous	   models	   of	   intestinal	  inflammation	  such	  as	  IL-­‐2-­‐/-­‐	  and	  IL-­‐10-­‐/-­‐	  	  animal	  models	  (Powrie	  et	  al.	  1996).	  	  In	  this	  study	  RAG2	  KO	  mice	  were	  used	  as	  recipient	  synergic	  hosts	  whereby	  mature	  T	   and	   B	   cells	   are	   absent	   due	   to	   an	   inability	   to	   undergo	   VDJ	   rearrangement	   to	  produce	   a	   functional	   antigen	   receptor	   (Shinkai	   et	   al.	   1992).	   	   It	   is	   important	   to	  note	   that	  RAG2-­‐/-­‐	  mice	   retain	  a	   functional	  and	  complete	   innate	   immune	  system	  including	   macrophages	   and	   dendritic	   cell	   subsets.	   Recipient	   hosts	   receiving	  naïve	   CD4+	   CD45Rbhi	   T	   cells	   go	   on	   to	   develop	   inflammation	   within	   the	   colon	  resulting	  in	  colitis	  typically	  following	  5-­‐8	  weeks	  of	  T	  cell	  transfer,	  although	  this	  time	  period	  varies	  depending	  on	  mouse	  strain	  and	  the	  animal	  facilities	  animals	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are	  housed	   in.	   	  During	   the	   time	  period	   following	  T	   cell	   transfer	   recipient	  mice	  progressively	   lose	   weight,	   this	   is	   usually	   accompanied	   by	   diarrhoea.	  	  Furthermore,	   histopathological	   analyses	   of	   proximal	   and	   distal	   colon	   sections	  from	   mice	   with	   active	   disease	   reveal	   mild	   to	   moderate	   inflammatory	   cell	  infiltration	  within	  the	  lamina	  propria	  and	  submucosa,	  epithelial	  cell	  hyperplasia	  and	  mucosal	  erosion.	  Additionally,	  this	  disease	  model	  is	  also	  frequently	  used	  to	  study	  the	  functionality	  of	  Tregs	  in	  their	  ability	  to	  actively	  suppress	  and	  limit	  the	  onset	   of	   intestinal	   inflammation.	   Tregs	   injected	   into	   recipient	   mice	   have	   also	  been	   shown	   to	   dynamically	   reverse	   established	   intestinal	   inflammation,	  demonstrating	   not	   only	   its	   potential	   therapeutic	   use	   within	   patients	   with	  established	  disease	  but	  indeed	  its	  usefulness	  as	  a	  tool	  to	  study	  Treg	  function	  in	  an	   intestinal	   inflammation	   model	   (Mottet	   et	   al.	   2003).	   	   Protection	   by	   Tregs	  against	  intestinal	  inflammation	  within	  this	  model	  has	  been	  shown	  to	  be	  exerted	  in	  an	  IL-­‐10	  dependent	  fashion	  (Asseman	  et	  al.	  1999).	  	  We	   decided	   utilise	   this	   disease	   model	   to	   assess	   if	   Tregs	   isolated	   from	  PKD2KI/KI	  mice	  were	  suppressive	  in	  the	  development	  of	  colitis	  in	  RAG2-­‐/-­‐	  synergic	  hosts,	   as	   an	   indication	   of	   Treg	   functionality.	   	   This	   study	   was	   ultimately	   to	  address	  if	  Tregs	  lacking	  PKD2	  catalytic	  activity	  are	  functional,	  but	  also	  addresses	  if	  resulting	  increase	  in	  Treg	  populations	  we	  observe	  in	  PKD2	  KI/KI	  mice	  is	  intrinsic	  or	  extrinsic	  (i.e.	  within	  cell	  or	  environment).	  The	  experimental	  approach	  for	  this	  study	  is	  described	  in	  Table	  5.1.	  	  It	  should	  be	  noted	  that	  although	  this	  study	  was	  set	   up	   with	   5	   mice	   per	   group,	   one	   mouse	   died	   (Group	   1)	   due	   to	   extenuating	  circumstances	  that	  were	  not	  related	  to	  development	  of	  colitis	  and	  another	  mouse	  (Group	  3)	  was	  removed	  from	  the	  study	  due	  to	  failed	  IP	  injection.	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Experimental	  group	   Phenotype	  of	  cells	   Number	   of	   cells	  
injected	  	  
Group	  1	  WT	  naïve	  only	   CD45RB	  high	  CD4+	  CD25-­‐	  
400,000	  cells	  
Group	  2	  PKD2	  KI/KI	  naïve	  only	   CD45RB	  high	  CD4+	  CD25-­‐	  
400,000	  cells	  
Group	  3	  WT	  naïve	  +	  WT	  Treg	   WT	  naïve	  CD45RB	  high	  CD4+	  CD25-­‐	  
WT	  Treg	  CD45RB	  low	  CD4+	  CD25+	  
400,000	  naïve	  +	  100,000	  Tregs	  	  
Group	  4	  WT	  naïve	  +	  PKD2KI/KI	  	  Treg	  	  
WT	  naïve	  CD45RB	  high	  CD4+	  CD25-­‐	  
PKD2	  KI/KI	  Treg	  CD45RB	  low	  CD4+	  CD25+	  	  
400,000	  naïve	  +	  100,000	  Tregs	  	  
Table	   5.1	   Experimental	   set	   up	   for	   in	   vivo	   colitis	   model	   to	   assess	   colitis	  development	  in	  naïve	  T	  cells	  and	  Treg	  cells	  lacking	  PKD2	  catalytic	  activity	  	  	   After	  injection	  of	  cells	  into	  synergic	  hosts	  the	  study	  was	  carried	  out	  for	  3	  weeks	   to	   assess	   the	   development	   of	   colitis,	   which	   was	   assessed	   by	   weekly	  weighing	  of	  the	  mice.	  	  RAG2-­‐/-­‐	   mice	   injected	   with	   WT	   naïve	   CD4+CD45Rbhi	   cells	   (Group	   1)	  displayed	   a	   slight	  weight	   gain	   after	   1	  week	   of	   T	   cell	   transfer,	   however	  within	  week	   2	   subsequently	   began	   to	   display	   clinical	   signs	   of	   colitis	   including	   loose	  stools	   and	  weight	   loss	   (Figure	   5.22).	  Within	   this	   group	   the	   average	  %	  weight	  change	  from	  initial	  weight	  by	  the	  end	  of	  the	  study	  was	  3.4%.	  In	  contrast,	  RAG2-­‐/-­‐	  mice	   injected	  with	  PKD2KI/KI	  	  naïve	  CD4+CD45Rbhi	   cells	   (Group	  2)	  began	   to	   lose	  weight	   from	  week	   1	   and	   consistently	   lost	  weight	   over	   the	   course	   of	   the	   study	  with	   the	   average	  %	  weight	   change	  was	  9.2%	   (Figure	  5.22A).	  RAG2-­‐/-­‐	   receiving	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WT	  naïve	  CD4+CD45Rbhi	  cells	  co-­‐injected	  with	  WT	  CD4+	  CD25+	  Tregs	  (Group	  3)	  displayed	  weight	  loss	  from	  week	  1	  which	  continued	  throughout	  the	  study	  where	  the	  %	  average	  weight	  change	  was	  8.6%	  by	  the	  end	  of	  the	  study	  (Figure	  5.22B).	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  Figure	   5.22	   Clinical	   colitis	   score	   monitored	   by	   percentage	   weight	   change	   in	  RAG2-­‐/-­‐	  recipient	  mice	  	  (A)	  %	  Body	  weight	   change	   from	  day	  0	  weight	   after	   adoptive	   transfer	  of	   either	  WT	  naïve	  T	  cells	  only-­‐	  (Group	  1)	  or	  PKD2KI/KI	  	  naïve	  T	  cells	  only	  (Group	  2).	  (B)	  %	  Body	  weight	   change	   from	  day	  0	   of	  RAG2-­‐/-­‐	  mice	   after	   injection	  with	   either	  WT	  naïve	  only	  (group	  1),	  WT	  naïve	  T	  cells	  +	  WT	  Tregs	  (Group	  3)	  or	  WT	  naïve	  T	  cells	  +	  PKD2KI/KI	  Tregs.	  Mice	  were	  monitored	  for	  total	  of	  3	  weeks.	  (4	  mice	  used	  per	  group	   (groups	   1	   and	   3),	   5	   mice	   per	   group	   (groups	   2	   and	   4).	   Data	   from	   1	  independent	  experiment.	  Experiments	  were	  performed	  in	  collaboration	  with	  Mr.	  George	  Ramsay,	  Doreen	  Cantrell’s	  lab,	  University	  of	  Dundee.	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WT naive+ PKD2 Treg 	  	  Figure	  5.23	  Tissue	  size	  in	  RAG2-­‐/-­‐	  mice	  after	  transfer	  of	  WT	  and	  PKD2	  KI/KI	  naive	  and	  Treg	  subsets	  Tissue	   weight	   and	   colon	   length	   from	   RAG2-­‐/-­‐	   recipient	   mice	   after	   transfer	   of	  indicated	  sets	  of	  cell	  after	  3	  weeks.	  (A)	  Spleen	  weight	  (g)	  (B)	  Colon	  weight	  (g)	  (C)	  Length	  of	  colon	  (cm)	  (4-­‐5	  mice	  per	  group	  n=1)	  *	   	  =	  p≤	  0.05	  and	  ***	  =	  p≤0.001	  analysed	  by	  students	   t	   test.	  Data	   from	  1	   independent	  experiment.	  Experiments	  were	  performed	  in	  collaboration	  with	  Mr.	  George	  Ramsay,	  Doreen	  Cantrell’s	  lab,	  University	  of	  Dundee.	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In	   addition	   to	   assessment	   of	   clinical	   markers	   such	   as	   %	   body	   weight	  change	   and	   size	   or	   length	   of	   tissues	   including	   the	   spleen	   and	   colon,	   we	   also	  received	   histopathological	   evaluation	   of	   tissue	   sections	   from	   the	   proximal	   and	  distal	   colon	   of	   all	   experimental	   groups.	   This	   was	   performed	   using	   tissue	  sectioning,	   HE	   staining	   and	   subsequent	   assessment	   by	   two	   independent	  pathologists	   for	  clinical	   signs	  and	  severity	  scoring	   for	  colitis.	  As	  can	  be	  seen	   in	  (Figure	  5.24A)	  under	  normal	  conditions	  the	  mucosa	  within	  RAG2-­‐/-­‐	  mice	  is	  well	  preserved	  with	  regularly	  arranged	  glandular	  crypts,	  there	  is	  also	  the	  presence	  of	  well	   differentiated	   goblet	   cells.	   	   Importantly,	   there	   is	   no	   inflammatory	   cell	  infiltration	  present	  within	  the	  lamina	  propria	  and	  submucosa.	  In	  contrast	  to	  this,	  RAG2-­‐/-­‐	  mice	   injected	  with	  WT	   naïve	   CD4+CD45Rbhi	   cells	   develop	  moderate	   to	  marked	  inflammatory	  cell	  infiltration	  within	  the	  lamina	  propria	  and	  submucosa.	  There	  is	  also	  the	  presence	  of	  focally	  extension	  moderate	  mucosal	  erosion	  (Figure	  5.24B	  indicated	  by	  blue	  arrows)	  	   Assessment	   of	   histological	   changes	   within	   the	   proximal	   colon	   of	   RAG2-­‐/-­‐	  receiving	   WT	   naïve	   CD4+CD45Rbhi	   cells	   revealed	   the	   presence	   of	   moderate	  inflammatory	   cell	   infiltration	   in	   the	   lamina	   propria,	   mild	   inflammation	   in	   the	  submucosa	  as	  well	  as	  mild	  to	  moderate	  crypt	  hyperplasia	  (Figure	  5.25A).	  These	  histopathological	  changes	  within	  the	  colonic	  architecture	  are	  consistent	  with	  the	  presence	   of	   established	   colitis.	   	   Assessment	   of	   histological	   changes	  within	   the	  proximal	   colon	   of	   RAG2-­‐/-­‐	   mice	   receiving	   PKD2KI/KI	   naïve	   CD4+CD45Rbhi	   cells	  displayed	  moderate	   to	  marked	   transmural	   inflammatory	  cell	   infiltration,	  which	  was	   most	   prominent	   within	   the	   lamina	   propria	   (Figure	   5.25B).	   These	   data	  illustrate	   that	   both	   WT	   naïve	   CD4+CD45Rbhi	   cells	   and	   PKD2KI/KI	   naïve	  CD4+CD45Rbhi	  cells	  were	  able	  to	  initiate	  and	  cause	  established	  colitis	  within	  the	  T	  cell	  transfer	  model.	  Interestingly	  naïve	  PKD2KI/KI	  CD4+CD45Rbhi	  cells	  appear	  to	  cause	   a	   minor	   exacerbated,	   or	   quickened,	   development	   of	   colitis	   as	  demonstrated	  by	  histology	  and	  by	  increased	  weight	  loss.	  	  	   Histological	  assessment	  of	  the	  proximal	  colon	  of	  RAG2-­‐/-­‐	  mice	  injected	  with	  WT	  naïve	  CD4+CD45Rbhi	  and	  WT	  CD4+	  CD25+	  Tregs	  displayed	  mild	  to	  moderate	  inflammation	   within	   the	   lamina	   propria	   and	   submucosa	   along	   with	   moderate	  hyperplasia	   of	   the	   glandular	   crypts	   (Figure	   5.26A).	   	   Interestingly,	   histological	  sections	   assessed	   from	   RAG2-­‐/-­‐	   injected	   with	   WT	   naïve	   CD4+CD45Rbhi	   cells	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  Figure	  5.26	  Histological	  sections	  in	  proximal	  colon	  of	  RAG2-­‐/-­‐	  hosts	  injected	  with	  WT	  naive	  +	  WT	  Tregs	  or	  WT	  naive	  +	  PKD2	  KI/KI	  Tregs	  (A)	   Proximal	   colon	   of	   RAG2-­‐/-­‐	   hosts	   receiving	   WT	   naïve	   CD4+	   CD45Rbhi	   cells	  (4x105)	   +	  WT	   CD4+	   CD25+	   Tregs	   (1x105)	   (B)	   Proximal	   colon	   of	   RAG2-­‐/-­‐	   hosts	  receiving	  PKD2	  KI/KI	  naïve	  CD4+	  CD45Rbhi	  cells	  (4x105)	  +	  PKD2	  KI/KI	  CD4+	  CD25+	  Tregs	  (1x105).	  (4x	  and	  10x	  magnification	  as	  indicated.	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WT naive+ PKD2 Treg 	  Figure	   5.27	   Assessment	   of	   histopathological	   changes	  within	   proximal	   colon	   of	  recipient	  RAG2-­‐/-­‐	  mice	  	  Severity	  score	  (0-­‐3)	  within	  proximal	  colon	  of	  RAG2-­‐/-­‐	  recipient	  mice	  for	  presence	  of;	   (A)	   goblet	   cell	   depletion	   and	   epithelial	   hyperplasia	   (B)	   lamina	   propria	  inflammatory	  cell	  infiltration	  (C)	  crypt	  abscesses	  (D)	  submucosal	  and	  transmural	  inflammatory	  cell	   infiltration.	   	   (E)	  Total	   colitis	   score	  of	  proximal	   colon.	   *	   	  =	  p≤	  0.05	  analysed	  by	   students	   t	   test.	  Two	  scores	  were	   taken	  per	  mouse	  per	   tissue.	  	  
Scoring	  was	  performed	  by	  Dr.	  Francesco	  Marchesi,	  University	  of	  Glasgow.	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  Figure	  5.29	  Mean	  clinical	  colitis	  score	  assessment	  and	  PMNs	  infiltration	  in	  RAG2-­‐/-­‐	  	  recipient	  mice	  	  (A)	  Average	  colitis	  score	  from	  histopathological	  assessment	  for	  individual	  mice	  (B)	   Average	   polymorphonuclear	   leukocyte	   (PMNs)	   infiltration	   score	   as	  indication	  of	  more	  severe	  tissue	  damage.	  (4	  mice	  used	  per	  group	  (groups	  1	  and	  3),	   5	  mice	   per	   group	   (groups	   2	   and	   4).	   Data	   from	   1	   independent	   experiment.	  
Scoring	  was	  performed	  by	  Dr.	  Francesco	  Marchesi,	  University	  of	  Glasgow.	  	  	  Collectively,	   these	   data	   reveal	   that	   although	   RAG2-­‐/-­‐	  hosts	   receiving	  WT	   naïve	  CD4+	  CD45Rbhi	  +	  WT	  Tregs	  did	  develop	  histopathological	  signs	  of	   inflammation	  and	  colitis	  they	  did	  have	  a	  lower	  mean	  colitis	  score	  when	  compared	  to	  RAG2-­‐/-­‐	  treated	   with	   WT	   naïve	   only	   	   (Figure	   5.29A).	   	   Additionally	   the	   pathologists	  concluded	   that	   there	   was	   an	   overall	   trend	   of	   increased	   severity	   in	   colonic	  inflammation	   when	   comparing	   with	   mice	   co-­‐injected	   with	   WT	   naïve	   CD4+	  CD45Rbhi	  +	  WT	  Tregs	  and	  WT	  naïve	  CD4+	  CD45Rbhi	  +	  PKD2KI/KI	  Tregs	  .	  One	  of	   the	  possible	  reasons	  behind	   lack	  of	  protection	  by	  PKD2KI/KI	  Tregs	   is	   the	  possibility	   that	  mice	   injected	   a	  mixture	   of	  WT	  naïve	   T	   cells	   and	   PKD2KI/KI	   had	  lower	  viability	  than	  WT	  naïve	  and	  WT	  Tregs	  or	  also	  the	  possibility	  that	  PKD2KI/KI	  Tregs	  simply	  failed	  to	  expand	  within	  tissues	  after	  injection	  into	  RAG2-­‐/-­‐	  recipient	  mice.	   	   To	   address	   this	   issue,	   upon	   ending	   the	   colitis	   study	   at	   3	   weeks	   we	  harvested	  spleen	  and	  mLNs	  and	  assessed	  them	  for	  presence	  of	  Tregs	  within	  all	  groups,	  including	  naïve	  only	  groups	  1	  and	  group	  2.	  	  Additionally,	  this	  allowed	  us	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to	   check	   that	  WT	  and	  PKD2KI/KI	  naïve	  only	  mice	  did	  not	  differentiate	   into	  Treg	  subsets	  after	   transfer	   into	  mice.	   	  Upon	  assessment	  of	  Treg	  population’s	  ex	  vivo	  we	  observed	  that	  only	  experimental	  groups	  3	  and	  4	  (WT	  naïve	  +	  WT	  Treg	  and	  WT	  naïve	  +	  PKD2KI/KI	  Treg)	  showed	  obvious	  Treg	  populations	  in	  both	  the	  spleen	  and	  mLN	  (Figure	  5.30A-­‐D).	  Importantly,	  experimental	  group	  1	  and	  2	  (WT	  naïve	  only	   and	  PKD2KI/KI	   naïve	  only)	   showed	   little	   development	   of	  Treg	  populations,	  although	  they	  were	  detectable	  at	  low	  levels.	  	  Indeed	  these	  data	  also	  revealed	  no	  significant	   changes	   in	   the	   expansion	   of	   PKD2KI/KI	   Tregs	   when	   compared	   to	  expansion	  of	  WT	  Tregs	  within	  recipient	  hosts.	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  Figure	  5.30	  Treg	  populations	  in	  RAG2-­‐/-­‐	  recipient	  mice	  at	  end	  of	  colitis	  study	  (A)	  Representative	  dot	  plots	  showing	  Treg	  populations	   in	  the	  spleen	  of	  RAG2-­‐/-­‐	  recipient	   mice	   after	   IP	   transfer	   of	   each	   experimental	   group	   after	   3	   weeks	   of	  transfer,	  shown	  by	  CD4	  surface	  expression	  and	  intracellular	  FoxP3	  expression	  by	  Flow	  cytometry.	  Numbers	  represent	  average	  %	  frequency	  and	  SD.	  (B)	  Dot	  plots	  showing	  Treg	  populations	  in	  the	  mLNs	  of	  RAG2-­‐/-­‐	  recipient	  mice	  after	  IP	  transfer	  of	   each	   experimental	   group	   after	   3	   weeks	   of	   transfer.	   (C)	   	   %	   Frequency	   of	  CD4+FoxP3+	   found	  within	   the	   spleen	   (D)	  %	   Frequency	   of	   CD4+FoxP3+	   found	  within	   the	  mLN.	   (4	  mice	   used	   per	   group	   (groups	   1	   and	   3),	   5	   mice	   per	   group	  (groups	  2	  and	  4).	  Data	  from	  1	  independent	  experiment.	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  Figure	   5.31	  RT-­‐PCR	   analysis	   of	   cytokine	  mRNA	   levels	   in	   proximal	   colon	   tissue	  from	  RAG2-­‐/-­‐	  mice	  after	  induction	  of	  colitis.	  	  	  (A)	   Relative	   IFNγ	   mRNA	   level	   (B)	   IL-­‐10	   (C)	   IL-­‐17.	   (Cytokine	   expression	   is	  relative	   expression	   to	   CD45)	   (4-­‐5	   mice	   per	   group).	   Data	   from	   1	   independent	  experiment.	  Experiment	  was	  performed	  in	  collaboration	  with	  Mr.	  George	  Ramsay,	  
Doreen	  Cantrell	  lab,	  University	  of	  Dundee.	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5.6 	  	  Discussion	  	  	   The	  aim	  of	  this	  chapter	  was	  to	  explore	  the	  role	  of	  PKD2	  catalytic	  activity	  in	  peripheral	  T	  cells	  specifically	  within	  the	  mucosal	  immune	  system,	  this	  included	  T	  lymphocyte	   subsets	   within	   the	   small	   intestine	   and	   within	   GALTs	   as	   we	   had	  observed	  a	  visible	   increase	   in	   the	   size	  of	  mLN	  and	  PPs	   tissue.	  Additionally,	  we	  sought	   to	   explore	   the	   requirement	   for	   PKD2	   catalytic	   activity	   in	   Treg	  development	   and	   effector	   function.	   	   Although	   accumulating	   evidence	  demonstrates	   a	   key	   role	   of	   PKD2	   catalytic	   activity	   within	   CD8+	   CTLs,	   the	  requirement	  for	  PKD2	  within	  T	  lymphocytes	  within	  the	  mucosal	  immune	  system	  remains	   or	   indeed	   within	   Treg	   development	   or	   effector	   function	   remains	  unaddressed.	  Assessment	  of	  mLNs	  of	  PKD2KI/KI	  mice	  by	  histology	  revealed	  the	  presence	  of	  expanded	  germinal	   centres	  with	   irregular	  architecture	  when	  compared	  with	  WT	  mLN	  tissue.	  	  Subsequent	  analysis	  of	  T	  and	  B	  lymphocytes	  within	  the	  mLN	  of	  PKD2KI/KI	  	  mice	  revealed	  a	  significant	  increased	  in	  the	  number	  of	  B	  lymphocytes,	  however	  we	   found	   no	   difference	   in	   the	   expression	   of	   GL-­‐7,	  which	  would	   have	  corresponded	  well	   with	   the	   histopathological	   data.	   Our	   analysis	   of	   PPs	  within	  WT	  and	  PKD2KI/KI	  was	  particularly	  difficult	  due	  to	  the	  nature	  of	  the	  small	  size	  of	  these	   lymphoid	   sites.	   However,	   histopathology	   analysis	   reciprocated	   the	  phenotype	   observed	   within	   mLN	   tissue	   in	   which	   PPs	   from	   PKD2KI/KI	   mice	  displayed	   expanded	   germinal	   centres.	   Surprisingly,	   although	   B	   lymphocyte	  numbers	  were	  normal,	  we	  observed	   a	   significant	   increase	   in	   the	   expression	  of	  GL-­‐7	   within	   the	   PPs	   of	   PKD2KI/KI	   mice,	   which	   did	   correlate	   with	   obtained	  histopathology	  data,	  demonstrates	  increased	  size	  in	  germinal	  centres	  formation.	  Furthermore,	   the	   presence	   of	   various	   expected	   lymphocyte	   populations	  confirmed	  that	  these	  tissues	  were	  indeed	  lymphoid	  PPs,	  rather	  than	  the	  presence	  of	   intestinal	  polyps	   for	  example.	  A	  wealth	  of	  studies	  comparing	  germ	  free	  mice	  and	   bacterial	   colonised	   mice	   demonstrate	   that	   the	   adaptive	   immune	   system,	  predominantly	  the	  mucosal	  compartment,	  is	  highly	  influenced	  by	  the	  presence	  of	  commensal	   microbiota	   within	   the	   intestine.	   Interestingly,	   this	   also	   includes	  direct	   influence	   on	   PP	   and	   germinal	   center	   size	   (Shroff	   et	   al.	   1995)as	   well	   as	  shaping	  multiple	   populations	   of	   immune	   cells	   including	   IgA	   producing	   plasma	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cells	   (Benveniste	   et	   al.	   1971),	   CD4+	   T	   cell	   subsets	   and	   TCRαβ+	   CD8αβ+	   IELs	  (reviewed	   (Macpherson	   &	   Harris	   2004)).	   It	   is	   tempting	   to	   speculate	   that	  PKD2KI/KI	  mice	  may	  display	  this	  phenotype	  as	  a	  result	  of	  lack	  of	  tolerance	  to	  oral	  or	   commensal	   antigens.	   This	   could	   be	   assessed	   by	   future	   studies	   by	   assessing	  tolerance	   induction	   in	  a	  PKD2KI/KI	   animal	   crossed	  onto	  an	  OT	   II	  background	   in	  which	  supplementation	  of	  animal	  drinking	  water	  with	  OVA	  peptide	  exists	  as	  an	  established	   model	   to	   assess	   oral	   tolerance	   induction	   (X.	   Zhang,	   Izikson,	   et	   al.	  2001b)	  (Pabst	  &	  Mowat	  2012).	  It	   was	   striking	   PKD2KI/KI	   mice	   had	   significantly	   increased	   CD4+	   CD25+	  FoxP3+	   Tregs	  within	  multiple	   peripheral	   lymphoid	   tissues,	   including	   the	  mLN	  and	  the	  spleen,	  which	  was	  not	  the	  case	  within	  the	  thymus.	  This	  suggested	  to	  us	  that	   rather	   than	   a	   defect	   within	   thymocyte	   development	   or	   increased	   thymic	  output	  of	  Tregs,	  the	  loss	  of	  PKD2	  instead	  may	  led	  to	  the	  increased	  conversion	  of	  CD4+	   naïve	   T	   cells	   into	   Tregs	   within	   the	   periphery.	   Further	   analysis	   revealed	  significantly	  expanded	  population	  of	  CD103+	  Tregs	  within	  PKD2KI/KI	  	  mice,	  which	  is	   well	   established	   marker	   for	   activated	   and	   memory	   Tregs	   (Lehmann	   et	   al.	  2002)	  (Huehn	  et	  al.	  2004)	  (Suffia	  et	  al.	  2005)	  (Banz	  et	  al.	  2003)	  (McHugh	  et	  al.	  2002).	   This	   result	   suggests	   that	   increased	   Tregs	   within	   PKD2KI/KI	   mice	   are	  antigen	  experienced	  with	  a	  memory	  phenotype.	  	  Surprisingly,	  these	  results	  were	  even	  more	   pronounced	  when	  we	   assessed	   aging	   PKD2KI/KI	  mice.	   As	   discussed,	  class	  IIa	  HDACs	  have	  been	  shown	  to	  regulate	  FoxP3	  stabilisation	  by	  acetylation	  of	   the	   N-­‐terminal	   of	   FoxP3	   protein.	   We	   therefore	   speculated	   that	   Treg	  conversion	  might	   be	   due	   to	   enhanced	   stabilisation	   of	   the	   FoxP3	   protein	   via	   a	  PKD-­‐HDAC	  mediated	   pathway.	   It	   was	   therefore	   surprising	   to	   find	   that	   loss	   of	  HDAC7	   did	   not	   result	   in	   the	   generation	   of	   Tregs,	   or	   indeed	   the	   abundance	   of	  FoxP3,	   although	   we	   did	   note	   a	   reduction	   in	   the	   number	   of	   nTregs	   within	   the	  thymus.	   It	   is	   plausible	   that	   the	   increase	   in	   CD4+FoxP3+	   Treg	   population	   is	   a	  consequence	   of	   on-­‐going	   inflammation	  within	   PKD2KI/KI	  mice.	   This	   speculation	  correlates	  well	  with	   the	  visible	   increase	   in	   the	  size	  and	  cellularity	  of	   the	  mLNs	  and	  PPs	   including	  observations	  within	  the	  histological	  changes	  observed	  which	  include	   larger	   germinal	   centres	  within	   PKD2KI/KI	  mice.	   This	   speculation	  would	  also	   concur	   from	   studies	   assessing	   Treg	   frequencies	   in	   patients	  with	   on-­‐going	  IBD	   in	   which	   increased	   abundance	   of	   CD4+	   FoxP3+	   T	   lymphocyte	   and	   FoxP3	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mRNA	   transcript	   are	   found	   in	   on-­‐going	   IBD	   lesions	   within	   the	   small	   intestine	  (Maul	   et	   al.	   2005)	   (Hölttä	   et	   al.	   2008)	   and	   within	   patients	   with	   rheumatoid	  arthritis	  (Leipe	  et	  al.	  2005).	  	  	   Analysis	  of	  T	   lymphocytes	  within	   the	   small	   intestine	   revealed	  a	   striking	  role	   for	   PKD2	   in	   the	   normal	   generation	   or	   homeostasis	   of	   lymphocytes	  within	  the	   gut,	  which	  was	   specifically	   limited	   to	   the	   intraepithelial	   layer	   in	  which	   the	  total	  numbers	  of	  IELs	  were	  significantly	  increased	  in	  PKD2KI/KI	  mice.	  	  Specific	  IEL	  populations	   within	   PKD2KI/KI	  mice	   were	   strikingly	   different	   from	  WT	   mice,	   in	  which	   TCRγδ+	   T	   lymphocytes	   normally	   predominant,	   however	   in	   contrast	  PKD2KI/KI	  mice	   had	   more	   TCRαβ+	   rather	   than	   TCRγδ+	   IELs.	   A	   more	   in	   depth	  analysis	   of	   these	   populations	   also	   implicated	   further	   dysregulation	  with	   these	  subsets	  including	  obvious	  differences	  between	  natural	  and	  induced	  populations	  of	  IEL.	  	  Specifically	  we	  observed	  significantly	  fewer	  TCRαβ+	  CD8αα+	  IEL,	  which	  was	  accompanied	  by	  an	  increase	  in	  TCRαβ+	  CD8αβ+	  cells.	  Interestingly,	  a	  similar	  phenotype	  is	  observed	  in	  TGF-­‐β-­‐/-­‐	  mice	  (Konkel	  et	  al.	  2011).	  Furthermore,	  within	  the	  same	  study	  TGF-­‐β	  has	  also	  been	  shown	  to	  be	  required	  for	  the	  proliferation	  of	  the	  precursor	  for	  the	  TCRαβ+	  CD8αα+	  IEL	  which	  are	  CD4-­‐	  CD8-­‐	  double	  negative	  thymocytes	   that	   have	   successfully	   rearranged	   a	   TCR	   and	   undergone	   positive	  selection	  so	  are	  therefore	  positive	  for	  CD5	  (Gangadharan	  et	  al.	  2006).	  PKD2	  has	  been	  implicated	  in	  the	  upregulation	  of	  the	  CD5	  protein	  via	  the	  phosphorylation	  of	   C-­‐Cbl,	   an	   ubiquitin	   ligase	   (Marklund	   et	   al.	   2003)	   (Navarro,	   Goebel,	   et	   al.	  2014b).	  Additionally,	  TGF-­‐β-­‐/-­‐	  IEL	  also	  express	  higher	   levels	  of	  CD103,	  similarly	  to	  PKD2KI/KI	  Tregs.	  	  It	  would	  be	  interesting	  to	  expand	  these	  studies	  in	  the	  future	  and	   address	   precursor	   number	   within	   the	   thymus	   of	   PKD2	  mice	   and	   address	  TGF-­‐β	   production	   within	   cells	   from	   PKD2KI/KI	   mice.	   Importantly,	   we	   also	  observed	  increased	  Tregs	  within	  the	  IEL	  and	  the	  LP	  layers	  of	  the	  small	  intestine	  in	  PKD2KI/KI	  mice.	  This	  was	  significant	  as	  it	   is	  well	  established	  that	  normal	  Treg	  presence	  within	   the	   IEL	   is	   extremely	   low	   (Ostanin	   et	   al.	   2010)	   (Denning	   et	   al.	  2007).	   To	   address	   the	   biological	   relevance	   of	   changes	   within	   gut	   lymphocyte	  populations	  within	  the	  small	  intestine	  of	  PKD2KI/KI	  mice	  an	  infection	  model	  could	  be	   carried	   out	   in	   the	   future.	   Established	   models	   to	   investigate	   the	   immune	  response	   within	   the	   gut	   include	   infection	   with	   L.Monocytogenes,	   toxoplasma	  
gondii,,	   rotavirus	   and	   helicobacter	   pylori	   (Huleatt	   et	   al.	   2001)	   (Kullberg	   et	   al.	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2006)	   (Liesenfeld	   2002)	   (Schreiner	   &	   Liesenfeld	   2009)	   (Pizarro-­‐Cerdá	   et	   al.	  2012).	  	  Although	  there	  are	  multiple	  possible	  mechanisms	  to	  explain	  the	  increase	  in	  abundance	  of	  Tregs	  within	  PKD2KI/KI	  mice	  we	  could	  not	  exclude	  the	  possibility	  that	  a	  lack	  of	  functionality	  within	  PKD2KI/KI	  Tregs	  was	  driving	  their	  proliferation	  in	   attempt	   to	   compensate	   and	   maintain	   immune	   regulation	   and	   homeostasis.	  	  This	  was	  plausible	  as	  loss	  of	  PKD2	  catalytic	  activity	  has	  been	  associated	  with	  lack	  of	   functionality	   in	  other	  T	   lymphocytes	   including	  CD4+	  naïve	  T	   cells	   and	  CD8+	  CTLs,	  in	  which	  severely	  reduced	  cytokine	  production	  by	  these	  subsets	  has	  been	  observed.	  To	   address	  Treg	   functionality	   in	  PKD2KI/KI	  mice	  we	   choose	   to	  use	   an	  intestinal	  in	  vivo	  model	  of	  inflammation.	  Analysis	  of	  Tregs	  lacking	  PKD2	  catalytic	  activity	  an	   in	  vivo	   colitis	  model	  revealed	  noteworthy	  results	   in	  which	  PKD2KI/KI	  Tregs	  displayed	  reduced	  ability	  to	  prevent	  the	  development	  or	  severity	  of	  colitis	  which	   was	   associated	   with	   severely	   reduced	   IL-­‐10	   levels	   within	   the	   proximal	  colon	  which	  was	  associated	  with	  increased	  IFNγ	  levels.	  In	  this	  context,	  IL-­‐10	  has	  been	   shown	   to	   be	   essential	   in	   the	   function	   of	   Tregs	   within	   intestinal	  inflammation	  (Asseman	  et	  al.	  1999)	  (Uhlig	  et	  al.	  2006).	  These	  results	  collectively	  implicate	   a	   role	   for	   PKD2	   within	   Treg	   effector	   function	   specifically	   the	  production	   of	   IL-­‐10	   and	   that	   Tregs	   lacking	   PKD2	   catalytic	   activity	   are	  nonfunctional	  within	  an	  intestinal	  model	  of	  inflammation.	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6 Final	  Discussion	  and	  Future	  Perspectives	  	  
6.1 Novel	   PKD	   inhibitors	   are	   specific	   for	   PKD	  but	   do	   display	  
individual	  off	  target	  effects	  	   The	  work	  within	  this	  thesis	  explores	  the	  role	  of	  PKD	  kinases	  in	  multiple	  cells	  of	   the	   mammalian	   immune	   system	   including	   cells	   from	   both	   the	   innate	   and	  adaptive	  lineages,	  as	  well	  as	  exploring	  a	  role	  for	  PKD	  within	  malignant	  myeloid	  cells.	   Accumulating	   evidence	   has	   implicated	   the	   PKD	   family	   in	   a	   wealth	   of	  fundamental	   biological	   processes	   including	   angiogenesis,	   proliferation	   and	   cell	  survival,	  cell	  motility	  and	  within	  various	  inflammatory	  pathways.	  	  It	  is	  therefore	  not	   surprising	   that	   PKD	   has	   been	   implicated	   in	   cancer	   development	   and	  progression.	   As	   a	   result,	   there	   have	   been	   significant	   advances	   in	   the	  development	   of	   small	  molecule	   inhibitors	   for	   PKD	   for	   their	   therapeutic	   use	   in	  cancer	  therapy.	  Previous	  studies	  have	  reported	  positive	  results	  in	  pancreatic	  and	  prostate	   cancer	  models	   (Wille	   et	   al.	   2014)	   (Ochi	   et	   al.	   2011)	   (Harikumar	   et	   al.	  2010)	  (LaValle	  et	  al.	  2012).	  Although	  improved	  bioavailability	  and	  specificity	  of	  these	  compounds	  will	  hopefully	  allow	  movement	  of	  these	  inhibitors	  into	  further	  studies	  little	  is	  known	  about	  their	  effect	  in	  the	  immune	  system,	  where	  PKD2	  has	  ben	   shown	   to	   be	   predominantly	   expressed	   and	   play	   a	   key	   role	   in	   effector	  functions	   of	   adaptive	   immune	   cells	   (Matthews	   et	   al.	   2000)	   (Matthews	   et	   al.	  2010)	  (Navarro,	  Feijoo	  Carnero,	  et	  al.	  2014a)	  (Spitaler,	  Emslie,	  Wood	  &	  Cantrell	  2006b).	  	  Data	  within	  this	  thesis	  provide	  significant	  insight	  into	  the	  specificity	  of	  novel	  inhibitors	   of	   PKD	  which	   was	   gained	   through	   the	   use	   of	   in	   vitro	   kinase	   screen	  profiling,	   adding	   to	   our	   knowledge	   of	   the	   off	   target	   effects	   displayed	   by	   these	  compounds.	   Importantly,	   all	   three	   novel	   inhibitors	   had	   no	   significant	   effect	   on	  PKC	   isoforms	   (Results,	  Chapter	  3),	  which	  has	   complicated	   the	  pharmacological	  inhibition	   of	   PKD	   in	   previous	   studies.	   Significantly,	   comparative	   analysis	  revealed	  that	  the	  common	  target	  was	  the	  inhibition	  of	  PKD.	  We	  also	  explored	  if	  pharmacological	  inhibition	  of	  PKD	  by	  these	  compounds	  led	  to	  biological	  results	  that	  would	   be	   expected	   from	   previously	   assigned	   functions	   of	   PKD	  within	   the	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literature.	   To	   this	   extent,	   our	   data	   yielded	   mixed	   results.	   Of	   note,	   the	  pharmacological	   inhibition	   of	   PKD	   within	   murine	   T	   lymphocytes	   severely	  reduced	  IL-­‐2	  and	  IFNγ	  production	  after	  TCR	  triggering,	  as	  reported	  in	  PKD2KO/KO	  and	  PKD2KI/KI	  CD4+	  and	  CD8+	  T	  lymphocytes	  (Matthews	  et	  al.	  2010).	  As	  PKD2	  as	  been	  implicated	  in	  the	  development	  and	  perhaps	  the	  progression	  of	  CML	  we	  also	  explored	   the	   use	   of	   novel	   small	   molecule	   inhibitors	   of	   PKD	   in	   a	   malignant	  myeloid	  cell	  line	  (human	  Bcr-­‐Abl+	  K562	  CML	  cells)	  (Mihailovic	  et	  al.	  2004)	  (Z.-­‐F.	  Yang	   et	   al.	   2013)	   (Bhattacharya	   et	   al.	   2011;	   H.	   Zheng	   et	   al.	   2011).	   One	  discrepancy	   with	   reports	   in	   the	   literature	   that	   was	   established	   in	   these	  experiments	   was	   that	   we	   could	   not	   detect	   any	   basal	   activity	   of	   PKD	   (either	  within	   the	   PKC	  mediated	   transphorylation	   site	   (Ser744/Ser748)	   or	  within	   the	  autophosphorylation	   loops	   (p.	   SER916)).	   Although	   additional	   reports	   have	  demonstrated	   that	   PKD2	   is	   tyrosine	   phosphorylated	   within	   the	   PH	   domain	  (Mihailovic	   et	   al.	   2004).	   If	   K562	   CML	   cells	   have	   constitutive	   tyrosine	  phosphorylation	  will	  need	  to	  be	  addressed	  in	  the	  future.	  Furthermore,	  to	  address	  constitutive	  PKD	  activity	  within	  CML	  cells,	  patient	  samples	  could	  be	  obtained	  to	  address	   this	   within	   clinical	   samples	   rather	   than	   with	   cell	   lines,	   which	   would	  provide	  a	  more	   relevant	  approach	   if	   these	   inhibitors	  are	   to	  be	  used	  within	   the	  clinic.	  Despite	  this,	  we	  did	  show	  that	  all	  three	  inhibitors	  effectively	  block	  phorbol	  ester	   induced	   activation	   of	   PKD	   using	   phospho-­‐flow	   cytometry.	   Additionally,	  PKD2	  has	  been	   implicated	   in	   the	   enhanced	   internalisation	  of	   the	   IFNAR1	   from	  the	  cell	  surface	  of	  CML	  cell	   line	  (KT1	  cells)	  mediated	  by	  the	  phosphorylation	  of	  serine	  residues	  within	  the	  IFNAR1	  degron.	  Within	  the	  same	  studies	   it	  has	  been	  shown	   that	   knockdown	   of	   PKD2	   or	   pharmacological	   inhibition	   of	   PKD	  (CID755673	  compound)	   led	  to	  reduced	  phosphorylation	  of	   the	  Ser535	  site	  and	  an	   increase	   in	   total	   IFNAR1.	   We	   established	   that	   the	   K562	   CML	   cell	   line	  displayed	  a	   similar	  phenotype	  with	   low	  surface	  expression	  of	   IFNAR1	  yet	  high	  levels	   are	   found	   intracellularly.	   Our	   experiments	   assessing	   the	   effect	   of	   12a,	  CRT101	   and	   CRT051	   compounds	   on	   IFNAR1	   expression	   gave	   mixed	   results	  where	   only	   the	  CRT101	   compound	   showed	   any	   significant	   increase	   of	   IFNAR1	  receptor	  expression	  within	  CML	  cells.	  	  	  As	   the	   CRT101	   is	   orally	   bioavailable,	   studies	   could	   be	   performed	   in	   the	  future	  to	  examine	  the	  effect	  of	  oral	  dosing	  of	  this	  compound	  could	  be	  performed	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in	   mice	   and	   its	   effects	   within	   the	   immune	   system	   assessed.	   This	   would	   be	  particularly	  interesting	  to	  look	  at	  Treg	  populations	  within	  the	  spleen	  and	  mLNs	  as	  we	  have	  shown	  that	  loss	  of	  PKD	  catalytic	  activity	  affects	  these	  populations	  in	  
vivo	   (Results,	  Chapter	  5).	  Although	   it	   is	  worth	  emphasising	   that	  although	   these	  novel	  compounds	  were	  highly	  specific	  for	  PKD,	  we	  did	  note	  individual	  off	  target	  effects	   that	   we	   believe	   may	   have	   affected	   results	   obtained	   from	   cell	   cycle	  analysis	   of	   and	   indeed	  our	   analysis	   on	  p.	   STAT5	   levels,	   both	  within	  K562	  CML	  cells.	  However,	  cancer	  research	  technologies	  are	  improving	  these	  compounds	  at	  the	  moment	  (Personal	  communication).	  	  	  	  
6.2 	  PKD2	  is	  dispensible	  for	  myeloid	  cell	  development	  in	  vivo	  
but	  may	  play	  a	  role	  in	  myeloid	  cell	  effector	  functions	  	   The	   second	   part	   of	   the	   project	   focused	   on	   PKD	   expression	   and	   function	  within	  myeloid	  cells	   through	  use	  of	   isoform	  specific	  PKD	  transgenic	  animals	   in	  an	   attempt	   to	   ascertain	   the	   true	   physiological	   role	   of	   PKD	   kinases	   in	   these	  processes.	  Work	   carried	   out	   within	   this	   thesis	   reports	   for	   the	   first	   time	   an	   in	  depth	   analysis	   of	   the	   expression	   of	   PKD	   kinases	   and	   their	   role	   within	   the	  development	   of	   myeloid	   cell	   in	   vivo	   (Results,	   Chapter	   4).	   	   These	   data	   is	  significant,	  as	  it	  reveals	  for	  the	  first	  time	  that	  PKD1	  and	  PKD2	  catalytic	  activity	  is	  dispensable	  for	  the	  generation	  of	  myeloid	  cells	  in	  vivo.	  A	  significant	  observation	  was	   the	   predominant	   expression	   of	   PKD2	   in	   primary	   myeloid	   cells	   including	  BMDMOs	  and	  BMDCs,	  similar	  to	  cells	  of	  the	  adaptive	  lineages.	  	  Importantly,	   we	   did	   not	   observe	   any	   defects	   within	   myeloid	   cell	  development	   (including	   cDCs,	   pDCs,	   neutrophils	   and	   macrophages	   from	   PKD	  mutant	  bone	  marrow	   in	  vitro	  or	  within	   the	  bone	  marrow	   in	  either	  PKD2KI/KI	  or	  PKD1WT/KI	  x	  PKD2KI/KI	  mice	  in	  vivo.	  Furthermore,	  these	  populations	  were	  normal	  within	  the	  spleen,	  suggested	  no	  obvious	  role	   for	  either	  PKD1	  or	  PKD2	  catalytic	  activity	  in	  the	  migration	  or	  homeostasis	  of	  these	  subsets.	  	  Our	   analysis	   of	   TLR	  mediated	   activation	   of	   PKD	   led	   to	   unexpected	   results	  that	   challenges	   previous	   reports	   in	   the	   literature	   that	   report	   PKD1	   is	   key	   for	  myeloid	  cell	  effector	  functions	  and	  is	  activated	  downstream	  of	  TLRs	  utilising	  the	  Myd88	  pathway.	   In	   these	  experiments	  we	  could	  not	  detect	   strong	  activation	  of	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PKD	   in	   response	   to	   TLR4	   or	   TLR9	   activation	   within	   either	   RAW264.7	  macrophages	  or	  BMDCs.	  Surprisingly,	  our	  preliminary	  data	  suggests	  a	  potential	  role	  for	  PKD	  activation	  downstream	  of	  dectin-­‐1:	  TLR2	  stimulation	  with	  zymosan	  and	  therefore	  implicates	  a	  role	  for	  PKD	  within	  antifungal	  immunity.	  It	  will	  need	  to	  be	  determined	   in	   future	  experiments	   if	  PKD	  activation	   is	  a	   result	  of	  either	  a	  combination	   of	   both	   dectin-­‐1:	   TLR2	   or	   by	   dectin-­‐1	   or	   TLR2	   individually.	   This	  could	  be	  achieved	  through	  use	  of	  single	  agonists	  for	  each	  receptor.	  	  	  Analysis	   of	   effector	   function	   of	   BMDCs	   lacking	   PKD2	   catalytic	   activity	  generated	   in	  vitro	  gave	  unexpected	  results	   in	  which	  we	  observed	  an	  overactive	  response	   to	   LPS	   characterised	   by	   increased	   costimulatory	   molecules	   when	  compared	  to	  WT	  BMDCs.	  Importantly,	  the	  functional	  relevance	  of	  this	  phenotype	  was	   explored,	   in	   an	   in	   vitro	   T	   lymphocyte	   activation	   model	   revealing	   that	  although	  loss	  of	  PKD2	  catalytic	  activity	  within	  BMDCs	  did	  not	  affect	  their	  ability	  to	  present	  peptide	  and	  activate	  OVA	  specific	  	  T	  lymphocytes,	  as	  demonstrated	  by	  	  successful	   upregulation	  of	   key	  T	   lymphocyte	   activation	  markers.	  However,	   our	  preliminary	  data	  show	  that	  T	  lymphocytes	  stimulated	  with	  PKD2KI/KI	  BMDCs	  did	  display	   heightened	   IFNγ	   production	   which	   is	   most	   likely	   being	   induced	   by	  increased	   IL-­‐12p40	   levels	   observed	   in	   PKD2KI/KI	   BMDCs	   (Athie-­‐Morales	   et	   al.	  2004).	  	  As	  discussed,	  these	  data	  collectively	  implicate	  a	  regulatory	  role	  for	  PKD2	  downstream	   of	   TLR	   ligation	   or	   indeed	   a	   role	   for	   limitation	   of	   the	   response	  directed	  by	  BMDCs.	  	  In	  this	  context,	  PKD	  has	  been	  implicated	  in	  the	  regulation	  of	  A20	  within	   the	  βTC3	   cell	   line	   (Liuwantara	   et	   al.	   2006),	  which	   is	   a	  well	   known	  negative	   regulator	   of	   TLR	   and	   NFκB	   pathways	   (Boone	   et	   al.	   2004).	   Future	  experiment	  will	  be	  required	   to	  assess	   if	   this	   is	   the	  case	  within	  myeloid	  cells	  as	  A20	  has	  a	  key	  role	  within	  DCs	  specifically	  and	  their	  mediation	  of	  normal	  immune	  homeostasis	  (Kool	  et	  al.	  2011).	  	  	  
6.3 PKD2	   catalytic	   activity	   is	   required	   for	   normal	   gut	  
associated	   lymphoid	   tissue	   homeostasis	   and	   Treg	  
development	  and	  function	  	  	   The	  final	  part	  of	  this	  project	  led	  us	  down	  an	  unexpected	  path	  to	  explore	  the	  loss	  of	  PKD2	  catalytic	  activity	  within	  T	  lymphocyte	  homeostasis	  within	  the	  small	  intestine	  and	   indeed	  within	   the	  development	  and	   function	  Treg	   subsets.	  These	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experiments	  provide	  much	  needed	  insight	  into	  a	  subject	  area	  where	  the	  role	  of	  PKD2	   has	   not	   been	   assessed.	   Ironically,	   the	   experiments	   described	   within	  Chapter	  5	  produced	  more	  questions	  than	  they	  answered.	  	  Strikingly,	   PKD2KI/KI	   mice	   displayed	   enlarged	   GALTs	   including	   mLNs	   and	  PPs.	  A	  similar	  phenotype	  was	  noted	  within	  PKD2KI/KI	  and	  PKD2KO/KO	  mice	  when	  crossed	  onto	  an	  OT	  I	  and	  OT	  II	  background,	  however	  increased	  tissue	  size	  within	  these	  mice	  was	  only	  associated	  with	  spleen	  and	  inguinal	  lymph	  nodes	  (Navarro	  et	  al.	  2012).	  	  Assessment	  of	  these	  tissues	  with	  histopathology	  revealed	  expanded	  germinal	   centres	  within	  PKD2KI/KI	  mice	   (Chapter	  5).	   It	   is	   tempting	   to	   speculate	  that	  this	  may	  be	  a	  result	  in	  a	  break	  in	  oral	  tolerance	  either	  to	  food	  antigen	  or	  to	  commensal	  bacteria	  within	  the	  gastrointestinal	  tracts	  of	  PKD2KI/KI	  mice	  (Pabst	  &	  Mowat	  2012)	  (Macpherson	  &	  Harris	  2004).	  although	  further	  experiments	  will	  be	  required	  to	  confirm	  this.	  	  Furthermore,	   TCRγδ	   populations	   in	   the	   gut	   are	   known	   to	   be	   essential	   for	  normal	   oral	   tolerance	   and	   our	   data	   demonstrate	   that	   TCRγδ	   are	   significantly	  reduced	   within	   the	   intraepithelial	   layer	   of	   PKD2KI/KI	   mice.	   In	   this	   context,	   it	  would	  be	  very	  interesting	  to	  assess	  the	  microbiota	  present	  within	  PKD2KI/KI	  mice,	  as	   it	   is	   becoming	   increasingly	   accepted	   that	   intestinal	   microbiota	   play	   an	  essential	   role	   in	   shaping	   the	   immune	   system	   and	   for	   normal	   homeostasis	   of	  multiple	   immune	  cell	   subsets	   (Belkaid	  &	  Hand	  2014)	  (H.-­‐J.	  Wu	  &	  E.	  Wu	  2014).	  Moreover,	   studies	   have	   demonstrated	   that	   the	   distinct	   bacterial	   species	   that	  make	  up	  the	  microbiota	  can	  favour	  or	  disfavour	  FoxP3+	  Treg	  induction	  (Atarashi	  et	  al.	  2014)	  (Atarashi	  et	  al.	  2011).	  Many	   of	   the	   experiments	   we	   sought	   to	   perform	   limited	   by	   the	   technical	  difficultly	   of	   successful	   intracellular	   staining	   for	   the	   FoxP3	   protein	   when	  combining	   this	   technique	  with	   other	  methods,	   for	   example	   phospho	   flow.	   It	   is	  also	  not	  possible	  to	  sort	  live	  FoxP3+	  cells	  without	  fixation	  and	  permeabilisation	  of	   these	   cells	   first	   thereby	   limiting	   their	   use	   for	   downstream	   applications.	   To	  overcome	  this	  difficult	  for	  future	  experiments	  to	  allow	  further	  charaterisation	  of	  the	  role	  of	  PKD2	  in	  Treg	  development	  and	  effector	  functions	  it	  would	  be	  greatly	  advantageous	  to	  cross	  the	  PKD2KI/KI	  mouse	  onto	  a	  FoxP3GFP	  strain	  (Fontenot	  et	  al.	  2005).	   	  Collectively,	   observations	   from	   the	   colitis	  model	   imply	   that	  Tregs	   from	  PKD2KI/KI	   mice	   are	   less	   protective	   in	   preventing	   the	   development	   or	   indeed	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limiting	   the	   severity	   of	   disease	   induced	   in	   this	   model.	   This	   will	   need	   to	   be	  confirmed	   with	   more	   intricate	   experiments	   to	   more	   directly	   assess	   cytokine	  production	  by	  PKD2KI/KI	  Tregs.	  This	  could	  be	  achieved	  by	  sorting	  (in	  the	  case	  of	  mice	  crossed	  on	  to	  the	  FoxP3GFP	  stain)	  WT	  and	  PKD2KI/KI	  CD4+	  FoxP3+	  Tregs	  and	  assessing	   cytokine	   production	   such	   as	   IL-­‐10	   and	   TGFβ.	   Additionally,	   a	   more	  global	   approach	   to	   investigate	   why	   loss	   of	   PKD2	   catalytic	   activity	   led	   to	   an	  accumulation	   of	   Tregs	   that	   have	   a	   memory	   like	   phenotype	   within	   multiple	  tissues	  of	  PKD2KI/KI	  mice	  would	  be	  to	  perform	  phosphoproteomics	  on	  these	  cell	  subsets	  in	  future	  experiments.	  Another	  important	  observation	  was	  the	  intriguing	  differences	  between	  T	  cell	  subsets	   within	   the	   IEL	   of	  WT	   and	   PKD2KI/KI	   	   mice.	   	   Significantly,	   we	   observed	  reduction	  of	  key	  regulatory	  subsets	  within	   this	   layer	   including	  TCRγδ+	  subsets	  but	  also	  TCRαβ+	  CD8αα+	  subsets	  both	  of	  which	  have	  been	  shown	  to	  perform	  key	  regulatory	   properties	   within	   the	   gut	   including	   maintenance	   of	   gut	   epithelium	  and	  resolution	  of	  inflammation.	  Although	  there	  are	  multiple	  possibilities	  to	  begin	  to	   explain	   this	   phenotype,	   there	   are	   two	   major	   mechanisms	   that	   could	   be	  explored	   in	   future	   experiments.	   Firstly,	   CD5	   is	   known	   to	   be	   required	   for	   the	  generation	   of	   these	   subsets	   within	   the	   thymus	   and	   PKD2	   has	   been	   directly	  implicated	   in	   the	   upregulation	   of	   the	   CD5	   via	   the	   phosphorylation	   of	   C-­‐Cbl	  (Marklund	   et	   al.	   2003)	   (Navarro,	   Goebel,	   et	   al.	   2014b).	   Secondly,	   TGFβ-­‐/-­‐	  mice	  have	   a	   similar	   phenotype	   within	   the	   intraepithelial	   layer,	   with	   decreased	  TCRαβ+	  CD8αα+	  subsets	  (Konkel	  et	  al.	  2011).	  As	  lack	  of	  PKD2	  catalytic	  activity	  has	   been	   shown	   to	   result	   in	   severely	   reduced	   cytokine	   production	   by	   T	  lymphocytes	   it	   is	   tempting	   to	   speculate	   that	   TGFβ	   production	   may	   also	   be	  affected.	  Furthermore,	  data	  generated	   in	  collaboration	  with	  Dr.	  George	  Ramsay	  within	   Professor	  Doreen	   Cantrell’s	   Lab	   (University	   of	  Dundee)	   has	   shown	   that	  PKD2KI/KI	  Th17	  cells	  display	  a	  significant	  reduction	  in	  the	  production	  of	  IL-­‐17	  in	  
vitro	  (Data	  not	  shown).	  	  Collectively,	  our	  data	  reveal	  novel	  and	  surprising	  roles	   for	  PKD	   in	  multiple	  cells	   within	   the	   immune	   system.	   Although	   there	   is	   much	   more	   to	   be	   learned	  about	   the	   specific	   details	   of	   PKD	   function	  within	   these	   cells,	   our	   studies	   have	  provided	   substantial	   evidence	   to	   clarify	   and	   identify	   the	   role	   of	   PKD	   isoforms	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within	   both	   myeloid	   cell	   and	   adaptive	   immune	   cell	   development	   and	   their	  effector	  functions.	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7 	  Appendix	  A	  	  	   Primer	  	   Sense	  primer	   Anti-­‐sense	  primer	  PKD1	   5'-­‐GTTCATAGAACACCGGCAGA-­‐3'	  	   5'GCCAAGACAAATCAACAGAAGC-­‐3'	  	  Table	  7.1	  Primer	  sequences	  for	  genotyping	  of	  PKD1WT/KI	  mice	  	  	  PKD1:	  predicted	  WT	  size	  -­‐	  600bp	  predicted	  PKD1	  heterozygous	  size	  -­‐635bp	  	  Primer	  	   Sense	  primer	   Anti-­‐sense	  primer	  PKD2	   5'-­‐AGTGGCACGTTCCCCTTCAATG-­‐3'	  	   5'-­‐CTTTGCCCAATCCCTTACAGCCT-­‐3'	  	  Table	  7.2	  Primer	  sequences	  for	  genotyping	  of	  PKD2KI/KI	  mice	  	  	  PKD2:	  predicted	  WT	  size	  -­‐	  236	  predicted	  homozygous	  -­‐	  344bp	  	  	  	  
Primer	  	   Sense	  primer	   Anti-­‐sense	  primer	  IFNγ	   5’-­‐TTACTGCCACGGCACAGTC-­‐3’	   5’-­‐AGATAATCTGGCTCTGCAGG-­‐3’	  IL-­‐17	   5’-­‐AGCTCCAGAAGGCCCTCAGACTACC-­‐3’	   5’-­‐CAGCTTTCCCTCCGCATTGACAC-­‐3’	  IL-­‐10	   5’-­‐CCCTTTGCTATGGTGTCCTTTC-­‐3’	   5’-­‐GATCTCCCTGGTTTCTCTTCCC-­‐3’	  CD45	   5’-­‐TGATGGTCACAGGATGTGAAG	  A-­‐3’	   5’-­‐ATGCCGAGTGCCTTCCT-­‐3’	  Table	  7.3	  Primer	  sequences	  used	  for	  detection	  of	  cytokine	  mRNA	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  Figure	  7.1	  PKD1	  forward	  primer	  sequence	  alignment	  	  	  
	  Figure	  7.2	  PKD1	  reverse	  primer	  sequence	  alignment	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8 	  Appendix	  B	  full	  kinase	  screen	  of	  Novartis	  12a,	  
CRT0066101	  and	  CRT0066051	  
	  	  



















































































































































































































































































































































































































































































































































































































































































































	  Figure	  8.1	  Full	  in	  vitro	  kinase	  screen	  Novartis	  12a	  compound	  at	  1μM	  against	  124	  kinases	  In	  vitro	  kinase	  screen	  of	  124	  kinases	  shown	  in	  descending	  order	  of	  %	  remaining	  activity	  (PKD1	  is	  shown	  in	  red)	  	  	  	  	  
	  	  
















































































































































































































































































































































































































































































3" 	  Figure	  8.2	  Full	  in	  vitro	  kinase	  screen	  for	  CRT101	  compound	  at	  1μM	  against	  124	  kinases	  In	  vitro	  kinase	  screen	  of	  124	  kinases	  shown	  in	  descending	  order	  of	  %	  remaining	  activity	  (PKD1	  is	  shown	  in	  red)	  	  	  	  
	  	  






















































































































































































































































































































































































































































































































" 	  Figure	  8.3	  Full	  in	  vitro	  kinase	  screen	  for	  CRT051	  compound	  at	  2.5μM	  against	  124	  kinases	  In	  vitro	  kinase	  screen	  of	  124	  kinases	  shown	  in	  descending	  order	  of	  %	  remaining	  activity	  (PKD1	  is	  shown	  in	  red)	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